<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"this document is a summary of the European Public Prosecutational Report (EPAR), which explains how the Committee for Humanitration (CHMP) has been judged to reach recommendations regarding the application of the drug."</seg>
<seg id="2">"if you need more information about your illness or treatment, please read the package version (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="3">"if you desire further information on the basis of recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as 5 mg, 10 mg, 15 mg and 30 mg tablets, as 10 mg, 15 mg and 30 mg melt letten (tablets that count itself in the mouth), as a solution to one (1 mg / ml) and as an injection solution (7.5 mg / ml)."</seg>
<seg id="5">"B. wirres thinking and speaking, Hallucinations (hearing or vision of things that are not present), distrust and madness; • Bipolar disorder, a psychological disease, in which the patients have a mental episodes (periods) alternately with periods of normal mood."</seg>
<seg id="6">Abilify is used to treat the moderate epic episodes and prevention of manic episodes in patients who are addressed in the past in the past.</seg>
<seg id="7">Injection solution is used for quick control of increased unrest or behavioural disorders when the oral intake of the drug is not possible.</seg>
<seg id="8">"in both diseases, the solution can take care of one or the melting items in patients, which is prepared from tablets difficulties."</seg>
<seg id="9">"in patients who are taking other medicines at the same time, which are exactly the same as Abilify, the dosage should be modified by Abilify."</seg>
<seg id="10">"this impairs the signal transmission between brain cells through" neurotransmitter, "i.e. chemical substances which enable communication between nerve cells with each other."</seg>
<seg id="11">Aripigobenzene probably acts mainly as a "partite Agonist" for the receptors for the neurotransmitters Dopamine and 5-hydroxytryptamin (also Serotonin).</seg>
<seg id="12">"this means that Aripigoethics like 5-hydroxytryptamine and dopamine, but in lower dimensions than the neurotransmitter works to activate the receptors."</seg>
<seg id="13">"as dopamine and 5-hydroxytryptamine in schizophrenia, and bipolar disorder is a role to normalize the activity of the brain, causing psychoteric or manic symptoms decreased and its revocation will be prevented."</seg>
<seg id="14">"the effectiveness of agbilify to prevent the resence of symptoms, was investigated in three studies over up to one year."</seg>
<seg id="15">The effectiveness of injector solution was compared in two studies on 805 patients with schizophrenia or similar diseases that compared to a placebo over a period of two hours with a placebo.</seg>
<seg id="16">"in a further study, Abilify about twelve weeks to 347 patients with Haloperidol, in another study the effectiveness of Abilify and placebo to prevent the resence to 160 patients where the manic symptoms were already stabilized with Abilify."</seg>
<seg id="17">The effectiveness of Abilify injection solution was compared in a study on 301 patients with bipolar disorder that suffered from Lorazepam (a different anti psychotikum) and placebo over a period of two hours.</seg>
<seg id="18">"in all studies, the change of symptoms experienced by the patients using a standard skala for bipolar disorder or the number of patients who investigates the treatment."</seg>
<seg id="19">"the company also carried out studies through to examine how the body takes the melting, and the solution to take."</seg>
<seg id="20">"in the two studies with the injection solution I showed patients who received Abilify in cans of 5,25 mg, 9,75 mg or 15 mg received a significant reduction in symptoms than the patients who received a placebo."</seg>
<seg id="21">In the application for the treatment of bipolar disorder decreased agbilify in four of five short-term studies more effective than placebo.</seg>
<seg id="22">Abilify that also prevented up to 74 weeks in more effective than placebo the re-employed episodes in previously treatable patients and if it was in addition to an existing treatment.</seg>
<seg id="23">Agbilify injections in 10- or 15-mg doses decreasing more effective than placebo the symptoms confused unrest and were similar to Lorazepam.</seg>
<seg id="24">"the most common side effects of Abilify (observed in 1 to 10 of 100 patients), extrapyramidale disorders (uncontrollable), lesnolence (trembling), lesnolence (decreasing), fatigue and exhaustion, restlessness, restless (sleeping disorders) and anxiety."</seg>
<seg id="25">"the Committee for Humanarzneira (CHMP) managed to conclude that the benefits of Abilify episodes at Bipolar-I-disorder, as well as in the prevention of a new manic episode in patients, the mainly manic episodes, and in which the manic episodes had over the treatment with Aripiprabenzene in terms of the risks."</seg>
<seg id="26">"in addition, the committee also came to the outcome that the advantages of injecting unrest and behavioural disorders in patients with schizophrenia or in patients with schizepisodes at Bipolar-I disorder, if a oral therapy is not suitable to overhead the risks."</seg>
<seg id="27">June 2004 the European Commission named Otsuka Pharmaceutical Europe Ltd. a permit for the establishment of Abilify in the entire European Union.</seg>
<seg id="28">ABILIFY is for the treatment of moderate until heavy manic episodes of the Bipolar disorder and for the prevention of a new manic episode in patients that were mainly manic episodes and their manic episodes for the treatment with Aripiprabenzene (see section 5.1).</seg>
<seg id="29">The recommended dose for ABILIFY is 10 or 15 mg / day at a lasting dose of 15 mg / day once daily independently of meals.</seg>
<seg id="30">An increased effectiveness in dosages over a daily dose of 15 mg was not proven although individual patients can benefit from a higher dose.</seg>
<seg id="31">The recommended dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combined therapy (see section 5.1). "</seg>
<seg id="32">The effectiveness of ABILIFY in treating schizophrenia and Bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">With regard to the bigger sensitivity of this patient group should be considered a lower initiate dose into consideration when clinical factors are right (see section 4.4).</seg>
<seg id="34">If the CYP3A4 Inductor is derived from combined therapy should be reduced the Aripivotal dosage to the recommended dose (see Section 4.5).</seg>
<seg id="35">The appearance of suizial behavior belongs to psychoteric diseases and affective disorders and was reported in some cases after the start or after a change of anti psychological therapy (see section 4.8).</seg>
<seg id="36">The results of an epidemiological study showed that in patients with bipolar disorder has no elevated Suizia-risk of Aripizbenzene in comparison to other Antipsychologists.</seg>
<seg id="37">Aripibenzene should be applied with caution in patients with known cardiovascular diseases (dehydration diseases), ceremonial disorders that treatment with blood pressure (dehydration, treatment with blood pressure drugs) or hypertone (including akzele and maligne form). "</seg>
<seg id="38">"3 Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="39">If with a ABILIFY treated patients signs and symptoms of a late dyspines should appear to reduce the dose or to break the treatment.</seg>
<seg id="40">"when a patient sign and symptoms developed to indicate to a mns, or unclear high fever without an additional clinical manifestation of mns, all antipsychotic infections, including ABILIFY."</seg>
<seg id="41">"therefore Aripizbenzene in patients with clampry waste in the anamnese or in states that are being used with clampry cases in connection with caution."</seg>
<seg id="42">"56 - 99 years) with Aripiprabenzene in patients with psychosis who have been associated with Alzheimer's disease, patients who have been treated with Aripizbenzene in comparison to placebo."</seg>
<seg id="43">"however, there were in one of these studies, a study with Fixer dosage, a significant relationship between the dosage and the demand for unwanted zerebrovascular events with Aripigoethatic patients."</seg>
<seg id="44">"hyperglycemic, in some cases extremely and associated with Ketoaziaus or hyperosmolar coma or death, was reported in patients who have been treated with atypical antipsychic substances, including ABILIFY."</seg>
<seg id="45">There is no exact risk assessment for hyperglycemic-related unwanted events with ABILIFY and other atypical antipsychotic agents of patients to allow direct comparisons.</seg>
<seg id="46">"Polydipher, polyurie, polyphagie and weakness) are observed and patients with diabetes Mellitus or with risk factors for diabetes Mellitus should be monitored regularly in terms of deterioration of glucoaches."</seg>
<seg id="47">"a weight gain is generally observed in schizophrenia, and in patients with biological agriculture, the use of anti psychologists, in which weight gain is seen or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="48">"due to the primary impact of Aripizbenzene in the Central-vense system, caution is recommended if Aripizbenzene in combination with alcohol or other central effective medicinal products is taken with the overlay side effects such as Sealing (see section 4.8)."</seg>
<seg id="49">"the H2-antagonist Famotidin, a Magensacid Blocker, reduces the resorption rate of Aripizbenzene, whereby this effect is not relevant to be clinically relevant."</seg>
<seg id="50">"in a clinical study with healthy Probanden boosted a high-effective CYP2D6-Inhibitor (Chinidin), the AUC von Aripigoethum 107%, while the Cmax remained unchanged."</seg>
<seg id="51">"it is to be expected that other high-effective infhibitors from CYP2D6, like fluoxetine and paroxetine, similar effects have and therefore should be made similar dosage."</seg>
<seg id="52">"at CYP2D6 'bad' (=" "poor") Metabolisierers can result the common application with high-effective Inhibitors of CYP3A4 in higher Plasmacia concentrations in comparison with CYP2D6 extensional Metabolishes. "</seg>
<seg id="53">"when you consider the common gifts of Ketoconazol or other high-effective CYP3A4-Inhibitors with ABILIFY, the potential benefits should overweigh the potential risks to the patient."</seg>
<seg id="54">"other high-effective Inhibitors from CYP3A4, such as Itraconazol and HIV-proteasinghibitors, may have similar effects and therefore should be made similar dosage."</seg>
<seg id="55">After placing the CYP2D6- or 3A4-Inhibitors should be raised the dosage of ABILIFY to the dosishheight at the beginning of the accompanying therapy.</seg>
<seg id="56">Dilanazem or Escitalopram) or CYP2D6 together with ABILIFY can be administrated with ABILIFY can be calculated with a moderate increase in Aripiechzol- Concentrations.</seg>
<seg id="57">In clinical studies shown doses of 10-30 mg Aripiprabenzene per day does not significant effect on metabolic effect of CYP2D6 (Dextromethylphan / 3-Methodology) and 3A4 (Wareprabenzene) and 3A4 (Dextromethorphan).</seg>
<seg id="58">"patients should be forgotten to notify her doctor if they are pregnant or have been planning a pregnancy during the treatment with Aripikheim."</seg>
<seg id="59">"due to the insufficient data base for the safety of men and due to the reproductive studies, this medicine should not be applied in pregnancy, unless the potential benefits are justified clearly the potential risk of the fetus."</seg>
<seg id="60">"as though other antipsychologists should also warned the patients before that, dangerous machines, including power vehicles, until they are sure that Aripivotes has no negative influence."</seg>
<seg id="61">The following side effects appeared more frequently (≥ 1 / 100) on than on placebo or were classified as possible medical relevant side effects (*):</seg>
<seg id="62">"the frequency of the below side effects may be defined according to the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">Schizophrenia - In a controlled long-term study about 52 weeks entered in patients who have been treated with Aripijylbenzene (25.8%) of EPS including Parkinsonism, Akathise and Dyskinia, compared to patients that have been treated with Haloperidol (57,3%). "</seg>
<seg id="64">In a placebo-controlled barbell study over 26 weeks was the incidence of EPS 19% in patients suffering from Aripiemic treatment and 13.1% in patients under placebo.</seg>
<seg id="65">"in another controlled long-term study of 26 weeks, the incidence of EPS 14,8% in patients who have been treated with Aripizbenzene, and 15,1% in patients under osteomapin therapy."</seg>
<seg id="66">Manc episodes at Bipolar-I-Disorder - In a controlled study over 12 weeks the incidence of EPS 23,5% in patients under Aripizolol- treatment and 53.3% for patients under Haloperidol treatment.</seg>
<seg id="67">"in another study over 12 weeks, the incidence of EPS 26,6% in patients under Aripiemic treatment and 17,6% for those under lithium treatment."</seg>
<seg id="68">In the long-term phase of over 26 weeks at a placebo-controlled study was the incidence of EPS 18.2% for patients under Aripizolol- treatment and 15.7% for placebo patients.</seg>
<seg id="69">"a comparison between the patient groups under Aripikylbenzene and placebo, in which potentially clinically significant changes of routinationally controlled laboratory parameters occurred, sugars are not medically significant differences."</seg>
<seg id="70">"increases the CPK (Kreatin-Phosphokinase), generally temporarily and asymptomatic, were observed at 3.5% of using Aripigoethics, compared to 2,0% of the placebo patients."</seg>
<seg id="71">"to the side effects that can occur in connection with an antipsychic therapy, and about their occurrence also in the treatment with Aripidebenzene, Spätdyskynia and Krampry, unwanted zerebrovascular diseases and diabetes Mellitus (see section 4.4)."</seg>
<seg id="72">In clinical studies and since the market launch were unintentional or dismissible supervisor with Aripiprabenzene alone in adult patients with estimated doses of up to 1260 mg and without death order.</seg>
<seg id="73">"although no information on the efficacy of a hemisalysis during the treatment of an overdose with Aripigoethes; however, it is unlikely that hamodialysis in the treatment of a overdose of benefits, since Aripivotes has a high plastic bag."</seg>
<seg id="74">It is assumed that the effectiveness of Aripizbenzene in schizophrenia and Bipolar-I disturbance on the combination of a partial agonistic effect on damine di2- and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a-receptors.</seg>
<seg id="75">"Aripigobenzene showed in vitro a high affinity to dopamine d2- and D3-receptor and a moderate affinity to dopamine d4-, to Serotonin 5HT2c- and 5HT7-, to alpha-1-adrenwater and for histamine-H1receptor."</seg>
<seg id="76">At Gabi of Aripiprabenzene in doses of 0.5 to 30 mg once daily about 2 weeks to healthy Probanden showed a doses-dependent reduction of the bindings of 11C Racloprid to a D2 / D3-receptor Liganden, on Nucleus caudatus and on Putinka. "</seg>
<seg id="77">In three placebo-controlled short-time studies (4 to 6 weeks) to 1,228 schizophrenia showed Aripizbenzene in comparison to placebo a statistically significant improvement of psychoteric symptoms.</seg>
<seg id="78">"in a Haloperidol-controlled study was 52 of the share of respondents in both groups similar (Aripigoeth77% and Haloperidol 73%)."</seg>
<seg id="79">"current values in Messskales, which were defined as secondary studies, including PANSS and the Montgomery-Asberg- Depressions scale, showed a significant stronger improvement than at Haloperidol."</seg>
<seg id="80">"in a placebo-controlled study over 26 weeks to stabilised patients with chronic schizophrenia, showed a significant increase of redemption rate, which was at 34% in the Aripivotal Group and 57% under placebo."</seg>
<seg id="81">"in a olanzapin-controlled, multinational double blind-blind study with schizophrenia over 26 weeks, the 314 patients had seen a weight gain of at least 7% compared to the starting sample (i.e. an increase of at least 5,6 kg with an average weight of ca."</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosing over 3 weeks of patients with a manic or mixed episode of the Bipolar-I-disorder showed Aripizylan compared to placebo excessive effectiveness in reducing manic symptoms over 3 weeks.</seg>
<seg id="83">In a placebo-controlled monotherapy study over 3 weeks with Fixer dosage with patients with a manor or mixed episode of the Bipolar-I-disorder showed Aripizbenzene compared to placebo none superlegative effectiveness.</seg>
<seg id="84">"in two placeboat and active-controlled monotherapy studies on 12 weeks in patients with a manor or mixed episode of a Bipolar Merkmalen, showed Aripizylan compared to placebo overheated effectiveness in week 3 and a lasting effect that was comparable with that of lithium or Haloperidol in week 12."</seg>
<seg id="85">Aripigobenzene also pointed out in week 12 a comparable share of patients with symptomatic remission of the mania on how lithium or Haloperidol.</seg>
<seg id="86">"in a placebo-controlled study over 6 weeks of patients with a manic or mixed episode of a Bipolar-I-disorder, with or without psychoteric characteristics which are partially over 2 weeks not at Lithium- or Valproat-Monotherapy in reducing military symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo-controlled study over 26 weeks followed by a long-time expansion phase over 74 weeks in a stabilisation phase before Randomocation, showed an remission to placebo about placebo in regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="88">Based on vitro-studies are the enzymes CYP3A4 and CYP2D6 for the stretching and Hydroxyethylbenzene in CYP3A4 catalyzed.</seg>
<seg id="89">"the mean eliminationshalbation period is nearly 75 hours for Aripizbenzene in extensively metaboisees about CYP2D6 and at approximate 146 hours in 'bad' (=" "poor") metaboisierers about CYP2D6. "</seg>
<seg id="90">"in Aripiprabenzene, there are no differences in the Pharmakocinetic between male and female healthy Probanden, as well as at a pharmacoinetic examination of schizophrenia."</seg>
<seg id="91">A Populations-specific evaluation on the pharmacoinetics are not a reference to clinically significant differences in relation to the ethnic tension or the impact of smoking on the pharmacoinetics of Aripizbenzene.</seg>
<seg id="92">The pharmacoinetic properties of Aripiprabenzene and Dehydro-Aripigobenzene were similar to patients with severe kidney-efficiency in comparison to young healthy propositions.</seg>
<seg id="93">"a single dose for Probanden with different radiogenic liver cirrhosis (Child-Pugh class A, B and C) showed no significant effect with regard to the impairment of the life C, which is not enough to draw conclusions on their metabolic capacity."</seg>
<seg id="94">"based on conventional studies on safety-harmacology, toxicity with repetitive gifts, reproductions, genotoxicity and the transerogeneous potential left the preclinical data to recognise any particular hazards for men."</seg>
<seg id="95">"toxikologically significant effects were observed merely with doses or expositions, which has significantly exceeded the maximum dosage or exposure when humans have only limited or no meaning for the clinical use."</seg>
<seg id="96">The effects inverted a dosing-dependent tricking-rinders (Lipofuscin pigment-accumulation and / or parenchomen / carcinoma at least 60 mg / kg / day (with the recommended dose of female Steady-State-Exposition (AUC) at the recommended Maximaldosis by humans).</seg>
<seg id="97">It also became a Cholelithiasis as a result of the sealing of sulphylbenzene in the Galle from monkeys to repetitive Gabe from 25 to 125 mg / kg / day (AUC) with recommended clinical dose or 16- to 81Carbon the recommended Maximaldosis by humans based on mg / m2).</seg>
<seg id="98">"however, the concentrates found in the human genes among the highest recommended daily dose of Sulfate-Konjugate von Hydroxy- Aripivotal no more than 6% of the concentrations, which were observed in the study over 39 weeks in the Galle of monkeys, and lie far under the limits (6%) in vitro-solubility."</seg>
<seg id="99">"in rabbits these effects were conducted according to dosages, which resulted in the positions of the 3- and 11ME of the middle steady-State AUC with the recommended clinical Maximaldosis, observed."</seg>
<seg id="100">"perforated blister packs of aluminium in fold with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="102">It is assumed that the effectiveness of Aripizbenzene in schizophrenia and Bipolar-I disturbance on the combination of a partial agonistic effect on damine di2- and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a-receptors.</seg>
<seg id="103">"22 In a placebo-controlled study over 26 weeks followed by a long-time expansion phase over 74 weeks in a stabilisation phase before Randomocation, showed an remission to placebo about placebo in regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="104">"27 Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="105">It is assumed that the effectiveness of Aripizbenzene in schizophrenia and Bipolar-I disturbance on the combination of a partial agonistic effect on damine di2- and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a-receptors.</seg>
<seg id="106">"34 In a placebo-controlled study over 26 weeks followed by a long-time expansion phase over 74 weeks in a stabilisation phase before Randomocation, showed an remission to placebo about placebo in regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="107">"39 Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="108">It is assumed that the effectiveness of Aripizbenzene in schizophrenia and Bipolar-I disturbance on the combination of a partial agonistic effect on damine di2- and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a-receptors.</seg>
<seg id="109">"46 In a placebo-controlled study over 26 weeks followed by a long-time expansion phase over 74 weeks in a stabilisation phase before Randomocation, showed an remission to placebo about placebo in regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="110">The recommended dose for Aripizbenzene is 10 or 15 mg / day at a lasting dose of 15 mg / day once daily independently of meals.</seg>
<seg id="111">"patients, the difficulties when the closing of ABILIFY tablets have, you can take the melting items alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="112">The appearance of suizial behavior belongs to psychoteric diseases and affective disorders that reported in some cases after the start or after a change of anti psychological therapy (see section 4.8).</seg>
<seg id="113">"Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="114">"clinical manifestations of a mns are high fever, muscle rigidity, alternating awareness of consciousness and signs autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and arrhythmia)."</seg>
<seg id="115">"a weight gain is generally observed in schizophrenia, and in patients with biological agriculture, the use of anti psychologists, in which weight gain is seen or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="116">Patients should be forgotten to notify her doctor if they are pregnant or pregnant during the treatment with Aripibenzene</seg>
<seg id="117">The following effects presented more frequently (≥ 1 / 100) on than on placebo or were classified as possible medical-related side effects of pharmaceuticals (*):</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosing over 3 weeks of patients with a manic or mixed episode of the Bipolar-I-disorder showed Aripizylan compared to placebo excessive effectiveness in reducing manic symptoms over 3 weeks.</seg>
<seg id="119">"58 In a placebo-controlled study over 6 weeks of patients with a manic or mixed episode of a Bipolar-I-disorder, with or without psychoteric characteristics which are partially over 2 weeks not at Lithium- or Valproat-Monotherapy in reducing military symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a placebo-controlled study over 26 weeks followed by a long-time expansion phase over 74 weeks in a stabilisation phase before Randomocation, showed an remission to placebo about placebo in regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="121">In rabbits these effects were according to dosages that have to expositions of the 3- and 11ME of the medium Steady-State AUC with recommended clinical clinical trials</seg>
<seg id="122">"patients, the difficulties when the closing of ABILIFY tablets have, you can take the melting items alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="123">"Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="124">"71 In a placebo-controlled study over 6 weeks of patients with a manic or mixed episode of a Bipolar-I-disorder, with or without psychoteric characteristics which are partially over 2 weeks not at Lithium- or Valproat-Monotherapy in reducing military symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="125">"patients, the difficulties when the closing of ABILIFY tablets have, you can take the melting items alternatively to ABILIFY tablets (see section 5.2)."</seg>
<seg id="126">"Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="127">"84 In a placebo-controlled study over 6 weeks of patients with a manic or mixed episode of a Bipolar-I-disorder, with or without psychoteric characteristics which are partially over 2 weeks not at Lithium- or Valproat-Monotherapy in reducing military symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg Fructose je ml 400 mg Sucrose per ml 1.8 mg methyl-4-hydroxybenzoat (E218) per ml 0.2 mg Propyl-4-hydroxybenzoat (E216) each ml.</seg>
<seg id="129">The recommended dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combined therapy (see section 5.1). "</seg>
<seg id="130">"to prevent restoring manic episodes in patients who have already received Aripizbenzene, the therapy will be continued with the same dose."</seg>
<seg id="131">"Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="132">"hyperglycemic, in some cases extremely and associated with Ketoaziaus or hyperosmolar coma or death, was reported in patients who have been treated with atypical antipsychic substances, including ABILIFY."</seg>
<seg id="133">There is no exact risk assessment for hyperglycemic-related unwanted events with ABILIFY and other atypical antipsychotic agents of patients to allow direct comparisons.</seg>
<seg id="134">92 In a clinical study with healthy Probanden boosted a high-effective CYP2D6-Inhibitor (Chinidin) the AUC by Aripiprabenzene around 107% while the Cmax remained unchanged.</seg>
<seg id="135">Dilanazem or Escitalopram) or CYP2D6 together with ABILIFY can be administrated with ABILIFY can be calculated with a moderate increase in Aripiechzol- Concentrations.</seg>
<seg id="136">Manc episodes at Bipolar-I-Disorder - In a controlled study over 12 weeks the incidence of EPS 23,5% in patients under Aripizolol-</seg>
<seg id="137">It is assumed that the effectiveness of Aripizbenzene in schizophrenia and Bipolar-I disturbance on the combination of a partial agonistic effect on damine di2- and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a-receptors.</seg>
<seg id="138">"in a olanzapin-controlled, multinational double blind-blind study with schizophrenia over 26 weeks, the 314 patients had seen a weight gain of at least 7% compared to the starting sample (i.e. an increase of at least 5,6 kg with an average weight of ca."</seg>
<seg id="139">97 In a placebo-controlled monotherapy study over 3 weeks with Fixer dosage with patients with a manor or mixed episode of the Bipolar-I-disorder showed Aripizbenzene compared to placebo none superlegative effectiveness.</seg>
<seg id="140">"in a relative bioavailability study, in which the Pharmakocinetics of 30 mg Aripizbenzene in tablet form was compared with 30 mg Aripizbenzene in tobacco value in tobacco value the solution and value of tablets at 122% (N = 30)."</seg>
<seg id="141">99 receivers became one Cholelithiasis as a result of the sealing of sulphylbenzene in the Galle from monkeys to repetitive Gabe from 25 to 125 mg / kg / day (AUC) with recommended clinical dose or 16- to 81Carbon the recommended Maximaldosis by humans based on mg / m2).</seg>
<seg id="142">"in rabbits these effects were conducted according to dosages, which resulted in the positions of the 3- and 11ME of the middle steady-State AUC with the recommended clinical Maximaldosis, observed."</seg>
<seg id="143">ABILIFY injection solution is applied to the quick control of Agiacy and behaviours in patients with schizophrenia or in patients with chronic episodes of the Bipolar-I disorder if a oral therapy is not recommendable.</seg>
<seg id="144">"once it is clinically appropriate, the treatment can be terminated with Aripivotal injection solution and will begin with the orational use of Aripidebenzene."</seg>
<seg id="145">To increase the Resorption and minimize the variability to minimize an injection at the M. Deltoideus or deep into the Gluteus-Maximus muscle under relocation of adipous regions.</seg>
<seg id="146">A lower dose of 5,25 mg (0,7 ml) can be obtained depending on the individual clinical state taking account of the already used or acute therapy (see Section 4.5).</seg>
<seg id="147">"if a further oral treatment with Aripigoethics, see the summary of the characteristics of the medication by means of ABILIFY tablets, ABILIFY enamel or ABILIFY solution to take."</seg>
<seg id="148">There are no investigations on the effectiveness of Aripiprabenzene injection solution in patients with demption and behavioural disorders that were different from schizophrenia and manic episodes of the Bipolar-I disorder.</seg>
<seg id="149">"if a parenteral therapy with Benzodiazepines in addition to the Aripigoethics, in addition, patients should be observed with regard to extreme maritime or blood pressure (see Section 4.5)."</seg>
<seg id="150">Research on safety and effectiveness of Aripigoethics solution lie for patients with alcohol or drugs (by prescribed or illegal drugs).</seg>
<seg id="151">Aripibenzene should be applied with caution in patients with known cardiovascular diseases (dehydration diseases), ceremonial disorders that treatment with blood pressure (dehydration, treatment with blood pressure drugs) or hypertone (including akzele and maligne form). "</seg>
<seg id="152">"Spätdyskinesia: in clinical trials, which was a year or less grounded, there were occasional reports on during the treatment with Aripiprylbenzene Dyskinia."</seg>
<seg id="153">"clinical manifestations of a mns are high fever, muscle stiffness, alternating awareness of consciousness and signs autonomous instability (irregular pulse or blood pressure, tachykardie, sweating and arrhythmia)."</seg>
<seg id="154">"Polydipher, polyurie, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucoaches."</seg>
<seg id="155">"a weight gain is generally observed in schizophrenia, patients and patients with biological symptoms, the use of antipsychic drugs, in which weight gain is seen or an unhealthy lifestyle, and could lead to serious complications."</seg>
<seg id="156">"nevertheless, the intensity of the Sedation was larger compared to the allest gift of Aripigoethics, in a study, in the healthy Probanden Aripivotal (15 mg dosage) as an unmistement intramusculine, and which at the same time Lorazepam (2 mg dosage) intramusculaire."</seg>
<seg id="157">"105 The H2-antagonist Famotidin, a Magensacid Blocker, reduces the resorption rate of Aripizbenzene, whereby this effect is not relevant to be clinically relevant."</seg>
<seg id="158">"at CYP2D6 'bad' (=" "poor") Metabolisierers can be extensively compared to CYP2D6 extensional metaboissing the common application with high-effective Inhibitors of CYP3A4 in higher Plasmaconecularists. "</seg>
<seg id="159">"other high-effective Inhibitors from CYP3A4, such as Itraconazol and HIV- Proteasinghibitors, may have similar effects and therefore should be made similar dosage."</seg>
<seg id="160">After placing the CYP2D6- or 3A4-Inhibitors should be raised the dosage of ABILIFY to the dosishheight at the beginning of the accompanying therapy.</seg>
<seg id="161">"106 Lorazepam (2 mg dosage) intramusculaire received, was the intensity of the Sedation larger compared to the allay of Aripibenzene."</seg>
<seg id="162">The following side effects appeared in clinical studies with Aripivotal injection solution more frequently (≥ 1 / 100) than on placebo or were classified as possible medical relevant side effects (*):</seg>
<seg id="163">"the frequency of the below side effects may be defined according to the following criteria: frequently (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects appear more frequently (≥ 1 / 100) than on placebo or were evaluated in clinical trials in oral studies as possible medical-quality side effects (*) in clinical research side effects (*):</seg>
<seg id="165">In a placebo-controlled barbell study over 26 weeks was the incidence of EPS 19% in patients under Aripizolol- treatment and 13.1% in patients under placebo.</seg>
<seg id="166">"in another study over 12 weeks, the incidence of EPS 26,6% in patients under Aripizolol- treatment and 17.6% for those under lithium treatment."</seg>
<seg id="167">In the long-term phase of over 26 weeks at a placebo-controlled study was the incidence of EPS 18.2% for patients under Aripiemic antibiotics and 15.7% for placebo patients.</seg>
<seg id="168">"a comparison between the patient groups under Aripikylbenzene and placebo, in which potentially clinically significant changes of routinationally controlled laboratory parameters occurred, sugars are not medically significant differences."</seg>
<seg id="169">"increases the CPK (Creatinphosphokinase), generally temporarily and asymptomatic, were observed at 3.5% of using Aripigoethics, compared to 2,0% of the placebo patients."</seg>
<seg id="170">"to the side effects that can occur in connection with an antipsychic therapy, and about their occurrence also in the treatment with Aripigoethics, Spätdyskinia and Krampry, unwanted zerebrovascular diseases, hyperglycemic and diabetes mellitus (see section 4.4)."</seg>
<seg id="171">110 and behavioural disorders that Aripiembenzene injustice with statistically significant enhancements can be compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">"in a placebo-controlled short-time study (24 h) with 291 patients with bipolar disorder, as well as Agiacy and behavioural disorders, was an statistically significant improvement in the symptomatic and behavioural dysfunctions compared to placebo and similar to the Lorazepam- Reference."</seg>
<seg id="173">The observed mean increase from the starting point on the PANSS Excitement Component score on the primary 2-hour end point was 5,8 for placebo, 9.9 for Lorazepam and 8.3 for Aripiepbenzene. "</seg>
<seg id="174">"in analyses of sub-groups in patients with mixed episodes or patients with severe talents, but a similar effectiveness was observed in terms of overall population, but a statistical Significanz could be determined due to a reduced patient account."</seg>
<seg id="175">In three placebo-controlled short-time studies (4 to 6 weeks) to 1,228 schizophrenia showed Aripizbenzene (oral) compared to placebo a statistically significant improvement of psychoteric symptoms.</seg>
<seg id="176">"in a Haloperidol-controlled study was 52 of the share of respondents in both groups similar (Aripigoeth77% (oral) and Haloperidol 73%)."</seg>
<seg id="177">"current values in Messskales, which were defined as secondary studies, including PANSS and the Montgomery-Asberg-Depressionsrl scale, showed a significant stronger improvement than at Haloperidol."</seg>
<seg id="178">"in a placebo-controlled study over 26 weeks to stabilised patients with chronic schizophrenia (oral) showed a significant increase in disduction rate, which was at 34% in the Aripizol- (oral) group and at 57% under placebo."</seg>
<seg id="179">"in a olanzapin-controlled, multinational double blind-blind study with schizophrenia over 26 weeks, the 314 patients had a weight gain of at least 7% compared to the starting sample (i.e. an increase of at least 5,6 kg with an average weight of ca."</seg>
<seg id="180">111 In a placebo-controlled study over 6 weeks with a manic or mixed episode of a Bipolar-I-disorder, with or without psychoteric characteristics which are partially over 2 weeks not at Lithium- or Valproat-Monotherapy in reducing military symptoms compared to monotherapy with lithium or Valproat. "</seg>
<seg id="181">"in a placebo-controlled study over 26 weeks followed by a 74-week study-extension in the stabilisation phase before Randomization during a stabilisation phase before Randomocation, showed an remission to placebo faced with regard to the prevention of a bipolar backdrop, predominantly in preventing a relapse in the mania."</seg>
<seg id="182">The Aripidebenzene AUC is in the first 2 hours following intramusicular injection 90% greater the AUC to Gabe of the same dosage as a tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">"in 2 studies with healthy propositions, the average time until reaching the maximum plasmaspiegels for 1 to 3 hours of application."</seg>
<seg id="184">The gift of Aripiprabenzene injections was well tolerated by rats and monkeys in no direct toxicity of a target organs after repetitive Gabe with a systemic exposure (AUC), the 15- and 5 times above the maximum human therapeutic extrusion of 30 mg intramusculine. "</seg>
<seg id="185">In studies for reproductions according to intravenous application there are no security relevant concerns about maternal exposure to 15- (rats) and 29 times (rabbits) above the maximum human therapeutic extrusion of 30 mg.</seg>
<seg id="186">"based on conventional studies with Aripigobenzene (oral) to safety spharmacology, toxicity with repetitive gifts, reproductions, genotoxicity and the transerogeneous potential left the preclinical data to recognise any particular hazards for men."</seg>
<seg id="187">Toxikologically significant effects were observed merely with doses or expositions which have significantly exceeded the maximum dosage or exposure when humans have only limited or no meaning for the clinical use.</seg>
<seg id="188">The effects umphate a dosing-dependent tricking-rinders (Lipofuscin pigment-accumulation and / or parenchomen-state-exposure (AUC) at 60 mg / kg / day (the 10-fold the middle steady-state-exposure (AUC) at the recommended Maximaldosis by humans).</seg>
<seg id="189">It also became a Cholelithiasis as a result of the sealing of sulphylbenzene in the Galle from monkeys to repetitive Gabe from 25 to 125 mg / kg / day (AUC) with recommended clinical dose or 16- to 81-in the recommended Maximaldosis by humans based on mg / m2).</seg>
<seg id="190">"in rabbits these effects were conducted according to dosages, which resulted in expositions of the 3- and 11-fold of the middle steady-state AUC with the recommended clinical Maximaldosis, observed."</seg>
<seg id="191">"Pharmakovigilar system The regulatory owners must ensure that before and while the product is marketed, the Pharmakovigilance system, as it is described in version 1.0 of module 1.8.1. of the authorisation item, furnished and functional."</seg>
<seg id="192">"according to the" CHMP guideline on Risk Management Systems for Medicinal products for human use "must be submitted to the updated risk management plan at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="193">"moreover, a later risk management plan has to be submitted, when new information is known to affect the current security data, the Pharmakovigilance plan or measures for risk management, within 60 days after an important milestone in the risk management system, upon request the EMEA."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablets EU / 1 / 04 / 276 / 003 49 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 276 / 008 49 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 013 49 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 018 49 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the listed unwanted effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="200">"it is applied to the treatment of adults who are suffering from a disease, which is characterized by symptoms like the hearing, seeing or foaming of things that are not available, distractions, unrelated language, wirres behavior and flextant mood."</seg>
<seg id="201">"ABILIFY is applied in adults to treat a condition with excessive sweeping, to have an excessive energy to need much less sleep as usual, very fast speaking with fast alternating ideas and sometimes strong friction."</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugar diabetes) in the family suffer from unarbitrary, irregular muscle movements, especially in the face heart or vascular disease, or vascular disease (transitory Attacke / TIA), abnormal blood pressure."</seg>
<seg id="203">"if you suffer as a valterer patient at dementia (loss of memory or other mental skills), you should notify you or a cubator / a relative to your doctor if you ever had a stroke or temporary vastation of the brain."</seg>
<seg id="204">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="205">Children and young people of ABILIPY is not applicable in children and adolescents since patients under 18 years of age are not yet investigated.</seg>
<seg id="206">"for taking ABILIFY with other medicines please inform your doctor or pharmacist, if you have to use other medicines or have recently taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="207">Medicines for treating cardiac disorders antidepressants or herbal medicines which are applied for treating depression and anxiety; medicines for treating an HIV infection antiquvulva caused to treat epilepsy to treat epilepsy.</seg>
<seg id="208">"pregnancy and breastfeeding you should not take ABILIFY if you are pregnant, unless you are discussed with your doctor."</seg>
<seg id="209">Transport and use of machinery you should not drive car and not use tools or machines until you know how ABILIPY works with you.</seg>
<seg id="210">"please take this medicine only upon consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIPY is too strong or too weak.</seg>
<seg id="212">"even if you feel better, change or put the daily dose of ABILIFY cannot ask without your doctor before asking."</seg>
<seg id="213">"if you have taken a larger amount of ABILIFY, when you should notice that you have more ABILIPY tablets have been taken care of your doctor (or if someone has taken some of your ABILIFY tablets), please contact your doctor."</seg>
<seg id="214">"if you have forgotten the intake of ABILIFY If you have forgotten a dose, take the forgotten dose as soon as you think, do not take a double dose for a day."</seg>
<seg id="215">"frequent unwanted side effects (with more than 1 of 100, less than 1 of 10 treatable) uncontrollable, fatigue, nausea, rejuvenation, sleep, restlessness, restlessness, restlessness, trembling, trembling and blurred."</seg>
<seg id="216">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 patients, less than 1 of 100 treated), especially when they arise from an underlying or siter position, or they can determine a accelerated pulse."</seg>
<seg id="217">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="218">"like ABILIFY, and content of Packing ABILIFY 5 mg tablets are rectangular and blue, with prebossing of A-007 and 5 on one side."</seg>
<seg id="219">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="220">"even if you feel better, change or put the daily dose of ABILIFY cannot ask without your doctor before asking."</seg>
<seg id="221">"like ABILIFY, and content of Packing ABILIFY 10 mg tablets are rectangular and rosscars, with preference of A-008 and 10 on one side."</seg>
<seg id="222">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="223">"even if you feel better, change or put the daily dose of ABILIFY cannot ask without your doctor before asking."</seg>
<seg id="224">"like ABILIFY looks and content of Packing ABILIFY 15 mg tablets are round and yellow, with preference of A-009 and 15 on one side."</seg>
<seg id="225">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="226">"even if you feel better, change or put the daily dose of ABILIFY cannot ask without your doctor before asking."</seg>
<seg id="227">"like ABILIFY, and content of the pack of ABILIFY 30 mg tablets are round and rosafdied, with preference of A-011 and 30 on one side."</seg>
<seg id="228">"171 When you suffer from dementia patient to dementia (loss of memory or other mental skills), you should notify you or a cubator / a relative to your doctor if you ever had a stroke or temporary cleansing of the brain."</seg>
<seg id="229">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="230">Important information about certain other components of ABILIFY patients who have no phenylalanine to take note that ABILIFY melting aspartame as a source of phenylalanine.</seg>
<seg id="231">Take immediately after opening the blister packet the tablet with dry hands and place the melting tablet into the whole to the tongue.</seg>
<seg id="232">"even if you feel better, change or put the daily dose of ABILIFY cannot ask without your doctor before asking."</seg>
<seg id="233">"if you have taken a larger amount of ABILIFY, when you should notice that you have more ABILIFY melt leted as recommended by your doctor (or if someone has taken some of your ABILIFY melting items), please contact your doctor."</seg>
<seg id="234">"calcium-trimetric, Crocomeldon, izcium, microcrystalline, microcrystalline, microcrystalline, microcrystalline, Aspartam, Acesulfam-Kalium, Vanille- Aroma Artificial (includes Vanilla and Ethylvanilla), Winery, Magnesium, Iron (III) - oxide (E172)."</seg>
<seg id="235">"like ABILIFY looks and content of Packing The ABILIFY 10 mg melt letten are round and rosafdied, with prebossing of" A "over" 640 "on one side and" 10 "on the other."</seg>
<seg id="236">"177 If you suffer from dementia patient to dementia (loss of memory or other mental skills), you should notify you or a cubator / a relative to your doctor if you ever had a stroke or temporary vastation of the brain."</seg>
<seg id="237">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="238">"calcium-trimetric, Crocomeldon, microcrystalline, microcrystalline, microcrystalline, microcrystalline, microcrystalline, Aspartam, Acesulfam-Kalium, Vanille- Aroma Artists, magnesium, magnesium, Iron (III) - hydroxid-oxide x H2O (E172)."</seg>
<seg id="239">"like ABILIFY looks and contents of the pack The ABILIFY 15 mg melt letten are round and yellow, with prebossing of" A "over" 641 "on one side and" 15 "on the other."</seg>
<seg id="240">"183 When you suffer from dementia (loss of memory or other mental skills), you should notify you or a cubator / a relative to your doctor if you ever had a stroke or temporary vastation of the brain."</seg>
<seg id="241">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="242">"like ABILIFY looks and contents of the pack The ABILIFY 30 mg melt letten are round and rosafdied, with prebossing of" "A" "on one side and" 30 "on the other."</seg>
<seg id="243">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="244">Transport and use of machinery you should not drive car and not use tools or machines until you know how ABILIPY works with you.</seg>
<seg id="245">190 Important information about certain other components of ABILIFY Eder ml ABILIFY solution to take contains 200 mg Fructose and 400 mg Sucrose.</seg>
<seg id="246">"when your doctor shared you that you suffer from a intolerance towards certain sugar, contact your doctor before you take this medicine."</seg>
<seg id="247">The dose to ABILIFY solution for inserts must be measured with the geant measuring tool or vaulted 2 ml trop pipette which are included in the package.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIPY is too strong or too weak.</seg>
<seg id="249">"if you have taken a larger amount of ABILIFY, when you should notice that you have more ABILIFY solution to take you than from your doctor (or if anyone's different ABILIPY solution to take account), please contact your doctor."</seg>
<seg id="250">"Dinatriumedetat, Fructose, Milky-4- hydroxybenzoat (E218), Propyl-4-hydroxybenzoat (E216), soyl-4-hydroxybenzoat (E216), sodium-hydroxybenzoat (E216), sodium-hydroxygen-Creme-Aroma with other natural flavours."</seg>
<seg id="251">"like ABILIFY, and content of Packing ABILIFY 1 mg / ml solution to take is a clear, colored to light yellow liquid in bottles with a child-safe polypropylene locking and up to 50 ml, 150 ml or 480 ml"</seg>
<seg id="252">"ABILIFY resin solution is applied to the rapid treatment of undisturbed unrest and desperate behavior, which are marked by symptoms such as: the hearing, seeing or foaming of things that are not available, distractions, unrelated language, wirres behavior and flextant mood."</seg>
<seg id="253">"people with this disease can also be depressed to feel guilty, anxious and tense. overheated high-esteem, the feeling excessive energy need to have much less sleep than usual, very fast speaking with alternating ideas and sometimes strong friction."</seg>
<seg id="254">"inform your doctor if you suffer from muscle stiffness or stiffness linked with high fever, sweating, altered state of mind or very quicker or irregular heartbeat."</seg>
<seg id="255">"when using ABILIFY with other medicines please inform your doctor or pharmacist, if you have to use other medicines or have recently been taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="256">Medicines for treating cardiac disorders antidepressants or herbal medicines which are applied for treating depression and anxiety; medicines for treating an HIV infection antiquvulva which are used to treat epilepsy.</seg>
<seg id="257">196 pregnancy and breastfeeding you should not apply ABILIFY if you are pregnant because you are discussed with your doctor.</seg>
<seg id="258">Transport and use of machinery you should not drive car and do not use tools or machines when you feel the application of ABILIFY injection solution.</seg>
<seg id="259">"if you have any concerns you wish to receive more ABILIFY injection solution than you need to believe, please talk to your doctor or pavement."</seg>
<seg id="260">"frequent unwanted side effects (with more than 1 of 100, less than 1 of 10 treated) by ABILIFY injection solution are tiredness, swelling, headaches, rubese, nausea and vomiting."</seg>
<seg id="261">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treatable) Some persons can have a changed blood pressure, especially when watching out of the song or sitting, or a fast pulp, have a dryness in the mouth or turned off."</seg>
<seg id="262">"frequent unwanted side effects (with more than 1 of 100, less than 1 of 10 treatable) uncontrollable, fatigue, aroused, a uncomfortable feeling in stomach, congestion, sleep, restlessness, restlessness, trembling, trembling and blurred."</seg>
<seg id="263">"if you need more information about your illness or treatment, please read the package version (also part of the EPAR), or contact your doctor or pharmacist."</seg>
<seg id="264">Abroad should only be applied under the supervision of a qualified oncologist to the use of Zytostatika (deadlines of cells).</seg>
<seg id="265">"in patients, where certain side effects may occur on the blood or the nervous system, the dose may be reduced or treatment have been interrupted."</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu</seg>
<seg id="267">"the effectiveness of Abraxane was investigated in a capitals, at the 460 women with metastatic breast cancer, of which about three quarters used earlier an anthracycline."</seg>
<seg id="268">The effect of Abroad (in all Gabe or as monotherapy) was compared with the conventional Paclitaxel drugs by means (given in combination with other medicines for reducing the side effects).</seg>
<seg id="269">"in total, in the capitudie 72 (31%) of 229 with Abroad patients treated on treatment, opposite 37 (16%) of the 225 patients received, conventional Paclitaxel included medicines."</seg>
<seg id="270">"if only the patients were treated because of metastatic breast cancer, there were no difference between drugs and survival as far as to deterioration of the disease and survival."</seg>
<seg id="271">"in contrast, with patients who had previously received other treatments of their metastatic breast cancer, in terms of these indicators, that it was more effective than conventional Paclitaxel included medicine."</seg>
<seg id="272">"it may not be applied with patient, breastfeeding, or before the beginning of the treatment low neutrality numbers in the blood."</seg>
<seg id="273">"the Committee for Humanity is fixed, that the first treatment was no longer proposes, more effective than conventional Paclitaxel's medicines and that it has to be used in contrast to other Paclitaxel medicines."</seg>
<seg id="274">"in January 2008, the European Commission of the company Abroad offers Bioscience Limited has a permit for the Tourist Information of Abroad in the entire European Union."</seg>
<seg id="275">"Abraxane-Monotherapy is indexed for the treatment of metastatic Mammakarcinoma in patients with the first-line treatment for metastatic disease (see also section 4.4)."</seg>
<seg id="276">In patients with severe neutrality (Neutrophilenumber &lt; 0,50 x 109 / l over a period of a week or longer) or heavy sensory Neuropathic therapy should be reduced the dose in the subsequent series on 220 mg / m2.</seg>
<seg id="277">"with sensory Neuropathie level 3 is the treatment to underbreak down to degree 1 or 2, and with all subsequent cycles must be reduced the dose."</seg>
<seg id="278">There are currently no adequate data for the recommendation of dosage adaptations in patients with mild to moderate impairment of the liver function (see section 4.4. and 5.2).</seg>
<seg id="279">No studies have been carried out with patients with impaired kidney function and there are currently no adequate data on the recommendation of dosage adaptations in patients with impairment of kidney function (see section 5.2).</seg>
<seg id="280">Abroad is not recommended for use in children under 18 years of age due to incomprehensiveness and effectiveness.</seg>
<seg id="281">Abraxane is a Albumin-built nano-formulation by Paclitaxel, which could be essentially different pharmacological characteristics as other formulations of Paclitaxel (see section 5.1 and 5.2). "</seg>
<seg id="282">"if an allergic reaction occurs, the medicine should be retrieved immediately and a symptomatic treatment should not be treated once again with Paclitaxel."</seg>
<seg id="283">"in patients, no renunciated treatment of treatment should be redirected to &gt; 1,5 x 109 / l, and the Thrombozytente has risen again to &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver dysfunctions (Bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abroad.</seg>
<seg id="285">"while an ambiguous treatment has not been proven, kardiale incidents in the indexed patients are not unusual, especially in patients with early anthracycline treatment or underlying heart disease or lunches disease."</seg>
<seg id="286">"in case of patients following the Gabions of Abraxane, decreasing and passing, these can be treated with the usual antiemetika and constiptive means."</seg>
<seg id="287">"Abraxane should not be practiced during pregnancy or in women in childbearing age, which are not effective, except the treatment of mother with Paclitaxel is unavoidable."</seg>
<seg id="288">Women of childbearing age should be used during and up to 1 month after treatment with Abraxane.</seg>
<seg id="289">Male patients who are treated with Abraxane will be advised during and up to six months after treatment no child.</seg>
<seg id="290">Male patients should advise themselves before the treatment about a sperm count because through therapy with exxane the possibility of irreversible infertility.</seg>
<seg id="291">"Abraxane may cause side effects such as tiredness (very frequently) and swelling (frequent), which can affect traffic and ability to use machines."</seg>
<seg id="292">"following are the most common and most important incidents of side effects, which appeared in 229 patients with metastatic Mammakarcinoma, which were treated in the pivotal phase III study once every three weeks with 260 mg / m2 Abroad were treated."</seg>
<seg id="293">Neutropenie was the most noticeable important hmatological toxicity (at 79% of the patients) and was quickly reversible and dosisdependent; Leukopenie was reported at 71% of the patients.</seg>
<seg id="294">Anemia (HB &lt; 10 g / dl) was observed at 46% of the associated patients and was most severe in three cases (HB &lt; 8 g / dl).</seg>
<seg id="295">In chart 1 the side effects are listed in conjunction with the Gift of Abroad as a monotherapy at any dose and indications in studies (N = 789).</seg>
<seg id="296">"very frequently (≥ 1 / 10); often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100); rare (≥ 1 / 10.000, &lt; 1 / 1.000); very rare (&lt; 1 / 10.000)."</seg>
<seg id="297">"occasionally: increased blood pressure, gaining weight, increased lacktatdehydrogenes in the blood, increased blood sugar, increased blood sugar, increased phosphate in the blood, reduced potassium in the blood of hereditary diseases:"</seg>
<seg id="298">"Dysphagie, Blessing, dries, dry mouth, sore gums, loose chair, opsophagitis, pain in the mouth, oral pain, rektal bleeding diseases of kidneys and urinary paths:"</seg>
<seg id="299">"pain in the breast corwall, weakness of musculature, anti-headache, power spasmen, sorrow spasmen, sorties in the scents, muscle weaken, Very common:"</seg>
<seg id="300">Restlessness 1 The frequency of oversensitivity reaction is calculated based on a definitions in connection in a population of 789 patients</seg>
<seg id="301">"since these events have been reported on a voluntary basis during the clinical practice, there are not estimates of actual frequency, and it has no cold connection with these events."</seg>
<seg id="302">Paclitaxel is a antimikrotubuli-ingredient which promotes the confiscation of the Mikrotubators from the tubes and microrotubuli by inhibition of their deolymerisation.</seg>
<seg id="303">"this stabilisation leads to an inscription of the normal dynamic reorganization of the mikrotubulary network, which is essential for the vital interphase and the mitotic cell functions."</seg>
<seg id="304">It is known that Albumin the transcytosis of Plasmacomponds has been conveyed into the endothelpers and within the framework of in-vitro studies proved that the presence of Albumin the transport of Paclitaxel promotes the endothelmets.</seg>
<seg id="305">It is assumed that this improved transendotteral transport is conveyed by the gp-60-Albuminreceptor and due to the Albuminous Proteins SPARC (secreted protein rich in Cysteine) a paclitaxel accumulation in the field of tumors.</seg>
<seg id="306">The application of Abraxane for metastatic Mammakarcinoma is treated by data from 106 patients in two independent distilled studies and of 454 patients who were treated in a randomized phase III comparative study.</seg>
<seg id="307">"in a study were treated 43 patients with metastatic Mammakarcinoma, which was treated in the form of an infusion between 30 minutes by a dose of 175 mg / m2."</seg>
<seg id="308">"in the second study, a dose of 300 mg / m2 is used as infusion between 30 minutes to 63 patients with metastatic Mammakarcinoma."</seg>
<seg id="309">This multi-centric study was carried out in patients with metastatic Mammakarcinoma which received every 3 weeks a monotherapy with Paclitaxel 175 mg / m2 as 3-hour infusion with premediation of an allergic reaction (N = 225) or in the form of Abraxane 260 mg / m2 as 30-minute infusion without premediation (N = 229).</seg>
<seg id="310">"when recording, 64% of patients had a affected single state (ECOG 1 or 2), 79% had visceral Metastasen and 76% had more than 3 metastasestals."</seg>
<seg id="311">"14% of patients previously had no chemotherapy, 27% had only an adjuvant chemotherapy, 40% only because of metastation and 19% for metastation and adjuvant treatment."</seg>
<seg id="312">"9 The results for general response rate and time until progression of the disease as well as progressional survival and survival for patients, die &gt; First-line therapy, are shown below."</seg>
<seg id="313">"neurotoxicity towards Paclitaxel has been replaced by improving a degree of patients, at a time during therapy a peripheral Neuropathie level 3."</seg>
<seg id="314">The natural course of peripheral Neuropathie to end on Baseline due to the cumulative toxicity of Abraxane to &gt; 6 treatment curses was not evaluated and is still unknown.</seg>
<seg id="315">The pharmacoinetics of the total-Paclitaxel after 30- and 180-minute infusions of Abraxane with a dose of 80 to 375 mg / m2 was established in clinical trials.</seg>
<seg id="316">The efficiency exposition (AUC) increased from 2653 to 16736 ng.h / ml analog to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 After intravenous Gabe of Abroad on patients with metastatic Mammakarcinoma in the recommended clinical dose of 260 mg / m2 took the paclitaxel Plasmaconconcentration on a multiphase way.</seg>
<seg id="318">The medium distribution volume was 632 l / m2; the high distribution volume indicates a far-reaching extravascular distribution and / or ordination of Paclitaxel.</seg>
<seg id="319">In a study with patients with advanced growth inhibits the pharmacoinetic properties of Paclitaxel after intravenous infusion of 260 mg / m2 Abroad is compared with the values after a 3-hour injections of 175 mg / m2 solvent Paclitaxel.</seg>
<seg id="320">The Clearance of Paclitaxel was higher (43%) than after an solvent Paclitaxel injection, and also the distribution volume was higher (53%). "</seg>
<seg id="321">In the published literature about in-vitro studies of human life-microsome and tissue coating is reported that Paclitaxel is primarily reported to 6α-Hydroxypaclitaxel and for two smaller metabolic (3 "-p-Hydroxypaclitaxel and 6α -3" -p-Dihydroxypaclitaxel) metabolized.</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 Abraxane with patients with metastatic colorectal induction of the unchanging impact of the unchanging odine and 3 "-p-Hydroxypaclitaxel and 3" -p-Hydroxypaclitaxel, which is down to a far-reaching non-renal Clearance. "</seg>
<seg id="323">"however, about patients at the age of over 75 years are only a few data available, as only 3 patients of this age group participated in pharmacoinetic analysis."</seg>
<seg id="324">The chemical and physical stability has been proven at 2 ° C to 8 ° C in the original carton and light light beyond 8 hours.</seg>
<seg id="325">Paclitaxel is a cyclical medicine and as well as with other potentially toxic substances should be taken care when dealing with Abroad?</seg>
<seg id="326">"using a sterile syringes will slowly become over a period of at least 1 minute 20 ml of a 9 mg / ml (0,9%) sodium-chloride solution in an Abroad-bottle."</seg>
<seg id="327">After complete encore the solution should rest the passage of at least 5 minutes to ensure a good bends of the solid.</seg>
<seg id="328">"then the breakwater should be slow for at least 2 minutes slowly and careful and / or inverted, up to a complete Resusement of the Pulvers is done."</seg>
<seg id="329">"if failures or seedlings are visible, the breakthrough-bottle has to become gently inverted to achieve before the application a complete Resuspension."</seg>
<seg id="330">The exact total dosing volume of the 5-mg / ml suspension is calculated and the corresponding amount of reprostitute Abroad is injected in an empty, sterile PVC- or non-PVC infusion bags. "</seg>
<seg id="331">"Pharmakovigilance system, the owner of the authorization must ensure that the Pharmakovigilance system, as described in version 2.0 and presented in module 1.8.1st of the authorisation item, and works before and while the medicine is brought into traffic."</seg>
<seg id="332">"Risikomanagementplan The owner of the authorization needed to perform the studies and other pharmaovigilance plan as described in version 4 of the Risikomanagementplan (RMP), as well as all subsequent updates of the RMP, which are agreed with CHMP."</seg>
<seg id="333">"according to the CHMP directive on Risikomanagementsystems for medicines for application to human being is to be submitted, simultaneously with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, an updated report is insufficient • If new information enter into the current security specification, the Pharmakovigilance plan or risk activities • Without of 60 days after reaching an important milestones (Pharmakovigilance or risk inspection) • On request of EMEA"</seg>
<seg id="335">"8 hours in the fridge in the average bottle, when they are kept in carton, to protect the content from light."</seg>
<seg id="336">"Abroad is used to treat Mammakarcinoma when other therapies were tried, but not successful, and if you do not come for anthracycline therapies in question."</seg>
<seg id="337">Abroad must not be used: • If you are hypersensitive (allergic) against Paclitaxel or one of the other components of Abraxane • If you are breastfeeding if your white blood cells are lower (starting values for neutrroyalty) of &lt; 1.5 x 109 / l - your doctor will inform you about)</seg>
<seg id="338">Particular caution at the application of Abraxane is required: • If you have an intermittent kidney function • If you suffer from numbness, tingling feeling, touching sensitivity or muscle weaken • If you suffer from serious liver problems • If you have heart problems</seg>
<seg id="339">"when using Abraxane with other medicines please inform the doctor if you apply other medicines or have recently applied, even if it could not cause prescription-related drugs because this might cause a interaction with hesxane."</seg>
<seg id="340">Women of childbearing age should be used during and up to 1 month after treatment with Abraxane.</seg>
<seg id="341">"in addition, they should advise themselves before the treatment about a sperm conservation, because the possibility of creating a lasting infertility treatment."</seg>
<seg id="342">Transport and use of machines Abroad may cause side effects such as tiredness (very frequent) and disappearances (frequent) which can affect traffic and ability to use machines.</seg>
<seg id="343">"if you also receive other medicines as part of your treatment, you should consult with regard to the driving or use of machines from your doctor."</seg>
<seg id="344">22 • impact on the peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrheh • weakness and tiredness</seg>
<seg id="345">"the frequent unwanted side effects (with at least 1 of 100 patients reports) are: • Hautes, dry disruptions • necessimisation • respiratory disorders • necessimisation • respiratory or difficulties when reading the mucous, reduced muscle coaches or difficulties when reading the mucous membranes, painless mouth or walty, painless mouth or wound tongue, mouthsoor • sleeping disorders"</seg>
<seg id="346">The rare side-Effects (at least 1 of 10.000 patients reports) are: • lung infection • skin reaction to a different substance after radiotherapy • blood-minded</seg>
<seg id="347">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="348">"if they are not used immediately, it can be stored in the throughput up to 8 hours in the fridge (2 ° C - 8 ° C), if they are stored in the Umcarton, to protect the content from light."</seg>
<seg id="349">Each throughput includes 100 mg Paclitaxel. • After the reconstitution contains 5 mg of Suspension 5 mg Paclitaxel. • The other component is Albuminate from people (including sodium-sodium and N Acetyltryptophan (Ph.Eur.)</seg>
<seg id="350">Precautions for the preparation and application Paclitaxel is a cyclical medicine and as well as with other potentially toxic substances should be taken care when dealing with Abroad?</seg>
<seg id="351">"using a sterile syringe should slow over a period of 1 minute 20 ml of a 9 mg / ml (0,9%) sodium-chloride solution in an Abroad-bottle-bottle."</seg>
<seg id="352">"then the breaker bottle for at least 2 minutes slowly and careful, and / or inverter, until a complete Resusement of the Pulvers is done."</seg>
<seg id="353">The exact total doses volume of 5 mg / ml Suspension calculate and the corresponding amount of reprostitute Abroad in an empty, sterile PVC infusion type IV injecting. "</seg>
<seg id="354">Parenteral medicines ought to be examined prior to the application of a reflections on any possible particles and discolorations whenever the solution or loss of this.</seg>
<seg id="355">"stability Ungeopened throughput with Abraxane, are stable until the date given on the packaging specified date, when the throughput in the radius is kept in order to protect the content from light."</seg>
<seg id="356">Stability of the inaugural Suspension in the average bottle After the first reconstitution should be filled with the suspension immediately into an infusion bags.</seg>
<seg id="357">"" "member states need to ensure that the holders of approvals for the incumbent prior to the market entry into dialysis centres and retail outlets with the following information and materials stored:"</seg>
<seg id="358">• Schuler brochure • summary of the characteristics of the pharmaceuticals (specialist information), labeling and pack-of products. • With unique visual presentation of the correct application of the product overloaded cooling boxes for the transport through patients. "</seg>
<seg id="359">"this means that Abaramed a biological medicine is similar, which is already approved in the European Union (EU) and also has the same ingredient (also" "reference" ")."</seg>
<seg id="360">"it will be used in patients with normal blood values, in connection with a blood-fusion complications could occur if in front of the procedure is not possible to expect a blood-blood-loss of 900 to 1 800 ml."</seg>
<seg id="361">"the treatment with abseamed needs to be initiated under the supervision of a physician, the experience in the treatment of patients with diseases that is displayed for the medication."</seg>
<seg id="362">"in patients with kidney therapy and in patients who want to make a self-circulation, Abseamed is injected into a vene."</seg>
<seg id="363">Injections can also be carried out by the patient or its supervisor unless they receive appropriate guidance.</seg>
<seg id="364">"in patients with chronic kidney disease, or patients who receive a chemotherapy should always be recommended in recommended area (between 10 and 12 grams per declining) in adults or between 9,5 and 11 g / dl in children)."</seg>
<seg id="365">"the power values of all patients are to control before treatment, to ensure that no iron ore lies, and iron supplements should be administrated throughout the treatment."</seg>
<seg id="366">"in patients who receive a chemotherapy, or in patients with kidney problems may be causing a anemia due to a erythropoietinmangel or thereby, that the body is not sufficient to the physical Erythropoietin."</seg>
<seg id="367">Erythropoietin will also be used before operations to increase the number of red blood cells and thus reduce the consequences of a blood loss.</seg>
<seg id="368">It is produced by a cell to which a gene (DNA) brought them to the formation of epoxetine alfa.</seg>
<seg id="369">Abseamed was regarded as an injection in an Vene in the framework of a capitals with 479 patients who caused by kidney problems caused by kidney problems caused by the reference problems.</seg>
<seg id="370">All patients participating in this study was at least eight weeks in Eprex / Erypo in a vene before they were either by seamed or continued Eprex / Erypo.</seg>
<seg id="371">Main indicator for the effectiveness was the change of the hermoglobinary values between the beginning of the study and the trial period in the weeks 25 to 29.</seg>
<seg id="372">"in addition, the company laid out the results of a study in which the effects of under the skin is injected abseamed with the those of Eprex / Erypo on 114 cancer patients were received."</seg>
<seg id="373">"in the study with patients who caused by kidney-problems caused by kidney-problems, the hermoglobination of patients were forced on abseamed, in the same measure, as for those patients who have received Eprex / Erypo."</seg>
<seg id="374">"in comparison to the patients who continue to be Eprex / Erypo, an increase of 0,063 g / dl of the output value of 12,0 g / dl."</seg>
<seg id="375">The most common side effect of Abseamed is an increase in blood pressure, which occasionally lead to symptoms of an Encephalopathy (brain problems) such as sudden, stending migrations and confecity can lead. "</seg>
<seg id="376">Abseamed may not be used in patients that may possibly be hypersensitive (allergic) against epoxettin alfa or any of the other components.</seg>
<seg id="377">"Abaramed as injecting under the skin is not recommended for treating kidney problems, as further studies are required to ensure that this is caused by no allergic reactions."</seg>
<seg id="378">The Committee for Humanarzneix (CHMP) wrote that for abseamed according to the provisions of the European Union of evidence that the medicine was a comparable quality, security and efficiency profile such as Eprex / Erypo. "</seg>
<seg id="379">"the company, the Abseamed, is provided for medical practitioners in all Member States, including information on the safety of the drug."</seg>
<seg id="380">August 2007 announced the European Commission of the company Medice medicines Pütter GmbH & Co KG approached by Abseamed of the entire European Union.</seg>
<seg id="381">"treatment of anemia and reduction of the transfusionary arfs in adults with solid tumours, maligar lymph or multiplem myelom which creates a chemotherapy at the beginning of the general condition (e.g. cardiovascular status, preexisting anemia at the beginning of chemotherapy)."</seg>
<seg id="382">"the treatment should only be carried out in patients with a medium-severe anemia (hemogglobin [HB] 10 - 13 g / dl [6,2 - 8,1 mmol / l], no iron pump should demand (4 or more units blood for women; 5 or more units of blood in men)."</seg>
<seg id="383">"for the reduction of external blot, Abseamed can be applied in front of a large electoral orthopedic intervention in adults without iron, where a high risk of transfusion jointing is expected."</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml are not used to participate in an autonomous blood-wide program.</seg>
<seg id="385">"the hermoglobin targets is between 10 and 12 g / dl (6,2 - 7,5 mmol / l), except for pediatric patients, where the hermoglobinical concentration between 9,5 and 11 g / dl (5.9 - 6,8 mmol / l) should be."</seg>
<seg id="386">Anämiesymptom and placements can vary depending on the age, gender and a period of disease; therefore the assessment of the individual clinical trial and disease is required by the doctor. "</seg>
<seg id="387">A increase in the tick-globals for over 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"due to the variability between patients may occasionally be observed in patients with individual hemoglobal values, or under the hermoglobin- target concentration."</seg>
<seg id="389">"given this hemoglobinitability should be tried across a corresponding dosage management, the hemoglobin target concentration of 10 g / dl (6,2 mmol / l) up to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="390">If the hemoglobinaries is worth more than 2 g / dl (1.25 mmol / l) per month or if the permanent Hämoglobinds 12 g / dl (7,5 mmol / l) is the epetin-alfa dosage to reduce 25%. "</seg>
<seg id="391">Patients should be monitored engaging to ensure that epoxettin alfa is required in the lowest permitted dose which is required for controlling the anemia and the anmiesysymptom.</seg>
<seg id="392">The present clinical results suggest that patients with initial very low HB value (&lt; 6 g / dl or &lt; 3,75 mmol / l) possibly need higher vibrations. (HB &gt; 8 g / dl or &gt; 5 mmol / l). "</seg>
<seg id="393">The present clinical results indicate that patients with initial very low HB value (&lt; 6.8 g / dl or &lt; 4.25 mmol / l) possibly need higher vibrations. (HB &gt; 6,8 g / dl or &gt; 4,25 mmol / l). "</seg>
<seg id="394">"starting dose 50 i.e. / kg three times per week with intravenous application, if necessary with a dosage increase of 25 i.e. / kg (three times per week), until the desired targets is achieved (this should be done in steps of at least 4 weeks)."</seg>
<seg id="395">Anämiesymptom and - folds may vary depending on the age, gender and a period of disease; therefore the assessment of the individual clinical trial and disease is required by the doctor. "</seg>
<seg id="396">"given this hemoglobinitability should be tried across a corresponding dosage management, the hemoglobin target concentration of 10 g / dl (6,2 mmol / l) up to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="397">Patients should be monitored engaging in order to ensure that epoxettin alfa is required in the lowest permitted dose which is required for controlling the anti-impromptom is required.</seg>
<seg id="398">If after 4 treatment weeks of hemoglobinaries at least 1 g / dl (0.62 mmol / l) or the Retikulocytenants increased by ≥ 40.000 cells / µl to the starting sample should be kept the dose of 150 i.e. / kg three times per week or 450 i.e. / kg once a week.</seg>
<seg id="399">If the hemoglobinbinge &lt; 1 g / dl (&lt; 0,62 mmol / l) and the Retikulozytenants &lt; 40.000 cells / µl compared to the output value should be raised the dose on 300 i.e. / kg three times per week.</seg>
<seg id="400">If after further 4 treatment weeks with 300 i.e. / kg three times a week of hemoglobinaries about ≥ 1 g / dl (≥ 0,62 mmol / l) or the Retikulocytenants around ≥ 40.000 cells / µl should be retained a dose of 300 i.e. / kg three times a week.</seg>
<seg id="401">"is on the other hand side of the hermoglobinaries about &lt; 1 g / dl (&lt; 0,62 mmol / l) or the Retikulocytenants around &lt; 40,000 cells / µl compared to the output value, is an approach to the epetin-alfa therapy unlikely and the treatment should be cancelled."</seg>
<seg id="402">Patients with mild anemia (hematokrit 33 - 39%) in which the prefabrication of ≥ 4 blood-canned is required, Abseamed in a dose of 600 i.e. / kg body weight twice weekly for 3 weeks before the operating procedure. "</seg>
<seg id="403">"with the Iron substitution, as early as possible - for example a few weeks before the beginning of the autonomous blood-round programme - will be available before the start of the seamed therapy of great iron reserves."</seg>
<seg id="404">"6 The recommended dosage is 600 i.e. / kg epointetin alfa, which once per week (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="405">"in this, epoxettin alfa preoperatively 300 i.e. / kg at each 10 consecutive days prior to the day of the intervention, as well as 4 days immediately afterwards."</seg>
<seg id="406">"alternatively, injecting at the end of the dialysis can be given above the hose of a Fistelnadel, followed by 10 ml isotonic cooker to make the hose and a sufficient injection of pharmaceuticals in the circulation."</seg>
<seg id="407">Patients who are under treatment with any erythropoetic at a erythroblastopenie (Pure Red Cell Aplasia, PRCA) should not receive Abseamed or another Erythropoetin (see section 4.4 - Erythroblastopenie). "</seg>
<seg id="408">Heart attack or stroke within one month before the treatment, instabilie Angina pectoris, increased risk for deep venthrothrombosis (e.g. anamnestic known Thromboemboeck). "</seg>
<seg id="409">"in patients who are planned for a larger electoral orthopaedic procedure, the application of epoxettin alfa in the following pre-progression, peripheral disease disease, peripheral disease disease, peripheral disease disease, peripheral cardiovascular disease; in patients with recently entered heart attack or cerebrovascular event."</seg>
<seg id="410">Erythroblastopenie (PRCA) Very rarely was reported on the occurrence of a decent-sized PRCA to Monate- to years of treatment with submittent Erythropoetin.</seg>
<seg id="411">"in patients with sudden impact loss, defined as a reduction of hemoglobal values (1 - 2 g / dl per month) with increased need for transformations (icalities, torture or vitamin B12-lack, ageing or inflammations, blood loss and hasholysis)."</seg>
<seg id="412">"when the Retikulocyte, taking into account the anemia (i.e. the Retikulocytes" index "), the Thrombozycytes, or &lt; 20.000%), the Thrombozytense and Leukozytente are normal, and if no other cause of an active anthropoetin are determined and an examination of the bone marks to the diagnosis of a PRCA."</seg>
<seg id="413">Data on immunity at subcutaneous application of Abseamed in patients with a risk for antically induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">8 In patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hemoglobin target.</seg>
<seg id="415">In clinical studies have been observed an increased Mortality risk and risk for serious cardiovascular events (ESA) with a hemanthropoese target concentration of over 12 g / dl (7,5 mmol / l). "</seg>
<seg id="416">"controlled clinical trials have no significant benefits that is attributed to the forks of epoch, when the hermoglobinical concentration on the control of the anmiesysymptom and avoiding blood transverse required concentration."</seg>
<seg id="417">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="418">In patients with chronic kidney-inefficiency and clinically evidant coronarer hereditary pathological disease or dust-infertility should not be exceeded under Section 4.2 recommended upper limit of the prisoners of the hermoglobin targets.</seg>
<seg id="419">"after the time of these findings, the treatment of anemia is infertility with epoxettin alfa in adults with kidney disease which are still not dialysis, the progression of kidney-state inefficiency is not accelerated."</seg>
<seg id="420">For tumours of chemotherapy should be taken into account for assessing the therapeutic efficiency of epoxettin alfa one 2 - 3-week delay between epoxettin-alfa-Gabe and the erythropoetin response (patients that may have been transfigured).</seg>
<seg id="421">If the HB increase is bigger than 2 g / dl (1.25 mmol / l) per month or a HB-value of 13 g / dl (see section 4.2 treatment of patients with chemotherapic anemia - dosage adjustment between 10 g / dl and 12 g / dl.</seg>
<seg id="422">The decision for the application recombinant Erythropoetine should be based on a risk-risk assessment under participation of each patient which should also consider the specific clinical context.</seg>
<seg id="423">"in patients who are planned for a larger electoral orthopedic intervention should be, if possible, before the beginning of epoxettin-alfa therapy the cause of anemia is investigated and treated accordingly."</seg>
<seg id="424">"patients who undergo to a greater electoral orthopedic intervention, there should be an adequate Thromboseprophylaxis, since it is an increased risk for thrombosis and vasculars diseases, particularly with a underlying cardiovascular disease."</seg>
<seg id="425">"in addition, it cannot be ruled that in treatment with epoxettin alfa for patients with a starting point binds of &gt; 13 g / dl a increased risk of post-operations / vasculine events can exist."</seg>
<seg id="426">"in several controlled studies was not proven for epoch, that they can improve the overall survival with symptomatic anemia and the risk of tumor progression."</seg>
<seg id="427">"4 months in patients with metastatic breast cancer, which became an chemotherapy, if a hemoglobin target concentration of 12 - 14 g / dl (7,5 - 8,7 mmol / l)"</seg>
<seg id="428">Becomes epoxettin alfa together with Ciclosporin is to be controlled the blood mirror of Ciclosporin and the Ciclosporindosis of rising hematocrit.</seg>
<seg id="429">In-vitro-investigations on tumours are not giving any information on an exchange effect between epoxetine alfa and G-CSF or GM-CSF regarding hämatological differentiation or proliferation.</seg>
<seg id="430">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anterrails, anoplanes, anoplanes, anoplanes, anchor-throatry treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="431">The most common incidence during the treatment with epoxettin alfa is a dosisdependent increase in blood pressure or the deterioration of an existing hypertension.</seg>
<seg id="432">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="433">Independent of the erythropoetin treatment can occur during surgical patients with cardiovascular disease after repetitive blood cells to thrombosis and vascular complications.</seg>
<seg id="434">The gentleman eptic epetin alfa is glycosified and concerning the amino acids and of the amino acids identical to the endogenic human anthrothropoetin which was isolated from the Urine anchor patients.</seg>
<seg id="435">It could be shown with the help of cultures of human bone strips that epoxettin alfa specifically stimulated the erythropoese and the leukopoese isn't influenced.</seg>
<seg id="436">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="437">1895 patients with solid tumors (683 mammacarcinome, 260 Bronchial cardio, 174 gynecological tumors, 300 gastrointestinal tumors and 478 other) and 802 patients with hermoblers. "</seg>
<seg id="438">Survival and Tumorprogression were examined in five great controlled studies with a total of 2833 patients; four of these studies were doubling placeable studies and</seg>
<seg id="439">In the open study there was no difference in overall survival between the patients with recombinant Erythropoetin treated patients and the inspection of the patient.</seg>
<seg id="440">"in these studies prove to the combined human human anthrothropoetin treated patients with anemia due to various common malignome consistent, statistically significant, statistically significant, statistically significant damage than with the controls."</seg>
<seg id="441">The overall survive in the studies could not be explained by differences in the incidence of Thrombosis and related complications at with recombinant humanen Erythropoetin examined patients and inspections.</seg>
<seg id="442">There is an increased risk for thromic bolabic events with tumor patient which can be treated with recombinable humanithropoetin and a negative effect on the overall survive cannot be excluded.</seg>
<seg id="443">"it is not clarified how far these results are handled on the application of recombinant humanistic erythropoetin in tumors, which can be transferred with chemotherapy, since a few patients with these characteristics were included in the verifiable data."</seg>
<seg id="444">Epoch according to repetitive intravenous application showed a half-time period of about 4 hours in healthy propositions and a somewhat prolonged half-time period of about 5 hours in patients with kidney-heart.</seg>
<seg id="445">"after subcutaneous injections, the Serum mirror of epoxettin alfa are much lower than the Serum mirror which can be achieved according to intravengeser injection."</seg>
<seg id="446">"there is no Kumulation: the Serum mirror remain equal, regardless of whether they are determined 24 hours following the first Gabe or 24 hours after the last gift."</seg>
<seg id="447">(bone markfibrose is a known complication of chronic kidney-efficiency in humans and could be attributed to a secondary hyperparathydism or unknown factors.</seg>
<seg id="448">"in a study on prisoners patients, which were treated three years with epoxettin alfa, the incidence of bone markers were treated with Dialysepatients who were not treated with epoxettin alfa, not increased)."</seg>
<seg id="449">"14 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to verminderened body weight, to a delay of the Ossification and an increase in fine mortality."</seg>
<seg id="450">These reports are based on vitro findings with cells from human tumor tissues which are used for the clinical situation but of unsafe signature.</seg>
<seg id="451">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="452">"the syringes are provided with graduation and the filling volume is displayed by a recorded label, so that if necessary, the dimensions of participation is possible."</seg>
<seg id="453">"the treatment with Abseamed must be initiated under the supervision of doctors, the experience in the treatment of patients with the above mentioned indications."</seg>
<seg id="454">"21 The recommended dosage is 600 i.e. / kg epointetin alfa, which once per week (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="455">23 In patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="456">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="457">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anoplanes, anoplanes, anoplanes, anatomy and patients suffering from epilthropoetin treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="458">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="459">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="460">"29 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to verminderened body weight, to a delay of the Ossification and an increase in fine mortality."</seg>
<seg id="461">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="462">"36 The recommended dosage is 600 i.e. / kg epointetin alfa, which once per week (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="463">38 When patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hemoglobin target.</seg>
<seg id="464">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="465">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anoplanes, anoplanes, anoplanes, anatomy and patients suffering from epilthropoetin treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="466">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="467">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="468">"44 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight, to a delay of the Ossification and an increase in fine mortality."</seg>
<seg id="469">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="470">"51 The recommended dosage is 600 i.e. / kg epointetin alfa, which once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="471">53 When patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="472">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="473">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anoplanes, anoplanes, anoplanes, anterior looses, retinal thrombosis, anchor-treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="474">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="475">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="476">"59 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epoxettin alfa to vermindergifted body weight, to a delay of the Ossification and an increase in fine mortality."</seg>
<seg id="477">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="478">"66 The recommended dosage is 600 i.e. / kg epointetin alfa, which once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="479">68 With patients with chronic kidney-infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="480">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="481">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anterrails, anoplanes, anoplanes, anoplanes, anatomy and patients suffering from epointetin treatment, reported as well as patients under epoxettin alfa, reported."</seg>
<seg id="482">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="483">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="484">74 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight to a delay of the Ossification and an increase in fine mortality.</seg>
<seg id="485">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="486">"81 The recommended dosage is 600 i.e. / kg epointetin alfa, which once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="487">83 At patients with chronic kidney-infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="488">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="489">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anarchal Thrombosis, anterial Thrombosis, anoplanes, anatomy and 86 blood cro, was reported in patients under ithropoetic treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="490">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="491">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="492">89 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight to a delay of the Ossification and an increase in fine mortality.</seg>
<seg id="493">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="494">"96 The recommended dosage is 600 i.e. / kg epointess alfa, which should once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="495">98 When patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hemoglobin target.</seg>
<seg id="496">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="497">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anoplanes, anatomy and 101 blood cro, was reported in patients under ithropoetic treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="498">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="499">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="500">104 In animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epoxettin alfa to vermindergifted body weight to a delay of the Ossification and an increase in fine mortality.</seg>
<seg id="501">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="502">"111 The recommended dosage is 600 i.e. / kg epointetin alfa, which once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="503">113 In patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="504">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="505">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anterrestrial Thrombosis, anterial Thrombosis, anterobrobes, anoplanes, anatomy, anatomy and patients suffering from epilthropoetin treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="506">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="507">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="508">119 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight to a delay of the Ossification and an increase in fine mortality.</seg>
<seg id="509">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="510">"126 The recommended dosage is 600 i.e. / kg epointetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="511">128 For patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="512">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="513">"over thrombal, vasculary events such as myocardiale Ischia, myokardrobes, anarchal Thrombosis, anterial Thrombosis, anterrails, anoplanes, anatomy and 131 blood cro, was reported as patients under eparthropoetin treatment, as well as patients under epoxettin alfa, reported."</seg>
<seg id="514">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="515">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="516">134 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight, to a delay of the Ossification and an increase in fine mortality. "</seg>
<seg id="517">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="518">"141 The recommended dosage is 600 i.e. / kg epointetin alfa, which once weekly over three weeks (day 21, 14 and 7) before the operational procedure and on the day of intervention (day 0)."</seg>
<seg id="519">143 In patients with chronic kidney infertility should not be exceeded under Section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="520">The hemmoglobinbinge should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase of hypertension.</seg>
<seg id="521">"over thrombal, vasculary events such as myocardiale Ischia, myocarifier, anterrestrial Thrombosis, anterian Thrombosis, anatomy and 146 blood circulation, anterobrobes, anatomy and patients suffering from epointetin treatment, reported as well as patients under epoxettin alfa, reported."</seg>
<seg id="522">An increased incidence of thrombovasculary events (see section 4.4 and Section 4.8 - General) was observed in patients under treatment with erythropoetine.</seg>
<seg id="523">"389 patients with Hemmoblaster (221) Myelome, 144 Non-Hodgkin- Lymphome and 24 more hemian tumors, 23 bronchial cardio, 21 gastrointestinal carcinoma and 30 more)."</seg>
<seg id="524">"149 In case of animal experimental studies with approximate the 20al of the application for the use of recommended Wochendosis led epetin alfa to vermindergifted body weight, to a delay of the Ossification and an increase in fine mortality."</seg>
<seg id="525">In the out of out-out application the patient Abseamed for a period of maximum 3 days outside of the cooler and not available over 25 ° C.</seg>
<seg id="526">"the holders of the approval for the institute started before the market entry, and in accordance with the competent authorities of the member states to provide medical professionals in Dialysis centres and retail outlets • Summary of the characteristics of the pharmaceuticals (specialist information), labeling and packing technology. • With unique educational representation of the correct application of the product supplying cooling boxes for the transport through patients."</seg>
<seg id="527">"the holders of approving the authorization has to ensure that in version 3.0 is described in version 3.0 and implemented in module 1.8.1st of the filing contract, and functional, before the medicine is applied in traffic and as long as the medicines used in transport."</seg>
<seg id="528">"the holders of the approval for the property is committed to conduct research and additional measures to the Pharmakovigilance, as agreed in version 5 in the module 1.8.2. of the authorisation of the Risk Management Plan (RMP), as well as in accordance with the CHMP actualization of the Risk Management Plan."</seg>
<seg id="529">"according to the" CHMP guideline on Risk Management Systems for Medicinal products for human use "at the same time, with the next updated report on the immacefulness of pharmaceuticals (perioodic Safety Update Report, PSUR) are provided."</seg>
<seg id="530">"in addition, an updated report should be submitted: • with receiving new information, the influence on the current security specifications (Safety Specification), the Pharmakovigilance plan or the measures for the risk reduction) milestones • by request by the EMEA"</seg>
<seg id="531">"• occurred within a month before your treatment a heart attack or a stroke force, • if you suffer from instabiler Angina Pectoris (first premiere or reinforced breast cancer) - if you have occurred at the risk of a blood swelling in the veins (deep Venenthrombosis) - if you have occurred before you earlier an annual blood flow."</seg>
<seg id="532">"you suffer the serious blood circulation of the heart (coronary heart disease), the arteries of legs or arms (peripheral disease of the carotides) or the brain (canebrovascular disease) you have recently had a heart attack or stroke."</seg>
<seg id="533">"during the treatment with Abseamed it can occur within the standardized rise to a slight dosisdependent increase in the blood circulation, which is back to further treatment again."</seg>
<seg id="534">Your doctor will perform regular bleeding during the first 8 weeks of treatment regularly.</seg>
<seg id="535">"iron gel, resolution of the red blood cells (hematolysis), blood loss, vitamin B12- or torture, should be taken into account and before the start of therapy with abseamed."</seg>
<seg id="536">Very rarely was reported on the occurrence of an antikerated Erythroblastopenie after Monate- to years of treatment with sublifestanem (under the skin comments) Erythropoetin.</seg>
<seg id="537">"if you suffer from Erythroblastopenie, he will set up your therapy with Abseamed and set how your anemia is best treated."</seg>
<seg id="538">"therefore Abseamed to be given by injecting in a vene (intravenous), if you are treated because of an anemia due to a kidney disease."</seg>
<seg id="539">"a high Hämoglobinds can be the risk of problems with the heart or blood vessels, and the sterberisiko could be increased."</seg>
<seg id="540">"in increased or increase potassium, your doctor can draw an interruption of treatment with seseamed up until the potassium values are back in the standardise."</seg>
<seg id="541">"if you suffer from chronic kidney-watering and clinically obvious coronary diseases, your doctor will make sure your doctor will make sure your hemoglobinum mirror a given value is not exceeded."</seg>
<seg id="542">"after the time of these findings, by the treatment of blood cells with seseamed with adults with chronic kidney drilled, which are not dialysis, the progression of kidney-state inefficiency is not accelerated."</seg>
<seg id="543">A 2 - 3-week delay between epoxettin-alfa forgive and the unwanted effects should be taken into consideration for the assessment of the effectiveness of abseamed.</seg>
<seg id="544">200 Your doctor will determine your values of the red blood colored (hemoglobin) and adjust your Abaramed dosage accordingly to keep the risk of a bleeding part) as possible as possible.</seg>
<seg id="545">"this risk should have taken care of the treatment with epoxettin alfa abled advantages, especially if you have a higher risk for thrombosis vasculine events, e.g. if you have an increased risk for thromboteric vasculine events (e.g. a deep venenthrombosis or pulley)."</seg>
<seg id="546">"if you are cancer, think that seamed like a growth factor for blood cells, and under certain circumstances the tumor may affect the tumor."</seg>
<seg id="547">"if you have a greater orthopedic surgery, should be investigated before treatment with Abseamed the cause of your anemia and treated accordingly."</seg>
<seg id="548">"if your values of the red blood-coloured (hemoglobin) are too high, you should not receive Abseamed, because an increased risk for bleaching blood after the surgery."</seg>
<seg id="549">"please inform your doctor or pharmacist if you are taking other medicines or have recently taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="550">"if you have Ciclosporin (means to suppression of the immune system) during your therapy, your doctor will arrange certain blood checks to measure the blood mirror of Ciclosporin."</seg>
<seg id="551">"laboratories have no interaction among epoxettin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means to build the immune system, for example at cancer (chemotherapy or HIV)."</seg>
<seg id="552">"depending on how your blood levels (anemia) on treatment, the dose may be adjusted approximately every four weeks to your condition under control."</seg>
<seg id="553">Your doctor will arrange regular blutttests to verify the treatment success and ensure that the drug works properly and your hemoglobinds will not exceed a specific value.</seg>
<seg id="554">"once you are well adjusted, you will receive regular doses of Abaramed between 25 and 50 i.e. / kg twice a week, divided into two equally big injections."</seg>
<seg id="555">Your doctor will arrange regular blutttests to review and ensure that your hemoglobinds will not exceed a specific value.</seg>
<seg id="556">"depending on how the anemia talks to the treatment, the dose may be adjusted approximately every four weeks to the state under control."</seg>
<seg id="557">"to ensure this and ensure that the hemoglobinds will not exceed a specific value, the dental doctor will perform regular bleeding."</seg>
<seg id="558">"if it is necessary to shorten the treatment time before surgery, a dose of 300 i.e. / kg to 10 consecutive days before surgery, on the day of the Rhinoplasty and another 4 days after the surgery."</seg>
<seg id="559">"however, if your doctor stops this for appropriate, also learn how you spolamed yourself under the skin."</seg>
<seg id="560">"heart, heart infestation, soul-blood circulation, stroke disorders of the brain, deep missive Thrombosis, pneumatic tenants, skirmisery, skirmisery, skirmisery in artificial kidneys were reported in patients under Erythropoetin-treatment."</seg>
<seg id="561">Eyelid and lips (Quincke-Ödem) and shocking allergic reactions with symptoms such as tingling, redness, itch and accelerated pulse were reported in rare cases. "</seg>
<seg id="562">Erythroblastopenie means that no longer have enough red blood cells in the bone mark (see section "Special caution when applying Abseamed is required).</seg>
<seg id="563">After repetitive blood flow it may occur - regardless of the treatment with seseamed - to a blood-frogs (thrombal vasculary events) come.</seg>
<seg id="564">The treatment with abseamed can deal with an increased risk of blood circulation after the surgery (post-surgical radical events) if your starting point is too high</seg>
<seg id="565">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or if you have side effects that are not specified in this usage information.</seg>
<seg id="566">"when a syringe from the refrigerator was taken and the room temperature has reached (up to 25 ° C), they must be used either within 3 days or be subject to it."</seg>
<seg id="567">Aclasta is used to treat the following diseases: • osteoporosis (an ailment that makes the bones who makes the bones as well as in men.</seg>
<seg id="568">"it will be applied in patients with a high facturally (bone breaks), including patients who recently suffered a little traumatical loops as when hinfall suffered; • Morbus Paget of the bone, a sickness that changes the normal course of bone growth."</seg>
<seg id="569">"in addition, patients with Morbus Paget should take at least 500 mg Kalzium twice daily for at least 10 days after treatment; patients with hip should be a large dose of vitamin D (50 000 to 125 000 IE) oral or injecting into a muscle."</seg>
<seg id="570">"the administration of paracetamol or obuckets (means of inflammation) just after the use of Aclasta can reduce the symptoms resulting in the three days following the infusion, such as fever, muscle aches, griecaches and headaches."</seg>
<seg id="571">"for the treatment of the Morbus Paget, Aclasta can only be prescribed by doctors, experience in treating this disease."</seg>
<seg id="572">"as the ingredient in Aclasta is the same as in Zometa, a part of the data material for Zometa was attracted by Aclasta."</seg>
<seg id="573">"during the first study, almost 8 000 older women were involved with osteoporosis, and it was investigated the number of spinal and hips fractures over a period of three years."</seg>
<seg id="574">"the second study was generated 2 127 men and women with osteoporosis over 50 years, which recently had a bounds of fracture. it was investigated the number of fractures over a period of up to five years."</seg>
<seg id="575">For Morbus Paget Aclasta was tested in two studies in a total of 357 patients and six months long with risedronat (another Bisphosphonate).</seg>
<seg id="576">Main indexator for the effectiveness was whether the salary of alkalabase in Serum (an enzyme that builds the bone subsection) in the blood again normalized or at least 75% compared to the output value.</seg>
<seg id="577">"in the study with older women, the risk of splifractures among patients under Aclasta (without other osteoporosemedia) over a period of three years compared to the patients on placebo by 70%."</seg>
<seg id="578">"compared to all the patients under Aclasta (with or without other osteoporosemedia) with those under placebo, the risk of hatefractures was reduced by 41%."</seg>
<seg id="579">"in the study with men and women with hips, 9% of the patients under Aclasta an Fraktur (92 of 1 065) compared to 13% of the patients under placebo (139 of 1 062)."</seg>
<seg id="580">Most side effects of Aclasta within the first three days after infusion and are less common in repetitive infusions.</seg>
<seg id="581">Aclasta must not be used in patients who may possibly be hypersensitive (allergic) against Zoledronics or other bisphosphonate or any other components.</seg>
<seg id="582">As with all bisphosphonors are subject to patients at Aclasta to the risk of kidney's risk and osteonekrose (die of bone tissue) in the jaws.</seg>
<seg id="583">"the manufacturer of Aclasta provides the clarification of doctors prepared to write the Aclasta to treat osteoporosis, as well as similar material for patients in which the side-side effects are explained and pointed out when they consult with the doctor."</seg>
<seg id="584">"April 2005, the European Commission held the company Novartis Europhy Limited with a permit for the use of Aclasta in the entire European Union."</seg>
<seg id="585">Conditions ODER restrictions on THE secure AND effective use of pharmaceuticals and drugs by DIE Member ZU implement SIND • Terms and Conditions ODER restrictions on THE secure AND effective application of pharmaceuticals, DIE by DIE Member ZU implement SIND "</seg>
<seg id="586">Treatment of osteoporosis in postmenopausal women and in men with an increased risk for fractures, including patients with a recent littly low-traumatic tenswear. "</seg>
<seg id="587">The patient care package is to be provided and the following core message include: • The package of contraindication of calcium and vitamin D, adequate physical activity, the non-smoothing and a healthy diet • Important signs and symptoms for serious illness • Wann on medical or nourishing help. "</seg>
<seg id="588">Treatment of osteoporosis • at postmenopausal women • in men with an increased risk for fractures, including patients with a recent littly low-traumatic drums. "</seg>
<seg id="589">For the treatment of postmenopausal osteoporosis and osteoporosis in men will be a intravenous infusion of 5 mg Aclasta once a year.</seg>
<seg id="590">"in patients with a low-traumatic hips, the agreement is recommended by the infusion of Aclasta two or more weeks after the operating supply of the hips (see section 5.1)."</seg>
<seg id="591">"for the treatment of the Morbus Paget, Aclasta should only be prescribed by physicians, the experience in the treatment of the Morbus Paget."</seg>
<seg id="592">After a treatment of the Morbus Paget with Aclasta has been observed a long reward period in patients (see section 5.1).</seg>
<seg id="593">"in addition, it is very advisable to ensure patient with Morbus Paget, in accordance with Morbus Paget, accordingly twice daily at least 500 mg thousands of calcium, for at least 10 days after the Gabe of Aclasta (see section 4.4)."</seg>
<seg id="594">In patients with a recent littly low-traumatic strokes will be a initiate osis from 50.000 to 125.000 i.e. orally or intra-muscular vitamin D before the first Aclasta Infusion recommended.</seg>
<seg id="595">"the frequency of symptoms which occur within the first three days after the administration of Aclasta, can be reduced by Gabe of Paracetamol or Ibuprofen shortly after the use of Aclasta."</seg>
<seg id="596">Patients with kidney failure (see section 4.4) In patients with a creatinin Clearance &lt; 35 ml / min Aclasta does not recommended as a limited clinical experience for these patients.</seg>
<seg id="597">Older patients (≥ 65 years) A dosage adjustment is not necessary since the bioavailability, distribution and elimination at older patients similar to the younger. "</seg>
<seg id="598">Children and young people Aclasta is not recommended for use in children and young people under the age of 18.</seg>
<seg id="599">Aclasta is not recommended for patients with severe kidney disease (Kreatinin-Clearance &lt; 35 ml / min) not recommended as for these patient-population only limited clinical experiences.</seg>
<seg id="600">An existing hypokalmal is before the beginning of the therapy with Aclasta by sufficient intake of calcium and vitamin D (see Section 4.3).</seg>
<seg id="601">"because of the quick entry of the effects of Zoledronics on the bone structure can develop a temporary, sometimes, whose maximum usually occur within the first 10 days after the infusion of Aclasta appearance (see section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable to ensure patient with Morbus Paget, in accordance with Morbus Paget, accordingly twice daily at least 500 mg old calcium, for at least 10 days after the Gabe of Aclasta (see section 4.2)."</seg>
<seg id="603">Cancer disease, chemotherapy, treatment with cortikostoids, poor oral hygiene) should be used before an application of Bisphosphonors a dental treatment with appropriate prevalves with appropriate prevalves. "</seg>
<seg id="604">"for patients who need the dental grips, do not require any data to whether the interruption of treatment with bisphosphonors will reduce the risk for osteonecroes in the orthodontic area."</seg>
<seg id="605">The clinical evaluation by the patient's doctor should be the basis for the treatment plan of each patient and are based on an individual benefit-risk assessment.</seg>
<seg id="606">The frequency of symptoms which occur within the first three days after administration of Aclasta can be reduced by Gabe of Paracetamol or Ibuprofen shortly after the use of Aclasta (see section 4.2).</seg>
<seg id="607">"the incidence of as serious suspenalties was received in patients who received Aclasta (1.3%) (51 of 3,862) compared to patients, the placebo (0,6%) (22 of 3,852)."</seg>
<seg id="608">In the osteoporosis studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]) was the overall prevalent between Aclasta (2.8%) and placebo (2.8%). "</seg>
<seg id="609">"very frequent (≥ 1 / 10), frequent (≥ 1 / 100, &lt; 1 / 10), occasional (≥ 1 / 1,000, &lt; 1 / 100), rare (≥ 1 / 10.000, &lt; 1 / 1.000), unwanted drugs are listed in chart 1."</seg>
<seg id="610">Kidnfunctioning Zoledronic acid was brought together as acceptance of the kidney function (i.e. an increase in Serum-Creatinins) and in rare cases as acclaimed kidney failure.</seg>
<seg id="611">The change in the Kreatinin Clearance (each year before administration) and the occurrence of kidney failure as well as a limited kidney function in a clinical trial at osteoporosis over three years comparable to the use of the Aclasta- and the placebo group.</seg>
<seg id="612">A temporary increase of the Serum Creatinins within 10 days of Gabe was observed at 1.8% of the patients treated with Aclasta treated patients compared to 0.3% of patients treated with placebo patients.</seg>
<seg id="613">"based on the evaluation of the laboratories, the temporary asymptomatic calcium values occurred within 2.3% of using Aclasta in a large clinical study treated patients compared to 21% of using Aclasta in the Morbus-Paget-trials."</seg>
<seg id="614">All patients received complementary amounts of vitamin D and calcium throughout the study for postmenopausal osteoporosis in the study on prevention of clinical fractures and in the Morbus-Paget-studies (see section 4.2).</seg>
<seg id="615">"in the study for avoiding clinical fractures, the vitamin D mirror were measured not routine work, but the majority of patients received an initiation of vitamin D before administration of Aclasta (see section 4.2)."</seg>
<seg id="616">"local reactions After the administration of Zoledronics in a large clinical study was reported on local reactions to the Infusionsite, such as redness, swelling and / or pain, reports (0.7%)."</seg>
<seg id="617">"osteonekrosen in the pine area occasionally was reported especially with cancer patients, over Osteonekrosen (primorr in the jaw) reported the with Bisphosphonors, including Zoledronic acid, treated."</seg>
<seg id="618">Many of these patients had signs for local infection including Osteomyelitis and the majority of reports refers to cancer patients according to dental extraction or other dental offices.</seg>
<seg id="619">7 study with 7.736 patients joined Osteonekrose in the orthodontics at one with Aclasta and on one with placebo patients treated.</seg>
<seg id="620">"in case of overdose, which leads to a clinically relevant hypokalmal energy, can be reached by Gabe of oregum and / or a intravenous infusion of Kalziumgluconat a compensation."</seg>
<seg id="621">Clinical effectiveness in the treatment of the postmenopausal osteoporosis (PFT) The effectiveness and security of Aclasta 5 mg once a year for 3 consecutive years was presented at postmenopausal women (BMD) with either a bone-value (BMD) with either a bone-tightening or a BMD-T-Score for the cabinets of ≤ 6 -2.5 with or without signs of an existing spool.</seg>
<seg id="622">Effects on morphometric inverts of a period of three years as well as after one year the frequency of one or more new spaculactures (see chart 2).</seg>
<seg id="623">Aclasta-treated patients from 75 years and older was compared to 60% reduced risk for vertine-fractures compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on muslifractures Aclasta pointed out the same effect over three years in a around 41% (95% CI, 17% to 58%) reduced risk for Hüftactures. "</seg>
<seg id="625">"effect on the bone density (BMD) Aclasta increased the bone density at the Lendenwiraric acid, hip and at distal radius compared to the placebo treatment significantly to all times (6, 12, 24 and 36 months)."</seg>
<seg id="626">"9 increase of bone density of the lumdenwirarine around 6.7%, the entire hip around 6.7%, the cry of 5,1% and the distal radius around 3.2%."</seg>
<seg id="627">Bone histology With 152 postmenopausal osteoporosis patients who were treated with Aclasta (N = 82) or placebo (N = 70) were taken from the pelvic from the pelvic.</seg>
<seg id="628">A microcomputertomographie- (µCT) analysis showed a increase in placebo patients compared to placebo a boost of trabecular bone architecture and the receipt of trabecular bone architecture.</seg>
<seg id="629">"bone markers The bones specific phosphate (BSAP), the N-terminale Propeptid of the type-I- collagen (P1NP) in Serum and the beta-C-Telopeptid (b-CTX) in Serum and the beta-C-Telopeptid (b-CTX) in Serum were determined in sub-groups of 517 up to 1,246 patients in periods of study."</seg>
<seg id="630">The treatment with an annual 5 mg dose Aclasta reduced BSAP after 12 months is significantly increased by 30% compared to the starting output and was held at 28% below the starting output up to 36 months.</seg>
<seg id="631">P1NP has been significantly increased by 61% below the starting sample after 12 months and was held at 52% below the output of 36 months.</seg>
<seg id="632">B-CTX was significantly increased by 61% below the initial value for 12 months and was held at 55% below the output of 36 months.</seg>
<seg id="633">"the vitamin D mirrors were measured not routine, but the majority of patients received a starting dose of vitamin D (50,000 up to 125.000 i.e. oral or intra-bear) 2 weeks before infusion."</seg>
<seg id="634">"overall mortality lay at 10% (101 patients) in which with Aclasta, compared with 13% (141 patients) in the placebo group."</seg>
<seg id="635">Effect on the bone mineral density (BMD) In the HORIZON-RFT-study increased the Aclasta treatment compared to the placebo treatment the BMD at the total timents and cry-up to all times score.</seg>
<seg id="636">The Aclasta therapy led over 24 months compared to the placebo treatment to an increase in the BMD by 5.3% at the total amount and around 4.3% at the Schenkelder.</seg>
<seg id="637">Clinical efficacy in men in the HORIZON-RFT-Study were 508-randomized and at 185 patients the BMD was judged after 24 months.</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the prevalence of clinical fractures was 7.5% at Aclasta-treated men compared to 8.4% at placebo.</seg>
<seg id="639">"in another study in men (study CZOL446M2308) was the once annual administration of Aclasta compared to once weekly gift of Alendronat, related to the progressive change of the Lendenwirbel-BMD after 24 months compared to the output."</seg>
<seg id="640">The clinical effectiveness of the treatment at Morbus Paget des Knockasta has been investigated with radiologically and patients aged over 30 years with radiologically confirmed (mean Serum-mirror of alkalic phosphate in accordance with the easiest up to an average high value in the study).</seg>
<seg id="641">11 The efficacy of an infusion of 5 mg Zoledronics compared to taking 30 mg credronat once daily during 2 months was proven in two six-month studies.</seg>
<seg id="642">The combined results was observed after 6 months a similar withdrawal of pain and pain-controlled compared to the output value for Aclasta and risedronat.</seg>
<seg id="643">Patients who have been addressed at the end of the sixth capitals as respondent (in therapy) were included in a follow-up phase.</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with risedronates treated patients, which could be treated at the follow-up study, the therapeutic approach could be treated with Aclasta, compared to 71 people with risedronat treatment, compared to the average duration of the follow-up phase of 18 months after the application."</seg>
<seg id="645">"unique and multiple 5 and 15 minutes continuous infusions of 2, 4, 8 and 16 mg Zoledronics at 64 patients, the following pharmacoinetic data that proved to be dosed."</seg>
<seg id="646">"after that, the Plasma frame took quickly down to &lt; 10% of the maximum value to 4 h and &lt; 1% after 24 h, followed by a long lasting phase, no more than 0.1% of the maximum value."</seg>
<seg id="647">"swift-phase disappearance from the big cycle with semi-cycle times t ½ α 0,24 and t ½ -1,87 hours, followed by a long elimination phase with a terminology of Eliminationshalbswerty. ½ g 146 hours."</seg>
<seg id="648">The early distributor phases (α-ß) represent the rapid resorption into the bones and the excretion over the kidneys.</seg>
<seg id="649">"in the first 24 h, 39 ± 16% of the remaining dose in urine, while the rest is mainly tied to bone tissue."</seg>
<seg id="650">"the overall body-Clearance is independent of the dose 5,04 ± 2,5 l / h and remains uninfluenced by gender, age, race or body weight."</seg>
<seg id="651">An extension of the infusion period of 5 to 15 minutes led to the acceptance of the Zoledroneous concentration by 30% at the end of infusion, but had no effect on the surface under the curve (Plasmaconconcentration against time). "</seg>
<seg id="652">"a decreased Clearance by cytochrom-P450-endure systems metallized substances is unlikely, because Zoledronics in humans not metabolized and because they are a watchman or even no direct and / or irreversible, commodity-dependent Inhibitor of the P450-"</seg>
<seg id="653">"special patient groups (see section 4.2) The renal Clearance of the Zoledronics correlised with the Creatinin Clearance, namely 75 ± 33% of the Creatinin Clearance, and was at 64% of the Middle 84 ± 29 ml / min (range 22 to 143 ml / min)."</seg>
<seg id="654">It results that a light (Clcr = 50- 80 ml / min) and an excessive kidney-disruption up to 35 ml / min no dosage adjustment of the Zoledronic acid demands.</seg>
<seg id="655">"because for heavy kidney-disruption (Creatinin- Clearance &lt; 30 ml / min) only limited data, are not possible for these populations."</seg>
<seg id="656">Akute toxicity The highest non-effective intravenous single dose was with mice 10 mg / kg body weight and with rats 0.6 mg / kg body weight.</seg>
<seg id="657">"in trials in dogs were dosing of 1,0 mg / kg (based on AUC the 6fold the recommended human therapeutic extrusion), administered over a period of 15 minutes, good and without a renal payment."</seg>
<seg id="658">"sub-chronic and chronic toxicity In studies with intravenilic application has been determined by doses of Zoledronics with rats, a total of 6 mg / kg as 15-minute infusion in 3-minute infusion in 3-minute infusion in 3-minute infusion in intervals of 2- 3 weeks (a cumulative dose which corresponds to the 7amp of human therapeutic extrusion, related to the AUC, corresponds to the AUC, equivalent to)."</seg>
<seg id="659">"in long-term studies with repetitive expositions, which guarantees the maximum of the intended Human exposition, the maximum of the intended Human exposure occurred, including the Gastrointestinal cord and the liver, as well as on the intravenous injections."</seg>
<seg id="660">The most common unfold in studies with repetitive Spongiosa in the Metaphyse of the long bones in animals in the growth phase with virtually all doses that reflects the pharmacological effect of the substance.</seg>
<seg id="661">An teratogenous we observed a teratogenity at doses from 0.2 mg / kg as outer and internal (visceral) abnormalities and such of the skeleton.</seg>
<seg id="662">On rabbits have no teratogenous effects or embryoo-fetal effects observed although the maternal toxicity at 0.1 mg / kg as a result erlower Serum-Kalzium mirror was defined.</seg>
<seg id="663">"if the medicine is not used immediately, the user is responsible for the stock time after preparation and conditions before the application; normally 24 h at 2 ° C to 8 ° C will not be exceeded."</seg>
<seg id="664">Aclasta is distributed as a pack with a bottle as packet unit or as a bundle consisting of 5 packages each with a bottle.</seg>
<seg id="665">Treatment of osteoporosis in postmenopausal women and in men with an increased risk for fractures, including patients with a recent littly low-traumatic tenswear. "</seg>
<seg id="666">The patient care package is to be provided and the following core message include: • The package of contraindication of calcium and vitamin D; appropriate physical activity, the non-smoothing and a healthy diet 17 • Important signs and symptoms for serious or nourishing help.</seg>
<seg id="667">"July 2007, complements on 29 September 2006, in the module 1.8.1 of the authorisation of the Pharmakovigilance system in force and works before and while the product will be marketed."</seg>
<seg id="668">"Risko-Management-Plan The owner of the approval for the event is obliged to perform the studies and the additional activities to the Pharmakovigration Plan, which are presented in the pharmaovigilance Plan (found) in Module 1.8.2 of the authorisation item and the following by the CHMP approved versions of the RMP KIT."</seg>
<seg id="669">"according to CHMP directive on risk management systems for human resources, the previously worked, should be submitted together with the next" Periodic Safety Update Report (PSUR). "</seg>
<seg id="670">"a supervisite RMP should be submitted • If new information will be announced, which could affect the present statements about safety, the Pharmakovigilance plan or activities to minimize the risk. • In the request of the EMEA. • At the requirement of EMEA."</seg>
<seg id="671">"Zoledronics is a representative of a sub-class class that is called Bisphosphonors, and is used for treatment of osteoporosis in postmenopausal women, the osteoporosis in men and by the Morbus Paget of the garlic."</seg>
<seg id="672">"blood mirror of sex hormones, especially estrogen, which are formed from androgens, play a role in rather gradual loss of bone mass who is observed in men."</seg>
<seg id="673">"at the Morbus Paget, the bone structure is too fast, and new bone material is structured, what the bone material is weaker than normal."</seg>
<seg id="674">Aclasta works by normalizes the bone structure that produces a normal bone-formation and thus gives the bone again strength.</seg>
<seg id="675">"if you are searching for a dental treatment or to educate a dental surgery, inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"when using Aclasta with other medicines please inform your doctor, pharmacist or the nursing staff, if you have to use other medicines or have recently been taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="677">"for your doctor, it is particularly important to know if you have medicine, from which it is known to compensate for them."</seg>
<seg id="678">"when using Aclasta, together with food and drinks, you can take in accordance with the instructions of your physician's sufficient liquid before and after treatment with Aclasta."</seg>
<seg id="679">Osteoporosis The usual dosage is 5 mg once per year that is administered by your doctor or nursing staff as infusion in a vene.</seg>
<seg id="680">"if you have recently broken the hips, is recommended that the administration of Aclasta two or more weeks after the operative care of the ridge."</seg>
<seg id="681">Morbus Paget The usual dosage is 5 mg that is administered by your doctor or nursing staff as infusion in a vene.</seg>
<seg id="682">"since Aclasta acts for a long time, you may need a further dose only after one year or longer."</seg>
<seg id="683">It is important to follow these instructions exactly to follow the calcium mirror in your blood during the time after infusion is not too low.</seg>
<seg id="684">"at Morbus Paget, Aclasta can take longer than a year and your doctor will inform you if you need a renewed treatment."</seg>
<seg id="685">"if the administration of Aclasta, you will immediately connect to your doctor or hospital in order to arrange a new date."</seg>
<seg id="686">Before termination of therapy with Aclasta if you are considering the end of the treatment with Aclasta please take your next doctor will be true and discuss this with your doctor.</seg>
<seg id="687">"side-side effects in connection with the first infusion often occur in (with more than 30% of patients), according to the subsequent infusions but less frequent."</seg>
<seg id="688">"fever and shaking, muscle, or yellowing pain and headaches, occur within the first three days after the administration of Aclasta."</seg>
<seg id="689">"currently it is unclear whether Aclasta causes this irregular heartbeat, but you should notice it to your doctor when you notice such symptoms after you have received Aclasta."</seg>
<seg id="690">"physical signs due to one to low calcium - concentration in blood, such as muscle crashes or creased sense, especially in the area around the mouth."</seg>
<seg id="691">"flu, sleeplessness, tiredness, mischievous, missiles, missiles, blackness, baked, cheeses, baked, cheeses, blackness, pink, compromising, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, scissors, tissue, and thirst."</seg>
<seg id="692">Persistent pain and / or non-healing wounds in the mouth or at the jaws were reported especially in patients who have been treated with Bisphosphonors because of other diseases.</seg>
<seg id="693">"over allergic reactions, including rare cases of breathing difficulties, nose, nose and angiodies (like for example swelling in the face, the tongue or in the rectangle), has been reported."</seg>
<seg id="694">"please inform your doctor, pharmacist or the nursing staff, if any of the listed side effects you have considerably impaired or simply side effects that are not listed in this usage information."</seg>
<seg id="695">"if the medicine is not used immediately, the user is responsible for storage time and conditions up to the application; normally 24 h at 2 ° C to 8 ° C will not be exceeded."</seg>
<seg id="696">"in patients with a recent, low-traumatic strokes is recommended to increase the infusion of Aclasta two or more weeks after the operative care of the hips."</seg>
<seg id="697">"before and after the administration of Aclasta, patients must be provided adequate with fluid; this is particularly important in patients who receive a diuretic therapy."</seg>
<seg id="698">"because of the quick entry of the effects of Zoledronics on the bone structure can develop a temporary, sometimes symptomatic, hymous, whose maximum usually occur within the first 10 days after the infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable, in patients with Morbus Paget, a sufficient supply of calcium, according to at least twice a day 500 mg casian calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently discovered low-traumatic hips, a initial dose of 50.000 to 125.000 i.e. orche or intra-muscular vitamin D is recommended in front of the infusion of Aclasta."</seg>
<seg id="701">"if you need more information about your illness or treatment, please read the package version (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="702">ACOMPLIA is additionally used to a diet and exercise to treat chronic disease (body mass index - BMI) of 30 kg / m ² or above or • the overweight (BMI of 27 kg / m ² or above) and beyond.</seg>
<seg id="703">"moreover, four studies have been conducted over 7 000 patients in which ACOMPLIA has been used compared to a placebo in comparison to a placebo."</seg>
<seg id="704">"to the studies on the attitude of smoking, there is no uniform results, so that the effect of ACOMPLIA on this application area was difficult to assess."</seg>
<seg id="705">"which risk is associated with ACOMPLIA? it has been observed with ACOMPLIA, which were observed during the studies (observing more than 1 of 10 patients), were nausea (nausea) and infections of the upper respiratory e. ng The full listing of the connection with ACOMPLIA-Side Effects is to be seen in the package."</seg>
<seg id="706">"it may also be applied in patients who are suffering from an existing severe depression or treated with antidepressants, since it can only cause the risk of depression and among other things in a small minority of patients."</seg>
<seg id="707">Caution is offered at the simultaneous use of ACOMPLIA with pharmaceuticals as Ketoconazol or Itraconazol (drugs against fungal infections), Ritonavir (a means to use at HIV- infection), Telithromycin or clarithromycin (antibiotics). LN</seg>
<seg id="708">The Committee for Humanity grew up to the conclusion that the effectiveness of ACOMPLIA with regard to the weight reduction in patients with obesity or overweight</seg>
<seg id="709">Medicines used in patients to need it out of health and not for cosmetic reasons (by providing insurability for patients and doctors) and around the Arz</seg>
<seg id="710">"he Additional to diet and exercise in the treatment of obesity (BMI ≥ 30 kg / m ²) or overweight patients (BMI &gt; 27 kg / m ²), who also show one or more risk factors such as type 2-diabetes or Dyslipidemia (see section 5.1)."</seg>
<seg id="711">ACOMPLIA is not recommended for use in children and young people under the age of 18 for the effectiveness of the effectiveness of the effectiveness and incomprehensibility.</seg>
<seg id="712">"La depressant diseases or voting changes with depressant symptoms were reported up to 10%, Suizidgeant at up to 1% of the patients that reported Rimonabant, reported (see section 4.8)."</seg>
<seg id="713">"and in depressants may not be applied Rimonabant, unless the benefits of treatment in individual case is the risk (see Section 4.3 and 4.8)."</seg>
<seg id="714">"he Also among patients, which - in addition to obesity in itself - no recognizable risks may appear depressed reactions."</seg>
<seg id="715">Related or other associated persons) are shown that it is necessary to monitor the realms of such symptomatic symptoms and immediately seek medical advice when these symptoms show. ln</seg>
<seg id="716">• Former patients The effectiveness and harmlessness of Rimonabant in the treatment of patients over 75 years were not sufficiently shown.</seg>
<seg id="717">Patients with a cardiovascular event (myokardinfarkt or stroke.) before less than 6 months were opened by studies with Rimonabant. ln</seg>
<seg id="718">"Rifampicin, phenytoine, phenol, carbamazepin, Johanniskites) is not assumed that the simultaneous Gabe of potent CYP3A4-inductors the Plasmaconconcentration of Rimonabant"</seg>
<seg id="719">"ness overweight patients as well as in patients with a obesity, and in addition to 3800 patients in further indications."</seg>
<seg id="720">The following table (table 1) shows the unwanted effects of placements unwanted effects in placebokontrolulated studies in patients that have been treated for weight reduction and because of accompanying metabolism.</seg>
<seg id="721">If the incidence statistically significant was higher than the corresponding placeborate (for unwanted Placeborate (for unwanted effects ≥ 1%) or when they were clinically relevant (for unwanted effects &lt; 1%). NG In the assessment of side effects will be explained the following frequency:</seg>
<seg id="722">"very frequently (≥ 10%); often (≥ 1, &lt; 10%); occasionally (≥ 0,1, &lt; 1%); rare (≥ 0,01, &lt; 0.1%); very t lä"</seg>
<seg id="723">"in a dreamy study, in which a limited number of persons have been administered by up to 300 mg were only observed."</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and one at the same time existing hypertension and / or Dyslipidemia.</seg>
<seg id="725">"N weight reduction according to a year was designed for ACOMPLIA 20 mg 6,5 kg, related to 1.6 kg for the placebo group (difference -4.9 kg CI95% -5.4, p &lt; 0,001)."</seg>
<seg id="726">"patients who have been treated with ACOMPLIA 20 mg, and 1.2 kg in the placebo group (difference -3.6 kg; CI95% -4.4, -3.3; p &lt; 0,001)."</seg>
<seg id="727">"after 2 years the difference in the entire weight reduction between ACOMPLIA and placebo -4,2 kg (CI95% -5.0%; -3,4, p &lt; 0,001)."</seg>
<seg id="728">9 weight reduction and other risk factors in the studies of patients without diabetes in which a mixed population of patients with</seg>
<seg id="729">Among Rimonabant 20 mg was a average waste by the Triglyceride of 6.7% (output worth triglyceride 1.62 mmol / l) compared to an increase of 5.6%</seg>
<seg id="730">"in a second study in patients with a obesity and so far untreated type-2- Diabetes (Serenade), was the absolute change in the HbA1c value (with an output value of 7,9% for both groups) after 6 months -0,8 for Rimonabant 20 mg and -0.3 under placebo"</seg>
<seg id="731">"the percentage share of patients, which reached a HbA1c- value of &lt; 7%, was 51% in the Rimonabant group and 35% in the placebo group."</seg>
<seg id="732">The difference of medium weight change between the 20 mg- and the placebo group lay at 3.8 kg (CI95% -5.0 (-2.8% &lt; 0.001). LN</seg>
<seg id="733">"improvement of the HbA1c-value in patients, the Rimonabant 20 mg had been taken approximately 50% through direct effects of Rimonabant and approximately 50% by the weight reduction. N eim Arz"</seg>
<seg id="734">2 hours reached the steady-State sculpture were reached after 13 days (Cmax = 196 ± 28,1 ng / ml; Ctrough = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"influence of food: he Probanden, received Rimonabant either in Nüchternal or after a fat meal, referred to at 67% increased Cmax respectively by 48% increased ng AUC."</seg>
<seg id="736">Patients with black skin colour can be up to 31% lower Cmax and one by 43% lower AUC as patients other ethnic populations.</seg>
<seg id="737">N populationharmacinetic analyses (age spectrum 18- 81 years) is estimated that a 75- year-round patient is an around 21% higher Cmax and a 27% higher AUC than a 40-year-year</seg>
<seg id="738">"5.3 Preclinical data for the safety of the consequential unwanted effects that were not observed in clinical trials which were not observed in animals after exposure in human therapeutic areas, as possibly relevant for the clinical application were evaluated:"</seg>
<seg id="739">"in some, however, not in all cases the start of the vulgar-related stress like dealing with the animals also seems to be connected to animals."</seg>
<seg id="740">"was given Rimonabant over a longer period before Paarung (9 weeks), which allowed a recovery from the initials of Rimonabant, so were unable to observe any unwanted effects on the inertility or cycloves."</seg>
<seg id="741">The influence of Rimonabant on preference and postnatal development was investigated at the rat in doses of up to 10 mg / kg / day.</seg>
<seg id="742">In a study on rats and postnatal development condemn an exposure with Rimonabant in utero and by means of lactation no changes in learning or in memory.</seg>
<seg id="743">Detailed information about this medicine are available on the website of the European Drug Agency (EMEA) http: / / www.huea.europa.eu / available. itte n eim Arz</seg>
<seg id="744">"La On the package of drugs, name and address of the manufacturer, the name and address of the manufacturer, which are responsible for the sharing of the concerned batch."</seg>
<seg id="745">"26 gravity events such as depression or voting changes were received in patients who reported ACOMPLIA, reported (see paragraph" which side effects "</seg>
<seg id="746">"If with you symptoms of depression (see below) during the treatment with ACOMPLIA, please contact your doctor and break the treatment."</seg>
<seg id="747">"shame, infestation, anxiety, juckriz, discounted, inclination, tilting, inclination, longing, longing, longing, longing and bustion, Hitzewalls, Sturz, grippale Infection, Gelblied insured."</seg>
<seg id="748">"please inform your doctor or pharmacist, if any of the listed side effects you have considerably impaired or simply side effects that are not specified in this usage information."</seg>
<seg id="749">"summary of the EPAR for the public, the present document is a summary of the European Public Prosecution (EPAR), which explains how the Committee for Humanarzneix (CHMP) has been assessed for recommendations regarding the application of the drug."</seg>
<seg id="750">Actos is used for the treatment of type 2-diabetes (also known as non-insulin-dependent diabetes). • It can not be displayed alone (monotherapy) in patients (especially overweight patient) in patients (especially overweight patients). • It can be applied together with another Diabetesmediation (Dual therapy).</seg>
<seg id="751">"it can also be applied in addition to metformin patients (especially overweight patients), which can not be satisfactory with metformin alone in the highest identifiable dose."</seg>
<seg id="752">"in combination with a sulfonyl resin or insulin can be retained the previous dose of Sulfonyl resin, except for patients with Hypoglycaemic (lower blood sugar); here should be reduced the dose of Sulfonyl resin and the insulin."</seg>
<seg id="753">"this means that the body is better to be upgraded in better, and the blood sugar levels can be better set to adjust type-2 diabetes."</seg>
<seg id="754">"for more than 1 400 patients the effectiveness of Actos in tripleo therapy was analysed; in addition, patients received a combination of metformin with a sulfonylharnosis, in addition they received up to 3.5 years either Actos or placebo."</seg>
<seg id="755">"in the studies the concentration of a substance in the blood has been measured in the blood (glycosity, HbA1c), which indicates how well the blood sugar is adjusted."</seg>
<seg id="756">"Actos led to a lowering of the HbA1c value, which makes the blood pressure in applying the doses of 15 mg, 30 mg and 45 mg were reduced."</seg>
<seg id="757">At the end of the tripleo study the effect of additional gifts of Actos to existing treatment with metformin and a sulfonylharnent in lowering the HbA1c values around 0.94% whereas the additional gifts of placebo led to a reduction of 0.35%.</seg>
<seg id="758">"in a small study, in which the combination of Actos and insulin at 289 patients was examined in addition the patients who took Actos in addition to insulin, a reduction in the HbA1c values of 0,69% after 6 months compared to patients who participated in addition to placebo."</seg>
<seg id="759">"the most common side-side effects associated with Actos were visual dysfunctions, infections of the upper respiratory (colds), weight gain and hymesthesia (decreased sensitivity to maturity)."</seg>
<seg id="760">"Actos may neither be used in patients who possibly reconceably (allergic) compared to Pioglitazone or one of the other components, nor in patients with liver problems, Herculinfertility, or diabetic Ketoacid - Surespiegel - in the blood)."</seg>
<seg id="761">It was decided that Actos in the scope of a monotherapy (in the sole use) as an alternative to the standard treatment with metformin patients should not appear in which metformes is not displayed.</seg>
<seg id="762">October 2000 the European Commission commissioned the company Takeda Europe R & D Centre Limited is a permit for the use of Actos in the entire European Union.</seg>
<seg id="763">"tablets are white to white, round, vaulted and wear on one side the markings" 15 "and on the other side the wording" ACTOS. "</seg>
<seg id="764">"Pioglitazon is also shown for the combination with insulin in patients with type 2 diabetes mellitus, whose blood sugar can be adjusted with insulin insufficient and for those metformin due to contraindications or intolerance is unsuitable (see Section 4.4)."</seg>
<seg id="765">"for the use of pioglitazon for patients under 18 years of age, no data is available, therefore the application in this age group is not recommended."</seg>
<seg id="766">"in patients, which are endangered by the presence at least one risk factor (e.g. early heart disease or symptomatic cardiovascular disease), the doctor should start the treatment with the lowest available dose and increase the dose."</seg>
<seg id="767">"patients should be observed on signs and symptoms of a infertility, weight gain or ohumble, particularly those with reduced carditis reserve."</seg>
<seg id="768">Patients should be observed on signs and symptoms of an infertility power that will be observed if pioglitazone is applied in combination with insulin.</seg>
<seg id="769">A kardiovasculars Outcome study with Pioglitazon for patients under 75 years with type 2 diabetes mellitus and preexisting advanced makrovasculine disorder.</seg>
<seg id="770">"in this study, an increase in reports of infertility levels, which however did not lead to an increase in mortality in the study."</seg>
<seg id="771">In patients with increased output liver disease (ALT &gt; 2.5 x upper limit of the standardization) or with other signs of a liver disease may not be used.</seg>
<seg id="772">"if the ALT mirrors up to the 3-fold of the upper limit of the standardised range, the liver disease is as soon as possible again."</seg>
<seg id="773">"if a patient symptoms develops according to a hepatic dysfunction, such as unresolved exercise, fatigue, appetite, and / or darker Harn, are the liver disease."</seg>
<seg id="774">The decision whether the treatment of patients with Pioglitazon will continue to be continued until the predominate of the laboratory parameters of the clinical evaluation.</seg>
<seg id="775">In clinical studies with Pioglitazone has been proven a dosing-dependent weight concentrations that can be staged by obesity and in some cases associated with a hydration.</seg>
<seg id="776">"as a result of a hemolocation, among the therapy with Pioglitazon a lower reduction in the middle heads (relative reduction by 4%) and of the Hematokrits (relative reduction of 4,1%)."</seg>
<seg id="777">Similar changes have been observed at comparative controlled studies with Pioglitazon in patients under metformin (relative reduction of the hemogrits around 3.6-4.1%) and to a lower extent also in patients under Sulfonylharnstoff and Insulin (relative reduction of the hermoeller around 1-2% and of the hematokrits around 1-3.2%).</seg>
<seg id="778">"as a result of increased insulin sensitive to patients, the Pioglitazone as oral branch or triple therapy with a sulfonylharnosis or as secondary therapy with insulin-dependent hyglycaemic."</seg>
<seg id="779">"following the market launch was reported among the treatment with thiazolidindians, including Pioglitazon, over a occurrence or deterioration of a diabetic Makulaödems with a reduction of visual acuity."</seg>
<seg id="780">"it is unclear whether there is a direct connection between the intake of Pioglitazon and the occurrence of Makulaödemen, but forceful doctors should be aware of the possibility of the visual acuity; a suitable ophthalmic waste should be considered."</seg>
<seg id="781">"in a summarizing analysis of announcements unwanted events regarding bone breaks, controlled, doubling clinical trials over a period of up to 3.5 years with more than 8.100 patients who have been treated with Pioglitazon."</seg>
<seg id="782">"the mere Fraktur inincidence was 1,9 fractures per 100 patient-years at the with Pioglitazon treated with teenage boys and 1.1 fractures for women who have been treated with a comparative mediation."</seg>
<seg id="783">"in Proactive study, a study about 3.5 years on the examination of cardiovascular events, fractures in 44 / 870 (5.3%) with Pioglitazon treated patients, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient-years) in patients who have been treated with a comparative mediation."</seg>
<seg id="784">Patients should be aware of the possibility of a pregnancy and if a patient wishes to be pregnant or if a patient wishes to impose this treatment (see Section 4.6).</seg>
<seg id="785">Studies on the examination of the interactions showed that Pioglitazon does not have any relevant effects on the pharmacoinetic or Pharmacology of Digoxin, Warmarin, phenocoumon and Metformin. "</seg>
<seg id="786">Interactions with pharmaceuticals that are metabolized by these enzymes, e.g. oral contraindications, cyclosporin, Calcium canlocker and HMGCoA-Reduction tasehemmer are not expected. "</seg>
<seg id="787">The simultaneous use of Pioglitazon with Gemfibrock (a cytochrom P450 2C8- Inhibitor) results in an increase in AUC from Pioglitazon to the 3-fold.</seg>
<seg id="788">The simultaneous use of Pioglitazon with Rifampicin (a Cytochrom P450 II C8-Inductor) results in a reduction of AUC by Pioglitazon to 54%.</seg>
<seg id="789">This is attributable that under treatment with pioglitazon which decreases in pregnant hyperinsulinemia and increased insulin resistance of the womens and thereby reduced the availability of metabolic substrates for the fetal growth.</seg>
<seg id="790">"very common &gt; 1 / 10; often &gt; 1 / 100, &lt; 1 / 10; occasionally &gt; 1 / 1000, &lt; 1 / 100; rare &gt; 1 / 10000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual accidents: unknown (of present data not estimated)."</seg>
<seg id="791">These lead to a temporary change in the Turgors and the billing indexes of the lens as they are also observed in other hypoglycemic agents.</seg>
<seg id="792">"in clinical studies with Pioglitazon, ALT junction, the upper limit of the standarrest of the standarrest is often the same as among placebo, however rare as in comparison groups under metformin or Sulfonylharnosis."</seg>
<seg id="793">In a Outcome study in patients with pre-existing advanced makrovasculine disease was the frequency of serious hernia efficiency at Pioglitazone by 1.6% higher than at placebo if pioglitazon respectively.</seg>
<seg id="794">"since the market launch it has been reported more about Herculine efficiency under Pioglitazon, however, more frequently if pioglitazon was used in combination with insulin or in patients with infertility efficiency in the anamnese."</seg>
<seg id="795">"a summarizing analysis of announcements unwanted events with regard to bone breaks out of randomized, controlled, doubling clinical trials over a period of up to 3.5 years with more than 8.100 patients in the patients with pioglitazon treated groups and over 7.400 patients treated with comparisons groups."</seg>
<seg id="796">"in the over a period of 3.5 years of ongoing Proactive study, fractures in 44 / 870 (5.1%) who treated with Pioglitazon treated with 23 / 905 (2.5%) with patients with a comparative mediation."</seg>
<seg id="797">"when taking the high-dose of 120 mg / day over four days, then 180 mg / day above seven days did not appear symptoms."</seg>
<seg id="798">Pioglitazon seems to work with a activation of specific core receptors (Peroxisome Proliferator. Receptor-g (PPAR-g)) results in the animal-model to an increased Insulinsensitiveness of Lebanese cells.</seg>
<seg id="799">It could be shown that Pioglitazon reduces glucoseproduction in the liver and increases the peripheral glucoupon in case of an insulin resistance.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclazid than monotherapy has been pursued over two years to investigate the time until decay of the therapeutic effects (defined as HbA1c ≥ 8.0% after the first 6 treatment of treatment).</seg>
<seg id="801">"at the time after two years after the start of therapy, a blood decreased roll (defined as HbA1c &lt; 8.0%) by Pioglitazone at 69% of patients treated patients (compared to 50% of patients under Gliclazid)."</seg>
<seg id="802">"in a placebokontroled study on 12 months, patients, whose blood sugar were adjusted despite three month-phase phase with insulin inadequate, to Pioglitazone or placebo."</seg>
<seg id="803">"in patients under the Pioglitazone reduced the average HbA1c - value around 0,45%, compared to the patients who continues just Insulin received; a reduction of insulphosities in which with Pioglitazon was observed."</seg>
<seg id="804">In clinical trials over one year showed themselves to Pioglitazon a statistically significant withdrawal of the Albumin / Creatinin-Quotiers in comparison to the output values.</seg>
<seg id="805">The effect of pioglitazon (monotherapy with 45 mg versus placebo) was tested in a small, on 18 weeks out of study on type-2 diabetics. "</seg>
<seg id="806">"in most clinical studies have been observed in comparison to placebo a reduction in the total plasma-triglyceride and the free fat acids, as well as the increase in the HDL- Cholesterinspels as well as neglious, however clinically not significantly significant increase LDL- cholesterol levels."</seg>
<seg id="807">In clinical trials over a period of up to two years reduced Pioglitazon compared to placebo, metformin or Gliclazid the total plasma-glyceride and the free fatty acids and increased the HDL cholesterol levels. "</seg>
<seg id="808">"compared to placebo was not statistically significant increase in LDL cholesterol levels, while under metformin and Gliclazid decreased values were observed."</seg>
<seg id="809">"in a study over 20 weeks reduced Pioglitazon, not only the sober-Triglyceride, but also improved the postprandial elevated Triglyceride-absorption as well as on the hepatic Triglyceride synthesis."</seg>
<seg id="810">"in the proactive study, a kardiovasculars Outcome study, 5238 patients with type 2 diabetes mellitus and preexisting advanced makrovascular disease in groups are randomised, which received over a period of up to 3.5 years in addition to existing antidiabetic and cardiovascular therapy either Pioglitazon or placebo."</seg>
<seg id="811">"according to orous application, Pioglitazon is quickly resorated, whereby the peak concentrations is reached on unchanging Pioglitazon in plasma usually 2 hours after application."</seg>
<seg id="812">"based on this basis, the contribution of M-IV for effectiveness in about the triple of the effectiveness of Pioglitazon, whereas the relative efficacy of M-II was minimal."</seg>
<seg id="813">"in Intergovernmental studies could be proven that Pioglitazon does not have any relevant effect on the pharmacoinetic or Pharmacology of Digoxin, Warmarin, phenocoumon and Metformin."</seg>
<seg id="814">The simultaneous use of Pioglitazon with Gemfibrock (a cytochrom P450 II C8-Inductor) or with Rifampicin (a Cytochrom P450 II C8-Inductor) or lowers the Plasmaconconcentration of Pioglitazon (see Section 4.5).</seg>
<seg id="815">"according to orational use of radioactive markered pioglitazone in humans the marker was mainly found in the feces (55%), and to a lower scale in the Harn (45%)."</seg>
<seg id="816">The medium plasma-elimination period of unchanging Pioglitazon is for people 5-6 hours and that of the entire active metabolic residences is at 16 - 23 hours.</seg>
<seg id="817">The Plasmaconconcentrations of Pioglitazon and its metabolic are lower than in patients with reduced kidney function lower than in healthy Probanden, with the rats of the ormal Clearance of the mother subsection but resembles. "</seg>
<seg id="818">"in toxikological studies occurred at mice, rats, dogs and monkeys coincidence after repetitive administration of plasmainstreaming, anemia and reversible excentric cardio hypertrophy."</seg>
<seg id="819">This is attributable that under treatment with pioglitazon which is decreased in the creation of hyperinsulinemia and increased insulin resistance of the womens and thereby reduced the availability of metabolic substrates for the fetal growth.</seg>
<seg id="820">In long-term studies (up to 2 years) at the Rat increased incidences of hyperplasia (in male and female ritating) and tumors (male ponds) of the urinary epithelium induces.</seg>
<seg id="821">In a animal-model of the familiar Polyposis (FAP) led the treatment with two other thiazolidindiones to an increased frequency of Kolontumors.</seg>
<seg id="822">"tablets are white to white, round, shallow and wear on one side the markings" 30 "and on the other side the wording" ACTOS. "</seg>
<seg id="823">"the mere Fraktur inincidence was 1,9 fractures per 100 patient-years at the with Pioglitazon treated with teenage boys and 1.1 fractures for women who have been treated with a comparative mediation."</seg>
<seg id="824">"in Proactive study, a study about 3.5 years on the examination of cardiovascular events, fractures in 44 / 870 (5.3%) with Pioglitazon treated patients, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient-years) in patients who have been treated with a comparative mediation."</seg>
<seg id="825">"in a further study over two years, the effects of a combined therapy of metformin with each pioglitazon or Gliclazid."</seg>
<seg id="826">In clinical trials over 1 year showed under pioglitazon a statistically significant withdrawal of the Albumin / Creatinin-Quotiers in comparison to the output values.</seg>
<seg id="827">"in a study over 20 weeks reduced Pioglitazon, not only the sober-Triglyceride, but also improved the postprandial elevated Triglyceride-absorption as well as on the hepatic Tryglizing synthesis."</seg>
<seg id="828">"although the study resulted in terms of its primary endpoint, which a combination of the overall mortality, not-deadly myokardinfarkt, ramplifargues, rampargues of leg-arteries, place the results close that with the intake of pioglitazon does not constitute cardiovascular risk risks."</seg>
<seg id="829">"tablets are white to white, round, shallow and wear on one side the markings" 45 "and on the other side the wording" ACTOS. "</seg>
<seg id="830">"in a summarizing analysis of announcements unwanted happenings from randomized, controlled, doubling clinical trials over a period of up to 3.5 years with more than 8.100 patients who were treated with Pioglitazon and more than 7.400 patients, the comparisons of bone breaks from women."</seg>
<seg id="831">"in Proactive study, a study about 3.5 years on the examination of cardiovascular events, fractures in 44 / 870 (5.3%) with Pioglitazon treated patients, compared with 23 / 905 (2.5%; 0,5 fractures per 100 patient-years) in patients who have been treated with a comparative mediation."</seg>
<seg id="832">"in a study over 20 weeks reduced Pioglitazon, not only the sober-Triglyceride, but also improved the postprandial elevated Triglyceride-absorption as well as on the hepatic Triglyceride synthesis."</seg>
<seg id="833">"on the pack of the drug, name and address of the manufacturer, which is responsible for the release of the respective batch."</seg>
<seg id="834">The pharmaceutical companies will be launched in September 2005 an additional 6 month periodic Periodic Safety Update Report (PSUR) and then annual PSURs unrich until a different final decision of CHMP.</seg>
<seg id="835">It must be an updated risk management plan under the CHMP guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"if you are involved in type 2-diabetes, Actos 15 mg tablets need control of your blood sugar levels by creating a better conversion of physical insulin."</seg>
<seg id="837">"if you know that you suffer from a sugar intolerance, please contact before taking account Actos 15mg tablets your doctor."</seg>
<seg id="838">"please inform your doctor or pharmacist if you have more medicines or have recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="839">"if you have Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorbenclamid, Gliclazid, Tolbutamid), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="840">"in some patients with a long-year type 2 diabetes mellitus and cardiac disease or early stroke, which were treated with actos and insulin, developed into infertility."</seg>
<seg id="841">"in clinical trials, in which pioglitazon with other ormal antidiabetic or placebo (real-free tablets) was compared to women (but not in men), Pioglitazon took a higher number of bone breaks."</seg>
<seg id="842">"if you have been taken to many tablets, or if any other or child has taken your medicine, you must immediately contact with a doctor or pharmacist."</seg>
<seg id="843">"as Actos looks and content of the pack Actos 15 mg tablets are white to white, round, vaulted tablets with the markings" 15 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="844">"if you are involved in type 2-diabetes, Actos 30 mg tablets need control of your blood sugar levels by creating a better conversion of physical insulin."</seg>
<seg id="845">"if you know that you suffer from a sugar intolerance, please contact before taking account Actos 30mg tablets your doctor."</seg>
<seg id="846">"if you assume Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorbenclamid, Gliclazid, Tolbutamid), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="847">"61 informing your doctor as soon as possible your doctor if you find signs of a calliid efficiency, such as unusual short-proof or rapid weight gain or local swelling (Ödeme)."</seg>
<seg id="848">"in clinical trials, in which pioglitazon with other ormal antidiabetic or placebo (real-free tablets) was compared to women (but not in men), Pioglitazon took a higher number of bone breaks."</seg>
<seg id="849">"as Actos looks and content of the pack Actos 30 mg tablets are white to white, round, flat tablets with the markings" 30 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="850">"if you are involved in type 2-diabetes, Actos 45 mg tablets need control of your blood sugar levels by creating a better conversion of physical insulin."</seg>
<seg id="851">"if you know that you suffer from a sugar intolerance, please contact before taking account Actos 45mg tablets your doctor."</seg>
<seg id="852">"if you assume Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorbenclamid, Gliclazid, Tolbutamid), your doctor will inform you whether you need to reduce the dose of your medicines."</seg>
<seg id="853">"66 In a few patients with long-year type 2 diabetes mellitus and cardiac disease or early stroke, which were treated with actos and insulin, developed into infertility."</seg>
<seg id="854">Inform as soon as possible your doctor if you find signs of a callious efficiency in finding how such an ordinary short-proof or rapid weight gain or local swelling (Ödemark).</seg>
<seg id="855">"in clinical trials, in which pioglitazon with other ormal antidiabetic or placebo (real-free tablets) was compared to women (but not in men), Pioglitazon took a higher number of bone breaks."</seg>
<seg id="856">"67 If any of the listed unwanted effects you have considerably impaired, or do not notice any side effects that are not listed in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="857">"as Actos looks and content of the pack Actos 45 mg tablets are white to white, round, flat tablets with the markings" 45 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="858">"this document is a summary of the European Public Prosecutational Report (EPAR), which explains how the Committee on Humanarzneix (CHMP) conducted the trials to recommendations regarding the application of the drug."</seg>
<seg id="859">"if you need more information about your medical condition or treatment of your disease, please read the package version (which is also part of the EPAR) or contact a doctor or pharmacist."</seg>
<seg id="860">"if you desire further information on the basis of recommendations of CHMP, please read the scientific discussion (which is also part of the EPAR)."</seg>
<seg id="861">Actraphane 10: solubility in 10% and Isophan Insulin 90% Actraphane 30: solubility in 40% and Isophan-Insulin 60% Actraphane 50: Instant Insulin 50% and Isophan-Insulin 50% and Isophan-Insulin 50%</seg>
<seg id="862">Actraphane is normally used once or twice a day when a fast initials will be desired along with a longer lasting effect.</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int</seg>
<seg id="864">"Actraphane was acquired in total 294 patients with type 1 diabetes, where the pancreas can not produce inulate in the body, and type 2-diabetes, where the body is unable to use the Insulin effectively."</seg>
<seg id="865">"in the study, after 12 weeks the concentration of a substance (glycosity) measured (HbA1c) measured, which indicates how well the blood sugar is adjusted."</seg>
<seg id="866">Actraphane led to a withdrawal of the HbA1c mirrors that were pointed out that the blood sugar levels were somewhat strongly influenced by another human insulin.</seg>
<seg id="867">Actraphane should not be used in patients that may possibly be hypersensitive (allergic) to human insulin (rDNA) or one of the other components.</seg>
<seg id="868">"in addition, the doses of Actuaphane may be adjusted when it can affect a number of other medicines which can affect blood sugar (the complete list is to be found in the package."</seg>
<seg id="869">The Committee for Humanity grew up to the conclusion that the benefits of Actraphane in the treatment of diabetes to prevail over the risks.</seg>
<seg id="870">October 2002 the European Commission commissioned the company Novo Nordisk A / S approached by Actraphane in the entire European Union.</seg>
<seg id="871">Mixed insulin products are usually used once or twice a day when a fast initials are desired along with a longer lasting effect desired.</seg>
<seg id="872">Injections must be charged at least 6 seconds long under the skin to ensure that the entire dose has been injected.</seg>
<seg id="873">Patients whose bloodds are significantly improved by a intensified insulin therapy and can be altered hypoglycemic symptom and should be advised accordingly.</seg>
<seg id="874">"any change regarding strength, brand (manufacturer), Insulphyp (fast-effective, bioinsulin etc), type of insulin (animal insulin, humaninsulin or insulin quota) and / or manufacturer method (by recombinant DNS compared to insulin animal origin), it can lead to change the dosage is required."</seg>
<seg id="875">"if the change is necessary for Actraphane in the patient a dosage adjustment, this can be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="876">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="877">"travelling to travelling over several times, the patient should be pointed to the Council of his physician, since such trips can lead to that insulin and meals must be applied or taken at other times."</seg>
<seg id="878">The doctor must therefore consider possible interactions during therapy and to consider his patients always penalties for others.</seg>
<seg id="879">4 Soviets Hypoglycemic as well as hyperglycaemia that can occur in a non-sufficiently controlled toxicity therapy, increase the risk of abnormalities and fertility in utero. "</seg>
<seg id="880">Severe hypoglycals can lead to awareness and / or crampry cases and with temporary or permanent disorders of the brain function and even death.</seg>
<seg id="881">Diseases of the nervous system occasionally - peripheral Neuropathie a rapid improvement of blood circulation can be associated with complaints that are considered acute painful Neuropathic and normally reversibel.</seg>
<seg id="882">5 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="883">Diseases of the skin and the lower tissue tissue occasionally - Lipodystrophy At the injector can be created a lipodystrophy if cancelled within the injection range.</seg>
<seg id="884">"general diseases and discomfort on the occasion of the occasion occasionally - Local oversensitivity in the injustice, the Insulintherapy can occur local oversensitivity, swelling, itching, pain and hematom on the injections)."</seg>
<seg id="885">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="886">"however, a hypoglycemic may develop gradually: • Easily hypoglycals can be treated by the orals of glucose or zuckering foods."</seg>
<seg id="887">"diabetics should therefore always have trauma gaps, sweets, biscuits or decreased fertility with awareness, treated with a intra-muscular or subcutaneous injection of glucoagon (0.5 to 1,0 mg) by a mustine assistant or by glucose, inintravenous by the doctor."</seg>
<seg id="888">"the effect starts within half an hour, the active maximum will be reached within 2 to 8 hours, and the total duration is up to 24 hours."</seg>
<seg id="889">Resorption The Resorption profile is to be explained that it is a mixture of insulin products with quicker or higher resorption.</seg>
<seg id="890">A series of legro (hydrolyse-) places in the humanly molecule have been considered; none of the educated metabolic metabolic has been active.</seg>
<seg id="891">"based on conventional studies on safety vulnerability, toxicity in repetitive Gabe, genotoxicity, for cardiogenous potential and to reproductions, the preclinical data will not identify any particular hazards for men."</seg>
<seg id="892">It is recommended - after the Actraphane throughput from the fridge has been taken from the refrigerator - the temperature of the Insulins on room temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="893">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="894">The doctor must therefore consider possible interactions during therapy and to consider his patients always penalties for others.</seg>
<seg id="895">"12 Soviets Hypoglycemic works as well as hyperglycemic, which can occur in a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="896">13 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="897">The terminale half-time (t ½) is therefore rather a measure of resorption as a measure of the elimination per se of the insulin from the plasma (insulin in blood circulation in a few minutes).</seg>
<seg id="898">It is recommended - after the Actraphane throughput from the fridge has been taken from the refrigerator - the temperature of the Insulins on room temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="899">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="900">"20 Soviets Hypoglycemic works as well as hyperglycemic, which can occur in a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="901">21 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="902">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective function of cartridge.</seg>
<seg id="904">It is recommended - after Actraphane penetration from the fridge has been taken out of the refrigerator - the temperature of the Insulins on room temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="905">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="906">"28 Both Hypoglycaemia as well as hyperglycemic, which can occur in a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="907">29 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="908">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="909">"36 Soviets Hypoglycemic, as well as hyperglycemic, which can occur in a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="910">37 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="911">"44 Soviets Hypoglycemic, as well as hyperglycemic, which can occur during a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="912">45 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="913">"some patients, where hypoglycemic reactions after a change of animal diseases, reported that the early warnsymptom of a hypoglycaemia is less pronounced or different from their previous insulin."</seg>
<seg id="914">"52 Both Hypoglycaemia as well as hyperglycemic, which can occur during a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="915">53 A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="916">Injectors must be prepared before injecting so that the dosisers appear on zero and appears an insulphant at the top of the injections.</seg>
<seg id="917">"59 patients, whose bloodds can be significantly improved by a intensified insulin therapy, the hypoglycemic symptom changed and should be advised accordingly."</seg>
<seg id="918">"both Hypoglycaemia as well as hyperglycemic, which can occur during a non-sufficiently controlled Diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="919">A intensification of insulin therapy with a ruptive improvement of the blood pressure can however be connected to a temporary deterioration of diabetic retinopathy.</seg>
<seg id="920">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="921">These prefabrication may only be used together with products that are compatible with them and ensure a safe and effective function of production.</seg>
<seg id="922">It is recommended - after Actraphane NovoLet was taken out of the refrigerator - the temperature of the Insulins on room temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="923">"67 patients whose bloodds are considerably improved by a intensified insulin therapy, the Hypoglycaemic symptoms can be changed and should be advised accordingly."</seg>
<seg id="924">"75 patients, whose bloodds can be significantly improved by a intensified insulin therapy, the hypoglycemic symptom changed and should be advised accordingly."</seg>
<seg id="925">"83 patients, whose bloodds can be significantly improved by a intensified insulin therapy, the hypoglycemic symptom changed and should be advised accordingly."</seg>
<seg id="926">"91 patients, whose bloodds can be significantly improved by a intensified insulin therapy, the hypoglycemic symptom changed and should be advised accordingly."</seg>
<seg id="927">"99 patients, whose bloodds can be significantly improved by a intensified insulin therapy, the hypoglycemic symptom changed and should be advised accordingly."</seg>
<seg id="928">"any change regarding strength, brand (manufacturer), Insulphyp (fast-effective, bioinsulin etc), type of insulin (animal insulin, humaninsulin or insulin quota) and / or manufacturer method (by recombinant DNS compared to insulin animal origin), it is required to make a change of dosage is required."</seg>
<seg id="929">It is recommended - after Actraphane InnoLet was taken out of the refrigerator - the temperature of the Insulins at spacing temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="930">It is recommended - after Actraphane FlexPen from the fridge has been taken from the refrigerator - the temperature of the Insulins on room temperature (not over 25 ° C) will be able to increase the manual for the first use.</seg>
<seg id="931">"on the pack of the drug, name and address of the manufacturer, which is responsible for the release of the respective batch."</seg>
<seg id="932">In the fridge (2 ° C - 8 ° C) Not infriing The throughput in the envelope to protect the content from light to ascend: not in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous application penetration of penal cartridges are intended for use with insulinincreators of Novo Nordisk. if the instructions resignane packs of actraphane 10 Penfill can only be used by one person</seg>
<seg id="934">In the fridge (2 ° C - 8 ° C) Not freezing The cartridge in the Umcarton to protect the content from light to ascend: not in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous application penetration of penal cartridges are intended for use with insulinincreators of Novo Nordisk's packet of instruction at Actraphane 20 Penfill must only be used by one person</seg>
<seg id="936">Subcutaneous application penetration of penal cartridges are intended for use with insulinincreators of Novo Nordisk's packet of instruction at Actraphane 30 Penfill must only be used by one person</seg>
<seg id="937">Subcutaneous application penetration of penal cartridges are intended for use with insulinincreators of Novo Nordisk. when applying the instructions of resignane packs of actraphane 40 Penfill may only be used by one person</seg>
<seg id="938">Subcutaneous application penetration of penal cartridges are intended for use with insulinincreators of Novo Nordisk. when applying the instructions of resignane packs of actraphane 50 Penfill can only be used by one person</seg>
<seg id="939">Subcutaneous application tick use with Actraphane 10 NovoLet are NovoFine injection injections provided for Actraphane 10 NovoLet may only be used by one person</seg>
<seg id="940">In the fridge (2 ° C - 8 ° C) Not freezing to protect light after breakthrough: not kept in the fridge or over 30 ° C</seg>
<seg id="941">Subcutaneous application tick use with Actraphane 20 NovoLet are NovoFine injection injections provided for Actraphane 20 NovoLet may only be used by one person</seg>
<seg id="942">Subcutaneous application tick use with Actraphane 30 NovoLet are NovoFine injections provided for Actraphans 30 NovoLet may only be used by one person</seg>
<seg id="943">Subcutaneous application tick use with Actraphane 40 NovoLet are NovoFine injection injections provided for Actraphane 40 NovoLet may only be used by one person</seg>
<seg id="944">Subcutaneous application tick use with Actraphane 50 NovoLet are NovoFine injections provided for Actraphans 50 NovoLet may only be used by one person</seg>
<seg id="945">Subcutaneous application tick use with Actraphane 30 InnoLet are NovoFine S injections of the instructions of resignane packs of Actraphane 30 InnoLet may only be used by one person</seg>
<seg id="946">This means that about half an hour after you have applied it to decline your blood sugar and that the effect will last about 24 hours.</seg>
<seg id="947">► when you allergic (hypersensitive) on this Insulinproduct, metacresol or one of the other components (see section 7 more information). "</seg>
<seg id="948">Watch out the symptoms of 5 which side effects are possible? described symptoms of a allergy. if you feel the first signs of a hypoglycaemia (symptoms of a sub-storage).</seg>
<seg id="949">"if your doctor has a change from an insulinart or brand to another, possibly the dose may be adjusted by your doctor."</seg>
<seg id="950">► Check out using the label, whether it is the right Insulintyp (► Desinect the Gummimembran with a medical pot. "</seg>
<seg id="951">"if this is not completely unexplored, if you get the throughput to your pharmacy, if it was not correct or frozen (see 6 How is Actraphane to preserve?)" "if it is not like to store Actraphane?)" "if it is not like it after the remainder."</seg>
<seg id="952">Use the injection technology that has recommended your doctor or your Diabetesberaterin recommended as ► Lassen you have injecting the injector of at least 6 seconds long under your skin to ensure that the full dose has been injected.</seg>
<seg id="953">"the warring of a submitting can suddenly occur and can be: cold silence, cold, headache, heartness, anxiety, anxiety, anxiety, anxiety, nervousness or trembling, anxiety, confusion, concentrates."</seg>
<seg id="954">"tell your own, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately have to consume a doctor."</seg>
<seg id="955">"you may not eat or drink nothing to eat or to drink, since you may cause a severe subjection, or even to death. if you had a sub-time damage or even to death. if you had a sub-time damage or even to death."</seg>
<seg id="956">"you can recover the consciousness faster, if you are familiar with the hormone Glucagon of a person who is familiar with whose gift is injected."</seg>
<seg id="957">"this may happen: • If you get too much insulin injecting, if you eat too little or give a meal • if you have more than usual physical."</seg>
<seg id="958">"amplified resin, thirst, impedness or fatigue, strawess or fatigue, strawed dry skin, mouthdry and fruity (according to Aceton)."</seg>
<seg id="959">• You have forgotten an inadvance injection of less insulin than you will need an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="960">"if you often give yourself an injection at the same place, at this point can be shrink at this point (Lipatrophy) or increase (Lipohypertrophy)."</seg>
<seg id="961">"if you notice deepening or thicknesses of your skin on the injection, tell your doctor or your Diabetesberaterin about it, because these reactions can affect yourself or the inclusion of your insulin, if you have injected into such a place."</seg>
<seg id="962">"you immediately look for a doctor on • if the symptoms of a allergy to other parts of the body spread, or • If you have suddenly feel unlikely and you will have welds, evil, hearty, you have obstruct, or you have the impression to become conscious mind."</seg>
<seg id="963">They may have a very rare severe allergic reaction to actraphane or one of its components (such called systemic allergic reaction).</seg>
<seg id="964">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="965">What Actraphane 30 contains - The ingredient is made by recombinant DNS technology hersulin human (30% as solubent Insulin and 70% as Isophan Insulin).</seg>
<seg id="966">"as Actraphane, and the contents of the packet The injections will be considered dull, white, watering suspension latches with 1 or 5 seats up to 10 ml or a bundle with 5 diameters to 10 ml each."</seg>
<seg id="967">Use the injection technology that has recommended your doctor or your Diabetesberaterin recommended as ► Lassen you have injecting the injector of at least 6 seconds long under your skin to ensure that the full dose has been injected.</seg>
<seg id="968">"it is recommended - after it was removed from the refrigerator - the temperature of the throughput on room temperature, before the Insulin according to the manual for the first use was restrained."</seg>
<seg id="969">"as Actraphane, and the contents of the packet The injections will be considered dull, white, watering suspension latches with 1 or 5 seats up to 10 ml or a bundle with 5 diameters to 10 ml each."</seg>
<seg id="970">► Check out using the label, whether it is to be the right Insulintype you always check the penetration of cartridge including the rubber. "</seg>
<seg id="971">Do not use them if any damage is visible or a gap between the rubber-pistons and the white tape of the label is visible.</seg>
<seg id="972">More information can be found in the manual of your insulininjective system. ► Desinect the rubber compound with a medical pot. ► Benefect always for each injection a new injector to avoid a contamination.</seg>
<seg id="973">"► in Insulininfusionspumpen ► When the Penfill or the device, which has been abandoned, damaged or broken, there is the danger of expiration of insulin ► if it was not correct or inhibitors (see 6 How is Actraphane to preserve?)" "if it is not equivalent to the reseller."</seg>
<seg id="974">"if you are treated with Actraphane 10 Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="975">"before you use the cartridge into the inulate system, move at least 20 times between positions a and b and from (see picture), so that the Glaskugel from one end of the cartridge to the other moves."</seg>
<seg id="976">Use the injection technology that has been described your doctor or your Diabetesberaterin and which was described in the operating instructions of your injection systems and the injector has been injected for at least 6 seconds long under your skin to ensure that the full dose was injected to remove the injections and actraphane without burnt injections.</seg>
<seg id="977">"183 draw your own, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately need to consume a doctor."</seg>
<seg id="978">• You have forgotten an inadvance injection of less insulin than you will need an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="979">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="980">"it is recommended - after it was removed from the refrigerator - the temperature of the penetration of penetration on room temperature, before the Insulin according to the manual for the first use was restrained."</seg>
<seg id="981">185 Cups always keep the cartridges always in the Umcarton if you don't use it to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - The ingredient is made by recombinant DNS technology. (10% as solubent Insulin and 90% as Isophan Insulin).</seg>
<seg id="983">"as Actraphane looks and the contents of the packet The injector will be considered dull, white, watering Suspension in packs with 1, 5 or 10 cartridges at each 3 ml."</seg>
<seg id="984">More information can be found in the manual of your insulininjective system. ► Desinect the rubber compound with a medical pot. ► Benefect always for each injection a new injector to avoid a contamination.</seg>
<seg id="985">"if you are treated with Actraphane 20 Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="986">"189 Saving your relatives, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately need to consume a doctor."</seg>
<seg id="987">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="988">191 Move the cartridges always in the Umcarton if you don't use it to protect them from light.</seg>
<seg id="989">What Actraphane 20 contains - The ingredient is made by recombinant DNS technology hersulate Insulin human (20% as solubent Insulin and 80% as Isophan Insulin).</seg>
<seg id="990">"as Actraphane looks and the contents of the packet The injector will be considered dull, white, watering Suspension in packs with 1, 5 or 10 cartridges at each 3 ml."</seg>
<seg id="991">More information can be found in the manual of your insulininjective system. ► Desinect the rubber compound with a medical pot. ► Benefect always for each injection a new injector to avoid a contamination.</seg>
<seg id="992">"if you are treated with Actraphane 30 Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="993">"195 Are you your relatives, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately have to consume a doctor."</seg>
<seg id="994">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="995">197 Move the cartridges always in the Umcarton if you don't use it to protect them from light.</seg>
<seg id="996">"manufacturer The manufacturer can be identified by the Chargers' designation, which is printed on the lashing of the cartons and on the label, are identified."</seg>
<seg id="997">"in case of the second and third place of the charger designation of the W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark"</seg>
<seg id="998">"in case of the second and third place of the charger designation of H7 or T6, the manufacturer of Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France."</seg>
<seg id="999">More information can be found in the manual of your insul system. ► Desinect the rubber compound with a medical pot. ► Benefect always for each injection a new injector to avoid a contamination.</seg>
<seg id="1000">"if you are treated with Actraphane 40 Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="1001">"201 sail your own, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately need to consume a doctor."</seg>
<seg id="1002">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1003">203 Move the cartridges always in the Umcarton if you don't use it to protect them from light.</seg>
<seg id="1004">What Actraphane 40 contains - The ingredient is made by recombinant DNS technology heroes in human (40% as solubent Insulin and 60% as Isophan Insulin).</seg>
<seg id="1005">More information can be found in the manual of your insul system. ► Desinect the rubber compound with a medical pot. ► Benefect always for each injection a new injector to avoid a contamination.</seg>
<seg id="1006">"if you are treated with Actraphane 50 Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="1007">"before you use the penetration of a cartridge into the insulin system, move at least 20 times between positions a and b and from (see picture), so that the Glaskugel from one end of the cartridge to the other moves."</seg>
<seg id="1008">"207 rewear your relatives, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately need to consume a doctor."</seg>
<seg id="1009">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1010">209 maintains the cartridges always in the Umcarton if you don't use it to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - The ingredient is made by recombinant DNS technology hersulate Insulin human (50% as solubent Insulin and 50% as Isophan Insulin).</seg>
<seg id="1012">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1013">► Check out using the label, whether there are a new Insul intype you always use for each injection a new injector to avoid a contamination. "</seg>
<seg id="1014">"► in Insulininfusionspumpen ► When the NovoLet has been abandoned, damaged or broken, is the danger of expiration of insulin ► if it was not correct or frozen (see 6 How is Actraphane to preserve?)" "if it is not equivalent to the reseller."</seg>
<seg id="1015">"the warring of a submitting can suddenly occur and can be: cold silence, cold, headache, heartness, anxiety, anxiety, anxiety, anxiety, nervousness or trembling, anxiety, confusion, concentrates."</seg>
<seg id="1016">"214 If any of the listed unwanted effects you have considerably impaired or simply side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1017">"in use of sensitive NovoLet prefabrication and such that are used shortly or as a replacement, are not kept in the fridge."</seg>
<seg id="1018">"it is recommended - after it was removed from the refrigerator - the temperature of the NovoLet finished production on room temperature, before the Insulin according to the manual for the first use."</seg>
<seg id="1019">"let the disconnection of your NovoLet finished pens always set, if NovoLet is not in use to protect the insulin from light."</seg>
<seg id="1020">"as Actraphane, and the contents of the packet The injections will be considered dull, white, watering Suspension in packs with 5 or 10 manufacturing each 3 ml."</seg>
<seg id="1021">"before every injection, review, whether or at least 12 units of insulin in the cartridge are left to ensure an excessive blend is ensured."</seg>
<seg id="1022">Go ahead to avoid the injection of air to avoid and make a correct dosage: • Hold you Actraphane 10 NovoLet with the injector after the top • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1023">"if airblases are present, they will continue to keep up in the cartridge • Dtraphane 10 NovoLet continues to keep the injections in the direction of the arrow (figure C) • While you keep the injection in the direction of the injection (figure D) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1024">"• If you put the observer once again on the finished pen, that the number 0 is facing the dosing stamp (figure E) • Controlment you, whether the printed knob is totally suppressed."</seg>
<seg id="1025">"if not, turn the cap, until the pressure pot is totally down, • Keep your Actraphane 10 NovoLet horizontal."</seg>
<seg id="1026">"if the pressure is not able to move freely according to the outside, Insulin from the injisnadel pressed • The scale on the cap displays 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1027">"the printing knob moves to the outside, while you turn the cap • The scale under the button displays 20, 40 and 60 units."</seg>
<seg id="1028">"check the number on the workbook directly next to the dosing stamp • note the highest number that you can get on the printing button • If you have a false dose, turn the box simply down or reverse until you have the correct number of units."</seg>
<seg id="1029">"otherwise, Insulin from the injections and the set of dose will not be correct, if you have attempted to adjust a dose of more than 78 units, run the following steps:"</seg>
<seg id="1030">Then take the cap and put it so again that the 0 of the dosing stamp lies opposite.</seg>
<seg id="1031">Be sure to press only while injecting on the printing knob. • Keep the pressure knob according to the injecting up to the injector from the skin was removed.</seg>
<seg id="1032">"if not, turn the cap, until the printed knob is totally down and then proceed as in the use of the application • Possibly, listen to the gaps of the printed head to a cliff device."</seg>
<seg id="1033">"it is possibly inaccurate • you can not set a dose which is higher than the number of in the cartridge verbs units • You can still use the residual scale, how much insulin is still remaining."</seg>
<seg id="1034">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1035">"224 If any of the listed unwanted effects you have considerably impaired or simply side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1036">226 ago every injection • Overcheck whether or at least 12 units are remaining in the cartridge to ensure that a moderate mixture is ensured.</seg>
<seg id="1037">Go to avoid the injection of air to avoid and make a correct dosage: • Hold you Actraphane 20 NovoLet with the injections upstairs • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1038">"if airblases are present, they will continue to keep up in the cartridge • Dtraphane 20 NovoLet continues to keep the injections in the direction of the arrow (figure C) • While you keep the injection in the direction of the injection (figure D) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1039">"if not, turn the cap, until the pressure pot is totally down, • Keep your Actraphane 20 NovoLet horizontal."</seg>
<seg id="1040">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1041">"234 If any of the listed side effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1042">236 At any injection • Overcheck whether or at least 12 units are remaining in the cartridge to ensure an excessive blend is ensured.</seg>
<seg id="1043">Go ahead to avoid the injection of air to avoid and make a correct dosage: • Hold you Actraphane 30 NovoLet with the injector near to top • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1044">"if airblases are present, they will continue to keep up in the cartridge • Dtraphane 30 NovoLet continues to keep the injections in the direction of the arrow (figure C) • While you keep the injection in the direction of the injection (figure D) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1045">"if not, turn the cap, until the pressure pot is totally down, • Keep your Actraphane 30 NovoLet horizontal."</seg>
<seg id="1046">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1047">"244 If any of the listed unwanted effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1048">246 Next every injection • Overcheck whether or at least 12 units are remaining in the cartridge to ensure an excessive blend is ensured.</seg>
<seg id="1049">Go ahead to avoid the injection of air to avoid and make a correct dosage: • Hold you Actraphane 40 NovoLet with the injector up • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1050">"if airblases are present, they will continue to keep up in the cartridge • Dtraphane 40 NovoLet continues to keep the injections in the direction of the arrow (figure C) • While you keep the injection in the direction of the injection (figure D) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1051">"if not, turn the cap, until the pressure pot is totally down, • Keep your Actraphane 40 NovoLet horizontal."</seg>
<seg id="1052">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1053">"254 If any of the listed unwanted effects you have considerably impaired or simply side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1054">"it is recommended - after it was removed from the refrigerator - the temperature of the NovoLet finished production on room temperature, before the Insulin according to the manual for the first use."</seg>
<seg id="1055">256 Next every injection • Overcheck whether or at least 12 units are remaining in the cartridge to ensure an excessive blend is ensured.</seg>
<seg id="1056">Go ahead to avoid the injection of air to avoid and make a correct dosage: • Hold you Actraphane 50 NovoLet with the injecting nadel upwards • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1057">"if airblases are present, they will continue to keep up in the cartridge • Dtraphane 50 NovoLet continues to keep the injection in the direction of the arrow (figure C) • While you keep the injection in the direction of the injection (figure D) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1058">"if not, turn the cap, until the pressure pot is totally down, • Keep your Actraphane 50 NovoLet horizontal."</seg>
<seg id="1059">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1060">"► in Insulininfusionspumpen ► When the Innolie has been abandoned, damaged or broken, there is the danger of expiration of insulin ► if it was not correct or frozen (see 6 How is Actraphane to preserve?)" "if it is not equivalent to the reseller."</seg>
<seg id="1061">"the warring of a submitting can suddenly occur and can be: cold silence, cold, headache, heartness, anxiety, anxiety, anxiety, anxiety, nervousness or trembling, anxiety, confusion, concentrates."</seg>
<seg id="1062">"264 If any of the listed side effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1063">"in use sensitive InnoLet prefabrication and such that will be used shortly or as a replacement, are not kept in the fridge."</seg>
<seg id="1064">"it is recommended - after it was removed from the refrigerator - the temperature of the InnoLet finished production on room temperature, before the Insulin according to the manual for the first use."</seg>
<seg id="1065">"let the disconnection of your gnoLet finished pens always set, if InnoLet is not in use to protect the insulin from light."</seg>
<seg id="1066">"as Actraphane, and the contents of the packet The injections will be considered dull, white, watering Suspension in packs with 1, 5 or 10 prefabrication to each 3 ml."</seg>
<seg id="1067">The movement must be repeated until the liquid is consistent and trapped • After the restrades perform all the following steps of injections without delay.</seg>
<seg id="1068">• Desinfect the rubber compound with a medical pot • Benefull up a new injector • Refill out the protective lasche from a Novofine S injections • Screw the injector of a Novofine S injection chap (picture 1B) • Zithrowing the great outer injections and the inner injections.</seg>
<seg id="1069">"• Controlment you always suppose if the regulator is complete, and the dosisregler is placed on zero • Make the number of units you need to rotate the number of units by turning the dosisers in clockwise (figure 2)."</seg>
<seg id="1070">Do not use the residual scale to measure your Insulindosis • You listen to each individually set unit a client.</seg>
<seg id="1071">Perform the injection technology that has shown your doctor • Enter the dose by pressing the button (figure 3).</seg>
<seg id="1072">"the dosisregler is on zero back and you listen to the injections • The injector needs to stay at least 6 seconds long under the skin, because the dosisers must not be block at zero, since you press the injections • Remove the injecting nadel according to the injection."</seg>
<seg id="1073">"medical personnel, family, and other operators have to consider general precautions to removal and disposal of injections to prevent unintentional embroidery with the injections."</seg>
<seg id="1074">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1075">"► in Insulininfusionspumpen ► When the FlexPen has been abandoned, damaged or broken, is the danger of expiration of insulin ► if it was not correct or frozen (see 6 How is Actraphane to preserve?)" "if it is not equivalent to the reseller."</seg>
<seg id="1076">"if you notice deepening or thicknesses of your skin on the injection, tell your doctor or your Diabetesberaterin about it, because these reactions can affect yourself or the inclusion of your insulin, if you have injected into such a place."</seg>
<seg id="1077">"274 If any of the listed side effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1078">"in use sensitive flexPen manufacturing and such that will be used shortly or as a replacement, are not kept in the fridge."</seg>
<seg id="1079">It is recommended - after it was removed from the refrigerator - the temperature of the FlexPen ready to rise in room temperature before the Insulin according to the manual for the first use of resusement.</seg>
<seg id="1080">"let the disconnection of your flex Pen is always set, if flexPen is not in use to protect the insulin from light."</seg>
<seg id="1081">"as Actraphane, and the contents of the packet The injections will be considered dull, white, watering Suspension in packs with 1, 5 or 10 prefabrication to each 3 ml."</seg>
<seg id="1082">"manufacturer The manufacturer can be identified by the Chargers' designation, which is printed on the lashing of the cartons and on the label, are identified."</seg>
<seg id="1083">"275 • In the second and third place of the Chargen name the character combination W5, S6, P5, K7, K7, K7, K7, K7, Novo Allé, DK-2880 Bagte, DK, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B Move the production lines between positions 1 and 2, so that the glass ball from one end of the cartridge to the other moves."</seg>
<seg id="1085">Move the production pen at least 10 times between positions 1 and 2 on and down to the liquid uniform white and trendy.</seg>
<seg id="1086">"• Um to reduce the risk of unintentional needle, you never put the inner touch on the injections again after you have taken them once."</seg>
<seg id="1087">279 G Hunting the FlexPen with the injector up and knock a few times with the finger easily against the cartridge so that there are available airblases above on the cartridge.</seg>
<seg id="1088">The dosage can be corrected both at the top and downwards by turning the dosage to the appropriate direction until the correct dose opposite the markings of the display.</seg>
<seg id="1089">"this document is a summary of the European Public Prosecutational Report (EPAR), which explains how the Committee for Humanitration (CHMP) has been judged to reach recommendations regarding the application of the drug."</seg>
<seg id="1090">"an effective element in Actrapid, Insulin human (rDNA), is produced with the procedure of the so called" recombinant technology ":"</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu</seg>
<seg id="1092">Actrapid may not be used in patients that may possibly be sensitive to insulin human (rDNA) or any of the other components.</seg>
<seg id="1093">"in addition, the doses of Actrapid may be adjusted when it is administered along with a number of other medicines which can affect blood sugar."</seg>
<seg id="1094">October 2002 the European Commission commissioned the company Novo Nordisk A / S approve the approval of Actrapid in the entire European Union.</seg>
<seg id="1095">"if two types of insulin mixed, first the amount of the refuge will be raised, then the quantity of the long-acting insulin."</seg>
<seg id="1096">"3 If changing to Actrapid in the patient a dosage adjustment is required, this can be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1097">"travelling to travelling over several times, the patient should be pointed to the Council of his physician, since such trips can lead to that insulin and meals must be applied or taken at other times."</seg>
<seg id="1098">"5 General diseases and complaints on the occasion of the occasion occasionally - Local oversensitivity, in the injustice, the Insulintherapy can occur local oversensitivity, swelling, itching, pain and hematom on the injections)."</seg>
<seg id="1099">"diabetics should therefore always have trauma gaps, sweets, biscuits or decreased fertility with awareness, treated with a intra-muscular or subcutaneous injection of glucoagon (0.5 to 1,0 mg) by a mustine assistant or by glucose, inintravenous by the doctor."</seg>
<seg id="1100">A clinical trial in a Intensive station to treat hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic sufferer (blood sugar 4,4 - 6,1 mmol / l) the Mortality around 42% reduced (8% compared to 4.2%). "</seg>
<seg id="1101">"the effect starts within half an hour, the active maximum will be reached within 1.5 to 3.5 hours, and the total duration is about 7 to 8 hours."</seg>
<seg id="1102">Children and young people The pharmacoinetic profile of Actrapid was investigated on a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1103">"the data is limited, however, the adoption is near that the pharmacoinetic profile in children and adolescents is similar to those of adults."</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0.5i.e. / ml - 1,0 i.e. / ml Insulin human in the Infusionfluids 0,9% D-Glucose and 10% D- Glucose with 40 mmol / l Caliumchloride are stable when using infusionbeutles made of polypropylene in room temperature for 24 hours long.</seg>
<seg id="1105">"11 If changing to Actrapid in the patient a dosage adjustment is required, this can be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1106">"travelling to travelling over several times, the patient should be pointed to the Council of his physician, since such trips can lead to that insulin and meals must be applied or taken at other times."</seg>
<seg id="1107">13 General diseases and complaints on the occasion of the occasion occasionally - Local oversensitivity during the injections during the Insulintherapy can occur local oversensitivity, swelling, itching, pain and hematom on the injections). "</seg>
<seg id="1108">"diabetics should therefore always have trauma gaps, sweets, biscuits or decreased fertility with awareness, treated with a intra-muscular or subcutaneous injection of glucoagon (0.5 to 1,0 mg) by a mustine assistant or by glucose, inintravenous by the doctor."</seg>
<seg id="1109">Children and young people The pharmacoinetic profile of Actrapid was investigated on a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1110">The intravenous use of Actrapid made of production or cartridges should be an exception and will only be made in situations where no flowmeters are available.</seg>
<seg id="1111">"if the change is necessary for Actrapid in the patient a dosage adjustment, this can be necessary during the first dosage or during the first weeks or months after the conversion."</seg>
<seg id="1112">21 diseases of the skin and the lower tissue tissue occasionally - Lipodystrophy At the injector can be created a lipodystrophy if failed to switch within the injection range.</seg>
<seg id="1113">Children and young people The pharmacoinetic profile of Actrapid was investigated on a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1114">29 diseases of the skin and the lower tissue tissue occasionally - Lipodystrophy At the injector can be created a lipodystrophy if cancelled within the injection range.</seg>
<seg id="1115">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="1116">Children and young people The pharmacoinetic profile of Actrapid was investigated on a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (aged between 13 and 17 years).</seg>
<seg id="1117">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="1118">"38 The clinical trial in a Intensive station to treat hyperglycemic (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic sufferer (blood sugar 4,4 - 6,1 mmol / l) the Mortality around 42% reduced (8% compared to 4.2%)."</seg>
<seg id="1119">"diseases of the immune system occasionally - Urtikaria, exanthem Very rare - anaphylaktic reactions symptoms generalized rinsect, including generalizable rash, cheapintestinal disorders, angioneurothic Ödem, breathing, low blood pressure and ohnness, unconsciousness."</seg>
<seg id="1120">46 A clinical trial in a Intensive station to treat hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic sufferer (blood sugar 4,4 - 6,1 mmol / l) the Mortality around 42% reduced (8% compared to 4.2%). "</seg>
<seg id="1121">In the fridge (2 ° C - 8 ° C) Not freezing The throughput in the envelope to protect the content from light to ascend: not in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended for use with Novo Nordisk Insulininjection-systems intended for actrapid penetration may only be used by one person</seg>
<seg id="1123">In the fridge (2 ° C - 8 ° C) Not freezing The cartridge in the Umcarton to protect the content from light to ascend: not in the fridge or over 30 ° C</seg>
<seg id="1124">Subcutaneous application tick use with Actrapid NovoLet are NovoFine injections provided to Actrapid NovoLet may only be used by one person</seg>
<seg id="1125">In the fridge (2 ° C - 8 ° C) Not freezing before light after breakthrough: not kept in the fridge or over 30 ° C</seg>
<seg id="1126">Subcutaneous application Zur use with Actrapid InnoLet are NovoFine S injections look at Actrapid InnoLet may only be used by one person</seg>
<seg id="1127">This means that about half an hour after you have applied it to decline your blood sugar and that the effect is about 8 hours.</seg>
<seg id="1128">► Check out using the label, whether it is about the correct insulin type. ► disinfect the rubber compound with a medical pot. "</seg>
<seg id="1129">"if this is not completely unexplored, if you get the throughput to your pharmacy, if it was not correct or frozen (see 6 How is Actrapid to retain?) ► When there is not clear as water and colourless."</seg>
<seg id="1130">Use the injection technology that has recommended your doctor or your Diabetesberaterin recommended as ► Lassen you have injecting the injector of at least 6 seconds long under your skin to ensure that the full dose has been injected.</seg>
<seg id="1131">"83 Are you your relatives, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately have to consume a doctor."</seg>
<seg id="1132">They may have a very rare severe allergic reaction to actrapid or one of its components (such called systemic allergic reaction).</seg>
<seg id="1133">"the injector solution is considered clear, colourless solution in packs with 1 or 5 flowmeters each 10 ml or a bundle packaging with 5 diameters to 10 ml each."</seg>
<seg id="1134">"89 Saving your own, friends and tight working, that they bring you in the case of conscience into the stable side, and immediately need to consume a doctor."</seg>
<seg id="1135">► Check out using the label, whether it is the right Insulintype you always check the cartridge including the rubber. "</seg>
<seg id="1136">"► in Insulininfusionspumpen ► When the Penfill or the device, which has been abandoned, damaged or broken; it is the danger of endurance in ► if it was not correct or frozen (see 6 How is Actrapid to retain?) ► When there is not clear as water and colourless."</seg>
<seg id="1137">"if you are treated with Actrapid Penfill and another Insulin in Penfill cartridges, you should use two insulin valve systems, each one for each insulin art."</seg>
<seg id="1138">"use the injection technology, which has been described your doctor or Diabetesberaterin and which was described in the operating instructions of your injection systems. ► For you to remove the injections of your injection systems at least 6 seconds long under your skin, to ensure that the full dose was injected to remove the injections and actrapid without up-up injections."</seg>
<seg id="1139">"• If on the second and third place of the charger designation of the W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark"</seg>
<seg id="1140">"• If on the second and third place of the batch name the character combination H7 or T6 is released, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1142">► Check out using the label, whether it is about the correct insulin type. ► Benefoot you are always a new injections to avoid a contamination. "</seg>
<seg id="1143">► in Insulininfusionspumpen ► When the NovoLet has been abandoned, damaged or depressed; there is the danger of expression of insulin ► if it was not correct or frozen (see 6 How is Actrapid to retain?) ► When there is not clear as water and colourless. "</seg>
<seg id="1144">"this may happen: • If you get too much insulin injecting, if you eat too little or give a meal • if you are more than usual physically tenant."</seg>
<seg id="1145">"let the disconnection of your NovoLet finished pens whenever he is not in use, to protect him from light."</seg>
<seg id="1146">Take the cap. • Desinfect the rubber compound with a medical pot • Benefull up a new injector attachment • Screw the injections of a NovoFine injections • Screw the injector of an NovoFine AoLet (picture A) • Zirow the large outer cap of the injector and the inner corrugation of the injections.</seg>
<seg id="1147">Go to avoid the injection of air to avoid and make a correct dosage: • Hold you Actrapid NovoLet with the injections upstairs • Klosters a few times with the finger slightly against the cartridge.</seg>
<seg id="1148">"if airblases are present, these are upwards in the cartridge • While you continue to upwards a click in the direction of the arrow (picture B) • During the injecting the injection (picture C) • Now you have to hit the injection head of the injector a drop in insulin."</seg>
<seg id="1149">"• If you put the workbook again in the finished pen, that the number 0 is facing the dosing stamp (Figures D) • Controlment you whether the printed knob is totally suppressed."</seg>
<seg id="1150">"if the pressure is not able to move freely, Insulin from the injisnadel pressed • The scale on the cap displays 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1151">"the printing knob moves to the outside, while you turn the cap • The scale under the pressure pot (regulator skala) shows 20, 40 and 60 units."</seg>
<seg id="1152">"107 • note the highest number that you can see on the drop of the button, • If you have set the two numbers, if you have a wrong dose to have a wrong dose, until you have set the correct number of units."</seg>
<seg id="1153">"turn them, down to the pressure knob totally below and you can take a resistance, then take the cap, and put them again on that the 0 of the dosing stamp."</seg>
<seg id="1154">Be sure to press only while injecting on the printing button • Keep the pressure knob according to the injecting up to the injector from the skin was removed.</seg>
<seg id="1155">"it is possibly inaccurate • you can not use a dose which is higher than the number of in the cartridge were remaining, but you can't use the balance in the cartridge still remaining, but you cannot use them to adjust your dose or select."</seg>
<seg id="1156">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1157">► in Insulininfusionspumpen ► When the Innolie was abandoned, damaged or depressed; there is the danger of expression of insulin ► if it was not correct or frozen (see 6 How is Actrapid to retain?) ► When there is not clear as water and colourless. "</seg>
<seg id="1158">"let the cap of your gnoLet finished pens whenever he is not in use, to protect him from light."</seg>
<seg id="1159">• Desinfect the rubber compound with a medical pot • Benefull up a new injector for an contamination by a NovoFine S injections • Screw the injector of an NovoFine S injecting the injector of the injector and the inner corrugation of the injections.</seg>
<seg id="1160">"the dosisregler is on zero back and you listen to the injections • The injector needs to stay at least 6 seconds long under the skin, since the dosisers must not be block at zero, since you press the injections • Remove the injector after each injection."</seg>
<seg id="1161">"antidiabetic antidiabetic (Mao-Hemmer), beta-enzyme, anatomy, Acetylsalicylic, anabricoids, Thiazide, Hecocortikoids, thyroympathetic, growth hormone, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1162">121 ► if it was not correctly abandoned or frozen (see 6 How is Actrapid to retain?) ► When there is not clear as water and colourless.</seg>
<seg id="1163">"if one of the listed unwanted effects you have considerably impaired or simply side effects, which are not specified in this usage information, please inform your doctor, your Diabetesberaterin or your pharmacist."</seg>
<seg id="1164">"let the disconnection of your flex Pen is always set, if he is not in use to protect him from light."</seg>
<seg id="1165">"F Keep the FlexPen with the injector up and knock a few times with the finger easily against the cartridge, in order to earn existing bubbles up in the cartridge."</seg>
<seg id="1166">The dosage can be corrected both at the top and downwards by turning the dosage to the appropriate direction until the correct dose compared to the marking of dosishness.</seg>
<seg id="1167">"Adenuric will be applied in patients who are already applied signs of crystal-deposits, including arthritis (pain and inflammation in the joints) or gypsum."</seg>
<seg id="1168">"if the uric cones, after two to four weeks still over 6 mg per decay, the dose may be increased once daily 120 mg once daily."</seg>
<seg id="1169">"during the first treatment rule, we can still occur gifted effect; therefore it is recommended that patients have at least during the first six months under treatment with Adenuric nor more medicines for the prevention of toxic accidents."</seg>
<seg id="1170">The medicine is not recommended in children and patients who had not examined an organtransplant as it was not examined for those groups.</seg>
<seg id="1171">"in the first study, at the 1 072 patients took part, the effectiveness of different Adenuric doses (once daily 80, 120 and 240 mg) with the one placebo (hymedikamente) and by Allopurinol (a different drug to treat hyperurikemia)."</seg>
<seg id="1172">In the second study two doses of Adenuric (once daily 80 and 120 mg) was compared with Allopurinol each year.</seg>
<seg id="1173">In both studies Allopurinol was used in a dose of once daily 300 mg; patients with kidney problems received only 100 mg per day.</seg>
<seg id="1174">"main indicator for the effectiveness was the number of patients, whose resin level in the blood for the last three measurements under 6 mg / dl."</seg>
<seg id="1175">"in the first study 48% (126 of 262) of patients, the Adenuric in a dose of once daily 80 mg participated, and 65% (175 of 269) of patients who once daily 120 mg once more than 120 mg / dl."</seg>
<seg id="1176">"compared to this, this was in 22% (60 of 268) of patients under Allopurinol and in none of the 134 patients under placebo of the case."</seg>
<seg id="1177">"the most common side effects of Adenuric (observed in 1 to 10 of 100 patients) are headache, infestation, nausea and normal liver values."</seg>
<seg id="1178">"especially in patients with heart conditions, there is possibly an increased risk of certain side effects that affect the heart and blood vessels."</seg>
<seg id="1179">"the Committee for Humanarzneira (CHMP) wrote to the conclusion that Adenuric was more effective in the lowering of the uric blood in the blood, but also a higher risk of side-side effects in connection with the heart and blood vessels."</seg>
<seg id="1180">"treatment of chronic hyperurikemia in diseases, who have already led to Uratabdeposits (including one from the nursing-history or currently present Gichtknots and / or a gifted)."</seg>
<seg id="1181">If the Serumharic cones after 2-4 weeks still &gt; 6 mg / dl (357 µmol / l) can be considered a dosage of ADENURIC 120 mg 1 x daily.</seg>
<seg id="1182">"in patients with severe kidney functions, the effectiveness and safety has so far not been studied (Creatinin- Clearance &lt; 30 ml / min, see section 5.2)."</seg>
<seg id="1183">"children and young people there are no experiences with children and young people, the application of Febuxostat in this patient group is not recommended."</seg>
<seg id="1184">"organtransplant, There is no experiences there at organtransplant, the application of Febuxostat in this patient group is not recommended (see section 5.1)."</seg>
<seg id="1185">Cardiovascular diseases At patients with the iconic cardiac disease or dekompromissticism is not recommended (see Section 4.8).</seg>
<seg id="1186">"as with other haric drugs, it can occur during treatment's face to an acute Gidecay, because through the lowering of the Serumharic asel, at first mobilizing in tissues can be mobilized in the tissues."</seg>
<seg id="1187">"B. in maligs diseases and their treatment, Leschiera Nyhan-syndrome) the absolute concentration of Xanthin in rare cases do so far rise, that it comes to a storage in the urinary tract."</seg>
<seg id="1188">Liver disease During the clinical trials of phase 3 were observed an easy payable levels of the Living environment with Febuuxostat patients treated (3.5%).</seg>
<seg id="1189">It is therefore recommended to perform an liver function before the beginning of the Febuxendostattreatment and further course according to clinical powers (see section 5.1).</seg>
<seg id="1190">Theophyllin Zophyllin Zophyllin was not carried out of interactivating studies at Febuxostat but it is known that the XO inscription can lead to an increase in theophysaophylline (an inhibition of metamorphosis of Theophyllin has also been reported for other XO-Hemmer).</seg>
<seg id="1191">At Probanden was the simultaneous Gabions of Febuxostat and Naprox 250 mg 2 x daily with a rise of Febuxtimatexposition (Cmax 28%, AUC 41% and t1 / 2 26%). "</seg>
<seg id="1192">In clinical studies the application of Naprox or other NSAR / Cox-2 shirts not in connection with a clinically significant increase in unwanted events.</seg>
<seg id="1193">Colchicetacin / Indometacin / hydrochlorthiazid / Warfare in Febuxostat can be applied together with Colchicine or Indometacin at the same time a dosage adjustment for Febuxostat or at the same time required.</seg>
<seg id="1194">"in a study with Probanden, 120 mg ADENURIC 1 x daily a medium 22% increase in AUC von Desipramine, a CYP2D6 substrate, which has been points on the CYP2D6-enzyme in vivo."</seg>
<seg id="1195">"Antazida It could be shown that simultaneous intake of a antacid, the magnesium hydroxid and aluminum hydroxid (around 1 hour) delay and a decrease in the Cmax around 32%, but no significant change in AUC causes."</seg>
<seg id="1196">Pregnancy data on a very limited number of exponed pregnancies do not leave at side effects of Febuxostat to pregnancy or the health of Fetus / newborn.</seg>
<seg id="1197">Animal experimental studies do not leave direct or indirect harmful effects on pregnancy, embryonic development or birth (see Section 5.3). "</seg>
<seg id="1198">Patients should be careful when taxes of a vehicle control to be careful from machines or in the exercise of hazardous activities until they may be somewhat sure that ADENURIC influences their performance.</seg>
<seg id="1199">A numerically higher inincidence of the test doctor reported cardiovascular events was observed in the total of the Allopurinol group in the pivotal study of phase 3 (1.3 versus 0.7 events per 100 patient-years) and in long term studies (1.4 versus 0.7 events per 100 patient-years) and could not be observed any statistical connection with Febuxostat.</seg>
<seg id="1200">The risk factors in these patients were a arterioskland erotic disease and / or a myokardinfarkt or a dekompendictive herziness in the disease history.</seg>
<seg id="1201">"frequent (≥ 1 / 100 to &lt; 1 / 10), occasional (≥ 1 / 1,000 to &lt; 1 / 1000) and rare (≥ 1 / 10.000 to &lt; 1 / 1000) side effects, which could be reported in the treatment group with 80 mg / 120 mg Febuxostat and the (test assessment) in a total of more than once reports, are presented in the following."</seg>
<seg id="1202">"infestation, nausea and break are more common in patients who are treated simultaneously with Colchicin. * * In the clinical studies have been observed in severe rashes or serious survival."</seg>
<seg id="1203">7 Offs long-term studies have been treated up to 906 patients up to 1 year long, 322 patients up to 2 years long, 57 patients up to 3 years and 53 patients treated up to 4 years with Febuxostat 80 mg / 120 mg. "</seg>
<seg id="1204">The events reported during the long term studies were reported similar to which in the studies of the Phase 3 were reported (see chart 1).</seg>
<seg id="1205">"the following treatment-related events were reported in all of the Febuxostat- treatment group more than once and occurred in patients, the Febuxostat 80 mg / 120 mg in long period of long-term studies (up to 4 years with an expositional period of &gt; 1,900 patients" years), the information that occasionally occasionally. "</seg>
<seg id="1206">The following treatment of events have been reported in the pivotal studies of phase 3 for these doses either not reported or with a lower incidence:</seg>
<seg id="1207">"diabetes, hyperlipidemia, sleeplessness, hioneness, racks, racks, rarities, protectal, protocolateness, erectile dysfunction, increase of potassium concentration in the blood, decline of the TSH concentration in the blood, decrease in the number of white blood cells."</seg>
<seg id="1208">Working mechanism Haric acid is in humans the end product of Purinmetism and arises within the scope of the reaction of hyxanthin → Xanthin → Haric acid.</seg>
<seg id="1209">"Febuxostat is a real, not Purin selective Inhibitor the XO (NP-SIXO) with a knee-value for those in vitro-inhibition, located below the nanomolar area."</seg>
<seg id="1210">Clinical study results The effectiveness of ADENURIC was described in two pivotal studies of phase 3 (APEX study and fact study as described below) which were conducted with 1.832 patients with hyperurikemia and greens.</seg>
<seg id="1211">The primary ingredient item was in every study of the patients in which the last three month of certain serum haric cones &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1212">Placebo (n = 134), ADENURIC 80 mg 1 x daily (n = 269), ADENURIC 120 mg 1 x daily (n = 269), ADENURIC 120 mg 1 x daily (n = 10) for patients with a Serumkreatininvalue at the course of &gt; 1.5 mg / dl and ≤ 2.0 mg / dl. "</seg>
<seg id="1213">The APEX study showed in terms of lowering the Serumharic cones under 6 mg / dl (357 µmol / l) (see chart 2 and figure 1) the statistically significant cans with ADENURIC 120 mg 1 x daily as well as with ADENURIC 120 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The fact-study showed with regard to the permanent lowering of the Serumharic lamination under 6 mg / dl (357 µmol / l) 1 x daily as well as with ADENURIC 120 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to the treatment of the usual dosage of Allopurinol 300 mg.</seg>
<seg id="1215">Patients with Serumkreatinans &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were collected for the analyses. * p &lt; 0.001 versus Allopurinol, # p &lt; 0,001 versus 80 mg</seg>
<seg id="1216">Lowering of the Serumharic asespiegels on &lt; 6.0 mg / dl (357 µmol / l) was observed in week 2 and maintain permanently over the entire treatment.</seg>
<seg id="1217">509 patients received Allopurinol 300 mg 1 x daily; 10 patients with Serumkreatinans &gt; 1.5 and &lt; 2.0 mg / dl received 100 mg 1 x daily.</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with kidney-division The APEX study was carried out the effectiveness of 40 patients with kidney-functionality (d.).</seg>
<seg id="1219">With ADENURIC was the primary ingredient item at 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily). "</seg>
<seg id="1220">There was no clinically significant differences in relation to the percentage of the Serumharic diseases in Probanden, irrespective of their kidney function (58% in the group with normal kidney function and 55% in the group with severe kidney dysfunctions). "</seg>
<seg id="1221">Primary endpoint in the subgroup of patients with Serumharic concentrations ≥ 10 mg / dl About 40% of the patients (APEX- and fact-study) had to study the course of ≥ 10 mg / dl.</seg>
<seg id="1222">The data collected in two years of the open extension study of the phase 3 showed that the permanent lowering of the Serumharic cones on &lt; 6 mg / dl (&lt; 357 µmol / l) a withdrawal of the incidence of toxic accidents (i.e. more than 97% of the patients required no treatment against a giftset).</seg>
<seg id="1223">"this was also associated with a reduction in the givile size, which at 54% of patients had a complete disappearance of the gifted up to month 24."</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostat (5,0%) and also in patients who received Allopurinol (5.8%) in open long term case studies (see section 4.4).</seg>
<seg id="1225">At healthy Probanden increased the maximum plasmaconconcentrations (Cmax) and the area under the Plasmaconcentric-time curve (AUC) of Febuxostat after appointments, simpler and multiplers cans of 10 mg to 120 mg doses proportional. "</seg>
<seg id="1226">"for doses between 120 mg and 300 mg is observed for Febuxostat an increase in AUC, which is greater than the dosdisproportionale increase."</seg>
<seg id="1227">"after taking easier or multiplers from 80 and 120 mg 1 x daily amounts approximately 2,8-3,2 µg / ml and 5,0-5,3 µg / ml."</seg>
<seg id="1228">"however, no clinically significant change was observed in the percentage of Serumharic concentration, provided that this has been tested (multiple doses of 80 mg)."</seg>
<seg id="1229">Distribution The seeming steady-state capacity (Vss / F) of Febuxostat is located in the range from 29 to 75 l after intake of cans of 10-300 mg.</seg>
<seg id="1230">The plasmaproteinformation of Febuxostat is approximately 99.2% (primary binding at Albumin) and is via the concentrates width that is reached with cans of 80 and 120 mg is constant.</seg>
<seg id="1231">"in vitro-studies in humanen Lebermikrosomen showed that these oxidative metals can be formed primarily by CYP1A1, CYP1C8 or CYP1A2, CYP1C8 or CYP2C9, and that Febuxostatglucoonid mainly generated by UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">After taking a 80 mg dose of 14C-marking Feb. at about 49% of the dose in the urine as unaltered Febuonid of the ingredient (30%), its well-oxidative metabolic and their conjugate (13%) as well as other unknown metabolic (3%). "</seg>
<seg id="1233">"in addition to the excretion over the urine also found approximately 45% of the dose as unaltered Febuxostat (12%), Acyl glucoonid of the ingredient (1%), its well-oxidative metabolic and their conjugate (25%) as well as other unknown metabolic (7%)."</seg>
<seg id="1234">Specific patient groups after taking multiplers in excess of 80 mg ADENURIC with patients with mild, moderate or heavy kidney-inefficiency changed the Cmax of Febuxostat not in relation to Probanden with normal kidney function. "</seg>
<seg id="1235">The average overall-AUC of Febuxostat around about the 1.8-fold of 7.5 μ in a group of normal kidney function on 13,2 μ g / ml in the group with severe kidney-function. "</seg>
<seg id="1236">12 Leberfunctionalentanglement After taking multi-pler cans of 80 mg ADENURIC with patients with mild (child-Pugh Classification A) or moderate-harder (Child-Pugh-classification B) the Cmax and AUC from Febuxostat and its metabolic are not significant compared to Probanden with normal liver function.</seg>
<seg id="1237">Age There were no significant changes in terms of the AUC of Febuxostat or whose metabolic doses for taking multiplers of ADENURIC with older patients compared to younger propositions.</seg>
<seg id="1238">"carcogenesis, mutagenesis, impairment of the inertility In male rebel has been a statistically significant increase of urinary cutters (Transitionpapillins and Karzinomes) only in connection with Xanthin stones in the high doses of exposure to humans, found."</seg>
<seg id="1239">These findings are seen as a result of a special Purinmetabolization and prefabrication and for the clinical use as not relevant.</seg>
<seg id="1240">It was established that Febuxostat in oral cans of up to 48 mg / kg / day does not have effect on the inertility and reproductions of male and female rats.</seg>
<seg id="1241">"at high doses, which stood about 4,3- for the humanititic exposure, joined maternal toxicity, entered with a lowering of the performance and a development delay in the offspring of rats."</seg>
<seg id="1242">"Teratologic studies at contracting oceses with expositions, the approximately 4,3-fold and in the tragic rabbits with expositions which is about the 13-fold the human therapeutic exposition, no teratogenous effects."</seg>
<seg id="1243">Colchicetacin / Indometacin / hydrochlorthiazid / Warfare in Febuxostat can be applied together with Colchicine or Indometacin at the same time a dosage adjustment for Febuxostat or at the same time required.</seg>
<seg id="1244">"infestation, nausea and break are more common in patients who are treated simultaneously with Colchicin. * * In the clinical studies have been observed in severe rashes or serious survival."</seg>
<seg id="1245">21 Offs long-term studies have been treated up to 906 patients up to 1 year long, 322 patients up to 2 years long, 57 patients up to 3 years and 53 patients treated up to 4 years with Febuxostat 80 mg / 120 mg. "</seg>
<seg id="1246">The primary ingredient item was in every study of the patients in which the last three month of certain serum haric cones &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1247">The data collected in two years of the open extension study of the phase 3 showed that the permanent lowering of the Serumharic cones on &lt; 6 mg / dl (&lt; 357 µmol / l) a withdrawal of the incidence of toxic accidents (i.e. more than 97% of the patients required no treatment against a giftset).</seg>
<seg id="1248">"26 as unaltered Febuxostat (3%), Acyl glucoonid of the ingredient (30%), its known oxidative metabolic and their conjugate (13%) as well as other unknown metabolic (3%)."</seg>
<seg id="1249">Leberfunctionalentanglement After taking multi-pler cans of 80 mg ADENURIC with patients with mild (child-Pugh Classification A) or moderate-heavy (Child-Pugh Classification B) and his metabolic are not significant compared to Probanden with normal liver function.</seg>
<seg id="1250">"carcogenesis, mutagenesis, impairment of the inertility In male rebel has been a statistically significant increase of urinary cutters (Transitionpapillins and Karzinomes) only in connection with Xanthin stones in the high doses of exposure to humans, found."</seg>
<seg id="1251">"the owner of the authorization may be made sure that a pharmaovigilance system is described as in version 2.0 module 1.8.1 of the authorisation item, ready before the medicine is brought into traffic, and so long is available as the medicine used in traffic."</seg>
<seg id="1252">"in compliance with the CHMP guideline at risk management systems for human resources, with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1253">"in addition, an update of the program is required • If new information occurs, which have an effect on the safety measurements, the Pharmakovigilance plan or activities on the risk inspection, • within 60 days after reaching more important milestones (Pharmakovigilance or Risikominimation) • to request the EMEA"</seg>
<seg id="1254">"in some people the uric acid in the blood and can reach concentrations, which is so high that Haric acid is unsoluble."</seg>
<seg id="1255">"if you keep the uric concentration through the 1 x daily intake of ADENURIC, the crystallation is prevented and achieved in this way with the time a mination of complaints."</seg>
<seg id="1256">ADENURIC must not be taken (allergic) against the ingredient of Febuxostat or one of the other components of ADENURIC.</seg>
<seg id="1257">"inform your doctor before you begin with taking this medication by using, • If you have a heartfelt or had or at any other heart problem. • If you have a heartfelt disease in consequence of a cancer disease or Lesch-Nyhan-syndromes (a rare condition in the blood), where you can find a lot of uric acid in the blood)."</seg>
<seg id="1258">"if you have a giantancase at the moment (sudden appearance of heavy pain, hypersensitivity, redness, heat transfer and money-swelling), wait before you start with the treatment with ADENURIC."</seg>
<seg id="1259">"that does not have to be in any way, but also with you, especially during the first treatment weeks or - months, occur if you take ADENURIC."</seg>
<seg id="1260">Your doctor will write to you any other medicines or to treat a gifted effect or to treat the associated symptoms (such as pain and joints).</seg>
<seg id="1261">"please inform your doctor or pharmacist if you are taking other medicines or have recently taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="1262">It is particularly important that you can take your doctor or pharmacist when you can take pharmaceuticals / apply as interaction with ADENURIC (for the treatment of cancer) • Theophylurin (for the treatment of asthma) • Theophylin (for the treatment of asthma) • Gophylin (for the blood of asthma) • limbs (for blood diseases)</seg>
<seg id="1263">No studies have been carried out on the effects of ADENURIC on the transport system and the ability to operate machines.</seg>
<seg id="1264">Please take ADENURIC therefore only after returning with your doctor if you know that you suffer from a intolerance towards certain sugar.</seg>
<seg id="1265">"on the back of the blister packs the single weekdays are pressurized, so you can check if you have taken a tablet. • The tablets need to be swallowed and can be taken with or without food."</seg>
<seg id="1266">"if you have not taken an overdose, please contact your doctor or to the emergency of the nearest hospital house."</seg>
<seg id="1267">"if you have forgotten the intake of ADENURIC, you will pick this quicker after, unless the next intake is shortly before."</seg>
<seg id="1268">"if you break the intake of ADENURIC, your uric concentration can rise again, and your complaints can be wasted out, because new judgment can be formed in your joints and kidneys, as well as their surroundings."</seg>
<seg id="1269">Frequent Effects (more than 1 of 100 patients treated but less than 1 of 10 treatable): • strives • Headache • Headache • rashes • nausea</seg>
<seg id="1270">"rare side effects (more than 1 of 10,000 treated, but less than 1 of 1,000 treated): • weakness • nervousness • Durability"</seg>
<seg id="1271">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="1272">ADENURIC is available in 2 blister packs with 14 tablets (pack of 28 tablets) or in 6 blister packs with 14 tablets (pack of 84 tablets).</seg>
<seg id="1273">- In case of heavy-duty cycle Epsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">Danmark, Norge, Suomi / Finland, Sverige, Ísland Institut produits Synthieves 33 SE - 164 51 Kista Sverige / Ruotþjóda Phone / Tlf / puh / Sími: + 46 8 588 370 70</seg>
<seg id="1275">"ADROVANCE is used for treatment of osteoporosis (a disease, where the bone breaks can be used in women after menopause, where a risk for a low vitamin D mirror."</seg>
<seg id="1276">"the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drink or immigrants (including antacid, calcium and vitalpenalties)."</seg>
<seg id="1277">"to avoid a maturity of the esophagus, the patient must take place until after the first food intake of the day, which shall take place at the earliest 30 minutes after taking the tablet."</seg>
<seg id="1278">"since Alendronat and vitamin D3 are already separated from each other in drugs that are approved in the European Union, the company placed data from earlier studies and published literature."</seg>
<seg id="1279">The company also carried out a study with 35 men and 682 postmenopausal women with osteoporosis by to mediate the effectiveness of ADROVANCE with regard to increasing the vitamin D reflection.</seg>
<seg id="1280">"after a 15-week treatment the proportion of patients with reduced vitamin D mirror was treated with ADROVANCE, which were treated with ADROVANCE (11%) than for those who took exclusively Alendronat (32%)."</seg>
<seg id="1281">"the company also put data before, which is shown in ADROVANCE included Alendronat-dose exactly the dose that is needed for preventing a bone lusts."</seg>
<seg id="1282">"the most common side effects (observed with 1 to 10 of 100 patients) are headaches, pain of movement apparats, dyspepilepsy (digestion), stiulence (digestion), stiulence (digestion), dysphagie (disruptions), dysphagie (gowl), splashagia (gaps), flashes abdomen (glowed belly), as well as sauces."</seg>
<seg id="1283">"in patients with any hypersensitivity (allergy) against Alendronat, vitamin D3 or any of the other components of ADROVANCE cannot be applied."</seg>
<seg id="1284">"it must not be applied in the diseases of the esophagus, in patients with Hypospcemia (light calories) or in patients who are not standing at least 30 minutes long or sitting."</seg>
<seg id="1285">Yanuar2007 the European Commission commissioned the company Merck Sharp & Dohme Ltd. a permit for the establishment of ADROVANCE in the entire European Union.</seg>
<seg id="1286">"capsule-shaped, white to broken white tablets, characterized with the extract of a bucks on one side and" 710 "on the other side."</seg>
<seg id="1287">"ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first food, beverage or immigrants (including antacid, calcium and vitamin supplements) for the day."</seg>
<seg id="1288">Following notes are precisely to follow to reduce the risk for malophageale irritation and related side effects (see section 4.4):</seg>
<seg id="1289">"• ADROVANCE should be switched after the day, only with a full glass of water (at least 200 ml). • The patients should not leave the tablet or tablet in the mouth, since a risk for oropharyngeal Ulzera. • The patients should not take place before the first food intake of the day, which shall take place at the earliest 30 minutes after taking the tablet."</seg>
<seg id="1290">B. pepper Ulcus, active gastrointestinal bleeding or surgical interventions in the upper Gastrointestinal cord except Pyloroplasty (see Section 4.3). "</seg>
<seg id="1291">"Ösophageal responses, such as Ösophagitis, malophageale Parrogers, rare followed by malophageal stripes, were reported by patients under the intake of Alendronat (partially were these severity and required an ambulance assignment)."</seg>
<seg id="1292">"the doctor is therefore attentive to all signs and symptoms, which should be pointed to possible malophageal irritation like dysphagie, pain while swallowing or retrospinal pain, or a new or sclimmering of heartburn the medicine (see section 4.8)."</seg>
<seg id="1293">"3 The risk of severe malophageal side effects seem to be raised in patients who do not take any correct, and / or after the occurrence of symptoms resulting in a malophageal irritation."</seg>
<seg id="1294">It is very important that all dosing instructions are passed on to the patient and be understood by the patient (see section 4.2).</seg>
<seg id="1295">"while in large the clinical trial with Alendronat no elevated risk was determined, were rare (according to market leadership) Mag- and Duodenalulzera, including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1296">"Osteonekrose of the jaws, usually reported in connection with a tooth extraction and / or a local infection (including Osteomyelitis), was reported in cancer pharynons predominantly dimentary bisphosphonate."</seg>
<seg id="1297">"there are no data available to give the indications if the depart of a bisphosphonate therapy in patients who need a kiefersurgical procedure, the risk of a osteonekrose of the jaws undermines."</seg>
<seg id="1298">The clinical assessment by the patient doctor is binding for therapy planning with each patient based on an individual benefit-risk assessment.</seg>
<seg id="1299">Patients should be dependent on taking a dose of taking a dose of ADROVANCE the tablet in the next morning after they have noticed.</seg>
<seg id="1300">"you should not take two tablets on the same day, but taking one tablet per week as originally planned to continue this weekday."</seg>
<seg id="1301">Other diseases that impaired the mineral change (such as vitamin D-lack and hypoparathyredentiality) should be treated before the beginning of the therapy with ADROVANCE.</seg>
<seg id="1302">"Alendronat foods and drinks (including mineral water), calcium-supplements, antazida and some oral medicines can affect the Resorption of Alendronat, when they are taken at the same time."</seg>
<seg id="1303">"therefore, patients must wait after taking Alendronat least 30 minutes before they take other medicines (see sections 4.2 and 5.2)."</seg>
<seg id="1304">"although specific Intergovernmental studies have not been carried out, Alendronat was taken jointly with a variety of usually prescribed medicines without having clinically relevant interactions."</seg>
<seg id="1305">ADROVANCE is intended solely for application in postmenopausal women and is therefore not responsible for pregnant women's pregnancy.</seg>
<seg id="1306">"animal studies with Alendronat leave no indication of directly compensating effects with regard to pregnancy, the embryonic / fetal or postnatal development."</seg>
<seg id="1307">"Osteonekrose of the jaws was reported in patients under Bisphosphonors, but most reports come from cancer patients, but was also reported with osteoporosis."</seg>
<seg id="1308">"nevertheless, the Serum-calcium intake up to &lt; 8.0 mg / dl (2,0 mmol / l) and the Serum - Phosphats up to ≤ 2.0 mg / dl (0,65 mmol / l) in both treatment groups with similar incidence."</seg>
<seg id="1309">"Alendronat as a result of a oral overdose may hypocalcemia, hypophosphatemia and side effects in the upper Gastrointestinal cord as magnets, Ösophagitis, Gastritis or Ulzera occur."</seg>
<seg id="1310">Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV light on the transformation of 7-stretching cholesterol concerning vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-Dihydroxyens D3 is increasing the intestinal resorption of calcium and phosphate, as well as the regulation of serum calcium, the renunciation of calcium and phosphate, the bone and bone ption."</seg>
<seg id="1312">"in severe cases, a lack of secondary hyperparathyreids, hypophosphatemia, weakness of the proximal musculature and Osteomalazie and so on an increased risk for steels and bone breaks with osteoporosis people."</seg>
<seg id="1313">"Bone mineral density) at the spine or hip, the 2.5 standard deviations under the mean value for a normal, young population is, or irrespective of bone-density than present pathological traffic."</seg>
<seg id="1314">Patients received ADROVANCE at lower strength (70 mg / 2.800 i.e.) (n = 350) or FOSAMAX (Alendronat) 70 mg once a week (n = 332); additional vitamin D supplement were prohibited.</seg>
<seg id="1315">After 15-week treatment the middle Serum mirror of 25-HydroxyeD (70%) in the group under ADROVANCE (70 mg / 2.800 i.e.) (56 nmol / l [23 ng / ml]) than in the group under Alendronat alone (46 µmol / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 i.e.) decreased significant after 15 weeks the proportion of patients with vitamin D infertility (Serve worth 25-hydroxyens D &lt; 37,5 nmol / l [&lt; 15 ng / ml]) around 62.5% compared to Alendronat alone (12% vs. "</seg>
<seg id="1317">Studies with Alendronat The therapeutic equalisation of alendronat once a week 70 mg (n = 519) and Alendronat 10 mg a day (n = 370) was proven in a multi-year-Multicultural study on postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronat on bone mass and frturinincidence at postmenopausal women were examined in two phase III studies of identical design (n = 944) as well as in the Fraktur Interventions- Study (FIT: N = 6.459).</seg>
<seg id="1319">In the phase III studies the middle councils of BMD with Alendronat 10 mg / day in relation to placebo after 3 years 8.3% at the spine, 5.9% at Femurhals and 7.4% at the Trochanter. "</seg>
<seg id="1320">"in the context of the placebo group was achieved compared to the placebo group a reduction of 48% (Alendronat 3,2% compared to placebo 6,2%) with the share of patients who suffered one or more spactures."</seg>
<seg id="1321">In the two-year renewal of these studies held the ascents of the BMD of spine and trochanter continues; also the BMD des Femurhalses and the entire body was stopped.</seg>
<seg id="1322">"fit consisted of two plazebokontroled studies, where Alendronat daily (5 mg every day above 2 years and then 10 mg a daily have been taken on either 1 or 2 years):"</seg>
<seg id="1323">In this study the daily gifts of alendronat the appearance of at least one new vertebral palaeum 47% (Alendronat 7.4% compared to placebo 15,0%).</seg>
<seg id="1324">Resorption against a intravenous reference was the mean orous bioavailability of Alendronat at women 0,64% for cans between 5 and 70 mg after nursing fasting and two hours prior to receiving a standardised breakfast. "</seg>
<seg id="1325">"the bioavailability took according to around 0.46% and 0,39% if Alendronat, one or half an hour before a standardised breakfast was taken."</seg>
<seg id="1326">"in osteoporosis, Alendronat was effective if it was taken at least 30 minutes before the first food or drinking of the day."</seg>
<seg id="1327">In healthy Probanden the gift of oratory prednison (20 mg three times a day above five days) in no clinically important variation of the orphanage of Alendronat (increase in the medium of 20% to 44%).</seg>
<seg id="1328">"9 distribution studies on rats have found that Alendronat arise according to intravengeous gifts of 1 mg / kg temporarily into wheat-divided, but then rapidly distributed in the bones, or by the urine."</seg>
<seg id="1329">"excretion After intravenous gift of a single dose of 14C-Alendronat, some 50% of radioactive marked substance within 72 hours with the Urin signpost and little or no radioactivity was re-found in the fastening."</seg>
<seg id="1330">According to intravenous gift of a single dose of 10 mg was the renal Clearance of Alendronat 71 ml / min and the systemic Clearance go not 200 ml / min.</seg>
<seg id="1331">Alendronat is not adowing to the saure or basic transport system of the kidneys signpost and therefore is not accepted that it affects people with the secretion of other medicines by these transport systems.</seg>
<seg id="1332">Resorption At healthy adult probanden (women and men) was following the gift of ADROVANCE after the gift of ADROVANCE after a meal of a meal the middle area under the Serum-concentration-time curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without considering charity vitamin D3 mirrors).</seg>
<seg id="1333">The average maximum concentration in Serum (Cmax) of vitamin D3 was 5,9 ng / ml and the mediation up to reaching the maximum Serumkonzentration (Tmax) 12 hours.</seg>
<seg id="1334">"biotope formalities vitamin D3 is measured rapidly in the liver quickly to 25-hydroxyens D3 hydroxyxyand then in the kidneys to 1,25-Dihydroxyens D3, the biologically active form, metabolized."</seg>
<seg id="1335">"Opening In case of gift of radioactive markered vitamin D3 to healthy Probanden was the average output of radioactivity in the urine after 48 hours 2,4%, in the fats after 4 days 4,9%."</seg>
<seg id="1336">"characteristics of the patient studies have shown that the proportion of Alendronat, who is not expired in the bones, quickly over the urine."</seg>
<seg id="1337">"although no clinical data can be imagined, nevertheless it is expected that the renal Elimination of Alendronat like in the animal is also reduced in patients with reduced kidney function."</seg>
<seg id="1338">"therefore, in patients with reduced kidney function is expected to be expected to expect a slightly increased accumulation of alendronat in the bones (see section 4.2)."</seg>
<seg id="1339">"Alendronat non-clinical data on basis of conventional studies on safety-harmacology, for chronic toxicity, for genotoxicity and the richest potential leave no particular hazards for men."</seg>
<seg id="1340">Studies on rats showed that the gift of alendronat abolic remembranes with the appearance of dystokie in the womens that was attributable to a hypocalcemia.</seg>
<seg id="1341">Micro-crystalline cellulose (E 460) Lactyl Siglyceride Gelatine Croscarmelodium Magnesium (Ph.Eur.) (E 572) Butylhydroxytoluol (Ph.Eur.) (E 321) strength, modified (Mais) Alaluminum natriumsilicat (E 554)</seg>
<seg id="1342">"Etui with sealed Aluminium / Aluminium-blister packs in Umcartons to 2 (1 Etui with 4 tablets), 6 (3 Etuis with 4 tablets), 12 (3 Etuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"rectangular, white to broken white tablets, characterized with the extract of a bucks on one side and" 270 "on the other."</seg>
<seg id="1345">"13 • The patients should not lie down after taking the ADROVANCE at least 30 minutes. • ADROVANCE should not be taken before bedtime, or before the first appearance of the day."</seg>
<seg id="1346">"the risk of severe malophageous side effects seem to be raised in patients who do not take any correct, and / or after the occurrence of symptoms resulting in a malophageal irritation."</seg>
<seg id="1347">"while in large the clinical trial with Alendronat no elevated risk was determined, were rare (according to market leadership) Mag- and Duodenalulzera, including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) vitamin D3 is produced in the skin by UV light on the transformation of 7-stretching cholesterol concerning vitamin D3.</seg>
<seg id="1349">Patients received ADROVANCE at lower strength (70 mg / 2.800 i.e.) (n = 350) or FOSAMAX (Alendronat) 70 mg once a week (n = 332); additional vitamin D supplement were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once a week was shown once a 24-week extension study of 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24-week treatment the middle Serum mirror of 25-hydroxyeD is significant higher in the 5.600-I.E.-vitamin D3-group (69 nmol / l [27.6 ng / ml)) than in the 2.800-I.E.-vitamin D3-group (64 nmol / l [25,5 ng / ml]). "</seg>
<seg id="1352">There was no statistical difference between the treatment of patients at the end of the patients with hypertension in the end of the 24-week extension.</seg>
<seg id="1353">3.8% of the entire hip in the group with 70 mg once a weekly or 10 mg a day.</seg>
<seg id="1354">In this study the daily gifts of alendronat the appearance of at least one new vertebral palaeum 47% (Alendronat 7.4% compared to placebo 15,0%).</seg>
<seg id="1355">"the bioavailability took according to around 0.46% and 0,39% if Alendronat, one or half an hour before a standardised breakfast"</seg>
<seg id="1356">Distribution studies on rats have found that Alendronat rose up after intravenious Gabe of 1 mg / kg temporarily into wheat-divided, but then rapidly distributed in the bones or by the urine. "</seg>
<seg id="1357">Resorption At healthy adult probanden (women and men) was after the gift of ADROVANCE (70 mg / 5.600 i.e.) after the opening of a meal the middle area under the Serum-concentration-time curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without regard to endogenic vitamin D3 mirrors).</seg>
<seg id="1358">The average maximum concentration in Serum (Cmax) of vitamin D3 was 12,2 ng / ml and the mediation up to reaching the maximum Serumkonzentration (Tmax) 10.6 hours. "</seg>
<seg id="1359">Smaller amounts are spread in fat and muscle tissue and are stored there as vitamin D3 to be retrieved later into the cycle.</seg>
<seg id="1360">21 vitamin D3 is rapidly processed in the liver quickly to 25-hydroxyens D3 hydroxyxyand then in the kidneys to 1.25-Dihydroxyens D3, the biologically active form, metabolized. "</seg>
<seg id="1361">No evidence has been found on a saturation of the pity of the garlic after longitude of cumulative intravenous doses up to 35 mg / kg in animals.</seg>
<seg id="1362">"Etui with sealed Aluminium / Aluminium-blister packs in Umcartons to 2 (1 Etui with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1363">"Pharmakovigance system The owner of the authorization has been able to make sure that a pharmaovigilance system is described as in version 2 module 1.8.1, the filing is available, and so long is available, as the market-marktated medicines will be brought into traffic."</seg>
<seg id="1364">"risk-Management Plan The owner of the authorization is committed to the author, studies and other pharmaovigilance Plan, which are described in the risk management plan (RMP) and his corresponding updates according to Version 1 module 1.8.2 of the authorisation of authorisation."</seg>
<seg id="1365">A later document in accordance with CHMP guideline at risk management systems for Humanity cutting systems with the next Periodic Saftey Update Report (PSUR).</seg>
<seg id="1366">"in addition, an update of the RMP - if new information is required, which have an effect on the safety fields, pharmaovigilance plan or activities to risk management (Pharmakovigilance or Risikominimation) − upon request of EMEA"</seg>
<seg id="1367">"take an ADROVANCE tablet according to you and before the first food and drink and before taking all other medicines, trying to swallow the tablet with a full glass of water (not with mineral water)."</seg>
<seg id="1368">"maybe you would like to read this later again. • If you have further questions, please contact your doctor or pharmacist. • This medicine was personally prescribed for you."</seg>
<seg id="1369">"in the interruptions, the eggs produce no female hormones, estrogen, more that help the skeleton of women healthy."</seg>
<seg id="1370">"the Brüche usually arise at the hip, the spine or the wrist and can not only cause pain, but also significant problems such as a curved attitude (" Witwenbuckel ") and a loss of flexibility."</seg>
<seg id="1371">"ADROVANCE prevents not only loss of bone mass, but also contributes to the bone of bone and decreasing the risk of spinal and hats."</seg>
<seg id="1372">"simplification of the esophagus or canyons (3) if it is not possible to sit down or stand up at least 30 minutes or stand, (4) if your doctor has established that your calcium content is lower in the blood."</seg>
<seg id="1373">"40 • If you have problems when selecting or having digestion, • If you have a sodium in the blood, • If you have cancer, • If you have cancer, • If you have a chemotherapy or radiation treatment, • If you do not go routinage to dental care."</seg>
<seg id="1374">These complaints can then occur in particular if the patients take the ADROVANCE tablet with a full glass of water and / or before expiry of 30 minutes after intake.</seg>
<seg id="1375">"for taking ADROVANCE with other medicines for calcium supplements, antazida and some other medicines for inserting the effectiveness of ADROVANCE at simultaneous intake."</seg>
<seg id="1376">"certain medicines or food additives may hinder the inclusion of the ADROVANCE contained in ADROVANCE, including artificial feeding, mineral, organs and the cholesterinsenkenden medicines cholestyramine and colestipol."</seg>
<seg id="1377">"please inform your doctor or pharmacist if you are taking other medicines or have recently taken / applied, even if it is not prescription-prescription medicine."</seg>
<seg id="1378">"please take this medicine only upon consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="1379">"please follow the hinder 2), 3), 4) and 5) to facilitate the transport of ADROVANCE tablet into the stomach and to make possible irritation of esophagus (Ösophagus - the tube, which connects your mouth with the stomach)."</seg>
<seg id="1380">(2) Take the ADROVANCE tablet according to the first appearance and prior to intake of any other medicines only with a full glass (minimum 200 ml) water (not with mineral water). • Not with mineral water or tea. • Not with saffron or milk.</seg>
<seg id="1381">(3) Do not go out - stay totally erect (sitting in the sitting or toes) - at least 30 minutes after taking the tablet.</seg>
<seg id="1382">"(5) If you have trouble or pain in the glow, pain behind the breast, replaceable, or to burn worse, ADROVANCE from and seek your doctor."</seg>
<seg id="1383">"(6) Wait according to the closing of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as antacid (magnetic-binding drugs), calcium or vitampreparate on this day."</seg>
<seg id="1384">"should you accidentally taken too many tablets at once, drink a full glass of milk and turn right to your doctor."</seg>
<seg id="1385">"if you have failed to take the intake of a tablet, take only one tablet in the next morning after you have noticed your atonement."</seg>
<seg id="1386">"frequently: • acid incubble; gings are embarrassed; pain in the canyons, socks of the esophagus (Ösophagus - the tube, which can cause your mouth with your stomach, • bone, muscle, and / or yellowing, • abdomen; boothing; persoils, • headaches; • Headache."</seg>
<seg id="1387">"occasionally: • nausea; break, • irritation and inflammations of the esophagus (Ösophagus - the tube, which combines your mouth with your stomach) or the magnude skin, • black or teembraced chair, • rash; juckwise skin."</seg>
<seg id="1388">"according to market entry, the following side effects have been reported (Frequently do not know): • (swivel) swelling, • fatigue, • hair loss, • orthodontics (Osteonekrose) in conjunction with the delay of teeth, • swelling of teeth, • swelling on hands or legs."</seg>
<seg id="1389">43 Dropbox is it helpful when you notice what complaints you had when they began and how long they stopped.</seg>
<seg id="1390">"the other components are microcrystine Cellulose (E 460), Lactosis, midsize Triglyceride, biscuits, high-quality silicon (Ph.Eur.) (E 321), Butyl hydroxytoluol (Ph.Eur.) (E 321), strength, modified (Mais), and aluminium-natriumsilicat (E 554)."</seg>
<seg id="1391">The tablets are available in Etuis with sealed aluminium / Aluminium-Blisterpackungen • 4 tablets (1 Etui with 4 tablets in aluminium-blister packs) • 12 tablets (3 Etuis with 4 tablets in aluminium-blister packs) • 40 tablets (10 Etuis with 4 tablets in aluminium-blister packs).</seg>
<seg id="1392">"in the interruptions, the eggs produce no female hormones, estrogen, more that help the skeleton of women healthy."</seg>
<seg id="1393">"48 • If you have allergies, • If you have problems when selecting or digestion, • If you have problems when you have cancer, • If you have cancer, • If you have cancer, • If you have a chemotherapy or radiation treatment, • If you do not go routinage to dental care."</seg>
<seg id="1394">"for taking ADROVANCE with other medicines for calcium supplements, antazida and some other medicines for inserting the effectiveness of ADROVANCE at simultaneous intake."</seg>
<seg id="1395">2) Take the ADROVANCE tablet according to the first appearance and prior to intake of any other medicines only with a full glass (minimum 200 ml) water (not with mineral water). • Not with mineral water or tea. • Not with saffron or milk.</seg>
<seg id="1396">"3) Leave you out, stay completely upright (sitting in the sitting or toes) - at least 30 minutes long after taking the tablet."</seg>
<seg id="1397">"5) If you have trouble or pain in the glow, pain behind the breast, replaceable, or to burn worse, ADROVANCE from and seek your doctor."</seg>
<seg id="1398">"6) Wait according to the closing of your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as antazida (magnetic-binding drugs), calcium or vitampreparate on this day."</seg>
<seg id="1399">"• (turning) swelling, • fatigue, • hair loss, • orthodontics (Osteonekrose) in conjunction with pushing soundproofing and infections, often after the naming of teeth, • swelling on hands or legs."</seg>
<seg id="1400">"tablets are available as rectangular, white to broken white tablets, characterized with the extract of a bucks on one side and" 270 "on the other."</seg>
<seg id="1401">Advocates will be administered for grown patients where a kidney or liver transplants to prevent the transplants of transplants through the immune system.</seg>
<seg id="1402">"since Tacrolim and Prograf / Prograf has already been employed in the EU, the company has submitted the results for previously completed studies with Prograf / Prograft and data from the published literature."</seg>
<seg id="1403">"furthermore, the results of a clinical study on 668 patients were submitted with kidney transplant, whereby the application of Advagraf with Prograf / Prograft or Ciclosporin was compared."</seg>
<seg id="1404">Main indicator of the effectiveness was the number of patients while the transplantation was adjusted after a treatment of a year (by example, as often a renewed organtransplantation or a revival of the dialysis was required). "</seg>
<seg id="1405">"in addition, shorter further studies of 119 patients were carried out and investigated patients with liver transplant and tested, such as Advagraf is recorded in comparison to Prograf / Prograft."</seg>
<seg id="1406">"Tremor (trembling), headache, nausea, infestation, disinfestation (hyperglycemic), diabetes, decreased blood sugar levels (hypertension), as well as sleeplessness (hypertension) as well as sleeplessness (Insomnia)."</seg>
<seg id="1407">In patients with any hypersensitivity (allergy) against Tacrolimus, Makroid antibiotics (such as Erythromycin) or any other components must not be applied. "</seg>
<seg id="1408">Patients and doctors have to be careful when others (especially herbal) medicines will be taken simultaneously with Advagraf as the Advagraf dose or dose of the same appropriate necessary must be adjusted accordingly.</seg>
<seg id="1409">"Hartl, retardiert-orange vatinekaph, printed in red ink with" 0.5 mg "and on the orbit captain with" "647"; "they contain white powder."</seg>
<seg id="1410">Only physicians who are familiar with immunosuppressive therapy and treatment of transplant patients should arrange this drug or make changes in immunosuppressive therapy.</seg>
<seg id="1411">"due to clinically relevant differences of the systemic exposure of Tacrolimus can lead this to transplantation or an increased incidence of side effects, including under- or overimmunology of repression."</seg>
<seg id="1412">Patients should always keep the same Tacrolim formulation and the corresponding daily dosing; transformations of the formulation or the regime should only be carried out under the narrow control of an in transplantation (see sections 4.4 and 4.8).</seg>
<seg id="1413">"as a result of an conversion to an alternative formulation, a therapeutic medicines must be done and appropriate dosage adjustment to ensure that the systemic exposure of Tacrolim remains."</seg>
<seg id="1414">The dosage of Advagraf should be primarily based on the clinical evaluation of aboration and compatibility in single case and to blood-reflection (see below) recommendations</seg>
<seg id="1415">"after conversion of prograf on Advagraf, the Tacrolimus should be controlled before conversion and over two weeks after conversion."</seg>
<seg id="1416">"on day 4 was systemic exposure, measured as Talmirror, with both formulations both at zero-and-transplants patients."</seg>
<seg id="1417">Careful and repetitive checks of the Tacrolim-Talmirror are recommended during the first two weeks after transplantation to ensure suitable substance exposure in the immediate transplant-phase.</seg>
<seg id="1418">Da Tacrolim is a substance with low Clearance can take several days until the steady State is reached.</seg>
<seg id="1419">"if the state of the patient is not permitted in the first post-operative phase, the Tacrolim-treatment invenous (Prograf 5 mg / ml Concentrate for the manufacturing of an infusionslsolution) are initiated by a dose of ca."</seg>
<seg id="1420">"for the duration of the use of tick repression of transplantation must be maintained, consequently a maximum duration of the orical therapy cannot be specified."</seg>
<seg id="1421">Dosing recommendations for prophylaxis of prophylaxis of transplant therapy should begin with 0,20 - 0,30 mg / kg / day than once daily gift in the morning.</seg>
<seg id="1422">Further dosing adjustments may be necessary later because the pharmacoinetic of Tacrolim can change in the course of stabilisation of the patient after transplantation.</seg>
<seg id="1423">Dosing recommendations - liver transplant prophylaxis of transplantation therapy should begin with 0.10 - 0.20 mg / kg / day than once daily gift in the morning.</seg>
<seg id="1424">Dosing recommendation - conversion from prograf on Advagraf must be put a transplantation of prograf capsules to a once daily intake of Advagraf, so this shift in relation 1: 1 (mg: mg), related to the entire daily dose. "</seg>
<seg id="1425">Nier- and liver transplantation for an conversion of other immunosuppresva on Advagraf once daily needs to start the treatment with the respectively in Nieren- and liver transplantation recommended for prophylaxis of transplantation.</seg>
<seg id="1426">"transplant on adult patients, which are placed on Advagraf, is a orale initiation dose of 0,15 mg / kg / day daily once in the morning."</seg>
<seg id="1427">Other transplants should do not have clinical experience with Advagraf during pulmonds and darmtransplants in a oral initiationosis from 0.2 mg / kg / day and at intestinal transplantation of 0,3 mg / kg / day to use. "</seg>
<seg id="1428">Dosage adjustment based in specific patient groups with reduced Leberfunction Zur maintenance of blood levels in the targeted area can be required in patients with severe liver dysfunctions a floating of the dosage.</seg>
<seg id="1429">Patients with reduced kidney function because the kidney function has no influence on the pharmacoinetic of Tacrolimus can be taken out of it that a dosage adjustment is not required.</seg>
<seg id="1430">"however, due to the nephrotoxical potential of Tacrolim, however, a meticulous monitoring of kidney function (including a regular determination of Serumkreatininspections, a calculation of the creatiincance and a monitoring of the urinary system) recommended."</seg>
<seg id="1431">Changeover by Ciclosporin on Advagraf At the changeover from an Ciclosporin- on a Tacrolim-based therapy is recommended (see sections 4.4 and 4.5).</seg>
<seg id="1432">Recommendations on the valley mirror in the full blot The dosage should be primarily based on the clinical evaluation of defectation and compatibility of the infestation of full-level Tacrolimus-Tallilim-Talmirror-controls.</seg>
<seg id="1433">"it is recommended for frequent controls of Tacrolim-Talmirror during the first two weeks after transplantation, followed by periodic checks during training therapy."</seg>
<seg id="1434">Blood-Talmirror of Tacrolim should also change after conversion of prograf on Advagraf, dosissing changes to immunosuppressive therapy or in simultaneous use of substances that could be controlled by Tacrolim (see Section 4.5). "</seg>
<seg id="1435">"since Advagraf is a medicine with a low Clearance, adjustments of the dose may need several days until the steady State entered."</seg>
<seg id="1436">The data in clinical trials can make sure that a successful treatment is possible in most cases when the Talmirror in the blood 20 ng / ml do not exceed.</seg>
<seg id="1437">In clinical practice the valley mirror of Tacrolim in the full blot in the first time after liver transplants normally in the area of 5 - 20 ng / ml and with - and hearttransplants patients at 10 - 20 ng / ml.</seg>
<seg id="1438">During the exploration therapy of Leber-, Nieren- und Carditransplantation were generally used blood-concentrations in the range of 5 - 15 ng / ml. "</seg>
<seg id="1439">"this has led to serious unwanted events, including transplantation or other side effects, which can occur in consequence of Tacrolim under- or overexposure."</seg>
<seg id="1440">Patients should always keep the same Tacrolim formulation and the corresponding daily dosing; transformations of the formulation or the regime should only be carried out under the narrow control of an in transplantation (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 For treatment adult patients with transplants proved to be proven towards other immunosuppresants, there are no clinical data for retardized formulation Advagraf."</seg>
<seg id="1442">"to the prophylaxis of transplant transplantation and transplants in child abuse are still not clinical data to retardized formulation Advagraf."</seg>
<seg id="1443">"because of possible interactions that can lead to a floating of tactical levels in the blood and a Attenuation of the clinical effect of Tacrolim (hypericum perforatum), or other plant breeds during treatment with Advagraf (see Section 4.5)."</seg>
<seg id="1444">"in patients with Diarrhö is a particularly careful monitoring of Tacrolimus- concentrations in the blood, since the Tacrolim blood mirror under such circumstances can be subject to considerable momentum."</seg>
<seg id="1445">"in rare cases, among Prograf was considered to observe a cardiomyopathy in Kammer- or septum hypertrophy, which can therefore also be observed under Advagraf."</seg>
<seg id="1446">"other factors that increase the risk of such clinical disorders, are already existing heart suffering, a treatment with cortikostoids, hypertension, nudi- or liver dysfunctions, infections, liquidity and oil."</seg>
<seg id="1447">"as with other immunosuppressiva, the effect of sunlight or UV light should be restricted by appropriate clothing or use of a solar code using a high protection factor."</seg>
<seg id="1448">"if patients, the Tacrolimus, symptoms for PRES like headaches, modified state of consciousness, clamping and visioning, should be a radiological examination (e.g.:"</seg>
<seg id="1449">"since Advagraf Hartl, retardians, Lactose is included in patients with the rare Galactosis-intolerance, leactase-lack or glucose-Galactose-Malabsorption special caution."</seg>
<seg id="1450">"the simultaneous use of drugs or herbal remedies, which are known as Hemmer or induction of CYP3A4, can influence metabolism of Tacrolim and thus reduce the blood values of Tacrolim."</seg>
<seg id="1451">It is therefore advisable to change the Tacrolimus- blood mirror with simultaneous gifts of substances that can change the CYP3A metabolism and to adjust the Tacrolim dosage to maintain simultaneous preservations (see sections 4.2 and 4.4).</seg>
<seg id="1452">A strong pronounced intereffect was performed with antimykcotics like Ketoconazol, Fluconazol, Itraconazol and Vorovazol and with the Macrolid antibiotic and HIV-Proteasehemania (z. "</seg>
<seg id="1453">"pharmacoinetical studies, that the rise of blood mirror mainly consists of the increased orphanage of Tacrolimus, caused by the inhibition of gastrointestinal fluid, resulting."</seg>
<seg id="1454">"high-performance prednisolon or methylprednisolon, as it is used in acutes degradation, can increase concentration by Tacrolim in the blood."</seg>
<seg id="1455">Effect of Tacrolimus on the metabolism of other medicines Tacrolim is known as CYP3A4-Hemmer; therefore the simultaneous application of Tacrolimus can be metabolized by CYP3A4 metabolized metabolic metabolism.</seg>
<seg id="1456">Da Tacrolim the Clearance of steroid contradictive and therefore can increase hormonal position is particularly careful in decisions about receptionate measures.</seg>
<seg id="1457">The results of animal have shown that Tacrolimus potentially reduce the Clearance of Pentobarbital and phenazon and extend their semi-prolongation.</seg>
<seg id="1458">"the results of a small number of investigations on transplant patients provide no indication that under Tacrolim compared to other immunosuppressiva, increased risk for unwanted events with regard to the course and the result of pregnancy."</seg>
<seg id="1459">In utero exposition recommends a surveillance of the newborn on possible harmful effects of Tacrolim (especially with regard to its effect on kidneys).</seg>
<seg id="1460">"there is the risk of an early birth (&lt; week 37) and a hyperkalianemia of the newborn (incidence 8 of 111 newborn, i.e.:"</seg>
<seg id="1461">The anti-acting profile of immunosuppsiva can often be found precisely because of the underpathic diseases of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"in the following, side effects according to their incidence in ascending order: very frequent (≥ 1 / 10), often (≥ 1 / 1,000, ≤ 1 / 100), rare (≥ 1 / 10.000, ≤ 1 / 1,000), very rare (≤ 1 / 10.000, not known (incidence based on the available data not to be estimated)."</seg>
<seg id="1463">"freshness disorders of the cardiotechnics, tachycardiovascular and cardiovascular, myocardiovascular, supraventricular Arrhythmics, Palacio atio, Anomalies in the EKG, abnorme heart and pulsation frequency</seg>
<seg id="1464">"infestation, nausea state and perimation, bleeding-intestinal and perimation, bleeding, pain in the stomach-intestinal areas and abdomen, dyspeptic signs and symptoms, obstipation, bacities, signs and symptoms in the stomach-intestinal - area"</seg>
<seg id="1465">"infections and parasitic disorders such as known in other high-effective immunosuppressiva is treated in patients having been treated with Tacrolim, bacterial, mycotic, protozoale) often increased."</seg>
<seg id="1466">Cases of BK-Virus-Associated Nephropathie and JC-Virus Association (PML) were reported in patients under immunosuppressive therapy, including therapy with Advagraf. "</seg>
<seg id="1467">It was reported on gutters or malignant Neoplasia including EBV- Associated diseases and skin tumors in conjunction with the treatment with Tacrolim.</seg>
<seg id="1468">"due to its high molecular weight, its low water solubility and the high binding on Erythrocytes and plasmaproteine can be accepted that Tacrolim is not dialyzing."</seg>
<seg id="1469">"comparative mechanism and pharmaodynamic effects on molecular level is likely to convey the effects of Tacrolim by its bond to a cyclic protein (FKBP12), which is responsible for enriching the connection in cell phone."</seg>
<seg id="1470">This results to a single-dependent locking of signal transmission rates due to the T-cell and thus prevents the transcription of a certain series of Lymphokin Genen.</seg>
<seg id="1471">Tacrolimus suppressed the activation of the T-cells and those from the T-Helper cells-dependent proliferation of the B-cells (like Interleukin-2, Interleukin-3 and g-Interferon) as well as the expression of the Interleukin-2 receptors. "</seg>
<seg id="1472">"12 Confirmed accreditation was within the first 24 weeks in the Advagraf group (N = 237) 32,6% and in the Prograf group (N = 234) 29,3%."</seg>
<seg id="1473">"patients survival rates after 12 months in 89,2% for Advagraf and 90.3% for prograf; in Advagraf-arm, 25 (14 women, 11 men) and in the Prograf-arm 24 (5 women, 19 men) deaths."</seg>
<seg id="1474">Kidney transplant The effectiveness and security of Advagraf and Prograf has been compared in combination with Mycod olatmofetil (MMF) and cortikostoids in 667 de Novo Niertransplants.</seg>
<seg id="1475">"patients survival rates after 12 months in 96.1% for Advagraf and 97.5% for prohanraf-arm, 10 (3 women, 7 men) and in the Prograf-arm 8 (3 women, 5 men) deaths."</seg>
<seg id="1476">"the effectiveness and security of prograf, Ciclosporin and Advagraf was compared in combination with basximab antibodies, MMF and cortikostoids, in the 638 de Novo Nierpergola."</seg>
<seg id="1477">The incidence at therapieversagen after 12 months (defined as death, transplantation and lack of torture data (N = 214), 15.1% in the Prograf group (N = 212) and 17.0% in the Ciclosporin group (N = 212). "</seg>
<seg id="1478">"the treatment differential -3,0% (Advagraf- Ciclosporin) (95,2% Konfidenzintervall [-9.9%, 4.0%]) for Advagraf vs Ciclosporin and -1.9% (Prograf-Ciclosporin) (95,2% Konfidenzintervall [-8,9%, 5,2%]) for Prograf vs Ciclosporin."</seg>
<seg id="1479">"in Advagraf-arm came 3 (men), in the prograf-arm 10 (3 women, 7 men) and in Ciclosporin-arm 6 (3 women, 3 men) deaths."</seg>
<seg id="1480">Published results of primary immunossion with Tacrolimus in the form of twice daily invented Prograf capsules after other primary organs prograf has developed into a recognized immunosuppressive for Pankemen-, pneumatic and intestinal transplantation. "</seg>
<seg id="1481">"175 course transplants patients, patients suffering from a Pankreastsplant and in 630 cases following a intestinal splantation is used as primary immunosuppressive."</seg>
<seg id="1482">"overall, the security profile of orally prograf was used in these studies the observations of the major studies in which prograf at Lebanese, Nieren- und Herztransplantation was used to primary immunossion."</seg>
<seg id="1483">"transit transplant in an intermediate analysis about a recent, multicentralized study with orally prograf has been reported on 110 patients who had either received Tacrolimus or Ciclosporin."</seg>
<seg id="1484">"also a chronological transplantation, the bronchiolitis obliteral syndrome, was less frequent to observe in the first year after the transplantation (2.8% versus 8,57%)."</seg>
<seg id="1485">"the survival rate after a year was 80,8% in Tacrolimus- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)."</seg>
<seg id="1486">With the Tacrolim patients treated it in 21.7% of cases to the emergence of a bronchiolitis obliterans compared to 38.0% below Ciclosporin (p = 0.025).</seg>
<seg id="1487">"the number of cases, in which of Ciclosporin on Tacrolim had to be converted (p = 0,02) than the number of patients that were made by Tacrolimus on Ciclosporin (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases, in which it came to none acute transplantation was after 6 months (57,7% versus 45,8%) and after 1 year (50% versus 33,3%) in the lungometre-group larger (Treede et al., J Heart Lung Transplant 2001; 20: 511)."</seg>
<seg id="1489">In a study the frequency of the emergence of a bronchiolitis obliterans- syndromes significant in patients with Tacrolim treated patients.</seg>
<seg id="1490">"Pankreastransplant A multi-centric study carried out with orally prograf was carried out at 205 patients who were at the same time a Pankemeni and kidney transplant, which received after a randomised trial Tacrolimus (n = 103) or Ciclosporin (n = 102)."</seg>
<seg id="1491">The orale Initiatives osis (via protocol) of Tacrolimus was 0.2 mg / kg / day and became after reaching the targeted Talmirror from 8 to 15 ng / ml per 5.</seg>
<seg id="1492">Intestinal transplant The published clinical results of a monocentric study involving oralistic immunosuppresiding at 155 patients (65 only Darm, 75 liver and Darm and 25 multiviszeral transplantations of 75% after 1 year, 5% after 5 years and 42% after 10 years. "</seg>
<seg id="1493">Methods for the morning detection of Epstein-Barr (EBV) - and CMV-infections that lead to talents of Tacrolimus that lead to talents between 10 and 15 ng / ml and recently transplantation (Abu-Elmagd et al., Ann Surg 2001; 234: 404). "</seg>
<seg id="1494">Factors such as low hematokritual and low protein concentrations lead to an increase in the unknown group of Tacrolimus which should be responsible for the transplantation in accordance with the transplantation.</seg>
<seg id="1495">"this can conclude that Tacrolim is almost completely metabolized in front of the excretion almost completely metabolized, whereby the excretion mainly takes place over the Galle."</seg>
<seg id="1496">"in stable patients, which were converted by Prograf (twice daily) on Advagraf (once daily) in relation 1: 1 (mg: mg), the systemic exposure of Tacrolim (AUC0-24) under Advagraf annals 10% lower than under Prograf."</seg>
<seg id="1497">"it is recommended for frequent controls of Tacrolim-Talmirror during the first two weeks after transplantation, followed by periodic checks during training therapy."</seg>
<seg id="1498">"21 For treatment adult patients with transplants proved to be proven towards other immunosuppresants, there are no clinical data for retardized formulation Advagraf."</seg>
<seg id="1499">"other factors that increase the risk of such clinical disorders, are already existing heart suffering, a treatment with cortikostoids, hypertension, nudi- or liver dysfunctions, infections, liquidity and oil."</seg>
<seg id="1500">"28 confirmed accounted rates was within the first 24 weeks in the Advagraf group (N = 237) 32,6% and in the Prograf group (N = 234) 29,3%."</seg>
<seg id="1501">"the effectiveness and security of prograf, Ciclosporin and Advagraf was compared in combination with basximab antibodies, MMF and cortikostoids, in the 638 de Novo Nierpergola."</seg>
<seg id="1502">"Hartl, retardized grasp gray yellow, printed in red ink with" "5 mg" "and the orbit captain with" "687", "they contain white powder."</seg>
<seg id="1503">"it is recommended for frequent controls of Tacrolim-Talmirror during the first two weeks after transplantation, followed by periodic checks during training therapy."</seg>
<seg id="1504">"37 For treatment adult patients with transplants proved to be proven towards other immunosuppresants, there are no clinical data for retardized formulation Advagraf."</seg>
<seg id="1505">"other factors that increase the risk of such clinical disorders, are already existing heart suffering, a treatment with cortikostoids, hypertension, nudi- or liver dysfunctions, infections, liquidity and oil."</seg>
<seg id="1506">44 confirmed accounted rates was within the first 24 weeks in Advagraf group (N = 237) 32.6% and in the Prograf group (N = 234) 29.3%.</seg>
<seg id="1507">"the effectiveness and security of prograf, Ciclosporin and Advagraf was compared in combination with basximab antibodies, MMF and cortikostoids, in the 638 de Novo Nierpergola."</seg>
<seg id="1508">"in total, 34 patients were made by Ciclosporin on Tacrolimus, while only 6 Tacrolim-patients required another therapy (Bechstein et al., Transplantation 2004; 77: 1221)."</seg>
<seg id="1509">Intestinal transplant The published clinical results of a monocentric study involving oralistic immunosuppresiding at 155 patients (65 only Darm, 75 liver and Darm and 25 multiviszeral transplantations of 75% after 1 year, 5% after 5 years and 42% after 10 years. "</seg>
<seg id="1510">"this can conclude that Tacrolim is almost completely metabolized in front of the excretion almost completely metabolized, whereby the excretion mainly takes place over the Galle."</seg>
<seg id="1511">"risk management plan is obliged to carry out the permission to approve the studies and additional pharmaovigilance plan as described in version 3.2 of the risk management plan (RMP), as well as all other updates of the RMP, which are approved by CHMP."</seg>
<seg id="1512">"according to the CHMP Guidelines to the risk management systems for pharmaceuticals for the application of the human being must be submitted simultaneously with the next periodic safety report (Periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">Perhaps you will also be given Advagraf also for the treatment of your liver transplant or transplants or any other transplants or because the immune response of your body could not be dominated by a predicted treatment.</seg>
<seg id="1514">"when taking Advagraf with other drugs, please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription, even if you are not prescription pharmaceuticals or remedies."</seg>
<seg id="1515">"Amiloride, Triamteren or Spironolacton), certain painters (non-steroidal anti-phoristical antiphlogistika such as Ibuprops), antioagulanzien or medicines for taking care for the treatment of diabetes mellitus."</seg>
<seg id="1516">Pregnant and breastfeeding if a pregnancy is planned or already exists, ask before taking all pharmaceuticals to your doctor or pharmacists at the Council. "</seg>
<seg id="1517">Transport and use of machines You may not set up at the wheel of a vehicle or use tools or machines when you feel after intake of Advagraf or sleeps.</seg>
<seg id="1518">Important information about certain other components of Advagraf Please take Advagraf before returning with your doctor if you know that you suffer from a intolerance towards certain sugar.</seg>
<seg id="1519">Make sure that you will always get the same Tacrolimus medicine when you redeem your prescription, unless your specialist is expressly agreed upon a change of the Tacrolim award. "</seg>
<seg id="1520">"if you get a medicine, whose appearance changes from the habit or the dosing instructions are changing, please contact your dental doctor or pharmacists, so that you can get the right medicines."</seg>
<seg id="1521">"so that your doctor can determine the right dose and adjust from time to time, he must then perform regular bleeding."</seg>
<seg id="1522">"if you have taken a larger amount of Advagraf when you should accidentally taken a bigger amount of Advagraf, you immediately seek your doctor or the emergency department of the nearest hospital house."</seg>
<seg id="1523">"if you have forgotten the intake of Advagraf If you have forgotten, take the capsules, please get this at the same day at the early time after."</seg>
<seg id="1524">If you break the intake of Advagraf At the end of the treatment with Advagraf the risk can increase the risk of your transplants.</seg>
<seg id="1525">"Advagraf 0,5 mg Hartl, retardiert, are Hartgelatinekaph, whose lightyellow upper part of" "647" "and whose oranges underpart are filled with" "647" "and which are filled with white powder."</seg>
<seg id="1526">"Advagraf 1 mg Hartl, retardiert, are Hartgelatinekapasses, whose white upper part of" "1 mg" "and whose oranges underpart are filled with" "677" "red and which are filled with white powder."</seg>
<seg id="1527">"Advagraf 5 mg Hartl, retardiert, are Hartgelatinekaph, whose grasp upper part with" 5 mg "and their oranges underpart are filled with" "687" "and which are filled with white powder."</seg>
<seg id="1528">România Astellas Pharma Internafanional Detalii de contact pentru România's Bucureş ti-Ploieş ti 42-44, Clă dire 1, Parter, 013696-Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovakká Republika Astellas Pharma s.r.o., organizač ná zloz ka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advate is used for treatment and prevention of bleeding in patients with hammophilia A (a due to the lack of factor VIII-related blood circulation).</seg>
<seg id="1531">Dosage and frequency of the application depends on whether Advate to treat bleeding or to prevent bleeding in surgical procedures.</seg>
<seg id="1532">Patients with halophilia A suffer from a factor VIII shortage of what blood-minded problems such as blood vessels in joints, muscles or inner organs. "</seg>
<seg id="1533">Octocog alfa is not extracted from human plasma but after a method that is called "recombinant DNA technology."</seg>
<seg id="1534">It is produced by a cell to which a gene (DNA) brought them to the formation of the human scent factor VIII.</seg>
<seg id="1535">"advocate is another combined in the European Union called Reinsate, similarly, however, is different, so that the drug does not contain proteins or animal origin."</seg>
<seg id="1536">"in three additional studies of patients with severe to moderate harrigophilia A, including a study with 53 children under six years, the application of pharmaceuticals was examined as well as in surgical procedures."</seg>
<seg id="1537">"in the capitals, the effectiveness of advocate was rated in the prevention of blood vessels in 86% of 510 new blood-sepisods with" "excellent" "respectively with" "good". ""</seg>
<seg id="1538">"the most common side effects of advocate (observed in 1 to 10 of 100 patients) are swelling, headaches, pyrexie (fever) and the formation of antibodies against factor VIII."</seg>
<seg id="1539">Advate must not be used in patients who may possibly be hypersensitive (allergic) against the human barinner factor VIII, mouse or hamsterling or one of the other components. "</seg>
<seg id="1540">"in March 2004, the European Commission sent to the company Baxter AG made a permit for the intervention of Advate in the entire European Union."</seg>
<seg id="1541">Dosage The dosage and duration of substitution therapy depends on the severity of the factor VIII-defect according to the place and the extent of blood circulation and the clinical state of the patient.</seg>
<seg id="1542">"in the following spherical events, the factor VIII activity should not be found under the specified plastic level (in% of the standard or in i.e. / dl)."</seg>
<seg id="1543">Injecting every 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeating until the pain and the akute impairment are removed.</seg>
<seg id="1544">Injection all 8-24 hours (6-12 hours in patients under 6 years) repeat the danger to the patient.</seg>
<seg id="1545">During the treatment process the control of the injections and the frequency of injections will be an appropriate determination of the factor VIII-Plasmasegel.</seg>
<seg id="1546">Individual patients can be differentiated in their reaction to a factor VIII different in vivo recovery and approaches different half-time.</seg>
<seg id="1547">3 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e. from factor VIII pro kg body weight at a distance of 2-3 days.</seg>
<seg id="1548">"if the expected factor VIII-Plasmach can not be reached or if the blood flow is not dominated by a reasonable dose, a test must be done if necessary to mediate a hibitor."</seg>
<seg id="1549">"in patients with high Inhibitorvalues, it is possible that the factor VIII therapy is not effective so that other therapeutic measures will need to be wounded."</seg>
<seg id="1550">"the agreement length is to be addressed after the patient, with a maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutralised antibodies against factor VIII is a known complication in the treatment of patients with hemophilia A.</seg>
<seg id="1552">These inthibitors are always opposed to the procoagulatory activity by factor VIII aligned IgG Immunglobulins that are quantified in Bethesda units (B.E.) per ml Plasma using modified Bethesda Assay.</seg>
<seg id="1553">"the risk to develop inhibitors, correlays with the extent of exposure to the factor VIII, whereby the risk within the first 20 exposition on the largest is dependent on genetic and other factors."</seg>
<seg id="1554">"in the treatment of patients (PTPs) with more than 100 exposition and anamnestically known Inhibitordevelopment, after conversion from a recombinant factor VIII product to another, the reoccur of (lowest) Inhibitors observed."</seg>
<seg id="1555">Due to the rare appearance of the harshhilia A in women lie about the use of factor VIII during pregnancy and breastfeeding no experiences.</seg>
<seg id="1556">"the incidents in the biggest number of patients raised inhibitors against factor VIII (5 patients) which arise all in previously untreated patients, which arise a higher risk for the formation of inthibitors, headaches (5 patients), fever and swelling (each 3 patients)."</seg>
<seg id="1557">"very frequently (≥ 1 / 10), often (≥ 1 / 100 to &lt; 1 / 10), occasionally (≥ 1 / 1,000 to &lt; 1 / 1000), rare (≥ 1 / 10.000 to &lt; 1 / 1,000), very rare &lt; 1 / 10.000),"</seg>
<seg id="1558">A) The percentage of patients was calculated by the sum of the individual patients (234). b) The unexpected decay of the blood flow factor was postoperatively (10 - 14 postoperative day) in a patient under continuous ADVATE infusion.</seg>
<seg id="1559">Blood-minded was maintained during the whole time and both the factor of VIII- mirror in plasma as well as the Clearance rate shown on 15 postoperative day.</seg>
<seg id="1560">In clinical studies with ADVATE at 145 children and adults 2 with diagnose heavy duty cycle A (FVIII ≤ 2%) and previous exposure to factor VIII- Konzentrats (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1561">In addition to none of the 53 paediatric patients with an age of under 6 years and diagnosed harder to moderate harrigophilia A (FVIII ≤ 2%) after prior exposure to factor VIII- Concentrates (≥ 50 days) a FVIII-Inhibitor established.</seg>
<seg id="1562">In previously the patient treatment of an ongoing clinical study formed 5 out of 25 (20%) with ADVATE treated patients Inhibitors against factor VIII.</seg>
<seg id="1563">The immune response of patients on traces of contaminated proteins was analyzed by the examination of antibodies against these proteins, laboratories and gems-side effects. "</seg>
<seg id="1564">"a patient showed both a statistically significant upward appearance as well as a persistent peak of antibodies against anti-Cho-cell, otherwise, however, no signs or symptoms resulting in an allergic reaction or hypersensitivity."</seg>
<seg id="1565">"in four patients the appearance of Urtikaria, Pruritus, rally, rash and increased number of eosinophiler granulocytes with several repetitive product compositions as part of the study reports."</seg>
<seg id="1566">7 How to other invenous products was reported on ADVATE via hypersensitivity of allergic type, including anaphypoetic / anaphylaktoider Reactions (incidence) reported. "</seg>
<seg id="1567">The activation factor VIII appears as a Cofactor for the active factor IX and accelerates the formation of activated factor X of factor X.</seg>
<seg id="1568">All pharmacoinetical studies with ADVATE were performed with severe or medium-heavy hammophilia A (basic value of the factor VIII-activity ≤ 2%).</seg>
<seg id="1569">"the pharmacoinetic parameters originates from a cross-Over-study with ADVATE in 100 previously, or &gt; 10 years, and are listed in the table below 3."</seg>
<seg id="1570">Table 3 summary of the pharmacoinetic parameters of ADVATE at 100 patients with heavy to moderate halophilia A (factor VIII &lt; 2%) PK-Parameter (pharmacoinetic)</seg>
<seg id="1571">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1572">Every single packet consists of a breakthrough-bottle with powder; a breakout of 5 ml liquid (both glass Type I with chlorobutyl-rubber) and a device to reconstitution (BAXJECT II).</seg>
<seg id="1573">"when the product is stored in the fridge, both flowed bottles with ADVATE powder and solvents from the refrigerator can be found in room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A significant increase in the pulse frequency can be seen through slowing or timeless underbreak the injtion usually get back again (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e. from factor VIII pro kg body weight at a distance of 2-3 days.</seg>
<seg id="1576">Due to the rare appearance of the harshhilia A in women lie about the use of factor VIII during pregnancy and breastfeeding no experiences.</seg>
<seg id="1577">"3 newborn (aged 1 month), toddlers (aged 1 month - 2 years), children (aged 12-16), youths (aged 12-16), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1578">In clinical studies with ADVATE at 145 children and adults 4 with diagnosed heels (≥ 150 days) and previous exposure to factor VIII- Concentrates (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1579">18 As with other intravenous products was reported by ADVATE via hypersensitivity of allergic type, including anaphypoetic / anaphylaktoider Reactions (incidence) reported. "</seg>
<seg id="1580">Table 3 summary of the pharmacoinetic parameters of ADVATE at 100 patients with heavy to moderate halophilia A (factor VIII &lt; 2%) PK-Parameter (pharmacoinetic)</seg>
<seg id="1581">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1582">"25 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e., from factor VIII per kg of body weight at a distance of 2-3 days."</seg>
<seg id="1583">"5 newborn (aged 1 month), toddlers (aged 1 month - 2 years), children (aged 12-16), youths (aged 12-16), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1584">In clinical studies with ADVATE at 145 children and adults 6 with diagnosed heels (≥ 150 days) and previous exposure to factor VIII- Konzentrats (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1585">29 As with other intravenous products was reported by ADVATE via hypersensitivity of allergic type, including anaphypoetic / anaphylaktoider Reactions (Frequently not known). "</seg>
<seg id="1586">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1587">"36 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e., from factor VIII per kg of body weight at a distance of 2-3 days."</seg>
<seg id="1588">"7 newborn (aged 1 month), toddlers (aged 1 month - 2 years), children (aged 12-16), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1589">In clinical studies with ADVATE at 145 children and adults 8 with diagnosed heels (≥ 150 days) and previous exposure to factor VIII- Konzentrats (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1590">40 As with other intravenous products was reported by ADVATE via hypersensitivity of allergic type, including anaphypoetic / anaphylaktoider Reactions (incidence) reported. "</seg>
<seg id="1591">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1592">47 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e. from factor VIII pro kg body weight at a distance of 2-3 days.</seg>
<seg id="1593">"9 newborn (aged 1 month), toddlers (aged 1 month - 2 years), children (aged 12-16), youths (aged 12-16), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1594">In clinical studies with ADVATE at 145 children and adults 10 with diagnosed heels (≥ 150 days) and previous exposure to factor VIII- Konzentrats (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1595">51 As with other intravenous products was reported by ADVATE via hypersensitivity of allergic type, including anaphypoetic / anaphylaktoider Reactions (incidence) reported. "</seg>
<seg id="1596">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1597">"58 prophylaxis tick-prophylaxis of blood-prophylaxis in patients with heavy hariophilia A should be doses between 20 and 40 i.e., from factor VIII per kg of body weight at a distance of 2-3 days."</seg>
<seg id="1598">"11 newborn (aged 1 month), toddlers (aged 1 month - 2 years), children (aged 12-16), youths (aged 12-16), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1599">In clinical studies with ADVATE at 145 children and adults 12 with diagnosed heels (≥ 150 days) and previous exposure to factor VIII- Konzentrats (≥ 150 days) showed only one patient after 26 Expositions with ADVATE an low Inhibitortiter (2.8 B.E. in modificated bethesda approach).</seg>
<seg id="1600">62 As with other intravenous products was reported by ADVATE via hypersensitivity of allergic type, including anaphysizing / anaphylaktoider Reactions (Frequently not known). "</seg>
<seg id="1601">"not clinical data, based on the studies on security spharmacology, to akuter, repetitive and local toxicity and towards genotoxicity, show no special risk for men."</seg>
<seg id="1602">"Pharmakovigance system The regulatory owners must ensure that a Pharmakovigilance system, as described in the chapter 1.1 of the chapter 1.8.1 of the pharmaceuticals was described, and that this system is located during the entire period, where the product remains on the market."</seg>
<seg id="1603">"as in the CHMP directive on the risk management policy for human-drug, these updates are to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• If new information is present, the impact on the valid security note, the Pharmakovigilance plan or measures to risk minimizing, • within 60 days after an important event (with regard to the pharmacoigbalance sheet or regarding a measure to risk minimization)"</seg>
<seg id="1605">1 breakthrough with ADVATE 500 I.E Octocog alfa, 1 throughput water for injectors, 1 BAXJECT II-Medical product. "</seg>
<seg id="1606">1 breakthrough with ADVATE 1000 I.E Octocog alfa, 1 throughput water for injectors, 1 BAXJECT II-Medical product "</seg>
<seg id="1607">Particular caution at the application of ADVATE is required to inform your doctor if you have recently been treated with factor VIII products especially if you have been using Inhibitors.</seg>
<seg id="1608">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1609">"in taking with other medicines please inform your doctor if you have any other medicines or have recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="1610">"your doctor will charge your dose ADVATE (in international units or i.e.), depending on your physical loading and your body weight, and whether it is used to prevent bleeding or treating blood vessels."</seg>
<seg id="1611">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1612">"in combination with operations catheter infections, lower number of red blood cells, swelling of limbs and joints, prolonged blood flow after the removal of a Drainage, verminderter Factor-VIII-Spiegel and postoperative hematoms."</seg>
<seg id="1613">Rare Effects of the introduction of drugs on the market has been envisaged over heavy and potential life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1614">Inform your doctor if any of the listed side effects you have considerably impaired or if you have side effects that are not listed in this package.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"notes for the production of the solution • Not to use on flowmeters and Umcarton the given application date. • The BAXJECT II does not use when its sterile barriers have damaged, its packaging is damaged or sign of a manipulation, as in the icon."</seg>
<seg id="1617">"important note: • Not to administer, before you have received the special training from your doctor or your doctor. • Appointing the product on Schwebeteilchen or discoloring."</seg>
<seg id="1618">"the solution should be slow with an infusion speed, which is applicable to the patient and should not exceed 10 ml per minute."</seg>
<seg id="1619">106 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1620">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1621">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1622">"occasional Side Effects Juckriz, Ampliking, uncommon flavourings, migraine, guardianity, distressing, distressing, bursting, bursting, rashes, creditches, rashes, extremists, extreme sweats,"</seg>
<seg id="1623">116 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1624">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1625">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1626">126 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1627">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1628">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1629">136 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1630">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1631">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1632">146 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1633">These symptoms can represent early signs of an anaphylaktic lap which can include in addition the following symptoms: extreme vibrations, awareness of consciousness and extreme breathing difficulties. "</seg>
<seg id="1634">"patients, the factor-VIII Inhibitors If the expected FaktorVIII mirror in your plasma with ADVATE can not be achieved or the blood flow cannot be dominated by factor VII."</seg>
<seg id="1635">"occasional Side Effects Juckriz, Ampliking, uncommon flavourings, migraine, guardianity, distressing, distressing, bursting, bursting, rashes, creditches, rashes, extremists, extreme sweats,"</seg>
<seg id="1636">Rare Effects of the introduction of drugs on the market has been envisaged over heavy and potential life-threatening reactions (Anaphylaxie) and other allergic reactions (see above).</seg>
<seg id="1637">156 In case of blood circulation should not fall into the factor VIII mirror within the corresponding time period (in% or in i.e. / ml).</seg>
<seg id="1638">"based on the data collected since the first-time data has been evaluated the CHMP the benefits risk, but considering that the security profile will be closely monitored for the following reasons:"</seg>
<seg id="1639">"therefore the CHMP on the basis of the security panel of ADVATE, which makes a filing of PSURs every 6 months, decided that the filming has to apply for further extensions in 5 years."</seg>
<seg id="1640">December 2008 Gendux Molecular Limited has officially launched the Committee for Humanity (CHMP) that the company will take its application for authorisation for the intervention of Li-Fraumeni cancer.</seg>
<seg id="1641">"however, the chest, the brain, the brain, the bones, or the pasture (tissues, which connects other structures in the body, and is based on them)."</seg>
<seg id="1642">"this is a kind of virus that has changed, genetically modified that it can wear an gene into the cells of the body."</seg>
<seg id="1643">"with the virus in Advexin, it is an" "Adenovirus", "that it has been changed that there is no copies of themselves and therefore cannot trigger infection with people."</seg>
<seg id="1644">Advexin could have been injected directly into the tumors and thus enable cancer cells to form the normal p53 protein.</seg>
<seg id="1645">"the p53 protein, which is formed by the non-defective in the human body existing p53 gene, is usually borne to restore corrupt DNA and to kill the cells when the DNA cannot be restored."</seg>
<seg id="1646">"at Li-Fraumeni-cancer, when the p53-gene is broken, the p53-protein is not working correctly, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"the company placed data from a study with a patient prior to the Li-Fraumeni Cancer in the area of subconstruction, in the bones and the brain."</seg>
<seg id="1648">"after CHMP, the answers of the company had been checked for the questions asked questions were still unsolved."</seg>
<seg id="1649">"based on the examination of the final documents created by CHMP to day 120 a list of questions that will be sent to the company."</seg>
<seg id="1650">"according to the CHMP, not sufficiently proved that the injections of Advexin at Li-Fraumeni-tumors will bring advantages to patients."</seg>
<seg id="1651">"the committee also had concerns regarding the processing of pharmaceuticals in the body, the type of administration and the safety of drugs."</seg>
<seg id="1652">"in addition, the company had not sufficiently proven that Advance can be produced in a reliable manner and that it is neither for the environment nor for people who come in close contact with the patient."</seg>
<seg id="1653">"the company made the CHMP not aware of whether the withdrawal of consequences for patients has to participate in clinical studies or" Compassionate-Use "programs with Advexin."</seg>
<seg id="1654">Changing substance release means that the tablets are so collectively that one of the effective elements immediately and the other slowly will be released over a few hours.</seg>
<seg id="1655">Aerinaze is used to treat symptoms of seasonal allergic Rhinitis (hypoisks caused by a allergy to pollen against pollen against pollen (mutilting nose) in patients with nasal skin swelling (mopter nose).</seg>
<seg id="1656">"for adults and young adults from 12 years the recommended dose of aerinaze twice daily a tablet, which should be taken with a glass of water with or without food."</seg>
<seg id="1657">"the duration of the treatment should be as short as possible and ended as soon as the symptoms, especially the swelling of the nasal skin (hide Nose)."</seg>
<seg id="1658">A treatment duration of more than 10 days is not recommended because the effects of drugs can be found on the constipation of the nose.</seg>
<seg id="1659">"the main-effective dimensions were the changes of the severity of the hypography of symptom, which reports from the patient before the beginning of the treatment and during the 15-day treatment."</seg>
<seg id="1660">"during the study the patients received their symptoms all 12 hours into a diary, and raised with a standard skala, as hard as the symptoms were in the last 12 hours."</seg>
<seg id="1661">"considering all the hypods of symptom out except the constipation of the nose reported the patients, the aerinaze assumptions caused by the acceptance of symptoms around 46,0%, compared to 35,9% in patients, the Pseudoephedrine alone."</seg>
<seg id="1662">"if only the swelling of the nasal skin was regarded, the patients shown among Aerinaze showed a lination of symptoms around 37,4% compared to 26.7% for the patients who took diloratadin alone."</seg>
<seg id="1663">"the most common side effects of aerinaze (observed with 1 to 10 of 100 patients) are Tachykardie (cordioneness), onsense, headache, fatigue, fatigue, harness, fatigue, Insomnia (sleeplessness), somnia and nervousness."</seg>
<seg id="1664">"Aerinaze may not be unsensitive (allergic) against Desloratadin, pseudoephedrine or one of the other components, against adrenerge agents or Loratadin (another medicine for the treatment of allergies)."</seg>
<seg id="1665">"Aerinaze should also not be used in patients, which are suffering from a bottled water pressure (hypertension), hypersanitation (hypertension), hypersanitation (hypertension), hypersanitation (hypertension), or have already caused a risk for the murdered stroke."</seg>
<seg id="1666">"on 30 July 2007, the European Commission commissioned the company SP Europe to make approval for the distributors of Aerinaze throughout the European Union."</seg>
<seg id="1667">"tablet can be taken with a glass of water, however, is in whole to swallow (d. h. without it to break down or too rough)."</seg>
<seg id="1668">Aerinaze should not be used due to the maleness of data for incomprehensibility and effectiveness (see section 5.1) not to children under 12 years of age.</seg>
<seg id="1669">The duration of the application is to keep as short as possible and should not be continued after finishing the symptoms.</seg>
<seg id="1670">It is recommended to limit the application time on 10 days since long-time application can decrease the activity of pseudoephedrine with the time.</seg>
<seg id="1671">After decrease in the swelling of the mucous membranes in the upper breath for the treatment of desloratadin can be continued as monotherapy.</seg>
<seg id="1672">"as Aeroephedrine contains, the medicine is also contradicated in patients who are treated with a monoaminoxidase (Mao) -Hemmer or within 2 weeks after the end of such a therapy."</seg>
<seg id="1673">"this is due to the alphamimetic activity at combined application of pseudoephedrine animals with other vasoundetine, Pergoid, Lisurid, acryylephrine, phenylephrine, Ephedrine, Oxymetazolin, Naphazolin, etc.)."</seg>
<seg id="1674">The safety and effectiveness of these combined therapy has not been tested for this patient and the data are not enough to address corresponding recommendations for dosing.</seg>
<seg id="1675">The safety and effectiveness of aerinaze were not tested in patients with kidney or liver functioning and do not submit the data to address corresponding recommendations for dosing.</seg>
<seg id="1676">Patients must be informed about that the treatment in the appearance of a hypertension or a tachykarthe or of palaces, cardiac disorders (like headaches or strengthening of the headaches) must be set. "</seg>
<seg id="1677">"in the treatment of the following patient groups, patients suffer from digialis • patients with hypertension • patients with hypertension • patients with a myokardinfarkt in the anamnese, diabetes mellitus, blowjob, or bronchospasm in the anamnese."</seg>
<seg id="1678">Aerinaze is final at least 48 hours before carrying out dermatologic tests because antihistaminika otherwise can prevent positive responses to indicators for skin reactions and reduce to their extent.</seg>
<seg id="1679">"in the framework of clinical trials of Desloratadin, in which Erythromycin or Ketoconazol, in addition, were not observed in clinically relevant interactions or changes of Plasmaconconcentration of Desloratadin."</seg>
<seg id="1680">"with the results of the psycho-servo tests could not be significant differences between the associated patients with Desloratadin and those with placebo patients, regardless of whether desloratadin alone or with alcohol was taken."</seg>
<seg id="1681">"it has not been identified for the metabolic of Desloratadin responsibly enzyme, so that interactions with other medicines can not be excluded completely."</seg>
<seg id="1682">"Desloratadin inhibits in-vivo CYP3A4 not, and in-vitro studies have shown that the medicine CYP2D6 is not inhibited and neither a substrate nor an Inhibitor of the P-glycoone."</seg>
<seg id="1683">"the inconceivable of the use of aerinaze during pregnancy is not secured, experiences from a large number of affected pregnancies, however, no increase in the frequency of abnormalities compared to the frequency of the normal population."</seg>
<seg id="1684">"as a reproduction of animal studies should not always be transferred to humans, and on the basis of vasoconstriktorical characteristics of pseudoephedrine should not be applied in pregnancy."</seg>
<seg id="1685">"however, patients should be clarified that in very rare cases it can lead to a impairment of transport or the ability to use machines."</seg>
<seg id="1686">"symptoms may vary between a ZNS Depression (Secoding, Apnoe, decreased mental attention, comanosis, coma, cardiovascular disease) and a tick-stimulation (sleeplessness, hallucinations) with possible letals."</seg>
<seg id="1687">"headache, anxiety, shyness, muscle weaken, and increased muscle tension, Euphorie, herinfertility, arachyardie, turbidity, nausea, naughty, tabolic, tamparie, tendal, limbs, and hypertension, or hypotony."</seg>
<seg id="1688">"a ZNS stimulation is particularly probable in children as well as Atropine-typical symptoms (mouthdry, pupillary, and - dilatation, Hauling, hyperthermia and gastrointestinal symptoms)."</seg>
<seg id="1689">This close both the inhibition of the inflammaternal cycles as IL-4, IL-6, IL-8 and IL-13 from human macells / Basophila as well as the inscription of the expression of the addresssmolecules P-Selecttin to endothelmets. "</seg>
<seg id="1690">"for single dose of a single dose with adults showed Desloratadin 5 mg no influence on standard sizes of the flight, including the amplified hoses or the tasks that are connected to the thread."</seg>
<seg id="1691">In controlled clinical trials was found in the recommended dosage of 5 mg a daily incidence of sfriction compared to placebo.</seg>
<seg id="1692">"the orale application of Pseudoephedrine in the recommended dosage can give other personomimetic effects, such as an increase in blood pressure, a Tachykardie or manifestations of a ZNS arousal."</seg>
<seg id="1693">"they took 1,248 patients aged between 12 and 78 years with seasonal allergic Rhinitis, where 414 patients Aerinaze tablets were received."</seg>
<seg id="1694">"in both studies the histamine effect of aerinaze tablets, determined by the total scores for the symptoms (except nasal membrane swelling), significantly higher than under a monotherapy with pseudoephedrine on the 2-week treatment period."</seg>
<seg id="1695">The effectiveness of aerinaze tablets with regard to the abswelling effect, determined by the nasal skin swelling, was significantly higher than under a monotherapy with Desloratadin over the 2-week treatment period. "</seg>
<seg id="1696">The effectiveness of aerinaze tablets showed no significant differences in terms of gender, age or ethnic group of patients. "</seg>
<seg id="1697">As part of a single dose of the pharmacoinetic study of Aerinaze is desloratadin within 30 minutes after administration of plasma.</seg>
<seg id="1698">"after the peroral application of aerinaze at healthy Probanden over 14 days the flow-weight of Desloratadin, 3-hydroxydesloratadin and pseudoephedrine on day 10."</seg>
<seg id="1699">"as part of a pharmacoinetic multi-professional study study, which was performed with the formulation as a tablet to healthy grown probanden was determined that four Probanders Desloratadin is unmistakeable."</seg>
<seg id="1700">A single-response study shows that exposure (Cmax and AUC) by Pseudoephedrine after the allone of pseudoephedrine biodegradation was equivalent to the Exposition of a aerinaze tablet.</seg>
<seg id="1701">"based on conventional studies on safety vulnerability, for toxicity in repetitive Gabe, for genotoxicity and reproductions, the preclinical data with Desloratadin, however, has no particular hazards for men."</seg>
<seg id="1702">"the combination does not give greater toxicity as their individual components, and the watched effects were generally related to the ingredient Pseudoephedrine."</seg>
<seg id="1703">"in reproductions, the combination of Loratadin / Pseudoephedrine at the ormal gifts in a dosage of up to 150 mg / kg / day and in rabbits in a dosage of up to 120 mg / kg / day not teratogen."</seg>
<seg id="1704">March 2007 and in Module 1.8.1 of the authorisation contract was established and works before and while the product is on the market.</seg>
<seg id="1705">Antihistaminika contribute to the relief of allergic symptoms by preventing it that histamine can unfold its effect.</seg>
<seg id="1706">"aerinaze tablets lenses, which occur in connection with seasonal allergic (hypods), such as Niese, running or jucking nose and trendy or juckable eyes at the constipation of the nose."</seg>
<seg id="1707">"20 Under certain circumstances, you can particularly sensitive to the vestial medicines pseudoephedrine that is contained in this medicine."</seg>
<seg id="1708">"(sugar-diseased), a stenositionate stomach ulcer, which leads to a tightening of stomach, the déchovies, or the esounded (breathing exercises), a clasp of the stomach cancer (breathing exercises), a clasp of lung cancer (breathing exercises), a breach, or problems with the liver, the kidneys or the bladder."</seg>
<seg id="1709">"inform your doctor if you are using the use of aerinaze the following symptoms or disease can occur or diagnosed: • Bluthochprint • Herzjagen, heartbeat • cardiac disorders • nausea and headaches or strengthening of existing headache."</seg>
<seg id="1710">"with intake of aerinaze with other medicines please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="1711">Transport and use of machines With application in the recommended dosage is not to be expected that Aerinaze leads to bends or bring attention to attention.</seg>
<seg id="1712">If you have taken a larger amount of aerinaze as you should inform you immediately your doctor or pharmacist if you should have a larger amount of aerinaze as you should.</seg>
<seg id="1713">"if you have forgotten the intake of aerinaze If you have forgotten, take a dose in time, get the application as soon as possible and turn the next dose at the designated time."</seg>
<seg id="1714">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="1715">"Duke, restlessness with more physical physical activity, mouth dry, pendulgence, sugar in the urine, increased blood sugar, thirst, fatigue, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness, nervousness and bends."</seg>
<seg id="1716">"heartbeat or cardiac arrhythmess, confusion, blurine, nose, wet, nose, nose, creature, nasal, nasal, cheeses, crampervation, obrobes, anxiety, anxiety, anxiety, anxiety and maturity."</seg>
<seg id="1717">"after the launch of Desloratadin has been very rare in cases of severe allergic reactions (breathing, piping respiratory, itch, boiler and swelling) or skin."</seg>
<seg id="1718">"over cases of Duke knock, cardio, baldness, anxiety, anxiety, soreness, restlessness, restlessness, restlessness, restlessness, restlessness, currants, clamplitis, and over cases of obtrusting live values was also very rare reported."</seg>
<seg id="1719">"it is available as 5 mg-tablet, 5 mg- Lyophilisate to take (soluble tablet), 2.5 mg- and 5 mg-melt letten (tablets that count itself in the mouth), 0.5 mg / ml-Sirup and as 0.5 mg / ml-solution for insertion."</seg>
<seg id="1720">"for children from one to five years the dosage is 1,25 mg once daily, which is in the form of 2.5 ml sirup."</seg>
<seg id="1721">"for children aged six to eleven years, the dose is 2.5 mg once daily, either in the form of 5 ml sirup or."</seg>
<seg id="1722">Aerius was studied in total eight studies with approximately 4 800 adults and young people with allergic Rhinitis (including four studies with seasonal allergic and two studies on patients that also have asthma).</seg>
<seg id="1723">"the effectiveness was measured by changing the change of symptoms (itch, number and size of the square, impairment of the sleep and performance of the day) before and after sixteenth treatment was established."</seg>
<seg id="1724">"further studies have been submitted to imply that the body determines the syrup, the solution to one and the melting items in the same way, as the tablets and application in children are harmless."</seg>
<seg id="1725">"allergic Rhinitis led when the results of all studies have been assembled, the two-week treatment with 5 mg of Aerius to an average decrease of the symptomscores (symptomscores) at 25 to 32%, compared to the acceptance of 12 to 26% in the patients who received a placebo."</seg>
<seg id="1726">"in the two studies at Urtikaria was the acceptance of the symptomscores after sixteenth treatment with Aerius 58 and 67%, compared to 40 and 33% compared to placebo patients."</seg>
<seg id="1727">"Aerius must not be used in patients who may possibly be hypersensitive (allergic) against Desloratadin, Loratadin or any of the other components."</seg>
<seg id="1728">"January 2001, the European Commission Decision of the company SP Europe make a permit for the use of Aerius throughout the European Union."</seg>
<seg id="1729">"one tablet every day, with one or without a meal, to the relief of symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1)."</seg>
<seg id="1730">There is limited experience of clinical trials for effectiveness in the application of Desloratadin in young people from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of intermitting allergic Rhinitis (appearance of symptoms for less than 4 days a week or less than 4 weeks) should be terminated according to the previous sense of disease and can be resumed after completion of symptoms and will be resumed with their re-return.</seg>
<seg id="1732">With the Persian allergic Rhinitis (appearance of symptoms to 4 or more days per week and over 4 weeks) can be recommended to patients during allergy time treatment.</seg>
<seg id="1733">Clinically relevant interactions were not found in clinical studies with Desloratadin tablets not specified when Erythromycin or Ketoconazol can be found in addition (see section 5.1).</seg>
<seg id="1734">In a clinically-pharmacological study was not reinforced by aserius and alcohol the high-performance effect of alcohol (see section 5.1).</seg>
<seg id="1735">"however, patients should be clarified that in very rare cases, it can lead to impairment of transport or the ability to use machines."</seg>
<seg id="1736">"in clinical trials in various indications, including allergic Rhinitis and chronically idiopathic Urtikaria, were reported by the recommended dose of 5 mg a day 3% more side effects in patients with Aerius, than in patients who were treated with placebo."</seg>
<seg id="1737">"the most common side-side effects, about the more common than in placebo were tiredness (1,2%), mouthdry (0,8%) and headaches (0,6%)."</seg>
<seg id="1738">"in a clinical study with 578 youthful patients from 12 to 17 years was the most common secondary effect of headache, these entered into 5.4% of patients who have been treated with desloratadin and treated with 6.6% of patients who were treated with placebo."</seg>
<seg id="1739">"in a multi-disciplinary study, with up to 45 mg of Desloratadin (nineteen clinical dose) have been applied, were not clinically relevant effects observed."</seg>
<seg id="1740">This includes both the inhibition of the release of proinflammats cytokens like IL-4, IL-6, IL-8 and IL-13 from human macells / Basophila as well as the inscription of the expression of the addiction smolecular cells. "</seg>
<seg id="1741">"as part of a clinical study involving multi-disciplinary study, in the Desloratadin in a dosage of up to 20 mg a day over 14 days has been administered over 14 days, has not been statistically significant or clinically relevant cardiovascular effect."</seg>
<seg id="1742">"in a clinically-pharmacological study, in the desloratadin in a dosage of 45 mg a day (the Neunple of the clinical dose) over ten days showed itself, not an extension of the QTc Intervalls."</seg>
<seg id="1743">"in a single doser study with adults showed Desloratadin 5 mg no influence on standard sizes of the flight, including the amplified hoses or the tasks that are connected to the thread."</seg>
<seg id="1744">"in patients with allergic Rhinitis, Aerius was effective in the relief of symptoms such as Niese, nose secretion and itch of the nose, itch, dreaming and redness of the eyes as well as itch at the palate."</seg>
<seg id="1745">"in addition to the established classification in saisonal and Perennial, the allergic Rhinitis can be shared depending on the duration of symptoms, as well as in intermitting allergic Rhineitis and persist Rhinoplasty."</seg>
<seg id="1746">Intermitting allergic Rhinitis is defined as a appearance of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persistent allergic Rhinitis is defined as a appearance of symptoms to 4 or more days per week and more than 4 weeks.</seg>
<seg id="1748">As shown by the overall scores of the questionnaire concerning the quality of life in Rhino-Conjunktivitis was shown to decreases Aerius effectively the allergic rhinitis.</seg>
<seg id="1749">The chronically idiopathic Urtikaria was a substitute for further forms of the Urtikaria since the underlying pathphysiology disirrespective of etiology with different forms is similar and chronic patients can become easier.</seg>
<seg id="1750">"as the history of histological disease is expected, is expected that Desloratadin is expected also with the chronically idiopathic Urtikaria, even in other forms of the Urbino to an improvement of symptoms; this is confirmed by the recommendations of clinical guidelines."</seg>
<seg id="1751">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urtikaria, Aerius was effective in improving asuritus and the degradation of size and number of squares at the end of the first doses."</seg>
<seg id="1752">"as in other studies with Antihistaminika in chronically idiopathic Urtikaria, the minority of patients who do not reacted on Antihistaminika, from the study."</seg>
<seg id="1753">An improvement of the itching to more than 50% has been observed at 55% of the patients with disaster to be treated with placebo patients compared to 19% of the placebo patients.</seg>
<seg id="1754">"the treatment with Aerius reduced the disorder of sleep and vigilly significant, as being measured by a 4-score on evaluating these variables."</seg>
<seg id="1755">"in a pharmacoinetic study, where patients can be compared with the general seasonal allergic Rhineitis population, was achieved by 4% of patients a higher concentration of Desloratadin."</seg>
<seg id="1756">There are no clues for a clinically relevant Kumulation after once daily use of Desloratadin (5- 20 mg) over 14 days before.</seg>
<seg id="1757">"however, that in the metabolic of Desloratadin responsibly enzyme has not yet been identified, so that interactions with other medicines will not be excluded completely."</seg>
<seg id="1758">Desloratadin shirt in-vivo not CYP3A4 and in-vitro-studies have shown that the medicine CYP2D6 is not inhibited and neither a substrate nor an Inhibitor of the P-glycotic.</seg>
<seg id="1759">In a single dosing study with Desloratadin in a dosage of 7.5 mg acting meals (fatty-rich breakfast) not upon the availability of Desloratadin.</seg>
<seg id="1760">"associated with Desloratadin and Loratadin performed, at a comparative degree of exposure of Desloratadin, no qualitative or quantitative differences with regard to the toxicity film by Desloratadin and Loratadin."</seg>
<seg id="1761">"based on conventional studies on safety vulnerability, toxicity in repetitive Gabe, genotoxicity and for reproductions, the preclinical data with Desloratadin have no particular hazards for men."</seg>
<seg id="1762">"colourless film (includes Lactosis-Monohydrat, hypromelless, Titanium, Macrogol 400, Indigocarmin (E 132)), colourless film (contains hypromelless, Macrogol 400), Carnaun Wax, bunt wax."</seg>
<seg id="1763">Aerius can be taken independently of the meals to prevent symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1764">The prescription doctor should be aware that most cases of Rhinoplasty can be caused by an infection (see below 4.4) and that no data are predestined to support a infectious Rhinitis with Aerius.</seg>
<seg id="1765">"in addition to the exclusion of upper respiratory infections, or anatomical anomalies should play a role in diagnosing the anamnese, physical investigations and appropriate laboratory and skin effects."</seg>
<seg id="1766">About 6% of adults and children between 2 and 11 years metabolize Desloratadin and find out a higher substacy (see under section 5.2).</seg>
<seg id="1767">"the safety of Aerius Sirup in children between 2 and 11 years, the restricted metabolize, is identical to those in children which are normal yet metabolize."</seg>
<seg id="1768">"this medicine contains Saccharse and Sorbitol; therefore patients should not take with hereditary problems of a fructose intolerance, glucose-Galactosis, or a Saccharase Isomaltase- infertility."</seg>
<seg id="1769">Clinically relevant interactions were not observed in clinical studies with Aerius tablets were not specified when Erythromycin or Ketoconazol can be found in addition (see section 5.1).</seg>
<seg id="1770">In a clinically-pharmacological study was not reinforced by aserius tablets and alcohol the high-performance effect of alcohol (see section 5.1).</seg>
<seg id="1771">The overall effects of side-effects in children from 2 to 11 years was similar to the Aerius Sirup group as well as the placebo group.</seg>
<seg id="1772">"in clinical studies with adults and young people in various indications, including allergic Rhinitis and chronically idiopathic Urtikaria, were reported in the recommended dose 3% more side effects in patients with Aerius than in patients who were treated with placebo."</seg>
<seg id="1773">"in a multi-dose study on adults and adolescents, with up to 45 mg of Desloratadin (nineteen clinical dose) have been applied, were not clinically relevant effects observed."</seg>
<seg id="1774">Children aged between 1 and 11 years old for an antihistamine therapy has been received from 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years).</seg>
<seg id="1775">Because the course of allergic Rhinitis / chronically idiopathic Urtikaria and the profile of Desloratadin in adults and children can be similar to the efficiencies of desloratadin in adults on the children population.</seg>
<seg id="1776">"as part of a clinical study with multi-disciplinary study of adults and adolescents, in the desloratadin in a dosage of up to 20 mg daily over 14 days has been used to be statistically significant, or clinically relevant cardiovascular effect."</seg>
<seg id="1777">"in a clinically-pharmaological study of adults and young people, in the desloratadin in a dosage of 45 mg a day (the Neunple of clinical dose) has been used for ten days at adults, not an extension of the QTc Intervalls."</seg>
<seg id="1778">In controlled clinical trials was found in the recommended dosage of 5 mg a daily basis for adults and young people not increased frequency of sfriction compared to placebo.</seg>
<seg id="1779">With a single day dose of 7.5 mg resulted in Aerius tablets with adults and young people in clinical studies to no impairment of the psychomotors.</seg>
<seg id="1780">"in clinically-pharmaological studies of adults it came with simultaneous intake of alcohol neither to reinforcement of alcohol induced power, nor to an increase in the mud."</seg>
<seg id="1781">"for adult and youthful patients with allergic Rhinitis were aserius tablets effective in the relief of symptoms such as Niese, nose secretion and itch of the nose, itch, tabolic and redness of the eyes as well as itch at the palate."</seg>
<seg id="1782">As shown by the overall scores of the questionnaire concerning the quality of life in Rhino-Conjunktivitis was shown to reduce Aerius tablets effectively the allergic rhinitis</seg>
<seg id="1783">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic Urtikaria, Aerius was effective in improving asuritus and the degradation of size and number of squares at the end of the first doses."</seg>
<seg id="1784">"the spread of this restricted metabolized phenomenon, was comparable to adults (6%) and children between 2 and 11 years (18% adults, 16% children) than with Caucasiern (2% adults, 3% children)."</seg>
<seg id="1785">Similar pharmacoinetic parameters were observed in a pharmacoinetic faceosis study with the sirupformulation of children between 2 and 11 years with allergic Rhinitis.</seg>
<seg id="1786">The load (AUC) by Desloratadin was after 3 to 6 hours higher and the Cmax approximately 3 to 4 times higher with a terminals of about 120 hours.</seg>
<seg id="1787">There are no clues for a clinically relevant impact accumulation after once daily use of Desloratadin (5- 20 mg) over 14 days in adults and adolescents.</seg>
<seg id="1788">"12 In different single dose studies showed that AUC- and Cmax values of Desloratadin in paediatric patients with the recommended doses comparable with those of adults, the desloratadin-sirup in a dosage of 5 mg received."</seg>
<seg id="1789">"for the metabolic of Desloratadin responsibly enzyme, however, has not yet been identified, so that interactions with other medicines can not be excluded completely."</seg>
<seg id="1790">"Aerius Sirup is offered in type-III-Braunlasers with child-safe polypropylene cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with a starren, persibly polystyrene measurement, calibrated with 2,5 ml and 5 ml or with a applicant for complements with scaling of 2.5 ml and 5 ml (only for 150 ml bottle)."</seg>
<seg id="1792">A dose of Aerius Lyophilisat once take place daily in the mouth to prevent symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1793">"immediately before the application the blister has to be carefully opened and the dose of the Lyophilisats can be taken from, without damaging it."</seg>
<seg id="1794">Clinically relevant interactions were not found in clinical studies with Aerius tablets were not applied when Erythromycin or Ketoconazol in addition were applied (see section 5.1).</seg>
<seg id="1795">"clinical trials in various indications, including allergic Rhinitis and chronically idiopathic Urtikaria, were reported by the recommended dose of 5 mg a day 3% more side effects in patients with Aerius tablets than in patients who were treated with placebo."</seg>
<seg id="1796">"in a multi-disciplinary study, in which up to 45 mg of Desloratadin (ninetine clinical dose) were observed, were not clinically relevant effects observed."</seg>
<seg id="1797">"in two single dose studies, Aerius Lyophilisat for insertion well tolerate; this was documented by clinical laboratories, medical investigations, Vitalsigns and EKG-Intervalldata."</seg>
<seg id="1798">"as part of a clinical study involving multi-disciplinary study, in the Desloratadin in a dosage of up to 20 mg once more than 14 days has been used during 14 days, has not been statistically significant, or clinically relevant cardiovascular effect."</seg>
<seg id="1799">"in a clinically-pharmacological study, in the desloratadin in a dosage of 45 mg a day (the Neunple of clinical dose) has been used for ten days, not an extension of the QTc Intervalls."</seg>
<seg id="1800">In controlled clinical trials was found in the recommended dosage of 5 mg a daily incidence of sfriction compared to placebo.</seg>
<seg id="1801">"with an 17 single dose with adults showed Desloratadin 5 mg no influence on standard - measurement sizes of the flight, including the amplified hoses or the tasks that are connected to the thread."</seg>
<seg id="1802">"in patients with allergic Rhinitis, Aerius tablets were effective in the relief of symptoms such as Niese, nose secretion and itch of the nose, itch, dreaming and redness of the eyes as well as itch at the palate."</seg>
<seg id="1803">As shown by the overall scores of the questionnaire concerning the quality of life in Rhino-Conjunktivitis was shown to decreases Aerius effectively the allergic rhinitis.</seg>
<seg id="1804">"18 In a pharmacoinetic study, where patients can be compared with the general seasonal allergic Rhineitis population, was achieved by 4% of patients a higher concentration of Desloratadin."</seg>
<seg id="1805">"food has no significant influence on AUC and Cmax of Aerius Lyophilisat, while food Tmax of Desloratadin from 2.5 to 4 hours and Tmax of 3-OH-Desloratadin from 4 to 6 hours extended."</seg>
<seg id="1806">Gelatine Mannitol Aspartame (E 951) Polacrilin-Kaliko Rulint Red (contains iron (III) -oxide (E 172) and hypromelless (E 464)) Aroma Tutti-Frutti water-free citron</seg>
<seg id="1807">An aserius 2.5 mg melting tablet once daily put in the mouth to prevent symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1808">Two aserius 2,5 mg melt lettued once daily in the mouth to prevent symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1809">There is limited experience of clinical trials for effectiveness in the application of Desloratadin in young people from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately before the application the blister needs carefully opened and the dose of the melting tablet are removed, without damaging it."</seg>
<seg id="1811">The effectiveness and harmlessness of Aerius 2,5 mg melting items in the treatment of children under 6 years have been not proven.</seg>
<seg id="1812">The overall frequency of side effects between the Desloratadine sirupture and the placebo group was the same and turned not significant from the adult safety profile.</seg>
<seg id="1813">"in the recommended dose, Aerius melt is equivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg Lyophilisat for acquiring formulation by Desloratadin."</seg>
<seg id="1814">"in the framework of a clinical study with multiple compounds, in the Desloratadin in a dosage of up to 20 mg a day of 14 days has been applied daily about 14 days, has not been statistically significant or clinically."</seg>
<seg id="1815">"with an individual dose with adults showed Desloratadin 5 mg no influence on standard - measurement sizes of the flight, including the amplified hoses or the tasks that are connected to the thread."</seg>
<seg id="1816">"the spread of this bad metabolized phenomenon, was comparable for adult (6%) and pediatric patients aged 2 to 11 years (6%, children 16%) greater than with Caucasiern (adults 2%, children 3%), the safety profile of these patients was not isolated from the general population."</seg>
<seg id="1817">In single dose-crossover studies by Aerius melt with Aerius 5 mg conventional tablets or aserius 5 mg Lyophilisat for inserts the formulations was equivalent.</seg>
<seg id="1818">"Aerius 2,5 mg tablets were not examined in pediatric patients, but in conjunction with the dosage studies in children, however, the pharmacoinetic data for Aerius melt studies, the use of 2.5 mg dosage for children from 6 to 11 years."</seg>
<seg id="1819">Food has no significant influence on AUC and Cmax of Aerius Aerius Lyophilisat to take during food Tmax of Desloratadin of 2.5 to 4 hours and Tmax of 3-OH- Desloratadin of 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of the preventive and clinical trials tests for the melting tablet that this formulation represents an unlikely risk for local irritations in clinical application.</seg>
<seg id="1821">Micro-crystallized cellulose intensity of Carboxymethacrylate-copper-copper-calcium hydrogen Bdispersal Silicium Cititumdioxide Eisenoxide Mannitol Aspartame (E951) Aroma Tutti Frutti</seg>
<seg id="1822">"the Kaltformblister foil consists of polyvinyl chloride (PVC) film, rests laminated on a aluminium foil, crush laminated on a polyvinyl chloride (PVC) film."</seg>
<seg id="1823">An aserius 5 mg melting tablet once daily put in the mouth to prevent symptoms in allergic Rhinitis (including intermitting and persist allergic rhinitis) and Urtikaria (see below section 5.1).</seg>
<seg id="1824">"in the recommended dose, Aerius 5 mg melt equivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg Lyophilisat for acquiring formulation by Desloratadin."</seg>
<seg id="1825">"as part of a clinical study involving multi-disciplinary study, in the Desloratadin in a dosage of up to 20 mg once more than 14 days has been used during 14 days, has not been statistically significant, or clinically relevant cardiovascular effect."</seg>
<seg id="1826">"with an 30 single-dose study with adults showed Desloratadin 5 mg no influence on standard - measurement sizes of the flight, including the amplifictional hoses or the tasks that are connected to the thread."</seg>
<seg id="1827">"in patients with allergic Rhinitis, Aerius tablets were effective in the relief of symptoms such as Niese, nose secretion and itch of the nose, itch, dreaming and redness of the eyes as well as itch at the palate."</seg>
<seg id="1828">In single dose-crossover studies by Aerius 5 mg melting tablet with Aerius 5 mg conventional tablets or aserius 5 mg Lyophilisat for inserts the formulations was equivalent.</seg>
<seg id="1829">The overall analysis of the preventive and clinical trials tests for the melting tablet that this formulation represents an unlikely risk for local irritations in clinical application.</seg>
<seg id="1830">"the safety of Desloratadin in children between 2 and 11 years, the restricted metabolize, is identical to those in children which are normal yet metabolize."</seg>
<seg id="1831">"this medicine contains Sorbitol; therefore patients should not take with hereditary problems of a fruity intolerance, glucose-Galactosis, or a Saccharase-Isomaltase-infertility."</seg>
<seg id="1832">The overall effects of side-effects in children from 2 to 11 years was similar to the diloratadin group similar to the placebo group.</seg>
<seg id="1833">"on children between 6 and 23 months the most common side-side effects were reported on the more common than in placebo, diarrhoe (3,7%), fever (2,3%) and sleeplessness (2,3%)."</seg>
<seg id="1834">"in an additional study were observed at a single dose of 2.5 mg of Desloratadin solution for taking no side effects in patients aged between 6 and 11 years."</seg>
<seg id="1835">In the recommended doses were the Plasmaconconcentrations of Desloratadin (see section 5.2) in the children's and adult population.</seg>
<seg id="1836">In controlled clinical trials was found in the recommended dosage of 5 mg a daily basis for adults and young people not increased frequency of sfriction compared to placebo.</seg>
<seg id="1837">"in addition to the established classification in saisonal and Perennial, the allergic Rhinitis can vary depending on the duration of symptoms, as well as in intermitting allergic Rhinitis and"</seg>
<seg id="1838">As shown by the overall scores of the questionnaire concerning the quality of life in Rhino-Conjunktivitis was shown to reduce Aerius tablets effectively the allergic rhinitis retained by seasonal allergic rhinitis.</seg>
<seg id="1839">"the spread of this restricted metabolized phenomenon, was comparable to adults (6%) and children between 2 and 11 years (18% adults, 16% children) than with Caucasiern (2% adults, 3% children)."</seg>
<seg id="1840">"as Aerius solution for taking the same concentration on Desloratadin, there was no bio-valence study, and it is expected to be expected that they corresponds to the syrup and tablets."</seg>
<seg id="1841">"in different single dose studies showed that AUC- and Cmax values of Desloratadin in paediatric patients with the recommended doses were comparable with those of adults, the desloratadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1842">"Sorbitol, Propylenglycol, Sucralose E 955, sodium citrate 2 H2O, natural and artificial flavors (Bubble-Gum), water-free citronyacid, sodium."</seg>
<seg id="1843">"Aerius solution to take is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III Braunlasers with a child-safe polyethylene with a multi-layer polyethylene."</seg>
<seg id="1844">All packaging sizes except the 150 ml packet size are offered with a measurement table with markings for dosages of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml packet size is a measuring spoon or a applicator for preparation for complements with scaling 2.5 ml and 5 ml attached.</seg>
<seg id="1846">"subsequently to the extension of the approval, the filming will submit the regularly updated reports on the inconceivable of a drug by every two years, except there will be something different from CHMP."</seg>
<seg id="1847">1 film-room 2 Filmtabletten 5 Filmtabletten 15 Filmtabletten 20 Filmtabletten 21 Filmtabletten 30 Filmtabletten 50 Filmtabletten 90 Filmtabletten 100 Filmtabletten</seg>
<seg id="1848">1 film-room 2 Filmtabletten 5 Filmtabletten 15 Filmtabletten 20 Filmtabletten 21 Filmtabletten 30 Filmtabletten 50 Filmtabletten 90 Filmtabletten 100 Filmtabletten</seg>
<seg id="1849">Syrup 30 ml with 1 measuring spoon 60 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1850">30 ml with 1 measuring spoon 60 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1851">1 dosage Lyophilisat to take 2 cans of Lyophilisat for inserts 15 cans of lyophilisat for inserting 15 cans of lyophilisat for inserting 30 cans of lyophilisat for insertion 50 cans of lyophilisat for insertion 50 cans of lyophilisat for insertion 50 cans of lyophilisat for insertion 50 cans of lyophilisat for inserting 100 cans of lyophilisat for insertion 100 cans of lyophilisat for inserting 100 doses Lyophilisat for inserting 100 doses Lyophilisat for insertion</seg>
<seg id="1852">5 melting-tabletten melting-tabletten melting-tabletten melting lettuals 20 melt letten 30 melting lettuals 60 melting lettued 90 melting lettuals 100 melting-coated 100 melting</seg>
<seg id="1853">Solution for inserting 30 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1854">Pregnancy and breastfeeding issues you during pregnancy and breastfeeding before taking all medicinal products or pharmacist to the Council.</seg>
<seg id="1855">Transport and use of machines At the application in the recommended dosage is not to be expected that Aerius leads to bends or bring attention to attention.</seg>
<seg id="1856">"if you have told by your doctor that you have a intolerance against certain sugar, ask your doctor before you take this medicine."</seg>
<seg id="1857">"regarding the treatment of treatment your doctor will determine the type of allergic Rhinoplasty, which you suffer and will define how long you should take aperius."</seg>
<seg id="1858">"if your allergic Rhinitis intermitting (the symptoms are rare as 4 days a week or less than 4 weeks, your doctor will recommend you a treatment scheme, depending on your previous disease."</seg>
<seg id="1859">If your allergic Rhinitis persist (the symptoms of 4 or more days per week occur and more than 4 weeks in order), your doctor can recommend you a longer continuous treatment. "</seg>
<seg id="1860">"if you have forgotten the intake of Aerius If you have forgotten your dose in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1861">"71 After market launch of Aerius was very rare in cases of severe allergic reactions (difficulties when breathing, piping breath, itching, kidney drash and swelling) and rash."</seg>
<seg id="1862">"over cases of cardips, cardio, droplness, plessness, sleeplessness, sleeplessness, plessness, restlessness, restlessness, humilience and uncommon body functioning was also very rare reported."</seg>
<seg id="1863">"explosive film consists of a coloured film (includes Lactos- Monohydrat, Hypromelless, Titanium, Macrogol 400, Indigocarmin (E 132)), colored film (contains hypromelless, Macrogol 400), Carnaubawax."</seg>
<seg id="1864">"Aerius 5 mg Filmtabletten are individually packed in blister packs with 1, 2, 3, 7, 10, 14, 15, 20, 21, 30, 50, 90 or 100 tablets."</seg>
<seg id="1865">"Aerius Sirup is shown for children aged between 1 and 11 years, young people (12 years and older) and adults, older people."</seg>
<seg id="1866">"important information about certain other components of Aerius you should not take on Aerius Sirup, if you are allergic to the color of E 110."</seg>
<seg id="1867">"if you shared your doctor that you possess an incompatibility with some sugar types, please contact your doctor before you take this medicine."</seg>
<seg id="1868">"if the Sirup is a applicant fûr preparation for inserting with scaling, you can use this alternative to take the appropriate amount of syrup."</seg>
<seg id="1869">"regarding treatment of treatment your doctor will determine the type of allergic Rhinitis that you suffer and will determine how long you should take Aerius Sirup."</seg>
<seg id="1870">"however, in children under 2 years of experience, fever and sleeplessness common side effects, during an adult tiredness, mouthdry and headaches were reported as with placebo."</seg>
<seg id="1871">"according to market launch of Aerius was very rare in cases of severe allergic reactions (difficulties when breathing, piping breath, itching, kidney drash and swelling) and rash."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with child-safe cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">Aerius Lyophilisate on entry improves the symptoms in allergic Rhinitis (by allergy highlighted inflammation of the nasal length, for example hypods or house dust-allergy). "</seg>
<seg id="1874">"for intake of Aerius Lyophilisat, together with food and drinks Aerius Lyophilisat for interference does not need to be taken with water or any other fluid."</seg>
<seg id="1875">"regarding treatment of treatment your doctor will determine the type of allergic Rhinitis that you suffer and will define how long you should take Aerius Lyophilisat."</seg>
<seg id="1876">"81 If you have forgotten the intake of Aerius Lyophilisat, If you have forgotten your dose in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1877">"according to market launch of Aerius was very rare in cases of severe allergic reactions (difficulties when breathing, piping breath, itching, kidney drash and swelling) and rash."</seg>
<seg id="1878">"Aerius Lyophilisat for entry is individually in blister packs with 1, 2, 3, 7, 7, 10, 14, 15, 20, 21, 30, 50 or 100 doses of the Lyophilisats."</seg>
<seg id="1879">Aerius Schmelztablette enhances the symptoms in allergic Rhinitis (by allergy highlighted inflammation of the nasal length, for example hypods or house dustmilk-allergy). "</seg>
<seg id="1880">With intake of aserius melting tablet together with food and drinks Aerius melt tablet is not taken with water or any other fluid.</seg>
<seg id="1881">"regarding the treatment of treatment your doctor will determine the type of allergic Rhinoplasty, which you suffer and will define how long you should have Aerius melt lettre."</seg>
<seg id="1882">"86 If you have forgotten the intake of aserius melt, If you have forgotten your dose in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1883">"Aerius melt tablet is individually packed in blister packs with 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 cans of the melting tablet."</seg>
<seg id="1884">With intake of aserius melting tablet together with food and drinks Aerius melt tablet is not taken with water or any other fluid.</seg>
<seg id="1885">"if you have forgotten the intake of aserius melt, If you have forgotten your dose in time, take them as soon as possible, and then follow the normal treatment plan."</seg>
<seg id="1886">"according to market launch of Aerius was very rare in cases of severe allergic reactions (difficulties when breathing, piping breath, itching, kidney drash and swelling) and rash."</seg>
<seg id="1887">"Aerius solution for income is shown for children aged between 1 and 11 years, young people (12 years and older) and adults, older people."</seg>
<seg id="1888">"if the solution to take a applicant for pre-prepared for complements with scaling, you can use this alternative to take the appropriate amount of solution to take."</seg>
<seg id="1889">"regarding treatment of treatment your doctor will determine the type of allergic Rhinitis that you suffer and will determine how long you should take Aerius solution to take."</seg>
<seg id="1890">"however, in children under 2 years of experience, fever and sleeplessness common side effects during an adult tiredness, mouthdry and headaches were reported as with placebo."</seg>
<seg id="1891">"97 Aerius solution for income is available in bottles with child-safe cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml packet size is a measuring spoon or a applicant fûr preparation for insertion with scalloys from 2.5 ml- and 5 ml doses.</seg>
<seg id="1893">June 2008 shared Novartis Vaccines and Diagnostics S.r.l. committee (CHMP) officially launched the company for Humanitunov to prevent the aviation of the aviour H5N1 influenza in adults and elderly people.</seg>
<seg id="1894">"Aflunov should be caused by adults and older people to protect the flu, caused by the tribe (type) H5N1 of influenza-A-virus."</seg>
<seg id="1895">"this is a special kind of vaccine, which could cause a trunk of the flu, which could cause a future pandemic."</seg>
<seg id="1896">"a influenza pandemic breaks out when a new trunk of the flu, which can easily spread from person to man because people do not have immunity (no protection) against it."</seg>
<seg id="1897">"after agreement of the vaccine, the immune system is recognising the immune system the parts of the flu-virus as" "physically" "and forms an antibody against it."</seg>
<seg id="1898">"thus, the immune system later is able to form in contact with a Griecvirus this pedigree of the ordinary antibodies."</seg>
<seg id="1899">"afterwards, the membranes grommet of the virus with the" surface surface "(proteins on the membrane surface, which detects the human body as a body-off), certified and used as a component of the vaccine."</seg>
<seg id="1900">"a inspection of some of the study centers showed that the study was not done according to the" "good clinical practice" "(GCP)."</seg>
<seg id="1901">The scope of the clinical data base for evaluating the safety of the vaccine not to fulfill the requirements of the guidelines of the EMEA for preventive vaccines.</seg>
<seg id="1902">"should you take part in a clinical trial and need more information about your treatment, please contact your doctor."</seg>
<seg id="1903">"if you desire further information on the basis of recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"it is applied in combination with other antiviral medicines for the treatment of adults and children over four years, which are caused by the humanen immunity level of type 1 (HIV-1) which are caused by the acquired Immune Deficiency Syndrome (AIDS)."</seg>
<seg id="1905">"for patients who can not swallow the capsules, there is asgenerase may be taken as a solution to income, but this cannot be taken together with ritonavir since the security of this combination was not investigated."</seg>
<seg id="1906">"Agenerase should only be removed if the doctor has been tested, which anti-virral medicines of the patient has been taken before, and the likelihood has been judged that the virus is being examined."</seg>
<seg id="1907">The recommended dose for patients over twelve years is 600 mg twice daily that can be taken along with twice daily 100 mg Ritonavir and with other antiviral medicines.</seg>
<seg id="1908">In children between four and twelve years and in patients with a body weight of less than 50 kg the recommended dose of asgenerase after the body weight.</seg>
<seg id="1909">Agenerase reduced in combination with other antiviral medicines the HIV amount of blood and keeps them at a low level.</seg>
<seg id="1910">"AIDS not to heal, however, cannot delay the damage of the immune system and thus the development of with AIDS connected infections and diseases."</seg>
<seg id="1911">"Agenerase was examined in combination with other antiviral medicines, but without ritonavir, in two main studies with 736 HIV-infected adults, which had not been treated with proteasehemania."</seg>
<seg id="1912">"that with low dosiertem Ritonavir increased medicine Agenerase was taken with 206 adults, who had taken formerly proteasehemmer, with other proteasehemania."</seg>
<seg id="1913">Main indicator for the effectiveness was the proportion of patients with not verifiable concentrations of HIV in the blood (virusload) or the change of virusload after treatment.</seg>
<seg id="1914">"in the studies with patients who had had taken no proteasehemmer, even after 48 weeks under Agenerase more patients had a Virusload under 400 copies / ml than at placebo, but Agenerase was less effective than Indinavir."</seg>
<seg id="1915">"for children, Agenera also has been reduced the Virusload, but with the children, which were treated earlier with proteasehemania, only very few to the treatment."</seg>
<seg id="1916">In the study with adults who were treated earlier with proteasehemania who were treated with Ritonavir reinforced medicine Agenerase after 16-week treatment as effective as other proteasehemmer:</seg>
<seg id="1917">"in the patients with HIV, that was against four other proteasehemmer resistant, there came under Agenerase together with Ritonavir to a greater waste after four weeks when in patients who participated their former protesters:"</seg>
<seg id="1918">"the most common side effects of Agenerase (observed if more than 1 of 10 patients) are headaches, Diarrhö (diarrings), Flatulency (Blessing), break-rash, rash and Fatigue (tiredness)."</seg>
<seg id="1919">"2 / 3 Agenerase may not be applied in patients, which may possibly be hypersensitive (allergic) against Amfavir or any of the other components."</seg>
<seg id="1920">"Agenerase may not be applied in patients who are being applied to patients (a herbal preparation for treating depression) or medicines that are just as asylum, and are in high concentrations in the blood of health harmful."</seg>
<seg id="1921">"as with other drugs against HIV exists for patients, the asgenerase, the risk of a lipodystrophy (die of bone tissue) or a immune response (symptoms of an infection, caused by the relaxing immune system)."</seg>
<seg id="1922">The Committee for Humanity grew up to the conclusion that the benefits of Agenerase in combination with other antiretroviral medicines for the treatment of with proteasehematic drugs used to treat HIV-1-inficated adults and children over four years compared to the risks.</seg>
<seg id="1923">"Agenerase is usually taken together with the pharmacoinetic amplifier, but the Committee adopted that the benefits of Agenerase in combination with ritonavir are taken in combination with ritonavir."</seg>
<seg id="1924">"Agenerase was originally licensed under" exceptional circumstances, as at the time the approval for scientific reasons only limited information. "</seg>
<seg id="1925">October 2000 the European Commission sent to the Glaxo Group Limited as a permit for the use of asgenerals throughout the European Union.</seg>
<seg id="1926">"Agenerase is in combination with other antiretroviral medicines to treat HIV-1- inficated, proteasehemmer (PI) -treatable adults and children from 4 years."</seg>
<seg id="1927">For usually Agenerase capsules to pharmacoinetic boosting of Amboavir can be administrated with low doses of Ritonavir (see sections 4.2 and 4.5).</seg>
<seg id="1928">The use of Amfavir should be taking into account the individual viral resistance and the pre-treatment of the patient (see section 5.1).</seg>
<seg id="1929">The bioavailability of Amfavir as a solution to take is 14% less than capfavir. therefore Agenerase capsules and solution to insertion on a milligram per milligram base is not interchangeable (see section 5.2).</seg>
<seg id="1930">The recommended dose for Agenerase capsules is 600 mg Amfavir twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="1931">2. if Agenerase capsules will be applied without the reinforced additives from Ritonavir (booklet) must be applied higher doses of apurase (1200 mg twice daily).</seg>
<seg id="1932">"the recommended dose for Agenerase capsules is 20 mg of Amfavir / kg body weight twice daily in combination with other antiretroviral medicines, up to a daily dose of 2400 mg Amfavir that should not be exceeded (see section 5.1)."</seg>
<seg id="1933">"the pharmacoinetic, effectiveness and safety of asgenerase in combination with low doses of ritonavir or other proteasehemania were not examined."</seg>
<seg id="1934">"Agenerase is not recommended for use in children under 4 years, due to the malignity of data for harmlessness and effectiveness (see section 5.2)."</seg>
<seg id="1935">Based on pharmacoinetic data should reduce the dose of Agenerase capsules in adult sufferers in adult sufferers to 450 mg twice daily and in patients with severe liver dysfunctions on 300 mg twice daily.</seg>
<seg id="1936">The simultaneous application is intended to treat patients with mild or moderate liver functioning with caution in patients with severe liver functioning, it is contradicated (see Section 4.3). "</seg>
<seg id="1937">Agenerase may not be given simultaneously with pharmaceuticals which possess a low therapeutic width and also represent substrate of the Cytochrom P450-Isoenzms 3A4 (CYP3A4).</seg>
<seg id="1938">Herbal supplements that include Johanniskell (Hypericum perforatum) may not be used due to risk reduction of plasiliavir during the intake of amathavir (see Section 4.5).</seg>
<seg id="1939">Patients should be pointed out that Agenerare or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="1940">The current antiretroviral therapy including treatment with Agenerase prevents not preventing the risk of transferring HIV to others through sexual contact or contamination with blood.</seg>
<seg id="1941">For usually Agenerase capsules are used together with low doses from Ritonavir and in combination with other antiretroviral medicines (see section 4.2).</seg>
<seg id="1942">Patients who suffer from chronic hepatitis B or C and have been treated with antiretroviral Combination therapy and have increased risk for heavy hepatic impacts of potentially deadly history.</seg>
<seg id="1943">In the case of simultaneous antiviral treatment of hepatitis B or C please read the concerned information of this medicine.</seg>
<seg id="1944">Patients with pre-existing reduced liver function including a chronically active hepatitis demonstrate an increased frequency of liver dysfunctions under a antiretroviral building therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">"the simultaneous use of Agenerare and Ritonavir, with fluticason or other Glucoooroids, that is not recommended that the potential benefits of treatment is systematic cortikosteroider effects including morbus Cushing and Suppression of the outpatient function (see Section 4.5)."</seg>
<seg id="1946">"as the contraception of the HMG-CoA-Reduction tase-Hemmer Lovastatin and Simvastatin strongly dependent on CYP3A4, is a simultaneous agreement with Lovastatin and Simvastatin due to the increased risk of mythia including rahabdomyolysen."</seg>
<seg id="1947">"4 For some medicines that can cause serious or life-threatening effects, such as carbamazepine, Phenobarbital, phenytoine, tricyclic antidepressants and warring (under supervision of the International standardization ratio), are available methods for determining the agents concentration."</seg>
<seg id="1948">"in patients who take these medicines at the same time, asgenerase can be less effective because of decreased plasmascult (see Section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolized interactions with amberavir, the effectiveness of hormonal contexchanges can be changed, but the information is not sufficient to estimate the kind of interactions."</seg>
<seg id="1950">"when Methadon simultaneously is given by Amfavir, patients should therefore be monitored on opiatry symptom, particularly when there are also low doses of ritonavir."</seg>
<seg id="1951">"because of the possible risk of a toxicity, due to the high propylism of the asgenerative solution to the one is contradicated in children under an age of four years and should be applied with caution at certain other patients."</seg>
<seg id="1952">"Agenerase should be placed on duration 5, when a rash is accompanied by systemic or allergic symptoms, or the mucous membranes are involved (see section 4.8)."</seg>
<seg id="1953">"in patients who received an antiretroviral therapy including proteasehemmer, hyperglycemic, or an exacerbation of an existing Diabetes Mellitus."</seg>
<seg id="1954">Many of the patients had other diseases to their therapy medicines which were associated with the development of diabetes mellitus or a hyperglycemic.</seg>
<seg id="1955">"B. higher age, and with drug-dependent factors, such as a longer androde antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="1956">"with hammophilen patients (type A and B) that were treated with proteasehemania, reports on an increase in bleeding including spontaneous coutaneous hematoms and hemanthroes."</seg>
<seg id="1957">In HIV-infected patients with serious immune defect it can develop an inflamed reaction to asymptomatic or residual opportunistic infections that leads to severe clinical states or deterioration of symptoms.</seg>
<seg id="1958">"although a multifactorial aptiology is accepted (including use of cortikostoids, alcohol consumption, heavy immunossion, higher Body-mass-index), cases of Osteonekrose particularly in patients with advanced HIV disease and / or long-term application of an antiretroviral Combinary therapy (ART)."</seg>
<seg id="1959">CYP3A4 substrate with low therapeutic width Agenerase may not be given simultaneously with pharmaceuticals which have a low therapeutic width and also represent substrate of the Cytochrom P450-Isoenzes 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with low therapeutic width Agenerase may not be traced together with pharmaceuticals and their active ingredients can be traced mainly via CYP2D6 and for the increased plastic level with serious and / or life-threatening side effects.</seg>
<seg id="1961">It was shown that Rifampicin a 82% reduction in AUC caused by Amagavir caused to lead to a virological failure and lead to a resistance development.</seg>
<seg id="1962">"in trying, the lowest plasmasculars in combination with ritonavir can be observed in combination with ritonavir, were observed very often unwanted effects on the liver."</seg>
<seg id="1963">Johanniskell (Hypericum perforatum) The Serum mirror of Amfavir can be brought out by the simultaneous application of herbal supplements with Johanniskish (Hypericum perforatum).</seg>
<seg id="1964">"when a patient takes before Johanniskell, are the amathavities and if possible to verify the Virusload and liberate the Johanniskum."</seg>
<seg id="1965">A dosage adjustment for one of the medication is not required when Nelfinavir is administered along with Amfavir (see also Efavich).</seg>
<seg id="1966">"508% increases, for Cmax against 30% lower than ritonavir (100 mg twice daily) in combination with Amfavir capsules (600 mg twice daily)."</seg>
<seg id="1967">"in clinical trials, doses were applied by 600 mg of Amfavir twice daily and Ritonavir 100 mg twice daily, which defines the effectiveness and harmlessness of this treatment."</seg>
<seg id="1968">52% lower if Amfavir (750 mg twice daily) in combination with Caletra (400 mg Lopinavir + 100 mg Ritonavir twice daily).</seg>
<seg id="1969">"the Cmin-values of Amfavir (600 mg twice daily) with Caletra (400 mg Lopinavir + 100 mg Ritonavir twice daily), are approximately 40 to 50% lower than if Amfavir (600 mg twice daily) in combination with 100 mg Ritonavir twice daily."</seg>
<seg id="1970">"a dosage for the simultaneous administration of Amfavir and Caletra cannot be given, however, there will be a engaging supervision, as the effectiveness and incomprehensibility of this combination is not known."</seg>
<seg id="1971">"there was no pharmacoinetic study conducted in combination with Didanosin, but it is recommended due to the antazidis component of Didanosin and Agenera (see antacid below)."</seg>
<seg id="1972">"therefore, at Gabe of Efavities in combination with Amfavir (600 mg twice daily) and Ritonavir (100 mg twice daily) no dosage adjustment is required."</seg>
<seg id="1973">"the treatment with Efavium in combination with Amfavir and Saquinavir is not recommended, since the exposure of both proteasehemmer would be low."</seg>
<seg id="1974">The effect of nevirapin to other proteasehemmer and available limited data can be dismissed that Nevirapin the Serumkonzentration may possibly be sensed.</seg>
<seg id="1975">"if this medicine should be used at the same time, caution is recommended as Delavirdin because of the decreases or possibly subtherapeutic plasmasculars could be less effective."</seg>
<seg id="1976">"when these medicines will be applied together; a thorough clinical and virological surveillance should be done, because an exact prediction of the effect of the combination of Amfavir and Ritonavir is difficult."</seg>
<seg id="1977">The simultaneous Gabe of Amfavir and Rifabutin led to an increase in Plasmaconconcentration (AUC) by Rifabutin by 193% and thus to a rise in with Rifabutin related side effects.</seg>
<seg id="1978">"if it is required for clinical reasons, Rifabutin together with Agenerase, becoming a reduction in the dosage of Rifabutin to at least half of the recommended dose, although there is no clinical data."</seg>
<seg id="1979">"pharmacoinetic studies with Agenerase in combination with Erythromycin were not carried out, but the plasmasculars of both drugs could be increased in case of simultaneous administration."</seg>
<seg id="1980">Simultaneous use of twice daily 700 mg Fosamprenavir and 100 mg Ritonavir at 200 mg Ketoconazol once daily led to an increase in the Cmax of Ketoconazol once a day compared to the value that has been observed after 200 mg Ketoconazol once daily without simultaneous use of fosamprenavir with Ritonavir.</seg>
<seg id="1981">"other medicines that are listed below, including substrates, Hemmer or induction of CYP3A4, if they are being applied together with Agenerase, possibly to interactions."</seg>
<seg id="1982">Patients should therefore be monitored on toxic responses to be monitored with these drugs when they are applied in combination with asgenerase.</seg>
<seg id="1983">"based on the data of other proteasehemmer it is advisable that antacid is not taken at the same time as asgenerase, as there can be resorous disorders."</seg>
<seg id="1984">"the simultaneous use of antiquvulva, which are known as enzyminants (phenytoine, phenobarbital, carbamazepine), with Amfavir can lead to a reduction of plasmascult of Amboavir."</seg>
<seg id="1985">"the Serum-concentrations of calcium-agates like Amlodipin, Dilupin, Nicorpin, Nimodipin, Nimopin, Nisopin and Verapamil can be raised 10 by amotavir, causing the activity and toxicity of this medicine."</seg>
<seg id="1986">Simultaneous intake with asgenerase can increase their Plasmaconconcentrations in conjunction with PDE5-Inhibitors in conjunction with PDE5-Inhibitors in conjunction with hypotension, vision dysfunctions and priapism (see section 4.4). "</seg>
<seg id="1987">"in a clinical trial, in the ritonavir 100 mg capsules twice daily together with 50 µg fluticasonpropionate intranasal (4 times daily) over 7 days at Probanc (4 times daily) over 7 days at Probanc (4 times) by approximately 86% away (90% -Confidenzintervall 82 to 89%)."</seg>
<seg id="1988">"consequently, the simultaneous gifts of Agenerase with Ritonavir is not recommended that the potential benefits of treatment is the risk of systemic cortical corrosive effects (see section 4.4)."</seg>
<seg id="1989">"at HMG-CoA Reduction tase-Hemmosis such as Lovastatin and Simvastatin, which is dependent strongly from CYP3A4, are pronounced enhancements of Plasmasculars in simultaneous administration of asgenerase."</seg>
<seg id="1990">"as Plasmaspio Enhancements of this HMG-CoA Reduction tase to Myopathy, including a rhabdomyolysis, the combined application of these medicines will not be recommended with Amboavir."</seg>
<seg id="1991">"there will be a common monitoring of the therapeutic concentrations to stabilization the mirror, since the plasmaconconcentrations of Cyclosporin, Rapamycin and Tacrolimus can be increased from amotavir (see section 4.4)."</seg>
<seg id="1992">"therefore, Agenerase may not be applied together with oral collazolam (see Section 4.3), during simultaneous use of asgenerase with parenteral midazolam caution."</seg>
<seg id="1993">Data at the simultaneous use of parenteral midazolam with other protestyhibitors will prove to a possible increase in Plasazolam from Midazolam to the 3- up to 4-fold.</seg>
<seg id="1994">"when Methadon together with Amfavir is going to be administered, patients should therefore be monitored on opiatry symptom, especially if there are also low doses of ritonavir."</seg>
<seg id="1995">"because of the slight negligence of historical footing, currently no recommendation can be given as the Amfavir- dosage is to adjust if Amfavir is administrated at the same time with methadon."</seg>
<seg id="1996">"at the same gift of Warberin or other oral antibodies together with Agenerase, an increased control of INR (International standardization Ratio) is recommended because of the possibility of Attenuation or reinforcement of anti-thrombosis effect (see section 4.4)."</seg>
<seg id="1997">The effect of an extra administration of Ritonavir on hormonal contraceptive is not predictable, therefore also alternative methods for contraception. "</seg>
<seg id="1998">A careful control of therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended in simultaneous Gabe of Agenerase (see section 4.4).</seg>
<seg id="1999">This medicine must be used during pregnancy only after careful consumption for the mother as compared to the possible risks for fetus.</seg>
<seg id="2000">"in the milk, Amboavir-related substances were proven, however, it is not known whether Amfavir is transferred to men into the mother's milk."</seg>
<seg id="2001">"a reproduction study on impairments, which was administered by the embedding in the uterus until the end of the breastfeeding of Amfavir, showed during breastfeeding time a decreased increase in the 12 body weight at night's income."</seg>
<seg id="2002">The further development of the offspring including tertility and reproduction capacity was not affected by the administration of Amagavir to the womtier.</seg>
<seg id="2003">The inconceivable of asgenerase was examined in adults and children from 4 years onwards in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2004">Most of the unbiase-related side effects were easily up to moderate, occurred early on and led to the treatment. "</seg>
<seg id="2005">"in many of these events, not clarified whether they are applied in connection with the intake of asgenerase or another at the same time to HIV treatment."</seg>
<seg id="2006">"most of the above-side effects come from two clinical trials (PROAB3001, PROAB3006), in which with proteasehemania not pre-treated patients 1200 mg Agenerase twice daily."</seg>
<seg id="2007">"events (degree 2 to 4), developed by the investigator as related to study programmes, and in more than 1% of the patients were performed, as well as under the treatment elaboration lab changes (degree 3 to 4) are listed."</seg>
<seg id="2008">The Antiretroviral Combination therapy has been associated with a redistribution of the body fat (Lipodystrophy) with HIV-patients including a loss of peripheral and façade fat tissues, hypertrophy of the breasts and dorsocervical liposuction. "</seg>
<seg id="2009">"under 113 antiretroviral not pretreated people who were treated with Lamivavir in combination with Lamivjudin / Zidovudin over a medium duration of 36 weeks, was only one case (stipulated) (&lt; 1%)."</seg>
<seg id="2010">In the study PROAB 3006 appeared at 245 NRTI- pre-treated patients under Amboavir 7 cases (3%) compared to 27 cases (11%) in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0.001).</seg>
<seg id="2011">"skin surcharges were usually easy to moderate, simply thematöser or makulopapulöser nature, with or without itch and entered spontaneously during the second treatment week and disappeared spontaneous within two weeks without having been broken down to the treatment with ants."</seg>
<seg id="2012">Cases of Osteonekrose were particularly reported in patients with generally known risk factors, advanced HIV disease or long-term application of an antiretroviral Combinotherapy (ART). "</seg>
<seg id="2013">In HIV-infected patients with serious immune defect can be developed at the time of an antiretroviral building therapy (ART) a spontaneous reaction to asymptomatic or residual opportunistic infections (see section 4.4).</seg>
<seg id="2014">"with PI pretreated patients, the 600 mg Agenerase twice daily along with low dosiertem Ritonavir (100 mg twice daily), the type and frequency of side effects (degree of 2 to 4) and laboratory changes (degree 3 to 4) and CPC value, which were received in patients, the Agenerase together with low dosiertem Ritonavir."</seg>
<seg id="2015">"in case of overdose, the patient is on signs of an intoxic (see section 4.8) to observe if necessary, are necessary supportive measures."</seg>
<seg id="2016">Amboavir binds to the active center of HIV-1 protesters and prevents the procesation vial gag- and Gag-pol- polyprotectant steps with the result of a education inreier not infectious virusparticles.</seg>
<seg id="2017">The antiviral activity of Amfavir in vitro against HIV-1 IIIB has been investigated both of akut and chronically infected cell lines (MT-4, CEM-CCRF, H9) as well as in peripheral blood vessels. "</seg>
<seg id="2018">"the 50% of Hemmkonzentration (IC50) from Amfavir lies in the range from 0,012 to 0,08 µm in akut inficated cells and amounts 0,41 µm in chronic cells."</seg>
<seg id="2019">The connection between the activity of Amfavir against HIV-1 in vitro and the inhibition of HIV-1 replication of man is not yet defined.</seg>
<seg id="2020">In the treatment of antiretroviral not pretreatable patients with the currently approved fosamprenavr / Ritonavir doses were used - as with other ritonavir treatment schemas with proteasmenhibitors - the described mutations are rarely observed.</seg>
<seg id="2021">"at sixteen of 434 antiretroviral is not prescribed patients, the 700mg Fosamprenavir twice daily in the study of ESS100732, entered into a virological failure to week 48 on, where 14 insulates were studied."</seg>
<seg id="2022">"a genotypical analysis of the isolates of 13 of 14 children, with which a virological failure are not assembled within the 59, with proteasehemania, showed pational patterns that were similar to those in adults."</seg>
<seg id="2023">"L10F / I / V, V11V, K2R, M3V, L48V, I43V, I60V, I60V, I43V, I43V, I85V, I85V, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90M, L90</seg>
<seg id="2024">In the study of APV30003 and its extension APV30005 (700 mg Fosamprenavir / 100 mg Ritonavir twice daily: N = 107) on patients with virological failure more than 96 weeks the following proteasehemmer mutations on:</seg>
<seg id="2025">In genotypical resistance-based analyses genotypical interpretations systems can be applied to shutdown the activity of Amfavir / Ritonavir or Fosamprenavir / Ritonavir / Ritonavir and ritonavir.</seg>
<seg id="2026">"the current (July 2006) ANRS-AC-11-algorithm for Fosamprenavir / Ritonavir defines resistance, or at least 4 of the following mutations L10F / I, L33F, I62V, I84V and L90M, with Ritonavir and a decreased probability of a virological response (resistance)."</seg>
<seg id="2027">"conclusions regarding the relevance of certain mutations or mutationsmuster, changes can be governed by additional data and it is recommended to always move the current interpretations systems for analysis of the results of resistance levels."</seg>
<seg id="2028">"on phänotypical resistance-based analyses, clinically valiant interpretations systems can be used in conjunction with the genotypical data to estimate the activity of Amfavir / Ritonavir or Fosamprenavir / Ritonavir and ritonavir."</seg>
<seg id="2029">Firms who distributes the diagnostic resistance patterns, have clinically-phenomenal Cut-offs (separations) for FPV / RTV which can be applied to the interpretation of results of a resistance tests. "</seg>
<seg id="2030">Each of these four with a reduced sensitivity to amathavir associative genetic patterns creates a certain crucible resistant against Ritonavir that remains the sensitivity to Indinavir and Saquinavir but generally received.</seg>
<seg id="2031">"there are currently data on crucifixture between Amfavir and other proteasehemas for all 4 Fosamprenavir resistance, either alone or in combination with other mutations."</seg>
<seg id="2032">Based on five-five antiretroviral is not prescribed for treatment (one of 25 isolates), Darunavir / Ritonavir (three of 25 isolates), Insecavir / Ritonavir (three of 24 isolates), Saquinavir (three of 24 insulates), Saquinavir (4 of 24 insulates) and Tipranavir / Ritonavir (4 of 24 insulates). "</seg>
<seg id="2033">"in the other way, Amfavir retains its activity against some other proteasehemmer-resistant insulates at; the receipt of these activity seems to be dependent on the number and type of resistance to the isolates."</seg>
<seg id="2034">Timely treatment is recommended to hold the accumulation of a variety of mutations in borders which can affect the following treatment of noble.</seg>
<seg id="2035">"the proof of the effectiveness of asgenerase in combination with Ritonavir 100 mg twice daily is based on the study PRO30017, a randomised open trial (Virusload ≥ 1000 copies / ml), with Ritonavir (100 mg twice daily) and nucleosidanaloga (NRTI) or a standard therapy (standard of care, SoC) with a PI, predominantly with a lower ritonavir."</seg>
<seg id="2036">One hundred-three-three-three (s = 163) patients with a weighted virus sensitivity to Agenerase, at least another PI and at least one NRTI were included in the sub-study A of PRO30017. "</seg>
<seg id="2037">The primary analysis presented the non-sub-embarrassment of APV / Ritonavir in comparison to the SoC-PI group with regard to the time-admittism (HIV-1-RNA) in the Plasma after 16 weeks in case of non-sub-pressure threshold of 0.4 log10 copies / ml.</seg>
<seg id="2038">The letter of the efficacy of uncurved Agenerase is based on two uncontrolled studies with total 288 HIV-inficated children aged 2 to 18 years old which were treated with PI.</seg>
<seg id="2039">"in the studies, Agenerase solution for one and capsules in doses of 15 mg / kg three times daily, 20 mg / kg three times daily, 20 mg / kg twice daily and 22.5 mg / kg twice daily, whereby the majority of patients 20 mg / kg twice daily."</seg>
<seg id="2040">"it was given no low dosified Ritonavir at the same time; the majority of the associated patients had previously been treated before at least one (78%) or two (42%), together with Agenerals adopted NRTIs."</seg>
<seg id="2041">"after 48 weeks, approximately 25% of the study included a plasma HIV-1-RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml with a median increase in CD4 cell count of 26 cells / mm ³ (n = 74) compared to the output."</seg>
<seg id="2042">19 Basing on these data should be considered at therapeutics optimisation with PI pretreated children of "unborn" Agenerase ".</seg>
<seg id="2043">"according to orous administration, the average duration (tmax) up to maximum serum concentration of Amfavir is approximately 1 to 2 hours for the capsule and about 0.5 to 1 hour for the solution."</seg>
<seg id="2044">"508% increases, for Cmax against 30% reduced, if Ritonavir (100 mg twice daily) together with Amfavir (600 mg twice daily)."</seg>
<seg id="2045">The agreement of Amfavir with a meal leads to a 25% of withdrawal of AUC but has no effect on the concentration of Amboavir 12 hours to dosage (C12).</seg>
<seg id="2046">"therefore, the minimum concentration in steady-State (Cmin, ss) remained uninfluenced by the food intake, although the simultaneous food intake, the scale and rate of the Resorption affects."</seg>
<seg id="2047">The seeming distribution volume is approximately 430 l (6 l / kg with a body weight of 70 kg) and leaves a large distributor volume as well as an enormous penetration of Amfavir from the bloodstream into the tissues.</seg>
<seg id="2048">"this change leads to a withdrawal of the total concentration of the ingredient in the plasma, whereby the quantity of irled ants that represents the active part, probably remains unchanged."</seg>
<seg id="2049">"while the absolute concentration of improbed amberavir remains unchanged, the percentage of free active component parts during the dosing concentration in steady-State in the Steady-State on the range of Cmax, ss up to Cmin, ss."</seg>
<seg id="2050">"therefore, medicines, the CYP3A4 inducing or inhibit or a substrate of CYP3A4, with caution will be given, if they are given at the same time with Agenerase (see paragraphs 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Agenerase capsules, either 20 mg / kg twice or 15 mg / kg three times a day, leads to a similar daily amberavir Exposure as in adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">"Amfavir is made up of the solution 14% less bidet, as of the capsules, therefore Agenerase Solution and Agenerase capsules are not interchangeable on a millimeters."</seg>
<seg id="2053">"the renal Clearance of Ritonavir neglected, therefore the effect of a kidney failure to be low on the Elimination of Amagavir and Ritonavir."</seg>
<seg id="2054">These treatment schemata lead to Amfavir-Plasmaspike comparable to those that achieves at healthy Probanden after a dose of 1200 mg Amfavir twice a day without simultaneous administration of Ritonavir.</seg>
<seg id="2055">"in long-term studies on the pulgeneity with amberavir on mice and rats, with male animals benigne hepatcellular Adenome in doses on the subposition on people, after twice daily Gabe of 1200 mg Amagavir."</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of the hepatcellular Adenome and karzinic has not yet been dissolved and the relevance of these watched effects for humans is unclear.</seg>
<seg id="2057">"from the present expositionsdata on human beings, both from clinical trials and the therapeutic application, however, however, little evidence for the acceptance of a clinical relevance of these findings."</seg>
<seg id="2058">"in a standard battery of In-vivo- and in-vitro-genotoxically tests, mouse-lymphoma tests, mouse-Lymphom test, microkernel and chromosenationest in human peripheral lymphocytes, was Amfavir neither mutages nor genotoxic."</seg>
<seg id="2059">This liver toxicity can be monitored and proven in clinical life by measuring AST, ALT and the activity of alkaline phosphate. "</seg>
<seg id="2060">"so far, in clinical studies have been observed in clinical trials in patients neither during the administration of asgenerase nor after the end of the treatment."</seg>
<seg id="2061">"studies on the toxicity in juveniles, which have been treated with the control of 4 days, showed both with the control and with amber used animals a high mortality."</seg>
<seg id="2062">"in a systemic plasma position, the significant exposure below (rabbits) or not significant exposure among therapeutic dosage was observed, however, a number of minor changes including Thymuselongation and a small skeleton changes have been observed in a delayed development."</seg>
<seg id="2063">24 When Agenerase capsules can be applied without the reinforced additives from Ritonavir (booklet) must be applied higher doses of apurase (1200 mg twice daily).</seg>
<seg id="2064">"the recommended dose for Agenerase capsules is 20 mg of Amfavir / kg body weight twice daily in combination with other antiretroviral medicines, up to a daily dose of 2400 mg Amfavir that should not be exceeded (see section 5.1)."</seg>
<seg id="2065">"the simultaneous application is intended to treat patients with watchful or slight liver functioning with caution, in patients with severe liver functioning, it is contradicated (see Section 4.3)."</seg>
<seg id="2066">"26 For some medicinal products, the serious or life-threatening effects may cause, such as carbamazepine, Phenobarbital, phenytoine, tricyclic antidepressants and warring (under supervision of the International standardization Ratio), are available methods for determining the ingredient concentration."</seg>
<seg id="2067">Agenerase should be placed on duration 27 when a rash is accompanied by systemic or allergic symptoms. (see Section 4.8).</seg>
<seg id="2068">"increased risk to a lipodystrophy has been associated with individual factors, such as higher age, and with pharmaceuticals and dependent factors, such as a longer androde antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2069">It was shown that Rifampicin a 82% reduction in AUC caused by Amagavir caused to lead to a virological failure and lead to a resistance development.</seg>
<seg id="2070">"508% increases, for Cmax against 30% lower than ritonavir (100 mg twice daily) in combination with Amfavir capsules (600 mg twice daily)."</seg>
<seg id="2071">"the Cmin-values of Amfavir (600 mg twice daily) with Caletra (400 mg Lopinavir + 100 mg Ritonavir twice daily), are approximately 40 to 50% lower than if Amfavir (600 mg twice daily) in combination with 100 mg Ritonavir twice daily."</seg>
<seg id="2072">"a dosage for the simultaneous administration of Amfavir and Caletra cannot be given, however, there will be a engaging supervision, as the effectiveness and incomprehensibility of this combination is not known."</seg>
<seg id="2073">"the treatment with Efavium in combination with Amfavir and Saquinavir is not recommended, since the exposure of both proteasehemmer would be low."</seg>
<seg id="2074">"when these medicines will be applied together; a thorough clinical and virological surveillance should be done, because an exact prediction of the effect of the combination of Amfavir and Ritonavir is difficult."</seg>
<seg id="2075">"if it is required for clinical reasons, Rifabutin together with Agenera, becoming a reduction in the dosage of Rifabutin to be at least half of the recommended dose 31, although there is no clinical data."</seg>
<seg id="2076">"the Serum-concentrations of calcium-agates like Amlodipin, Dilupin, Nicorpin, Nipppin, Nimodipin, niche, pin pin and Verapamil may be increased by amotavir, causing the activity and toxicity of this medicine."</seg>
<seg id="2077">"in a clinical trial, in the ritonavir 100 mg capsules twice daily together with 50 µg fluticasonpropionate intranasal (4 times daily) over 7 days at Probanc (4 times daily) over 7 days at Probanc (4 times) by approximately 86% away (90% -Confidenzintervall 82 to 89%)."</seg>
<seg id="2078">"at the same gift of Warberin or other oral antibodies together with Agenerase, an increased control of INR (International standardization Ratio) is recommended because of the possibility of Attenuation or reinforcement of anti-thrombosis effect (see section 4.4)."</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg Ethinylestradiol plus 1.0 mg Norethindron) led to a withdrawal of AUC and Cmin by Amboavir by 22% respectively.</seg>
<seg id="2080">This medicine must be used during pregnancy only after careful consumption for the mother as compared to the possible risks for the fetus.</seg>
<seg id="2081">"a reproduction study on impairments, which was administered by the embedding in the uterus until the end of the breastfeeding of Amfavir, showed during breastfeeding time a decreased increase in the body weight at night's income."</seg>
<seg id="2082">The inconceivable of asgenerase was examined in adults and children from 4 years onwards in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2083">"in case of overdose, the patient is on signs of an intoxic (see section 4.8) to observe if necessary, are necessary supportive measures."</seg>
<seg id="2084">The antiviral activity of Amfavir in vitro against HIV-1 IIIB has been investigated both of akut and chronically infected cell lines (MT-4, CEM-CCRF, H9) as well as peripheral blood vessels. "</seg>
<seg id="2085">"50% of Hemmkonzentration (IC50) from Amfavir lies in the range from 0,012 to 0,08 µm in akut ininfected cells (1 µm = 0,50 µg / ml)."</seg>
<seg id="2086">"in the other way, Amfavir retains its activity against some other proteasehemmer-resistant insulates at; the receipt of these activity seems to be dependent on the number and type of resistance to the isolates."</seg>
<seg id="2087">"based on these data should be considered in the therapy optimization with PI pretreated children of" "ungeboostertem" "Agenerase". ""</seg>
<seg id="2088">"while the absolute concentration of improbed amberavir remains unchanged, the percentage of free active component parts during the dosing concentration in steady-State in the Steady-State on the range of Cmax, ss up to Cmin, ss.."</seg>
<seg id="2089">"therefore, medicines, the CYP3A4 inducing or inhibit or a substrate of CYP3A4, with caution will be given, if they are given at the same time with Agenerase (see paragraphs 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">The renal Clearance of Ritonavir neglected; therefore the effect of a kidney failure is likely to be low on the Elimination of Amagavir and Ritonavir.</seg>
<seg id="2091">"in long-term studies on the pulgeneity with amberavir on mice and rats, with male animals benigne hepatcellular Adenome in doses on metering feeders (mice) or damage - folding (Ratte) of the exposure to people after twice daily gift of 1200 mg Amfavir."</seg>
<seg id="2092">The underlying mechanism for the emergence of the hepatocular Adenome and karzinic has not yet been dissolved and the relevance of these watched effects for humans is unclear.</seg>
<seg id="2093">"however, from the present expositionsdata on human beings, both from clinical trials and the therapeutic application has however little evidence for the adoption of a clinical relevance of this evidence."</seg>
<seg id="2094">"in a standard battery of In-vivo- and in-vitro-genotoxically tests, mouse-lymphoma tests, mouse-lymphoma tests, microkernel and chromosenationest in human peripheral lymphocytes, was Amfavir neither mutages nor genotoxic."</seg>
<seg id="2095">"studies on the toxicity in juveniles, which have been treated with the control of 4 days, showed both with the control and with amber used animals a high mortality."</seg>
<seg id="2096">"these results can conclude that in juveniles are not yet fully mature, so that Amfavir or other critical components of formulation (z."</seg>
<seg id="2097">"Agenerase solution for income is available in combination with other antiretroviral medicines for the treatment of HIV-1-inficated, proteasehemmer (PI) -treatable adults and children from 4 years."</seg>
<seg id="2098">"the use of ritonavir" "agroase" "Agenerase solution to the one was neither associated with PI pretreated patients with PI pretreated patients."</seg>
<seg id="2099">The bioavailability of Amfavir as a solution to take is 14% less than capfavir. therefore Agenerase capsules and solution to insertion on a milligram per milligram base is not interchangeable (see section 5.2).</seg>
<seg id="2100">Patients should as soon as they are able to swallow the capsules with the intake of solving the solution (see section 4.4).</seg>
<seg id="2101">The recommended dose for Agenerase solution is 17 mg (1,1 ml) Amfavir / kg body weights three times daily in combination with other antiretroviral medicines to a daily dose of 2800 mg Amiliavir that should not be exceeded (see section 5.1).</seg>
<seg id="2102">"in addition, there must be no dosage for simultaneous use of asgenerase solution to one and low dosiertem Ritonavir, this combination of these patients should be avoided."</seg>
<seg id="2103">"although a dosage adjustment for Amfavir is not necessary for amnesty, is an application of asgenerase solution for taking in patients with kidney contests (see Section 4.3)."</seg>
<seg id="2104">"due to the potential risk of a toxic reaction as a result of high propylene glycoon, Agenerase solution for taking children under 4 years, with pregnant women, in patients with reduced liver function or liver failure and in patients with kidney failure."</seg>
<seg id="2105">The simultaneous administration can lead to a combined inhibition of metabolic inscription of this medicine and may cause serious and / or life-threatening side effects such as cardiac dysfunctions (z.</seg>
<seg id="2106">Patients should be pointed out that Agenerare or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="2107">The current antiretroviral therapy including treatment with Agenerase does not prevent the risk of between HIV on other through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that can cause serious or life-threatening effects, such as carbamazepine, Phenobarbital, phenytoin, tricyclic antidepressants and warring (under supervision of the International standardization Ratio), are available methods for determining the ingredient concentration."</seg>
<seg id="2109">Agenerase should be placed on duration if a rash is accompanied by systemic or allergic symptoms. (see Section 4.8).</seg>
<seg id="2110">"increased risk to a lipodystrophy has been associated with individual factors, such as higher age, and with pharmaceuticals and 49-dependent factors, such as a longer androde antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2111">"with hammophilen patients (type A and B) that were treated with proteasehemania, reports on an increase in bleeding including spontaneous coutaneous hematoms and hemanthroes."</seg>
<seg id="2112">It was shown that Rifampicin a 82% reduction in AUC caused by Amagavir caused to lead to a virological failure and lead to a resistance development.</seg>
<seg id="2113">"508% increases, for Cmax against 30% lower than ritonavir (100 mg twice daily) in combination with Amfavir capsules (600 mg twice daily)."</seg>
<seg id="2114">Simultaneous intake with asgenerase can increase their Plasmaconconcentrations in conjunction with PDE5-Inhibitors in conjunction with PDE5-Inhibitors in conjunction with hypotension, visual dysfunctions and priapism (see section 4.4). "</seg>
<seg id="2115">Based on data to 54 other CYP3A4-Inhibitors are expected to oral Gabe from Midazolam signed by Midazolam is expected.</seg>
<seg id="2116">The potential risk for man is not known. Agenerase solution may not be used due to possible toxic reactions of fetus to the contained Propylenglycol during pregnancy (see Section 4.3).</seg>
<seg id="2117">"in the milk, Amboavir-related substances were proven, however, it is not known whether Amfavir is transferred to men into the mother's milk."</seg>
<seg id="2118">"a reproduction study on impairments, which was administered by the embedding in the uterus until the end of the breastfeeding of Amfavir, showed during the breastfeeding time a decreased increase in the 55 postal balance in the night's income."</seg>
<seg id="2119">The inconceivable of asgenerase was examined in adults and children from 4 years onwards in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2120">"in many of these events, not clarified whether they are applied in connection with the intake of asgenerase or another at the same time to HIV treatment."</seg>
<seg id="2121">In the treatment of antiretroviral not pretreatable patients with the currently approved fosamprenavr / Ritonavir doses were used - as with other ritonavir treatment schemas with proteasmenhibitors - the described mutations are rarely observed.</seg>
<seg id="2122">"early outbreak of a defending 60 therapy is recommended to hold the accumulation of a multitude of mutations in borders, which can affect the following treatment."</seg>
<seg id="2123">62 bases on these data should be considered at therapeutics optimisation with PI pretreated children of "unborn" Agenerase ".</seg>
<seg id="2124">"the seeming distribution volume is approximately 430 l (6 l / kg with a body weight of 70 kg), and can be found on a major Vetroid volumes as well as an enormous penetration of Amfavir from the bloodstream into the tissues."</seg>
<seg id="2125">The underlying mechanism for the emergence of the hepatcellular Adenome and karzinic has not yet been dissolved and the relevance of these watched effects for humans is unclear.</seg>
<seg id="2126">"in a systemic plasma position, the significant exposure below (rabbits) or not significant exposure among therapeutic dosage was observed, however, a number of minor changes including Thymuselongation and a small skeleton changes have been observed in a delayed development."</seg>
<seg id="2127">"maybe you would like to read this later again. − If you have further questions, please contact your doctor or pharmacist. − This medicine was personally prescribed for you."</seg>
<seg id="2128">"it can harm other people, even if these have the same complaints as you. − If any of the listed side effects you have greatly impaired, or do not notice any side effects, please inform your doctor or pharmacist."</seg>
<seg id="2129">Your doctor will typically apply to asgenerase capsules together with low doses Ritonavir to reinforce the effect of asgenerase.</seg>
<seg id="2130">The use of asgenerase will be based on your doctor for you performed on your doctor for you and your treatment's treatment.</seg>
<seg id="2131">Inform your doctor if you suffer from one of the above diseases or take any of the above drugs.</seg>
<seg id="2132">"if your doctor is recommended that you have to take Agenerase capsules along with low doses from Ritonavir to reinforce the effect (boosting), make sure you have read carefully before the treatment used by the usage information on Ritonavir."</seg>
<seg id="2133">"as well, there are no adequate information about the use of Agenerase capsules with ritonavir to the efficiency of prevention in children aged 4 to 12 years or in general in patients under 50 kg of body weight."</seg>
<seg id="2134">"therefore, it is important that you can read the section" At intake of asgenerase with other drugs, before you start with the intake of asgenerase. "</seg>
<seg id="2135">"possibly you need additional factor VIII to control the blood distances. − At patients, the an antiretroviral building therapy, can occur a redistribution, accumulation or a loss of body fat."</seg>
<seg id="2136">"if you are certain medicine that can lead to serious side effects, such as Carbamazepine, phenytoine, ycyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, to minimise possible safety problems."</seg>
<seg id="2137">It is advised that HIV-positive women ought to do their children under no circumstances to avoid a transfer of HIV.</seg>
<seg id="2138">Transport and operation of machines There were no studies on the influence of asgenerase based on the suspension or the ability to use machines.</seg>
<seg id="2139">"please take this medicine only upon consultation with your doctor, if you know that you suffer from a intolerance towards certain sugar."</seg>
<seg id="2140">"Didanosin), it is advisable that you take this more than an hour before or after Agenera, otherwise the effects of asgenerase can be decreased."</seg>
<seg id="2141">Dosage of asgenerase capsules is 600 mg twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2142">"if your doctor decides that intake of Ritonavir is not suitable for you, you will have to take higher doses (1200 mg Amfavir twice daily)."</seg>
<seg id="2143">"85 Damit Agenerase brings an optimum use as possible, it is very important that you have the entire daily dose that your doctor has prescribed."</seg>
<seg id="2144">"if you have taken a larger amount of asgenerase, when you should have more than the prescribed dose of asgenerase, you should immediately contact your doctor or pharmacist contact."</seg>
<seg id="2145">"if you have forgotten the intake of asgenerase If you have forgotten the intake of asgenerase, just take it once you think and then get the intake as before."</seg>
<seg id="2146">"in the treatment of an HIV infection, it is not always possible to say whether to-track side effects by Agenerase, by other medicines which are taken at the same time, or caused by HIV disorder."</seg>
<seg id="2147">"headaches, sakes, disease-esteem, disease, blocking rash, blowing, blacks or itch) - occasionally the rash may have hardened nature and you to break the intake of this medication by means of force."</seg>
<seg id="2148">"reconciliation, depression, sleeping disorders, Apatiloss tingling in the lips and in the mouth, uncontrollable stomach, soft chairs, increase of certain Leberenzymme, the transaminasinasas called Amylase"</seg>
<seg id="2149">Increased blood levels for sugar or cholesterol (a certain blood fond) increases blood values of a substance called Bilirubin swelling of the face, the lips and the tongue (angioöder). "</seg>
<seg id="2150">"this can close oloss of leg, poor and face, a fat looting at the stomach and in other inner organs, breast enlargement and obesity in the neck."</seg>
<seg id="2151">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="2152">"therefore, it is important that you can read the section" At intake of asgenerase with other drugs, before you start with the intake of asgenerase. "</seg>
<seg id="2153">"in some patients who receive an antiretroviral Combination treatment, can be one as Osteonekrose (die of bone tissue, as a result of insufficient blood supply of the garlic)."</seg>
<seg id="2154">"Didanosin), it is advisable that you take this more than an hour before or after Agenera, otherwise the effects of asgenerase can be decreased."</seg>
<seg id="2155">"94 Damit Agenerase brings a great benefit as possible, it is very important that you have the entire daily dose that your doctor has prescribed."</seg>
<seg id="2156">"if you have forgotten the intake of asgenerase If you have forgotten the intake of asgenerase, take it as soon as you think and put it as before."</seg>
<seg id="2157">"headaches, sakes, disease-esteem, disease, blocking rash, blowing, blacks or itch) - occasionally the rash may have hardened nature and you to break the intake of this medication by means of force."</seg>
<seg id="2158">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="2159">Dosage of asgenerase capsules is 600 mg twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2160">"thus Agenerase can bring about possible use as much as possible, it is very important that you have the entire daily dose that your doctor has prescribed."</seg>
<seg id="2161">"if you have taken larger amounts of apurase, when you should have more than the prescribed dose of asgenerase, you should immediately contact your doctor or pharmacist contact."</seg>
<seg id="2162">The use of ritonavir "tooh" Agenerase solution to the one was neither associated with proteasehemania or treated patients with proteasehematic patients.</seg>
<seg id="2163">For use lower doses of Ritonavir (usually applied to reinforcement of the effect [booklet] by Agenerase capsules) together with Agenerase solution to one can take no dosing recommendations.</seg>
<seg id="2164">Ritonavir solution to take part) or in addition propylenglycol during intake of asgenerase solution (see also Agenerase may not be taken).</seg>
<seg id="2165">"your doctor will possibly be on side-side effects associated with the propylenglycolcontent of the asgenerase solution to take in connection, watching, especially if you have a kidney or liver disease."</seg>
<seg id="2166">"111 If you have certain medicines that can cause serious side effects, such as carbamazepine, Phenobarbital, phenyycin, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, to minimise possible safety issues, to minimize possible safety problems."</seg>
<seg id="2167">Ritonavir solution to take) or an Propylenglycol included during the intake of asgenerase cannot be taken (see Agenerase may not be taken).</seg>
<seg id="2168">Important information about certain other components of asgenerase solution to the One that contains propylene glycol that can lead in high doses with side effects.</seg>
<seg id="2169">Propylenglycol can cause a number of side effects including tampry cases which cause cardiac and the reduction of the red blood cells (see also Agenerase may not be taken (see adresses of asgenerase is required precautions).</seg>
<seg id="2170">"if you have forgotten the intake of asgenerase If you have forgotten the intake of asgenerase, just take it once you think and then get the intake as before."</seg>
<seg id="2171">"headaches, sakes, disease-esteem, disease, blocking rash, blowing, blacks or itch) - occasionally the rash may have hardened nature and you to break the intake of this medication by means of force."</seg>
<seg id="2172">"this can close oloss of leg, poor and face, a fat looting at the stomach and in other inner organs, breast enlargement and obesity in the neck."</seg>
<seg id="2173">"the other components are propylenglycol, Macrogol 400 (polyethylene), Acesulfam-Kalium, Saccharin-sodium, charcoal, natural peppermines, Citronologic acid, sodium-Citrate, sodium-Diate water."</seg>
<seg id="2174">"the application prevalence and duration of the treatment with Aldara depend on the treatment of aldara, aldara up to a maximum of 16 weeks, it is weekly during one or two four-week treatment cycles, with four weeks break between the treatment cycles, three times a week."</seg>
<seg id="2175">The creams is widened in front of the bedtime thinner to the affected skin surfaces so that they remain enough long (about eight hours) on the skin before they washed washed.</seg>
<seg id="2176">"in all studies, Aldara was compared with a placebo (the same creme, but without the active ingredients). • Aldara was tested in four main studies to 923 patients with Warzen in the genital area of 16 weeks."</seg>
<seg id="2177">"main indexator for the effectiveness was the number of patients with complete acceptance of the treatment of warts. • Aldara was also examined in 724 patients with small Basucelain carcinoma in two studies, where patients were treated for six weeks and Aldara or the placebo either daily or fifty times a week."</seg>
<seg id="2178">Main indicator for the effectiveness was the number of patients with complete acceptance of tumors after twelve weeks. • Aldara was also tested in two studies in total 505 patients with cactine keratants.</seg>
<seg id="2179">"in all studies there was more effective than the placebo in every four main studies 15% to 52% at the associated patients, but only 3% up to 18% with placebo patients treated with placebo patients in comparison to 0% up to 3% in the placebo group."</seg>
<seg id="2180">The most common side effects of Aldara (observed if more than 1 of 10 patients) are reactions to the application of cream (pain or itch).</seg>
<seg id="2181">"clinically typical, not hypertrophies, not hypertrougine Keratants (AKS) on the face or on the scalp on immuno exercises, if the size or the number of lesions limit the effectiveness and / or the acceptance of a clytherapy forms and other topical treatment options contaminated or less suitable."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before the Zubettingen to apply and 6 to 10 hours on the skin."</seg>
<seg id="2183">"the treatment with Imiquimod-Creme will continue to continue until all the visible fires are gone, or up to a maximum of 16 weeks per treatment period."</seg>
<seg id="2184">"interruption in the above treatment process should be wounded, when intense local dette reactions occur (see section 4.4) or if in the treatment area an infection is observed."</seg>
<seg id="2185">If the follow-up examination 4 to 8 weeks after the second treatment period the treatment are covered only incomplete if different therapy should be started (see section 4.4).</seg>
<seg id="2186">If a dose has been omitted to carry the patient the creams as soon as they noticed it and then continue with the usual therapy plan.</seg>
<seg id="2187">"Imiquimod-Creme is placed in a thin layer, and in the fragile rinsulated skin range, up to the creams completely moved."</seg>
<seg id="2188">"it should be followed by these patients a reduction, between the benefits of treatment with Imiquimod and the risk associated with a possible conlimation of their autoimmune disease."</seg>
<seg id="2189">This patient should take a reduction in these patients between the benefits of treatment with Imiquimod and the risk associated with a possible organs or GRAFT-versus-host- reaction.</seg>
<seg id="2190">"in other studies, in which no daily anticipation has been carried out, two cases of severe phimosis, and a case with one to the circumcision of the leading stripes."</seg>
<seg id="2191">"during an application of Imiquimod-Creme in higher than the recommended doses, there has been enhanced risk for heavy local barrons (see section 4.2.) In rare cases also observed a treatment of severe local barirritation caused a treatment and / or to a temporary physical impairment."</seg>
<seg id="2192">"in cases where such reactions occurred at the outcome of the urethra, some women had difficulties when waterfalls, which was required a emergency relief and a treatment of the affected area."</seg>
<seg id="2193">The application of Imiquimod creams directly following a treatment with other kutan application for the treatment of external feigners in the genital and perial range has not been a clinical experience.</seg>
<seg id="2194">"limited data refers to a increased rate of feigwarts reproductions on HIV-positive patients, Imiquimod-Creme has shown a lower efficiency in this patient."</seg>
<seg id="2195">"the treatment of the bassocinoma of Imiquimod with Imiquimod within 1 cm to the eyelid, the nose, lips or hair loss has not been investigated."</seg>
<seg id="2196">Local skin reaction are common but the intensity of these reactions usually takes place in general during therapy or reactions form after completion of treatment with Imiquimod creams.</seg>
<seg id="2197">"if it is necessary due to the complaints of the patient, or because of the severity of the local skin reaction, a treatment period may be made of several days."</seg>
<seg id="2198">The clinical result of therapy can be assessed after the regeneration of the treatment of treatment approximately 12 weeks after the end of the treatment.</seg>
<seg id="2199">"currently, no data on long term healing rates are available after the treatment of more than 36 months after the treatment should be held at superfiziella Basalcellcardio other suitable treatments."</seg>
<seg id="2200">"in patients with recurrent and pretreated BCCs are not clinical experiences, therefore the application is not recommended in the treatment of tumors."</seg>
<seg id="2201">Data from an open clinical trial point out that with large tumors (&gt; 7.25 cm2) a lower probability of response to the Imiquimod therapy.</seg>
<seg id="2202">"Imiquimbo was not investigated for the treatment of actinal Keratants, inside the nose or the ears or in the lips area."</seg>
<seg id="2203">There are only very limited data about the application of Imiquimod for the treatment of actinal keratants to anatomical spots outside the face and the scalp.</seg>
<seg id="2204">"the available data on the actine Keratosis on the subpoor and hands does not support the effectiveness in this field of use, therefore such application will not be recommended."</seg>
<seg id="2205">Local skin reaction often occur on, but these reactions usually take in the course of therapy to intensity or go after the procedure of therapy with Imiquimod creams. "</seg>
<seg id="2206">"when local skin reactions to the patient cause great discomfort, or very strongly, the treatment can be suspended for some days."</seg>
<seg id="2207">"out of the data of an open clinical study is emerging, patients with more than 8 ACs are shown a lower rate of salvation than patients with less than 8 lesions."</seg>
<seg id="2208">"due to immunodeant properties, Imiquimod Creme should be applied with caution in patients who receive an immunosuppressive treatment (see 4.4)."</seg>
<seg id="2209">"from animal studies have no direct or indirect harmful effects on pregnancy, the embryonic development, the detergent or postnatal development (see 5.3)."</seg>
<seg id="2210">"although neither after a unique topical application quantifiable application mode (&gt; 5ng / ml), no recommendation can be given during breastfeeding period."</seg>
<seg id="2211">Most often asked questions and possibly as likely or possibly with the application of Imiquimod cream in connection related side effects in the studies with three times weekly treatment were local reactions to the place of the treatment of the Feigwarts (33,7% of the treatment of the incubators treated patients).</seg>
<seg id="2212">"among the most commonly reported and as likely, or possibly with the application of the Imiquimod creams in the related side effects belong to the application place with a frequency of 28,1%."</seg>
<seg id="2213">The clinical trial of 185 with Imiquimod-Creme treatated Basaliom-patients from a placebo-controlled study of phase III reported side effects are listed below.</seg>
<seg id="2214">The most common as likely or possibly with the application of the Imiquimod creams in the related incidence were in these studies a reaction at the application of the applicant (22% of the patients with Imiquimod treated patients).</seg>
<seg id="2215">"side effects, which were evaluated by 252 in placebokontrolulated clinical trials of phase III with Imiquimod-Creme treated patients with actinal keratosis are listed below."</seg>
<seg id="2216">"this according to the evaluation of the clinical signs of clinical trials indicates that it worked in these placebo-controlled studies with three times weekly treatment with Imiquimod-creams frequently to local barretions including Erythem (61%), erosion / waste sheets (23%) and oil (14%). (see Section 4.4)."</seg>
<seg id="2217">"this according to test-plan designed by clinical signs indicates that in these studies with five times weekly treatment with Imiquimod-Creme very often found to heavy inventors (13%), heavy emrogers (13%), and for heavy bowels and sales (19%)."</seg>
<seg id="2218">In clinical trials to study the application of Imiquimod for the treatment of cactine Keratosis has been established Alopezie with a frequency of 0.3% (5 / 1214) in the treatment process or in the surrounding area.</seg>
<seg id="2219">"the full-lasting reception of 200 mg Imiquimod, which corresponds to the content of about 16 bags, could lead to nausea, headaches, mygies and fever."</seg>
<seg id="2220">"the clinically serious suspenalties, which occurred according to several ormal doses of &gt; 200 mg, consisted in hypotonie, which appears to orous or intravenous liquids."</seg>
<seg id="2221">In a pharmacoinetic examination was proven to the topical application of Imiquimod increasing systemic concentrations of the alphainterferons and other cytokine.</seg>
<seg id="2222">In 3 zulistive phase 3 active studies could be shown that the efficacy in relation to a full balance of the Feigns in a Imiquimod treatment was clearly superior to a placebo treatment.</seg>
<seg id="2223">"at 60% of the total of 119 with Imiquimbo, patients were completely inclined with patients; this was at 20% of the 105 with placebo patients with placebo patients (95% CI):"</seg>
<seg id="2224">"a full separation could be achieved at 23% of 157 with Imiquimod treated male patients, opposite 5% of 161 with placebo patients treated male patients (95% CI):"</seg>
<seg id="2225">The effectiveness of Imiquimod at five-day application per week over 6 weeks was investigated in two double bedrooms, placebo-controlled clinical studies were investigated. "</seg>
<seg id="2226">The auditore were histological confirmed individual primary superfizipper with a minimum size of 0.5 cm and a maximum diameter of 2 cm.</seg>
<seg id="2227">"the data from an open, uncontrolled long-term study after four years of present data show that approximately 79.3% [95% CI (73.7%, 84.9%)] of all treated patients were clinically cured and this was also 48 months long."</seg>
<seg id="2228">"the effectiveness of Imiquimbo at three times weekly periods of 4 weeks, interrupted by a four-week, treatment free period, was examined in two double-ups, placebokontrolulated clinical studies."</seg>
<seg id="2229">"the patients had clinically typical, visible, discrete, not hyperlabial AK- lesions within a-related 25 cm2 large treatment arethan on the uncareful scalp or in the face."</seg>
<seg id="2230">The two-year data from two combined monitoring studies show for patients with clinical abortion following one or two treatment periods of 27% (35 / 128 patients).</seg>
<seg id="2231">The deserted indications of the neigners, Aktine Keratosis and superfizielles Basucinoma occur in paediattic patients generally not up and were therefore not examined. "</seg>
<seg id="2232">Aldara Creme was investigated in four randomised, doubling placebo-controlled studies on children aged 2 to 15 years with Molluscum Contagiosum (Imiquimod n = 576, placebo n = 313). "</seg>
<seg id="2233">The effectiveness of Imiquimbo could not be shown in these studies in the event (3x / week for a period of ≤ 16 weeks).</seg>
<seg id="2234">A minimal systemic recording of the 5% of Imiquimod creams by the skin of 58 patients with cactinal keratosis was observed during three times weekly use during three weeks.</seg>
<seg id="2235">"the highest medication concentrations in the Serum at the end of the week 16 were observed between 9 and 12 hours and pray 0,1, 0,2 and 1,6 ng / ml used in the face of the face (12.5 mg, 1 insertion), on the scalp (25 mg, 2 bags) and on the hands / poor (75 mg, 6 bags)."</seg>
<seg id="2236">The calculated obvious half-time period was about 10times higher than the 2staged semiconductor after the subcutaneous application in a previous study; this indicates a prolonged Retention of the medication by means of the skin.</seg>
<seg id="2237">The data on systemic exposure shown that the resorption of Imiquimod was low in MC-diseased skin of patients aged 6 - 12 years old and comparable to that with healthy adults and adults with cactic keratosis or superfiziellem Basalchemoma.</seg>
<seg id="2238">"in a four-month study on the painting toxicity at the Rat, the cans of 0,5 and 2,5 mg / kg KG is a significant body weight and increased cardio-weight; a four month long run-run study conducted at the mouse has no similar effects."</seg>
<seg id="2239">A two-year study on carcinogens at mice with mice administration at three days a week induced no tumors at the application.</seg>
<seg id="2240">"the corresponding mechanism is not known, but since Imiquimod has only a low system absorption from the human skin and is not mutation, is a risk for people due to the systemic exposure to be very low."</seg>
<seg id="2241">"the tumors entered the group of mice, treated with the real free cream, formerly and in larger numbers than in the control group with low UVR."</seg>
<seg id="2242">"it can harm other people even if these same symptoms are as you. − If any of the listed side effects you have greatly impaired, or do not notice any side effects, please inform your doctor or pharmacist."</seg>
<seg id="2243">● Coleigwarts (Condylomata acuminata) which have formed on the skin in the area of genitals (Geschlechtsorganic) and Anus (After) ● rogenital Basalchemoma This is a frequent anzutative, slowly growing form of the skin pretension with very low probability of spreading to other parts of the body. "</seg>
<seg id="2244">"if it remains uncovered, it may lead to discharges, especially in the face - hence an early detection and treatment is important."</seg>
<seg id="2245">Aktine Keratoses are smoother areas of the skin that occur in people who were exposed a lot of the sun-time during their previous life.</seg>
<seg id="2246">"Aldara should only be applied at flat actine Keratants in the face and on the scalp in patients with a healthy immune system, where your doctor has chosen that Aldara for you which is best suited to you."</seg>
<seg id="2247">Aldara Creme supports your physical immune system in the production of natural substances that help your body to fight against superficial bassocinoma or for the infection with feigners of the responsible virus.</seg>
<seg id="2248">O if you've used earlier once Aldara Creme or others who consult your doctor before you consult with your immune system before you consult Aldara Creme only when treating your immune system. o please contact with your immune system. o Avoid the contact with eyes, lips and nasal skin. "</seg>
<seg id="2249">"in accidental contact the cream through removable with water removed. o wounds, don't get more Creme than your doctor. o If you prepare the creams by Aldara Creme not with an association or pavement. o Falls reactions to the treatment of Aldara Creme do not occur with an association or pavement, wash the cream with a mild soap and water."</seg>
<seg id="2250">"once the reactions occur, you can continue the treatment. o informing your doctor if they have not a normal blood picture."</seg>
<seg id="2251">"if this daily cleaning is not carried out under the foreskin, with increased appearance of prefabrication swelling, dune, the skin or difficulties when rejection of the foreskin."</seg>
<seg id="2252">"contact Aldara Creme not in the Urethra (Harthra), in the vagina (divorce), the Zervix (cervix) or within the anus (After)."</seg>
<seg id="2253">Intake of other medicines have serious problems with your immune system, you should use this medication for no more than a treatment cycle. "</seg>
<seg id="2254">If you have intercourse with feigns in the genital area of intercourse is the treatment with Aldara Creme after intercourse (not before) perform.</seg>
<seg id="2255">"please inform your doctor or pharmacist if you apply other medicines or have recently applied, even if it is not prescription-prescription medicine."</seg>
<seg id="2256">"breastfeeding your baby during treatment with Aldara Creme, not known as Imiquimod into the mother's milk."</seg>
<seg id="2257">The frequency and duration of the treatment are different at feigwarts, bassocinoma and cactyl keratants (see specific instructions for each application area). "</seg>
<seg id="2258">"wear a thin layer of Aldara Creme on the clean, dry skin set with the Feigns on and relieve the cream carefully placed on the skin, until the creams completely moved."</seg>
<seg id="2259">Men with Feigwarts under the foreskin must pull the foreskin every day and wash the rash below (see section 2 "What must you consider before the application of Aldara Creme?).</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">"6 weeks each stay 5 days a week for a sufficient amount of Aldara cream, to cover the affected area and 1 cm around this area."</seg>
<seg id="2262">Very frequent Effects (with more than 1 of 10 patients expected) Frequent Side Effects (with less than 1 of 10 patients expected) for rare side-effects (with less than 1 of 1000 patients expected) very rare side effects (with less than 1 of 10,000 patients expected)</seg>
<seg id="2263">Notify your doctor / doctor or your pharmacist / your pharmacist immediately when you feel at ease during the application of Aldara Creme.</seg>
<seg id="2264">"if your skin reacted to strongly on treatment with Aldara Creme, you should not use the cream with water and a mild soap, wash your doctor or your pharmacists."</seg>
<seg id="2265">A reduced number of blood cells can make you anchodious for infections; they can make sure that when you are faster a blouse flue or it can give up demption.</seg>
<seg id="2266">Inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or you have side effects that are not specified in this usage information.</seg>
<seg id="2267">"in addition, you can rename Juckreiz (32% of patients), burning (26% of patients) or pain in the fields that you have worn Aldara Creme (8% of the patients)."</seg>
<seg id="2268">"usually, it is more lighter skin reactions, which takes place within about 2 weeks after placing the treatment again."</seg>
<seg id="2269">"occasionally notice some patients changes at the application site (wounding, inflammation, swelling, landing, bubbles, Dermatitis) or maturity, nausea, dry-like symptoms and fatigue."</seg>
<seg id="2270">"occasionally, some patients suffer from changes at the application site (Bluten, inflammation, griffles, griffles, griffles, canceration, canceration, cerviation, skulsion, farrheal, farrheal, farrheal, fancy, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness, weakness</seg>
<seg id="2271">Aldurazyme is used for the enzymes in patients with secured diagnosis of a Mukopolysaccharithos I (MPS I; α-L-Iduronidase fails) to treat the non neurological manifestations of the disease (the symptoms which is not associated with brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (glycoaminky cane, GAGs) are not constructed and thus gather in most organs in the body and compensate them."</seg>
<seg id="2273">"the following non neurological symptoms of MPS I can occur: enlarged liver, rigid joints, the movements are frightened, verminated lung-volume, heart and austerity."</seg>
<seg id="2274">"the treatment with Aldurazyme should be monitored by a doctor, the experience in the treatment of patients with MPS I or other hereditary metabolic Diseases."</seg>
<seg id="2275">"the administration of Aldurazyme should occur in a hospital or clinic with revitational equipment, and patients need under circumstances prior to administration of appropriate medicines to prevent an allergic reaction."</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu</seg>
<seg id="2277">"in the study, the safety of pharmaceuticals was tested, however, it was also tested its effectiveness (by reducing its effect with regard to reducing Gag concentrations in the urine and regarding the size of the liver)."</seg>
<seg id="2278">"in children under the age of five years Aldurazyme the gag concentrations in the urine around 60%, and half of the patients treated at the end of the study a normal large liver."</seg>
<seg id="2279">"the most common side effects of aldurazyme at patients aged over five years (observing more than 1 of 10 patients) are headache, nausea, bthroats, rthropathy (laughter), rethroats, fathamy (joint pain), Hitzegeeing, fever and reactions to the infusion."</seg>
<seg id="2280">"very common side effects in patients under five years of high blood pressure, decreased blood pressure, decreased oxygen saturation (accelerated heart rate), fever and shook."</seg>
<seg id="2281">Aldurazyme may be used in patients who possibly have greatly oversensitive (allergic) on laronidase or one of the other components (anaphylaktic reaction).</seg>
<seg id="2282">"the European Drug Agency (EMEA) is every year every new information that may possibly be known, examine and update this summary required."</seg>
<seg id="2283">"the manufacturer of Aldurazyme will be patient, the Aldurazyme will get in terms of the reaction to the infusion and the development of antibodies."</seg>
<seg id="2284">June 2003 the European Commission Decision the Company Genzyme Europe B.V. a permit for the use of Aldurazyme throughout the European Union.</seg>
<seg id="2285">Laronidase is a recombinant form of humanen α-L-Iduronidase and is produced using recombinant DNA technology using simple Hamster Ovary (Chinese Hamster Ovary, eggs of the Chinese HAMSTERS). "</seg>
<seg id="2286">Aldurazyme is a longtime enzymes in patients with secured diagnosis of a Mukopolysaccharithos I (MPS I, α-L-Iduronidase-lack) to treat the non-neurological manifestations of the disease (see section 5.1). "</seg>
<seg id="2287">The treatment with Aldurazyme should take place by a doctor who owns experience in the treatment of patients with MPS I or other hereditary metabolism.</seg>
<seg id="2288">"the initial infusion rate of 2 e / kg / h can, if the patient is carrying this, every 15 minutes in individual steps on a maximum loss of 43 E / kg / h."</seg>
<seg id="2289">The safety and effectiveness of Aldurazyme for adults over 65 years has not been established and for these patients cannot be recommended dosage.</seg>
<seg id="2290">The safety and effectiveness of aldurazyme in patients with kidney or liver infertility has not been established and for these patients cannot be advised any dosing scheme.</seg>
<seg id="2291">"with Aldurazyme treated patients can develop infusion-related reactions, which are defined as any related incidence that occurs during infusion or until the end of the Infusionary (see section 4.8)."</seg>
<seg id="2292">"for this reason, especially these patients should continue to be monitored engaging, and the infusion of Aldurazyme should only be made available in a reasonable clinical environment in the revitational equipment for medical emergencies."</seg>
<seg id="2293">"due to the clinical phase-3 study, almost all patients IgG antibodies are to be formed against Laronidase, usually within 3 months from the treatment of treatment."</seg>
<seg id="2294">Patients who develop antibodies or symptoms of an infusion conditional reaction must be treated with caution when using Aldurazyme (see sections 4.3 and 4.8).</seg>
<seg id="2295">"because little experience regarding the recovery of treatment after a lengthy break, must be cautious due to the theoretically increased risk reaction after a break of treatment."</seg>
<seg id="2296">60 minutes before starting the infusion with drugs (antihistaminika and / or antipyreships) to minimize the potential appearance infusion responses.</seg>
<seg id="2297">"in the event of mild or moderate-related response, the treatment with antihistaminika and paracetamol / obuprops should be wounded and / or a reduction of infusion rate to the half of the infusion rate, where the reaction occurred."</seg>
<seg id="2298">"in the case of a single, serious infusion-related response needs to be stopped, until the symptoms are led to the decline, treatment with antihistaminika and paracetamol / Ibuprops."</seg>
<seg id="2299">Infusion can be resumed with a reduction of infusion rate on 1 / 2 - 1 / 4 of infusion rate where the reaction has occurred.</seg>
<seg id="2300">3 are (Antihistaminika and paracetamol / Ibuprofen and / or Corticosteroids) as well as a reduction of infusion rate on 1 / 2 - 1 / 4 of the infusion rate.</seg>
<seg id="2301">Aldurazyme should not be applied simultaneously with chloroquin or Procain because a potential risk of an interference with the intracellular recording of Laronidase.</seg>
<seg id="2302">"animal experimental studies do not leave direct or indirect harmful effects on pregnancy, the embryonic development, birth and postnatal development (see Section 5.3)."</seg>
<seg id="2303">"no data on newborn that were exposed to Laronidase about the mother's milk, predestined, is recommended, during treatment with Aldurazyme not to breastfeeding."</seg>
<seg id="2304">Side effects in clinical trials were primarily associated to infusion-related reactions which were observed at 53% of patients in the phase 3-3 study (treatment duration up to 4 years) and at 35% of patients in the study with participants under 5 years of age (treatment duration up to 1 year).</seg>
<seg id="2305">"unwanted pharmaceuticals in connection with Aldurazyme, which were observed during phase 3 years or older in total of 45 patients aged between 5 years or older in a treatment of treatment of up to 4 years; often (≥ 1 / 10); often (≥ 1 / 100 to &lt; 1 / 10)."</seg>
<seg id="2306">"in some patients with severe MPS-I-conditioned involvement of the upper respiratory trails and lungs in the history performed more heavy reactions, including bronchospasm, respiratory and facial skin (see section 4.4)."</seg>
<seg id="2307">"children unwanted pharmaceuticals related to Aldurazyme, which have been reported during a phas- 2 study with a total of 20 patients aged under 5 years, with the most severe reduction form and a treatment of duration up to 12 months, have been listed in the table."</seg>
<seg id="2308">"100 E / kg of intravenous once a week (recommended dose), 200 E / kg of intravenous once a week, 200 E / kg of intravenous every 2 weeks or 300 E / kg of intravenous every 2 weeks."</seg>
<seg id="2309">"during most patients it came to a seroconversion in three months after the start of treatment at a seroconversion, whereby the patients aged under the age of 5 years came to a seroconaire version (average of 26 days compared to 45 days in patients aged 5 and older)."</seg>
<seg id="2310">"until the end of the phase 3-3 study (or up to a premature extinction from the study), in 13 / 45 patients none by radioimmunopocagitation (Rip) Assay expivotal antibodies had come before, including 3 patients, where it has never been to Seroconversion."</seg>
<seg id="2311">Patients with faults up to the lowest antibodies suspended to a robust reduction in the gag mirrors in Harn during patients with high antibodies an variable reduction of Gag in the Harn was arrested.</seg>
<seg id="2312">Four patients (three in the phase 3 study and one in the phase 2 study) showed a marginal to low neutrality inhibitorous effect on enzymatic Laronidase- activity in vitro which seemed to impair the clinical effectiveness and / or reducing Gag in Harn.</seg>
<seg id="2313">"the presence of antibodies seemed to be in relation to the incidence of undesirable drug reactions, even if the appearance of unwanted pharmaceuticals typically came together with the formation of IgG antibodies."</seg>
<seg id="2314">The justification of the enzyme therapy is in one of the hydrolysis of the accumulated substrate and the prevention of further accumulation of adequate restoration of the enzymes.</seg>
<seg id="2315">"after invenous infusion, Laronidase is rapidly taken out of the cycle and taken into the lysosomes, most likely over Mannose-6-phosphate - receptors."</seg>
<seg id="2316">"the safety and effectiveness of Aldurazyme were examined in a randomised, doubles, placebonated phase-3 study on 45 patients aged 6 to 43 years."</seg>
<seg id="2317">"although patients were rected for the study, the majority of patients received from the middle phenomenon, and only one patient pointed out the serious phenomenon."</seg>
<seg id="2318">Patients have been recruited if they had an forcized expiratory volume (FEV) of less than 80% of the estimated value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">Primary outcomes for the effectiveness were the percentage change of the estimated FEV and the absolute salary in the 6-Minut- Gehtest.</seg>
<seg id="2320">All patients were subsequently rected for an open-label extension (182 weeks) each week 100 E / kg Aldurazyme.</seg>
<seg id="2321">After 26 weeks therapy the aldurazyme treated patients opposite the placebo group to improve the lung function and the enclosure that is shown in the following table.</seg>
<seg id="2322">"in the open extension study, an improvement and / or maintenance of these effects of up to 208 weeks in deraldurazyme / Aldurazyme Group and of 182 weeks in the placebo / Aldurazyme Group, as shown from the following table."</seg>
<seg id="2323">The acceptance of the estimated procentric FEV is not significant in this period of clinically not significant and the absolute lung volumina increased further proportional to the height of growing children.</seg>
<seg id="2324">"from the 26 patients with a hepateged before the treatment reached 22 (85%), until the end of the study a normal living size."</seg>
<seg id="2325">Within the first 4 weeks a serious decay of the gag-mirror in the Harn (µg / mg Kreatinin) has been established until the study constant constant.</seg>
<seg id="2326">"with regard to heterogeneous pathologies, which was taken into account with the use of a combined repository, route in 6-minutes Gehtest, Moving house (58%), was generally an improvement in 26 patients (58%), no change in 10 patients (22%) and a deterioration of 9 patients (20%)."</seg>
<seg id="2327">"it was conducted a one-year-year-2 study conducted in which mainly the security and pharmacoinetic of Aldurazyme was examined in the study at the time of their inclusion in the study under 5 years old (16 patients with heavy clamping form and 4 with the middle level form)."</seg>
<seg id="2328">In four patients the dosage was increased because of elevated GAG- mirror in the Harn in week 22 in the last 26 weeks on 200 E / kg.</seg>
<seg id="2329">"for several patients a size growth (n = 7) and a weight gain (n = 3) established after the Z-Score for this age group, the younger patients with the moderate delay form (&lt; 2,5 years), and every 4 patients with the middle level of course."</seg>
<seg id="2330">In a phase 4 study studies have been carried out to pharmaaerodynamic effects of different aldurazyme metering schemes on the Gag-mirror in the Harn, the Living volume and the 6-minute Gehtest. "</seg>
<seg id="2331">"100 E / kg of intravenous once a week (recommended dose), 200 E / kg of intravenous once a week, 200 E / kg of intravenous every 2 weeks or 300 E / kg of intravenous every 2 weeks."</seg>
<seg id="2332">"the dosing scheme with 200 E / kg of intravenous every 2 weeks can represent patients, the difficulties with weekly incidents, however, is not proven that the long-term clinical effectiveness of these two dosing schemes is equivalent."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will any new information that will be available annually, and if necessary, the summary of the characteristics of the medication is updated."</seg>
<seg id="2334">The pharmacoinetic profile among patients under the age of 5 was similar to the elderly and less strongly affected patients.</seg>
<seg id="2335">"based on conventional studies on safety-harmacology, toxicity at unique gift, toxicity in repetitive gifts and reproductions, the preclinical data will not identify any particular hazards for men."</seg>
<seg id="2336">"since no tolerances were carried out, this medicine may not be mixed with other medicines, except with the under 6.6."</seg>
<seg id="2337">"if the easy-to-use preparation is not used immediately, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution is carried out under controlled and validated aseptic conditions."</seg>
<seg id="2338">5 ml of concentarte for the production of a solution in throughput (type - I-glass) with stoppers (silicone Chloropyl-rubber) and sealing (aluminium) with fixing flap (polypropylene).</seg>
<seg id="2339">10 preparation of the Aldurazyme Infusion (using aseptical technique) • Je after the weight of the individual patient first the number of dilution can determine.</seg>
<seg id="2340">"the owner of the approval for the use has been able to complete the following study programme within the given time, whose results are the basis for the annual announcement of the benefit-risk."</seg>
<seg id="2341">"this Register will be treated with a long-term security and efficiency information on patients that have been treated with Aldurazyme, as well as data on the natural progredience of the disease in patients without these treatment."</seg>
<seg id="2342">"in patients who suffer from MPS I, is an enzyme called α-L-Iduronidase, the certain substances in the body (glycosaminoglycane), either in small amount before or this enzyme missing completely."</seg>
<seg id="2343">If you are allergic (hypersensitive) compared to one of the components of Aldurazyme or if you have a severe allergic reaction to Laronidase.</seg>
<seg id="2344">An infusion conditional reaction is every side effect that occurs during infusion or until the end of the Infusionary appearance (see section 4 "Worldwide side effects are possible.).</seg>
<seg id="2345">"when using Aldurazyme with other medicines Please inform your doctor if you are taking medicines, chloroquin or Procain because an indication of a reduced effect of Aldurazyme."</seg>
<seg id="2346">"please inform your doctor or pharmacist if you have taken other medicines or recently taken, including not prescription pharmaceuticals."</seg>
<seg id="2347">Notes for the handling - thinner and application The concentarte concerning the preparation of an infusion solution must be inclined prior to the application and is intended for intravenous application (see information for doctors and medical practitioners).</seg>
<seg id="2348">"the initial infusion rate of 2 e / kg / h can, if the patient is carrying this, every 15 minutes gradually increased to a maximum loss of 43 E / kg / h."</seg>
<seg id="2349">"in some patients with severe MPS I- conditional participation of the upper respiratory paths and lungs in the history, but severe reactions to, including bronchospasm, respiratory and facial skin."</seg>
<seg id="2350">"very frequent (occurrence in more than 1 of 10 patients): • Headache • Dermatologists • Dermatologists • Dermatologists • Yellow, pain, pain, pain, refrain • Shaker • Shüttel • Hypertone • less oxygen in the blood • reaction to the infusion."</seg>
<seg id="2351">"the European Drug Agency (EMEA) will any new information that will be available annually, and if necessary, the package will be updated."</seg>
<seg id="2352">"if the easy-to-use preparation is not used immediately, this is no longer than 24 hours at 2 ° C - 8º C, provided that the dilution is carried out under controlled and validated aseptic conditions."</seg>
<seg id="2353">Preparation of the Aldurazyme Infusion (using aseptical technique) • Je after the weight of the individual patient first the number of dilution can determine.</seg>
<seg id="2354">Alimta is being applied together with Cisplatin (a different drug against cancer) if cancer is not reside (drugs against cancer) or "Maligne" (by an surgery alone can't be removed) and "Maligne" (by an surgery alone can't be removed) and "Maligne" (with surgery alone) is not easy to other parts of the body). • advanced or metastatic CRC.</seg>
<seg id="2355">"Alimta is used in patients who have not been treated before, in combination with Cisplatin and in patients who have previously used other chemotherapies earlier than any therapy."</seg>
<seg id="2356">"to reduce side effects, patients should take part during treatment with Alimta an Corticosteroid as well as foloric acid (a vitamin) and injections of vitamin B12."</seg>
<seg id="2357">"when Alimta is administered along with Cisplatin, in addition, before or after the gift of Cisplatin in addition an" Antiemetics "(medicines for striking) and liquids (around a liquid hand)."</seg>
<seg id="2358">"in patients whose blood flow changes or when certain other side effects occur, the treatment should be decreased, deposited or the dosage will be reduced."</seg>
<seg id="2359">The active form of Pemetrexed slowed the formation of DNA and RNA and prevents the cells.</seg>
<seg id="2360">"the transformation of Pemetrexed into its active form goes easy to cancer cells in cancer cells, as in healthy cells, which leads to higher concentrations of the active form of pharmaceuticals and a longer active period of cancer cells."</seg>
<seg id="2361">"for the treatment of the maligs Cheuramesotoxoms was examined Alimta in a capitals of 456 patients, which had never received chemotherapy against their disease before."</seg>
<seg id="2362">"in the treatment of non-commercial lung cancer, the effects of Alimta were treated in a study on 571 patients with local advanced or metastatic disease, which previously had already been treated with chemotherapy with the effects of Docetaxel (another medicine against cancer)."</seg>
<seg id="2363">Alimta also was compared with gemcitabin (another medicine against cancer) and both in combination with Cisplatin in a study on 1 725 patients who had never received chemotherapy for lung cancer.</seg>
<seg id="2364">"patients who have been treated with Alimta and Cisplatin, survived on average 12,1 month, compared with 9,3 months in the sole administration of Cisplatin."</seg>
<seg id="2365">"in patients who had previously received an chemotherapy, was the average survival time with Alimta 8,3 months, compared to 7.9 months at Docetaxel."</seg>
<seg id="2366">"in both studies, however, patients in which cancer did not fall into the plate epithelial cells, in the administration of Alimta longer over-life cycle than with the comparative drug."</seg>
<seg id="2367">September 2004 the European Commission sent the company Eli Lilly Nederland B.V. a permit for the launch of Alimta in the entire European Union.</seg>
<seg id="2368">Every thoroughfare has to be analyzed with 4.2 ml 0.9% iger sodium loride solution (9 mg / ml) - what a solution of 25 mg / ml results.</seg>
<seg id="2369">The corresponding volume of the necessary lectursis is taken from the throughput and with 0.9% iger sodium-chloride solution (9 mg / ml) to 100 ml further (see section 6.6).</seg>
<seg id="2370">ALIMTA is shown in combination with Cisplatin is shown to first-line treatment of patients with locally advanced or metastatic bronchial cardiology (see section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is shown for treatment in second-line treatment of patients with lo- kal advanced or metastatic non-commercial bronchial historiography (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body area (KOF) adopted as intravenous infusion over a period of 10 minutes on the first day of every 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² KOF as infusion over a period of 2 hours after completion of the Pemetrexed- Infusion on the first day of every 21-day treatment cycle.</seg>
<seg id="2374">"in patients with non-small bronze karzinom, the recommended dose of ALIMTA 500 mg / m ² KOF extends as intravenous infusion over a period of 10 minutes on the first day of every 21 day treatment cycle."</seg>
<seg id="2375">"for reduction of incidence and severity of skin reaction must be given the day before and on the day of the Pemetrexed gifts, as well as the day after treatment a cortikosteroid."</seg>
<seg id="2376">"during the seven days before the first dose of Pemetrexed must be taken at least 5 cans of folks, and the intake must be continued during the whole treatment ceremony, as well as for another 21 days after the last Pemetrexed- dosage."</seg>
<seg id="2377">Patients must also have an intra-muscular injection of vitamin B12 (1000 micrograms) in the week before the first Pemetrexed dose as well as after every third generation cycle.</seg>
<seg id="2378">"in patients who receive Pemetrexed, should be created before each Gabe a complete blood picture, including a differentiation of the leucocytes and a Thrombozytenative."</seg>
<seg id="2379">The alkaline Phosphatase (AP), aspartame-Transaminase (AST or SGOT) and Alanin-Transaminase (ALT or SGPT) should be ≤ 3-fold of the upper limit value. "</seg>
<seg id="2380">At the beginning of a new treatment cycle must take place a dosage inspection at the beginning of the Nadirs of the blood image or the maximum non-hmatological toxicity of the predictive therapy.</seg>
<seg id="2381">"after recovery, patients must be treated according to references in tables 1, 2 and 3 will be treated for ALIMTA as monotherapy or in combination with Cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of National Cancer Institute Common Toicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degrees 2 bleeding.</seg>
<seg id="2383">"should patients not develop-hmatological toxicity ≥ degrees 3 (except neurotoxicity), the patient has to be interrupted by ALIMTA, up to the patient the value in front of the treatment"</seg>
<seg id="2384">The treatment with ALIMTA needs to be broken when in patients after 2 dosistive toxicity or non-hmatological toxicity level 3 or 4 appearance or so- with the appearance of degrees 3 or 4 neurotoxicity.</seg>
<seg id="2385">Clinical studies have no indication that in patients at the age of 65 years or in comparison to patients aged 65 years a raised annotoratory risk.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years of age due to incomprehensiveness and effectiveness.</seg>
<seg id="2387">"in clinical studies were necessary in patients with a creatinin Clearance of ≥ 45 ml / min no dosage adjustment necessary, which hints for all patients recommended dosage adjustment."</seg>
<seg id="2388">The data base for patients with a creatinine clearance of less than 45 ml / min was not sufficient; therefore the application is not recommended (see section 4.4).</seg>
<seg id="2389">"however, patients were examined with a live functionality of &gt; the 1.5-folding of the upper Bilirubin- border values and / or transaminasensive (in Abdominance of liver sufferings) or &gt; 5.0-fold of the upper limit value (in presence of liver sufferings), not specifically examined in the studies."</seg>
<seg id="2390">Patients must be monitored with regard to Kno- and Pemetrexed should not be administered to patients before whose absolute neutrroyalty points again a value of ≥ 1500 cells / mm ³ and the Thrombo- cyst number has reached a value of ≥ 100.000 cells / mm ³.</seg>
<seg id="2391">A dosage reduction for further cycles is based on the Nadir of the absolute neutrality speed, Thrombozytense and maximum non-hmatological toxicity as they observed in the preceding treatment cycles. (see section 4.2). "</seg>
<seg id="2392">"a lower toxicity and a reduction in degrees 3 / 4 hämatological and non-smoking toxicity such as Neutropenia, febrile Neutropenia and infection with degrees 3 / 4 Neutropenie became beo-, if a pre-treatment with folic acid and vitamin B12 had taken place."</seg>
<seg id="2393">"therefore all patients need to be dependent on Pemetrexed patients treated, folklore and vitamin B12 as prophy- laktic measure for reduction-borne toxicity (see section 4.2)."</seg>
<seg id="2394">Patients with mild to medium-infertility (Creatinin-Clearance 45 to 79 ml / min) must avoid simultaneous non-steroidal anti-cyber acid (&gt; 1.3 g daily) for at least 2 days before the therapy, on the day of therapy and mindes- TENS 2 days after the therapy with Pemetrexed (see Section 4.5). "</seg>
<seg id="2395">"all patients, for which a therapy with Pemetrexed is provided, the intake of NSAIDs with a long half-term stay for at least 5 days prior to therapy, on the day of therapy and at least 2 days after the therapy with Pemetrexed (see Section 4.5)."</seg>
<seg id="2396">"many patients where these events occurred, corresponding risk factors for the appearance of renal events, including dehydration, pre-existence of hypertension or diabetes."</seg>
<seg id="2397">Therefore in patients with clinically significant liquids - accumulation in transcellular space a Drainage of ergonomics before the Pemetrexed treatment.</seg>
<seg id="2398">"5 serious cardiovascular events, including Myokardinfarkt, and ceremebrovascular events have been reported in clinical studies with Pemetrexed occasionally, when this ingredient usually has been administered in combination with a different cytotoxical ingredient."</seg>
<seg id="2399">"for this reason, the simultaneous application of attenuated Lebenshilfe (except Gelbfieber, these vaccination is contaminated) is not recommended (see Section 4.3 and 4.5)."</seg>
<seg id="2400">"as the possibility of irreversible damage caused by Pemetrexed, men should be advised before the treatment - ginn, advice regarding the sperm conservation."</seg>
<seg id="2401">In patients with normal kidney-function ≥ 80 ml / min) can be high cans of non-steroidal anti-phylic antiphylic acid in high doses (≥ 1.3 g daily) to a reduced Pemetrexed excretion with the result of a multi-multicoloured advancement of side effects.</seg>
<seg id="2402">"therefore, caution is recommended when patients with normal kidney function (Creatinin-Clearance ≥ 80 ml / min) high doses of NSAIDs or Ace- tylsalicylic acid in high dosage."</seg>
<seg id="2403">"Ibuprofen) or Acetylsalicyl- acid in high dosage for at least 2 days before the treatment, on the day of therapy and mindes- TENS 2 days after the therapy with Pemetrexed (see section 4.4)."</seg>
<seg id="2404">"there is no data regarding the Interactionpotentials as with NSAIDs with a long semiconductor, such as Piro- xicam or Rofecoxib, the simultaneous application with Pemetrexsed for at least 5 days prior to therapy, on the day of therapy and at least 2 days after the therapy with Pemetre- xed avoided."</seg>
<seg id="2405">The large intra-individual Variability of the low-level status during the disease and the possibility of interactions between oral antioagulanzien and antineoplastic chemotherapy requires a increased monitoring frequency of INR (International normalities ratio) if the decision was made to treat the patient with orals antiocagulani.</seg>
<seg id="2406">"there are no data for the use of Pemetrexed at pregnancy, but as with ande- ren antimentolites are expected for an application in the pregnancy severe birth-defective."</seg>
<seg id="2407">"Pemetrexed should not be applied during pregnancy, except if the requirements for the mother and the risk for the fetus (see section 4.4)."</seg>
<seg id="2408">"as the possibility of irreversible damage caused by Pemetrexed, men should be advised before the treatment of treatment, advice regarding the sperm level."</seg>
<seg id="2409">It is not known as Pemetrexed into the mother's milk and unwanted effects in the distilled cleans cannot be excluded.</seg>
<seg id="2410">"the following table shows the frequency and severity unwanted effects that reported in &gt; 5% of 168 patients with Mesotoxom and the randomized Cisplatin and Pemetrexed Er-, and 163 patients with Mesotoxom, which received randomised Cisplatin as monotherapy."</seg>
<seg id="2411">"side-side effects: very frequent (≥ 1 / 10, frequently (≥ 1 / 100 and &lt; 1 / 10), occasionally (≥ 1 / 1,000 and &lt; 1 / 1000), very rare (&lt; 1 / 10.000), and not known (based on the available data of spontaneity)."</seg>
<seg id="2412">"* reference to National Cancer Institute CTC version 2 for each toxicity" "* * which was derived from the term" "kidney / genital trakt" "* * * referred to National Cancer Institute CTC (v2.0; NCI 1998) should be flavouring and hair loss only as degrees 1 or 2."</seg>
<seg id="2413">"for this table a threshold of 5% specified for inclusion of all events, in which the related medical practitioner has held a connection with Pemetrexed and Cisplatin for possible."</seg>
<seg id="2414">Clinically relevant CTC Toxicity who reported at &lt; 1% (occasionally) of the patients were reported randomised Cisplatin and Pemetrexed received, inverted arrhythmic and motoric Neuropathic. "</seg>
<seg id="2415">"the following table shows the frequency and severity unwanted effects, which reported in &gt; 5% of 265 patients were reported randomized Pemetrexed as monotherapy with gifts of torture - re and vitamin B12, as well as 276 patients, the randomized Docetaxel as monotherapy erhiel-."</seg>
<seg id="2416">* reference to National Cancer Institute CTC version 2 for every toxicity degree. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported hair loss only as degrees 1 or 2.</seg>
<seg id="2417">"for this table a threshold of 5% specified for inclusion of all events, in which the related medical practitioner has held a connection with Pemetrexed for possible."</seg>
<seg id="2418">Clinically relevant CTC Toxicity who reported at &lt; 1% (occasionally) of the patients were reported randomized Pemetrexed, inverted supraventricular Arrhythmia. "</seg>
<seg id="2419">"the clinically relevant laboratory toxizarity level 3 and 4 was compared with the previous results of three single pemetrexed monotherapiestudis (12,8% compared with 5,3%) and an increase of Alanintransaminase (15.2% compared to 1.9%)."</seg>
<seg id="2420">These differences are likely to lead to differences in the patient-population as well as the Pha- se 2 trials both chemonaive as well as significantly pretreated breast cancer with existing liver sufferers and / or abnorate output value of the liver tests.</seg>
<seg id="2421">"the following table shows the frequency and severity unwanted effects, which could be possible in connection with the study programmes; they were reported with &gt; 5% of 839 Patilles, the randomised Cisplatin and Pemetrexed received randomised Cisplatin and Gemcitabin received."</seg>
<seg id="2422">11 * P-values &lt; 0,05 comparison of Pemetrexed / Cisplatin and Gemcitabine / Cisplatin, using the "Fisher Exact. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should taste flavour and hair loss only as degrees 1 or 2."</seg>
<seg id="2423">"for this table, for inclusion of all events, in which the related doctor was held a connection with Pemetrexed and Cisplatin for possible to set a threshold of 5%."</seg>
<seg id="2424">Clinically relevant toxicity that reported at ≥ 1% and ≤ 5% (often) of the patients were reported randomised Cisplatin and Pemetrexed received by:</seg>
<seg id="2425">"clinically relevant toxicity, which reported in &lt; 1% (occasionally) of the patients were reported the rangallizes Cisplatin and Pemetrexed, inverted:"</seg>
<seg id="2426">"serious kardical events, including Myokardinfarkt, Angina pectoris, erebrovascular Insular and transitory artist, which is usually administered in combination with a different cytotoxical ingredient, occasionally reported."</seg>
<seg id="2427">"clinical studies were reported in patients with Pemetrexed treatment occasionally cases of Coli- tis (including intestinal and rektal bleeding, sometimes deadly abandoned, intestinal nekrose and Typhlitis)."</seg>
<seg id="2428">In clinical trials were reported in patients with Pemetrexed treatment occasionally cases of sometimes deadly loss of pneumonia with respiratory infertility.</seg>
<seg id="2429">It was reported on cases of akutem kidney failure at Pemetrexed Monotherapy or in combination with other chemotherapy (see section 4.4).</seg>
<seg id="2430">There were cases of radii pneumatic tis in patients who were reported before, during or after their peyrexed therapy (see section 4.4). "</seg>
<seg id="2431">ALIMTA (Pemetrexed) is an antineoplasty antifolate who exerted its effect by weight-dependent metabolic processes, which are necessary for cellreplication. "</seg>
<seg id="2432">In vitro studies shown that Pemetrexed as an antifolate has been blocked with several attacks (DHFR) and glycinamidribonucleotidfor- myltransferring (GARFT) and glycinamidribertucleotidforgot myltransferring (GARFT) and glycinamidybontase (GARFT) and Purpose Biosynthesis of Thymidin- and Purinnucleotides.</seg>
<seg id="2433">"EMPHACIS, a multi-centric, randomised, simple-blush phase 3 study by ALIMTA plus Cisplatin against Cisplatin with chemonaiven patients with maligned Cheuramesotoxom, that with ALIMTA and Cisplatin treated patients with maligned ohuramesotoxom, that with ALIMTA and Cisplatin treated patients with maligned rouramesotoxom, that with ALIMTA and Cisplatin treated patients with maligned rouramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with ALIMTA and Cisplatin treated patients with malignant maduramesotoxom, that with AL</seg>
<seg id="2434">Primary analysis of this study was carried out in the population of all patients that were received in the treatment of therapy (randomized and treated).</seg>
<seg id="2435">A statistically significant improvement of clinically relevant symptoms (pain and dyspnoe) relating to the maligs Cheuramesotizom was shown in the ALIMTA / Cisplatin-Arm (212 patients) compared to the allyoungest Cispla- Tin-arm (218 patients).</seg>
<seg id="2436">The differences between the two treatment epilepsy are determined by improving the pneumatic parameters in the ALIMTA / Cisplatin-Arm and a deterioration of the lung function in the period of the control.</seg>
<seg id="2437">"a multi-centric, randomized, open phase III study with ALIMTA against Docetaxel in patients with locally advanced or metastatic NSCLC after previous chemotherapy (intent to treat Population n = 283) and from 7,9 months in with docetaxel treated patients (ITT n = 288)."</seg>
<seg id="2438">"an analysis of influences of histology on the treatment process fell to favor of ALIMTA with a predominantly non-epithelial histological type (n = 0,61-1,00, p = 0,047), customized HR = 1,56; 95% CI = 1,08-2,26, p = 0,018)."</seg>
<seg id="2439">"limited data of a separately-randomized, controlled Phase 3 study show that efficiency dates (survival and progressional survival) for Pemetrexed between patients with (n = 540) and without (n = 540) pre-treatment by Docetaxel."</seg>
<seg id="2440">The efficiencies analyses of the PQ Population are consistent with the analyses of the ITT Population and support the non-sub-embarrassment of the ALIMTA Cisplatin combination opposite the gemcitabin Cisplatin combination.</seg>
<seg id="2441">Intermediate PFS was 4.8 months for the combination of ALIMTA Cisplatin compared to 5.6% (95% CI = 27.3 - 33,9) for the combination ALIMTA Cisplatin towards 28,2% (95% CI = 25.0 - 31,4) for the combination of Gemcitabin Cisplatin.</seg>
<seg id="2442">The analysis of the influences of the NSCLC histology on survival showed clinically relevant sub- differences according to histology, see below. "</seg>
<seg id="2443">Ci = Confidenzintervall; ITT = intent-to-treat; N = size of the overall population a statistically Significant for non-sub-intervals for HR (= Hazard Ratio) clearly under the non-subjection border of 1,17645 (p &lt; 0.001). "</seg>
<seg id="2444">"patients who have been treated with ALIMTA and Cisplatin (16.4% versus 28,9%, p &lt; 0,001), Erythrocytfusions (1.8% versus 4,5%, p = 0,002)."</seg>
<seg id="2445">"in addition, the patients required the gift of Erythropoetin / Darbopsimtin (10.4% versus 18.1%, p &lt; 0,001), G-CSF / GM-CSF (3,1% versus 6,1%, p = 0,004), and iron preparation (4.3% versus 7,0%, p = 0,021)."</seg>
<seg id="2446">"pharmacoinetic properties of Pemetrexed to Gabe as monotherapeutics were examined with various solid tumors in cans of 0,2 - 838 mg / m ² in Infusi- for over a period of 10 minutes."</seg>
<seg id="2447">Pemetrexed is mainly unchanged in the Urin signposted and 70% to 90% of the total dosage will be observed within 24 hours of application unchanged in the jungle.</seg>
<seg id="2448">Pemetrexed has a total surface of 91.8 ml / min and half the half-time in plasma is 3.5 hours in patients with normal kidney-conduction (Creatinin Clearance 90 ml / min).</seg>
<seg id="2449">In a study with beagle-dogs that have been preserved for 9 months of intravenous Bolus injections were observed antikulary changes (Degreenration / Nekrose of the seminiferen epithelial tissue).</seg>
<seg id="2450">Unless otherwise un- plus are the storage times and conditions after preparation in the responsibility of the user and should normally exceed 24 hours at 2 to 8 ° C unless the preparation / dilution has taken under controlled and validated aseptic conditions.</seg>
<seg id="2451">"trigger the content of 100 mg-throughput with 4.7 ml 0,9% iger sodium-chloride solution (9 mg / ml) without preservatives, resulting from it a solution with a concentration of about 25 mg / ml Pemetrexed."</seg>
<seg id="2452">The resulting solution is clear and coloring ranges from Collos to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2453">Each throughput must be recorded with 20 ml 0.9% iger sodium loride solution (9 mg / ml) - solves what a solution of 25 mg / ml results.</seg>
<seg id="2454">"23 severe cardiovascular events, including Myokardinfarkt, and ceremebrovascular events have been reported in clinical studies with Pemetrexed occasionally, when this ingredient usually has been administered in combination with a different cytotoxical ingredient."</seg>
<seg id="2455">"* reference to National Cancer Institute CTC version 2 for each toxicity" "* * which was derived from the term" "kidney / genital trakt" "* * * referred to National Cancer Institute CTC (v2.0; NCI 1998) should taste flavour and hair loss only as degrees 1 or 2."</seg>
<seg id="2456">"for this table a threshold of 5% specified for inclusion of all events, in which the report I held a connection with Pemetrexed and Cisplatin for possible."</seg>
<seg id="2457">* reference to National Cancer Institute CTC version 2 for every toxicity degree. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported hair loss only as degrees 1 or 2.</seg>
<seg id="2458">29 * P values &lt; 0,05 comparison of Pemetrexed / Cisplatin and Gemcitabine / Cisplatin, using the "Fisher Exact. * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should taste flavour and hair loss only as degrees 1 or 2."</seg>
<seg id="2459">"clinically relevant toxicity, which reported in &lt; 1% (occasionally) of the patients were reported the rangallizes Cisplatin and Pemetrexed, inverted:"</seg>
<seg id="2460">"an analysis of the influences of histology on the treatment fell to Gunsten from ALIMTA with a predominate HR = 0,61; 95% CI = 0,61-1,00, p = 0,047; 95% CI = 1,08; 95% CI = 1,08-2,26, p = 0,018)."</seg>
<seg id="2461">"trigger the content of 500 mg-throughput with 20 ml 0,9% iger sodium-chloride solution (9 mg / ml) without preservatives, resulting from it a solution with a concentration of about 25 mg / ml Pemetrexed."</seg>
<seg id="2462">The resulting solution is clear and the annoys ranges from colourless to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2463">"Pharmakovigance system The owner of the authorization has to ensure that the pharmaceutical - kovigilance system, as described in version 2.0 is ready and ready to approve the product as soon as the product is placed in the market and while the product is in the market."</seg>
<seg id="2464">"risk Management Plan The owner of the approval for the institute are committed to the studies and the additional Pharmacology's activities according to Pharmakovigilance plan, as agreed in version 1.2 of the Risk Management Plan (RMP), presented in modules 1.8.2. of approval for the intimacy and all the following updates of the RMP that were decided by CHMP."</seg>
<seg id="2465">"according to" CHMP guideline on Risk Management Systems for Medicinal products for human use "must be filed with the next" "Periodic Safety Update Report" "(PSUR)."</seg>
<seg id="2466">"in addition, an updated report must be submitted • If new information have to be submitted, which could have an effect on the current security specs, the Pharmakovigilance plan or risk of risk. milestones • On request by the EMEA"</seg>
<seg id="2467">ALIMTA 100 mg powder for making a concentrator for the production of an Infusionslums - ALIMTA 500 mg powder to produce a condoms for the production of an infusioning form.</seg>
<seg id="2468">ALIMTA is preserved in patients who have no previous chemotherapy to the be- plot of the maligs Cheuramesotoxoms (malignant condition of the rippine) in combination with Cisplatin, another medicine used to treat cancer. "</seg>
<seg id="2469">"if you have a kidney suffer or earlier one, please discuss this with your doctor or hospital networks, as you may not get ALIMTA."</seg>
<seg id="2470">"with you will be carried out before each infusion blood cells, it will be checked whether your nelling and liver function is sufficient and whether you have enough blood cells to get ALIMTA to 49."</seg>
<seg id="2471">Your doctor will possibly change the dose or treatment where it requires your general condition and if your blood values are too low.</seg>
<seg id="2472">"if you also receive Cisplatin, your doctor will ensure that your body contains sufficient water and you get the notable medicines to avoid the break before and after the Cisplatinum gift."</seg>
<seg id="2473">"should you have a hydration collection around the lungs around the lungs, your doctor can fix these fluid before you get ALIMTA."</seg>
<seg id="2474">"if you want to be a child during the treatment or during the first 6 months after the treatment a child, please talk to your doctor or pharmacist."</seg>
<seg id="2475">Interdependencies with other medicines please tell your doctor if you are medicines for pain or inflammations (Schwellun-) as such drugs, the "non-steroidal anti-phlogistika" (NSAIDs), including medicines that are not prescription) (like Ibupros). "</seg>
<seg id="2476">"depending on the planned Daemary of your ALIMTA-Infusion and / or the extent of your kidney function, your doctor will tell you what other medicines you can take on, and when."</seg>
<seg id="2477">"please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription, although it is not prescription."</seg>
<seg id="2478">"a hospital aggression, the nursing staff or a doctor will mix the ALIMTA powder with sterile 0,9% iger sodium-chloride solution (9 mg / ml) before it is applied to you."</seg>
<seg id="2479">Your doctor will write you cortison tablets (according to 4 mg of Dexametha- son two times a day) that you have to take on day during and on the day after the use of ALIMTA.</seg>
<seg id="2480">"your doctor will take you to take the acid (a vitamin) to take or multivitamins, the folic acid contain (350 to 1000 micrograms), which you must take during the use of ALIMTA a time daily."</seg>
<seg id="2481">The week before the application of ALIMTA and approximately every 9 weeks (corresponding 3 cycles of treatment with ALIMTA) you will also receive an injection of Vi- tamin B12 (1000 micrograms).</seg>
<seg id="2482">"is described in this usage information a side effect as" "very frequently", "this means that they have been reported by at least 1 of 10 patients."</seg>
<seg id="2483">"will be described as" "frequently", "this means that they reported by at least 1 of 100 patients but was reported less than 1 of 10 patients."</seg>
<seg id="2484">"will be described as" "occasionally", "indicates that they reported by at least 1 of 1,000 but less than 1 of 100 patients reported a side effect as" "rarely", "this means that they have been reported by at least 1 of 10,000 but less than 1 of 1,000 patients."</seg>
<seg id="2485">"fever or infection (often): if you have a body temperature of 38 ° C or above, sweating or other signs of an infection (because you may have less white blood cells as normal, which is very common)."</seg>
<seg id="2486">If you feel tired or weak to feel quickly in breathing or blass (because you may then have less hemoglobin as normal is what is very common).</seg>
<seg id="2487">"if you find a bending of the tooth, the nose or the mouth, or any other blood, which does not come to a stagnant or unexpected blueberry (because you might have less blood plunge than normal, which is very common)."</seg>
<seg id="2488">"occasionally (occurs at least 1 of 1,000 patients on, but less than 1 of 100 patients) increased pulse rate Colitis (inflammation of the internal stroke of the collitis) Interstititis pneumonitis (displacement of the lung in the intestinal) odeme (discharge of water into the body tissue, which leads to swelling)."</seg>
<seg id="2489">"rarely (occurs with more than 1 of 10,000 patients, but less than 1 of 1,000 patients)" Radiation Recall "(a rash like a severe sunburn), appearance on the skin that was suspended (several days to years) of a radiation therapy."</seg>
<seg id="2490">"occasionally occurred in patients, the ALIMTA, usually in combination with other cancer members, received a stroke of stroke or stroke."</seg>
<seg id="2491">"in patients who received before, during or after their ALIMTA treatment can also receive a criminal offences of the lung tissue, can occur through radiation caused by the lung tissue, which stands with the radiotherapy in connection)."</seg>
<seg id="2492">"52 Informing your doctor or pharmacist, if any of the listed unwanted effects you have to adversely affects or if you have side effects, which are not listed in this package."</seg>
<seg id="2493">"if such, the chemical and physical stability of the diluted and the Infusionslate solution in storage in the refrigerator or at 25 ° C for a period of 24 hours."</seg>
<seg id="2494">"Tél / Tel: + 32- (0) 2 548 84 84, both, and repliction of the balance."</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf: + 45 45 26 6100 Germany Lilly Germany 2222 Eesti Eli Lilly Limited Eesti filiaal "</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Tel: + 39- 055 42571} Betty: + 357 22 715000 Latvija Eli Lilly Holdings Limited atstovybulation Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos (Lda tel: + 351-21-4126600 România Eli Lilly România S.R.L.</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Sweden AB Tel: + 468- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Phone: + 44- (0) 1256 315999</seg>
<seg id="2500">Trigger the content of 100 mg-throughput with 4.7 ml 0.9% iger sodium loride solution (9 mg / ml) without preservatives of about 25 mg / ml Pemetrexed results.</seg>
<seg id="2501">Redeem the content of the 500 mg-throughput with 20 ml 0.9% iger sodium loride solution (9 mg / ml) without preservatives of about 25 mg / ml Pemetrexed results.</seg>
<seg id="2502">The resulting solution is clear and coloring ranges from Collos to yellow or green yellow without that the pro- reduction is impaired.</seg>
<seg id="2503">It is used in excess adult with a body index (Body Mass Index - BMI) from ≥ 28 kg per square meter in combination with calorient poor, fetched diet. "</seg>
<seg id="2504">Patients who take the Alli and take no weights after 12 weeks should contact their physician or pharmacist.</seg>
<seg id="2505">"these enzymes are inhibited in food, they can not build some fats in food, thereby causing around a quarter of the food allied undaut the intestine the intestine."</seg>
<seg id="2506">In a third study Alli was compared with 391 overweight patients with a BMI between 25 and 28 kg / m2 with placebo.</seg>
<seg id="2507">"in the two studies in patients with a BMI of ≥ 28 kg / m2 had patients, the Alli 60 mg participated, after a year a average weight loss of 4,8 kg compared to 2.3 kg in taking placebo."</seg>
<seg id="2508">"in the study with Alli in patients with a BMI between 25 and 28 kg / m2, no longer could be observed for the patient-relevant weight loss."</seg>
<seg id="2509">"the most common side effects of Alli (observed if more than 1 of 10 patients) are subject areas at After, Flatus (Winds) with overlap, fetal / öliger chair, cancelsilia (fur), Flatulency (Winds) and soft chairs."</seg>
<seg id="2510">It must not be used in patients who will be treated with Ciclosporin (to prevent the organs of transplantation) or with pharmaceuticals such as warts in preventing blood clauses.</seg>
<seg id="2511">"it may also not be applied in patients who are recorded at a long term Malabsorption bolt (with which not enough nutrients cover from the digestive tract) or to Cholestase (a liver disease), and during pregnancy, or by firing mothers."</seg>
<seg id="2512">July 2007 the European Commission sent to the Glaxo Group Limited as a permit for the publication of Orlistat GSK throughout the European Union.</seg>
<seg id="2513">Alli is used for weight reduction of adults with overweight (Body-Mass-Index BMI ≥ 28 kg / m2) Inzated and should be used in conjunction with a slightly hypokalorical, fetched diet. "</seg>
<seg id="2514">"alli must not be applied by children and young people under 18, since not enough data for the effectiveness and security."</seg>
<seg id="2515">"however, Orlistat however was only minimal resorated, is necessary in partitions and in patients with reduced Lebanese and / or kidney function, no adaptation of dosage is necessary."</seg>
<seg id="2516">• hypersensitivity against the ingredient or one of the other components • simultaneous treatment with Ciclosporin (see Section 4.5) • Chronos Malabsorption • pregnant (see Section 4.6) • Sttimely treatment with warring or other oral antiagulanzien (see sections 4.5 and 4.8)</seg>
<seg id="2517">The probability of the advancement gastrointestinal symptoms (see section 4.8) can increase when alli is taken together with a fat-range or fat diet.</seg>
<seg id="2518">"since the weight reduction in diabetes can be seized with improved metabolic control, patients who take a medicine against diabetes, before the beginning of a therapy with alli a doctor or pharmacists, because the dosage of antidiabetic can be adjusted."</seg>
<seg id="2519">Patients who take alli as well as drugs against hypertension or an increased cholesterol level you should ask your doctor or pharmacist whether the dosage of this medicine needs to be adjusted.</seg>
<seg id="2520">"it is recommended to meet additional fluctuating policies, in order to bow that in the case of serious Diarrhö possible failure to detect the orical controversition (see Section 4.5)."</seg>
<seg id="2521">Both in a study on interactions of pharmaceuticals as well as in several cases with simultaneous use of organs and Ciclosporin was observed an absenation of Ciclosporin Plasmasculars.</seg>
<seg id="2522">"in combination of warding or other oral antibodies in combination with orlistat, the Quick values could be influenced by the Quick values (internationally normative Ratio, INR) (see section 4.8)."</seg>
<seg id="2523">"in most patients who have been treated in clinical studies up to 4 full years with Orlistat, the concentrations of vitamins A, D, E and K and the beta carotins in the standardization area."</seg>
<seg id="2524">"however, the patients should be advised before bedtime a supplement of the multivitamin supplement to ensure an adequate vitamination (see section 4.4)."</seg>
<seg id="2525">"after the gift of an unmaldose Amiodaron was observed with a limited number of volunteer volunteers, which at the same time Orlistat was observed, a slight withdrawal of the Amiodaron-Plasmaconconcentration."</seg>
<seg id="2526">Animal experimental studies showed no direct or indirect harmful effects on pregnancy, embryonic development, birth or postnatal development (see Section 5.3). "</seg>
<seg id="2527">"the side effects of Orlistat are mainly gastrointestinal nature and hang together with pharmacological effect of pharmaceuticals, since the absorption of recorded fat is prevented."</seg>
<seg id="2528">The gastrointestinal effects were obtained from clinical studies with Orlistat 60 mg over a period of 18 months to 2 years and were generally light and temporarily.</seg>
<seg id="2529">"the frequencies are defined as follows: very frequent (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10), occasionally (≥ 1 / 1,000, &lt; 1 / 1,000), and very rare (&lt; 1 / 10.000), not known (frequency based on the available data not to be estimated)."</seg>
<seg id="2530">"the incidence of known side effects, which were determined according to the market launch of Orlistat, is not known as these events have voluntarily reported by a population uncertain size."</seg>
<seg id="2531">† It is plausibel that treatment with alli with regard to possible or actual gastrointestinal side effects can lead.</seg>
<seg id="2532">Single stroke of 800 mg of Orlistat and multi-disciplinary field of up to 400 mg three times a day were collected over a period of 15 days at normalgean important and overweight progressions that occurred recently without significant clinical trials.</seg>
<seg id="2533">"in the majority of delivery within the majority of organs of organs, either no side effects or similar effects have been reported as with the recommended dose of Orlistat."</seg>
<seg id="2534">"based on investigations on humans and animals can be attributed from a rapid reversal system, which can be attributed to the Libyan properties of orlistat."</seg>
<seg id="2535">The therapeutic effect is geared in the lumens of the stomach and the upper dune by kovalents against the active serin-rest of gastric and panky Lipasen.</seg>
<seg id="2536">"clinical trials was derived, that 60 mg of Orlistat, threw times a day, the absorption of approximately 25% of the food is blocked."</seg>
<seg id="2537">"two double-bark, randomized, placebokontroled studies in adults with a BMI ≥ 28 kg / m2, the effectiveness of 60 mg of Orlistat, which was taken three times a day in combination with a hypokalorical, fatty-induced diet."</seg>
<seg id="2538">"primary parameters, the change in body weight compared to the output value (at the time of Randomisation), as follows: as a change of the body weight in the study course, the more than 5% or more than 10% of their initial weight have lost (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction over 12 months was observed, the largest weight loss entered the first 6 months."</seg>
<seg id="2540">The average change in overall cholesterol was with Orlistat 60 mg -2.4% (starting 5.20 mmol / l) and with placebo + 2.8% (starting 5.26 mmol / l).</seg>
<seg id="2541">The average change of the LDL Cholesterols with Orlistat 60 mg -3.5% (output worth 3.30 mmol / l) and with placebo + 3.6% (output worth 3.41 mmol / l).</seg>
<seg id="2542">"at Taillencircumference, the average change -4.5 cm with Orlistat 60 mg (output 103,7 cm) and with placebo -3.6 cm (output 103,5 cm)."</seg>
<seg id="2543">Plasmaconconcentrations of not metabolized orlistat were 8 hours after the orical Gabe of 360 mg Orlistat not measurable (&lt; 5 ng / ml).</seg>
<seg id="2544">7 In general the metric doses could not be metabolized metlistat in Plasma only sporadisch and in extremely low concentrations (&lt; 10 ng / ml or 0,02 µmol) and without signs of a Kumulation. "</seg>
<seg id="2545">"in a study with adipous patients, which was administered for minimally resorated dose, namely M1 (in position 4 hydrolysing Lactonring) and M3 (M1 to split the N-Formyl-Leucine group), identified the approximate 42% of the total plasmaconconcentration."</seg>
<seg id="2546">"based on conventional studies on safety, toxicity, toxicity in repetitive Gabe, genotoxicity, the preclinical data can be seen no particular danger to human beings."</seg>
<seg id="2547">"Pharmakovigilance system, the owner of the authorization must ensure that the Pharmakovigilance system must be described in the version 1.8.1st of the authorisation item, and works before and while the product is available on the market."</seg>
<seg id="2548">"Risikomanagementplanning The owner of the authorization should carry out the studies and additional pharmaovigilance plan as described in the Pharmakovigilance plan and thus agreed to the agreement of the Risikomanagementplan (RMP) of October 2008 as well as all other updates of the RMPs, which will be agreed with the Committee for Humanity (CHMP)."</seg>
<seg id="2549">According to CHMP Guidelines to risk management systems for humanity must be submitted simultaneously with the next PSUR (Periodic Safety Update Report).</seg>
<seg id="2550">"furthermore, an updated report should be submitted: • If new information is available to provide current security guidelines, the Pharmakovigilance plan or risk management activities, within 60 days of attending an important, the Pharmakovigilance or Risikominimation concerning the milestones on request of the European pharmaceutical agency (EMEA)"</seg>
<seg id="2551">"12 PSURs The owner of the approval for the incumbent will bring about the extension of approval for the alli 60 mg Hartl's PSURs every 6 months, then for two years of annual and after all three years."</seg>
<seg id="2552">"not use, • If you are under 18, • If you are pregnant or breastfeeding, • If you have pregnant or other blood diluted, • If you have warring or other blocking (condition of the liver, if you have been bothered on organs (illness of the liver, if you have problems with the food intake, if you have problems with the food intake (chronic painting)."</seg>
<seg id="2553">"• take three times a day with every main meal, the fat includes one capsule with water. • You should take once daily, before bedtime, a multivitamintablette (with the Vitamins A, D, E and K). • You should not apply any longer than 6 months."</seg>
<seg id="2554">"application: • take three times a day with every main mahlist the fat includes, a capsule with water. • You should take once daily, before bedtime a multivitamintablette (with Vitamins A, D, E and K). • You should not apply any longer than 6 months."</seg>
<seg id="2555">"maybe you would like to read this later again. • If you need your doctor or pharmacist, if you need more information or advice. • If you have no more weight reduction, ask a doctor or pharmacist to advice."</seg>
<seg id="2556">"maybe you have to end the intake of alli. • If any of the listed side effects you have considerably impaired, or do not notice any side effects that are not listed in this usage information, please inform your doctor or pharmacist."</seg>
<seg id="2557">What do you need to consider before taking alli? • alli must not be used • The intake of alli is required • At intake of alli with other medicines • At intake of alli with food and drinks • pregnancy and breastfeeding • transport and use of machines 3.</seg>
<seg id="2558">How is alli take? • How can you prepare your starting point? o select your starting point for your weights? o adults from 18 years o How long should i take alli? o If you have alli taken into great quantities o If you have forgotten the intake of alli 4.</seg>
<seg id="2559">Which side effects are possible? • serious side-effects • Very frequent Effects • Frequent Side Effects • Frequently Effects • Frequently effects on blood tests • How can you control the nutrient-related requirements?</seg>
<seg id="2560">Further information • What alli contains • How alli contains and contents of the pack • pharmaceutical companies and manufacturers • Additional helpful information</seg>
<seg id="2561">Alli serves the weight reduction and is used for overweight adults from 18 years with a Body-Mass Index (BMI) of 28 or above. alli should be used in conjunction with a fat and calorie diet.</seg>
<seg id="2562">The BMI helps you to determine whether you have a normal weight in proportion to your body size.</seg>
<seg id="2563">"even though these diseases initially do not cause you to feel uncomfortable, you should nevertheless ask your doctor to ask for a checkup."</seg>
<seg id="2564">"for each 2 kg body weight you can decrease within a diet, you can lose an additional kilograms with the help of alli."</seg>
<seg id="2565">"please inform your doctor or pharmacist if you are taking other medicines or have recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="2566">Ciclosporin is used for organtransplants in severe rheumatoid arthritis and certain severe dental diseases. • Warwick in or other drugs that have a bleeding effect.</seg>
<seg id="2567">Orale receptioncontraception and alli • The effect of oral adorating means to the pregnancies (pill) will be disguised or lifted if you have strong diarrhö (diarrheel).</seg>
<seg id="2568">Please contact your doctor or pharmacist if you are: • Amiodaron to treat cardiac arrhythmia. • Acarbosis to treat diabetes.</seg>
<seg id="2569">"ask your doctor or pharmacist if you take alli, and if you need medicines for hypertension, since possibly the dosage needs to take care of a high cholesterol level, since possibly the dosage needs to be adjusted."</seg>
<seg id="2570">How to define your calorienziele and fettoberment you can find out more information on the blue sites in section 6.</seg>
<seg id="2571">"if you leave a meal or a meal contains no fat, you do not take capsel. alli can only work if the food is fat."</seg>
<seg id="2572">"if you are taking the capsule in combination with a meal, that contains too much fat, risk-borne creases (see section 4)."</seg>
<seg id="2573">"to get your body to the new eating habits, you start already before the first capsule with a kalorie- and fatty-induced diet."</seg>
<seg id="2574">"nutritional supplements are effective as you can redone at any time, what you eat, how much you eat and it is likely to make you easier to change your dietary habits."</seg>
<seg id="2575">"to achieve your target weight, you should define in advance two daily goals: one for calories and one for fat."</seg>
<seg id="2576">"• nourish yourself well-induced to reduce the probability for nutritionists (see section 4). • Try to move more, before you start with the intake of the capsules."</seg>
<seg id="2577">Remember in advance your doctor if you are not familiar with physical activity. • Stay you are not active during intake and also after ending the intake of alli physically active.</seg>
<seg id="2578">• alli may not be taken longer than 6 months. • If you can notice after twelve weeks use of alli no reduction of your weight, please ask your doctor or pharmacist to advice. "</seg>
<seg id="2579">"under circumstances, you must end the intake of alli. • At a successful weights, it is not about to return the diet and return to the old habits."</seg>
<seg id="2580">"• If less than an hour has passed since the last meal, get the intake of Kapsel. • If more than an hour since the last meal have passed, do not take a capsule one."</seg>
<seg id="2581">"blocking, with and without öligem discharge, sudden or more multiplumped and soft chair) are due to the working mechanism (see section 1)."</seg>
<seg id="2582">"severe allergic reactions • severity allergic reactions can be seen in the following changes: severe respiration, welds, rampes, itching, juices in the face, heart racks, circuits."</seg>
<seg id="2583">"29 Very frequent unwanted side effects These can take in more than 1 of 10 people, the alli take the sudden chair, a sudden chair • soft chair • soft chair, watch your doctor or pharmacist, if one of these side effects can be strengthened or impaired them considerably."</seg>
<seg id="2584">"frequent Effects These can take part in 1 of 10 people, the alli take, occur. • Mag- (pancre-) aches, • Incontinence (chair) • Incontinence (chair) • Incontinence Reconciliation • Encoder informing your doctor or pharmacist, if one of these side effects can be strengthened or impaired them considerably."</seg>
<seg id="2585">Effects on blood tests It is not known as often these effects occur. • an increase of specific liver disease • effects on blood circulation in patients that take warring or other blood-damage (antikoaguliish) medicines.</seg>
<seg id="2586">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="2587">"the most common side effects depend on the mode of the capsules, and thereby arise that vert fat from the body will be off."</seg>
<seg id="2588">These side effects normally occur within the first week after treatment at the beginning of a treatment at this time, as you have not yet been reduced the liposuction content in the diet. "</seg>
<seg id="2589">"with the following rules you can learn to minimize the food-related assessment: • Beginning you already spent some days, or better a week prior to the first intake of capsules with an fatty-induced diet. • learn more about the usual obesity of your favorite foods and over the size of the portions that you normally have to take."</seg>
<seg id="2590">"if you know exactly how much you eat, decrease the likelihood you out of understanding your liposable limit. • Connect your recommended liposuction on daily meals."</seg>
<seg id="2591">"save the amount of calories and fat that you are allowed to take a meal, not to take them in the form of a fat range or to take it in other programs for weight reduction. • Most of those who may occur in other programs for weight reduction, they learn to control them with time through adaptation of their diet."</seg>
<seg id="2592">• The medicines for children can not be accessed. • You may not apply alli after the expiry date. • Not over 25 ° C. • The bottle contains two white sealed containers with Silicagel who serve to serve the capsules trough.</seg>
<seg id="2593">"if you do not waste this in any case. • You can guide your daily dose alli in the blue chain box (shuttle), which is attached to this package."</seg>
<seg id="2594">"FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">Obesity has influence on your health and increases the risk for the emergence of various serious diseases such as: • Bluthochmarking • Diabetes • Excellent cancer diseases • Osteoarthritis • Osteoarthritis talk to your doctor about your risk for these diseases.</seg>
<seg id="2596">"a lasting weights, for example by improving the diet and more movement, the discharge of serious illness can Prevention, and has a positive influence on your health."</seg>
<seg id="2597">"choose meals that contain a wide range of nutrients, and learn to and to nourish permanently healthy."</seg>
<seg id="2598">Energy is also measured in kilojoule which you can also find as indication of packaging of food. • The recommended calorie intake is how many calories you should take a maximum of per day.</seg>
<seg id="2599">"note the further down in this section tables. • The recommended fat range in grams is the maximum amount of fat, which you should take with every meal."</seg>
<seg id="2600">"which quantity is suitable for you, take the below information that is suitable for you, which is suitable for you. • The background of the function of the capsule is decisive."</seg>
<seg id="2601">"if you take the same amount of fat, as before, this can mean that your body can not process this amount of fat."</seg>
<seg id="2602">"through compliance with recommended fat fat you can maximize the weights and at the same time, the probability for serious losses. • You should try to gradually increase gradually."</seg>
<seg id="2603">"34 These reduced calorie intake, it should allow you to be gradually losing about 0,5 kg per week to weight without having fruit and disappointments."</seg>
<seg id="2604">"the more active you are, the higher is your recommended calorie intake. •" "righteous physical activity" means that you can work daily or other physical activity. • "" Medium Physical activity "means, e.g. by moving daily 150 kcal, 30- to 45-minute gardening or 2 km running in 15 minutes."</seg>
<seg id="2605">• For permanent weights of weight it is necessary to put themselves realistic calorie and liposal goals and to keep it too. • meaningful is a nutritional logbook with information on calorie and obesity of your meals. • Entry to move more before you begin with the intake of alli.</seg>
<seg id="2606">"the alli program to support the weights combines the capsules with a nutritional plan and a large number of other information materials that can help you to nourish, and fetal induced to nourish and guidelines to become physically active."</seg>
<seg id="2607">"in conjunction with a customized program to support the weights, you can help you develop a healthier lifestyle and achieve your target weight."</seg>
<seg id="2608">Aloxi is used by chemotherapy (as Cisplatin) as well as in chemotherapy (such as Cisplatin) as well as in chemotherapy (like cyclophosphamid, Doxorubicin or carboplatin). "</seg>
<seg id="2609">The effectiveness of Aloxi can be used by the additional Gabe of an Corticosteroids (a medicine that can be used as an antiemetics).</seg>
<seg id="2610">The application for patients under 18 years of age is not recommended as to the effects in this age group is not enough information.</seg>
<seg id="2611">"this means that the ingredient of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as a serotonin) to the receptors in the intestine."</seg>
<seg id="2612">Aloxi was investigated in three main studies of 1 842 adults who received chemotherapies which are strong or excessive trigger for nausea and vomiting.</seg>
<seg id="2613">"in chemotherapy, the strong trigger for exercise and exciters have been treated in 59% of patients who were treated with Aloxi, in the 24 hours after chemotherapy, in the 24 hours of chemotherapy (132 of 223), to 57% of the Ondansetron treated patients (126 of 221)."</seg>
<seg id="2614">"in chemotherapies, the moderate saviour for nausea and omiting, 81% of patients treated with aloxi, in the 24 hours after chemotherapy (153 of 189), opposite 69% of the Ondansetron treated patients (127 of 185)."</seg>
<seg id="2615">With a comparison with Dolasetron these values at 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">"March 2005, the European Commission launched in Helsinki Birex Pharmaceuticals Ltd. a permit for the establishment of Aloxi in the entire European Union."</seg>
<seg id="2617">Aloxi is indiated: to the prevention of accounterfeiting and vomiting at strong emetogener chemotherapy due to cancer disease and for the prevention of nausea and vomiting at moderate agetogener chemotherapy due to a cancer disease.</seg>
<seg id="2618">The effectiveness of Aloxi to the prevention of nausea and vomiting that is inducted by a strong emetogenic chemotherapy by adding an before chemotherapy given Corticosteroids.</seg>
<seg id="2619">"since Palonosetron, the Thonosetron can prolonging patients with anamnesty obstipation or signs of an subtle Ileus after injecting injections."</seg>
<seg id="2620">"however, as with other 5HT3-antagonists, however, caution is offered at equal gift of Palonosetron with pharmaceuticals which prolonged the QT interval or in patients where the Qt- interval is extended or which is up to such a renewal."</seg>
<seg id="2621">"except in connection with another chemotherapy, Aloxi should neither be used in the days after chemotherapy, nor for the treatment of nausea and testing."</seg>
<seg id="2622">"in Preclinical trials inhibits Palonosetron the against tumors aligned chemotherapeutics not (Cisplatin, Cyclophosphamid, Cytarabin, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">"in a clinical trial, no significant pharmacoinetic interaction between a unique intravenous dose of Palonosetron and a steady-stat- concentration of a CYP2D6-Inhibitors."</seg>
<seg id="2624">"in one of a population of pharmacoinetic analysis was shown that the simultaneous gifts of CYP2D6-Inhibitors (Amiodaron, Celoxetine, oxoxetine, agoxetine, Chinonavir, seroxaline, seroxaline, seroxaline, seroxaline, seroxetine, seroxetine, seroxetine, and Terbinocin) has no significant impact on the Clearance of Palonosetron."</seg>
<seg id="2625">"experience on the use of Palonosetron in human pregnancies can not be applied, therefore Palonosetron in pregnant women should not be applied, unless it is necessary by the patient doctor."</seg>
<seg id="2626">"in clinical studies were the most common in a dose of 250 micrograms to observable side effects (total 633 patients), which at least possibly with aloxi in connection stood, headache (9%) and Obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10.000) of oversensitivity, realizations and reactions on the administration of the place (burning, curing, complaints and pain) were reported in post-marketing experiences."</seg>
<seg id="2628">In the group with the highest dosage shown similar frequencies of unwanted events as in other dosing groups; there were no dose-ingredient relationships to observe.</seg>
<seg id="2629">"there were no Dialysis studies, due to the large distribution volume, a dialysis is probably not effective therapy with an Aloxi- overdose."</seg>
<seg id="2630">"in two randomised double-previous studies were reported a total of 1,132 patients, which received a moderate emetogenic chemotherapy with ≤ 50 mg / m2 Cycloogetron, with patients compared to the 32 mg Ondansetron (half-hour 7,3 hours), which was given to day 1 without the Dexamethason intravenously."</seg>
<seg id="2631">"in a randomised double-previous study, a total of 667 patients, which were a strong emetogenic chemotherapy with ≥ 60 mg / m2Cisplatin, &gt; 1,500 mg / m2 Cyclophosphamid and Dacarbazine and 250 or 750 micrograms of Palonosetron, with patients compared to the 32 mg Ondansetron that were given to day 1 intravenous."</seg>
<seg id="2632">Results of studies with default emetogener chemotherapy and the study with strong emetogener chemotherapy are summarized in the following tables.</seg>
<seg id="2633">In clinical studies for the indications of chemical chemotherapy (CINV) were the effects of Palonosetron in blood pressure, heart rate and ECG parameters including the corresponding effects of Ondansetron and Dolasetron. "</seg>
<seg id="2634">According to the evidence of clinical investigations Palonosetron has the ability to block the Ioncological De- and Repolarisation of the Ionenkanals and extend the duration of the action potential.</seg>
<seg id="2635">"the aim of the study conducted at 221 healthy Propositions, the evaluation of the ECG-effects of i.v. administered Palonosetron in single parts of 0,25, 0,75 and 2,25 mg."</seg>
<seg id="2636">Resorption After intravenous gift follows an initial withdrawal of Plasmaconconcentrations a slow elimination of the body with an average terminology of about 40 hours.</seg>
<seg id="2637">The average maximum Plasmaconconcentration (Cmax) and the area under the Concentration period (AUC0- ∞) are generally in the entire dosage range of 0.3- 90 μ g / kg in gestion and cancer victims doses.</seg>
<seg id="2638">"after intravenous gifts of Palonosetron 0,25 mg every second day for a total of 3 cans, the average of the Palonosetron-Plasmaconconcentration at 42 ± 34%."</seg>
<seg id="2639">"from pharmacoinetic simulations is emphasized that at once daily Gabonosetron in 3 consecutive days reached total frequency (AUC0- ∞) with the following unique intravenous objection of 0,75 mg. however, the Cmax after the deposits of 0,75 mg was higher."</seg>
<seg id="2640">About 40% are eliminated via the kidneys and some more 50% are converted into two primary metabolic metabolic on less than 1% of the antagonistic effect on 5HT3 receptor.</seg>
<seg id="2641">"in-vitro studies for metabolic, showed that CYP2D6 and, in reduced dimensions, the Isoenzme CYP3A4 and CYP1A2 at the Metabolism of Palonosetron."</seg>
<seg id="2642">"Elimination After a intravenous single dose of 10 micrograms / kg [14C] -Palonosetron have been found approximately 80% of the dose within 144 hours in the Urine, Palonosetron, made about 40% of the given dose."</seg>
<seg id="2643">According to a unique intravenous bolt in Healthy was the total of 173 ± 73 ml / min and the renal Clearance 53 ± 29 ml / min.</seg>
<seg id="2644">"in patients with severe liver functioning, the terminale Eliminationshalbeit and the average systemic exposure with Palonosetron increases, a reduction of the dosage is thus not justified."</seg>
<seg id="2645">"in clinical studies have been observed only according to expositions, which is considered sufficient over the maximum human therapeutic exposure, which indicates a low relevance for the clinical use."</seg>
<seg id="2646">10 out of preclinical trials made evidence that Palonosetron can only block in very high concentrations Ionenkancies who are involved in ventricular de- and Repolarisation and can extend the action-level duration.</seg>
<seg id="2647">"high cans of palonosetron (each dosage corresponded in about the 30zzle of the therapeutic exposition in humans), which were given daily over two years, led to a multiplied incidence of Lebertas, pituitary, Pankreas, Sankreas, Sankreas, not with mice, but not with mice."</seg>
<seg id="2648">"the underlying mechanisms are not completely known, but due to the used high doses and since Aloxi is determined by humans for a unique application, the relevance of these results are being low for man."</seg>
<seg id="2649">"the owner of this approvals for the law must inform the European Commission on the plans for the company, in the context of this decision approved."</seg>
<seg id="2650">"• If any of the listed unwanted effects you have considerably impaired, or do not notice any side effects that are not specified in this usage information, please inform your doctor."</seg>
<seg id="2651">"• Aloxi is a clear, colourless injection solution for injecting in an Vene. • The ingredient (Palonosetron) is part of a group of drugs used as serotonin- (5HT3-) Antagonists, which may cause the effect of a serotonin beading chemical substance, which may occur in connection with chemotherapy due to cancer."</seg>
<seg id="2652">21 At the application of Aloxi with other medicines please inform your doctor if you are taking other medicines or have recently taken / applied or recently as it is not prescription-prescription medicine.</seg>
<seg id="2653">"pregnant If you are pregnant or believe, pregnant will your doctor will not give you Aloxi, unless it is clear."</seg>
<seg id="2654">Ask before taking all pharmaceuticals to your doctor or pharmacist to advice if you are pregnant or believe, pregnant. "</seg>
<seg id="2655">In some very rare cases it came to allergic reactions to Aloxi or to burning or pains at the entrance site.</seg>
<seg id="2656">"like Aloxi and the contents of the Packing Aloxi injection solution is a clear, colourless solution and is available in a package with 1 flowmeter made of glass, which contains 5 ml of the solution."</seg>
<seg id="2657">"heavy-duty-duty-duty-duty-duty-duty-duty-sufficient-level-level-level-level-level-level-sufficient-level-level-level-level-level-level-level-level-level-level-level-level-care)," "10 Сancy-weight care]" "10 Сancy-weight care]" "10-minded people" "sleep". ": + 359 2 975 13 95 (6)"</seg>
<seg id="2658">Latvija Pharmacy | 54-5: ertration of the Street Riga, LV-1011 Tel: + 37167502185 Lietuva uab PharmaSwiss-eimyniš. "</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK phone: + 44 1244 625 152</seg>
<seg id="2660">"in June 2006, the Committee for Humanity (CHMP) have been a negatives, in which the affirmation of the approval for the use of hepatitis C intended to treat hepatitis C to the treatment of hepatitis C 6 million IE / ml injection solution was recommended."</seg>
<seg id="2661">This means that Alpheon developed a biological medicine called Roferon-A with the same quartz effective component should already be approved in the EU (also "Reference Frame").</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long half) hepatitis C (one through a viral infection).</seg>
<seg id="2663">"in a microscopic investigation, the Lebanese damage shows the liver tissue damage, in addition, the values of the Living enzymms Alanin- Aminotransferase (ALT) increases in the blood of the standard."</seg>
<seg id="2664">"it is produced by a yeast, in which an gene (DNA) has been brought to the formation of the ingredient."</seg>
<seg id="2665">"the manufacturer of Alpheon placed data to compare the comparison of alpheon with Roferon-A (active structure, composition and purity of pharmaceuticals, effectiveness, safety and effectiveness in hepatitis C)."</seg>
<seg id="2666">In the study on patients with hepatitis C the effectiveness of alpheon was compared with the effectiveness of reference to 455 patients.</seg>
<seg id="2667">"in the study, how many patients were measured from a total of 48 treatment weeks as well as 6 months after setting up the treatment to the drug admins (d. h. no signs of the virus in the blood)."</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int</seg>
<seg id="2669">"furthermore, concerns have raised concerns, that the data on the stability of the ingredient and the market will not be exerted."</seg>
<seg id="2670">"the number of patients with hepatitis C, which focused on treatment with alpheon and Roferon-A to the clinical study was similar."</seg>
<seg id="2671">After setting the treatment with alpheon flame retarded the disease with more patients back than in the reference process; it also had alpheon more unwanted effects.</seg>
<seg id="2672">"apart from that, in the study the test results for the examination of the question, the drug is a immune response (d. h. the body forms antibodies - special proteins - against drugs) trigger, not sufficiently validated."</seg>
<seg id="2673">It can be applied to the treatment of Impetigo (one with crushing skin infection) and small inficated Lazerations (risk or intersections).</seg>
<seg id="2674">"altargo is not to be used for treating infections, which were verifiable or probably caused by methicillinresistant sthylococcus aureus (MRSA), because Alargo against this type of infections may not work."</seg>
<seg id="2675">"altargo may be applied in patients from the age of nine months, but for patients under 18 years of age may not exceed 2% of the body surface."</seg>
<seg id="2676">"if the patient is not talking about two to three days, the doctor should examine the patient again and consider alternative treatments."</seg>
<seg id="2677">It works by block the bacterial stbosomes (the parts of the bacterial which are produced and inhibits the growth of bacteria.</seg>
<seg id="2678">The main indicator of the effectiveness was carried out in all five studies of the proportion of patients whose infection was elaborated after the end of the treatment.</seg>
<seg id="2679">119 (85.6%) of 139 patients under Altargo and 37 (52.7%) of the 71 patients under placebo spoke to the treatment.</seg>
<seg id="2680">"in the treatment of infected Hautwences, Altargo and Cefalexin similar response: if the results of both studies have been assembled in Hautwund, talked about 90% of the patients of both groups to the treatment."</seg>
<seg id="2681">"however, in these two studies however, however, that Altargo was caused by the treatment of obscene (eirecated holograms in the body-tissue) or of infections that were subsequently caused by MRSA, not effective enough."</seg>
<seg id="2682">The most common secondary effect with altargo (which was observed in 1 to 10 of 100 patients) is a maturity of the client.</seg>
<seg id="2683">"the Committee for Humanity is lifted up to the conclusion that the benefits of Altargo in the short-time treatment of the following superficial skin infections compared to the risks, • Impetigo, • ininfected small Lazations, deterrent or seated wounds."</seg>
<seg id="2684">"in May 2007, the European Commission sent to the Glaxo Group Ltd. a permit for the intimacy of the Altargo to the entire European Union."</seg>
<seg id="2685">Patients with which shows no improvement within two to three days should still be examined and an alternative therapy should be considered (see section 4.4).</seg>
<seg id="2686">"in the event of a sensitizing or heavy local irritation by applying retapamulin Salbe, the treatment is supposed to be carefully checked and an adequate alternative treatment of the infection."</seg>
<seg id="2687">Retapamulin should not be used to treat infections in which MRSA is known as Erreger (see section 5.1).</seg>
<seg id="2688">In clinical trials in secondary open wounds was the effectiveness of retapamulin in patients with infections caused by a Methicillin resistance and hylococcus aureus (MRSA) were insufficient.</seg>
<seg id="2689">"an alternative therapy is supposed to be considered, if after a 2- to 3-day treatment no improvement or deterioration of the infected place occurs."</seg>
<seg id="2690">The effect of the simultaneous use of retapamulin and other topical resources on the same skin space has not been investigated and the simultaneous application of other topical medicines is not recommended.</seg>
<seg id="2691">"due to the small plasmacia concentrations, which were achieved for topical application on abed skin or infected superficial wounds, is a clinically relevant inscription in vivo (see section 5.2)."</seg>
<seg id="2692">3 After simultaneous Gabe of 2 times a day 200 mg Ketoconazol increased the middle retapamulin AUC (0-24) and Cmax to topical application of 1% retapamulin salbe on abed skin of healthy grown men around 81%.</seg>
<seg id="2693">"due to the low system exposure to topical application in patients, dosage adjustment is not kept required when topical retapamulin during a systemic treatment with CYP3A4 Inhibitors."</seg>
<seg id="2694">Animal studies have shown a reproduction of reproductive medicine and are insufficient in relation to a statement on the birth and the octal / postnatal development (see Section 5.3).</seg>
<seg id="2695">Reapamulin Salbe should only be used during pregnancy only if a topical anti-bacterial therapy is clearly indicative and the use of reapamulin the gift of an systematic antibiotic.</seg>
<seg id="2696">"when deciding whether the breastfeeding is continued / ended or the therapy with Altargo continues, is between the benefit of stables for the baby and the benefit of the altargo therapy for the woman."</seg>
<seg id="2697">"in clinical studies of 2150 patients with superficial skin infections, the altargo was used, the most commonly reported secondary effect of irritation at the end of the place, which is about 1% of the patients."</seg>
<seg id="2698">"mode Retapamulin is a semi-synthetic derivative of Pleuromutilin, a substance that is isolated by Fermentation from Clitopilus passeckerianus (formerly Cheurotus passeckerianus)."</seg>
<seg id="2699">The hosts of Retapamulin is based on the selective imitation of bacterial protein synthesis through interaction at a certain bond of the 50S subunit of bacterial Ribosoms which differs from the bond forms of other ribosomal interruptive antibacterial substances.</seg>
<seg id="2700">Data point out that the bond is involved in Bosbosomales protein L3 and lies in the region of the ribosomales P-binding place and the Peptidyltransferasezentcentre.</seg>
<seg id="2701">"by connecting to this bindings inhibit Cheuromutiline the PeptidylTransfer, block partial P-binding and prevent the normal formation of active 50S ribosomal elevators."</seg>
<seg id="2702">"should be conceived on the basis of the local prevalence of resistance to the use of reapamulin at least some infectious forms, a consultation by experts should be targeted at least."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of retapamulin towards S.aureus, regardless of whether the isolates were delicate or resistant to methicillin."</seg>
<seg id="2704">In case of failure to treat S.aureus should be considered the presence of tribes with additional virus factors (like PVL = Panton-Valentine Leucocidin).</seg>
<seg id="2705">Resorption In a study with healthy adults was placed 1% retapamulin Salbe daily under occlusion on intact and decreased skin for up to 7 days.</seg>
<seg id="2706">"516 patients (adults and children), the 1% retapamulin Salbe twice daily for 5 days to topical treatment of secondary traumatic wounds, were obtained individual plasmaple."</seg>
<seg id="2707">The sampling was made in the days 3 or 4 in adult patients before the surgery and the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual systemic intake in people after topical application of 1% Salbe at 200 cm2 abed skin (Cmax = 22 ng / ml; AUC (0-24) = 238 ng · h / ml) 660-time lower than the retapamulin IC50 for the PGP shirt."</seg>
<seg id="2709">Metabolism The in vitro oxidative Metabolism of Retapamulin in humanen Lebermikrosomen was created by CYP3A4, under the lowest participation of CYP2C8 and CYP2D6 (see Section 4.5). "</seg>
<seg id="2710">"in studies on oral toxicity (50, 150 or 450 mg / kg) that were carried out over 14 days, there were signs of adaptive liver and thyroid changes."</seg>
<seg id="2711">In-vitro-review on genmutation and / or chromosomale effects in the mouse-Lymphoma test or in cultures of human peripheral bleeding bleeding as well as in the rats microscopes for in-vivo-examination chromosomal effects.</seg>
<seg id="2712">"there were neither male nor female signs of reduced stocks of 50, 150 or 450 mg / kg / day, which has achieved up to 5 times higher exposure to people (topical application on 200 cm2 abed skin:"</seg>
<seg id="2713">"in an embryonic mode (see above), at oral doses of ≥ 150 mg / kg / day (according to the ≥ 3-folding of the estimated human exposure (see above)), development stoxizarity (decreased body weight of the fetus and delay Ossification) and maternal toxicity."</seg>
<seg id="2714">"the owner's holders must ensure that a Pharmakovigilet system must be present as in the module 1.8.1 of the authorisation item (Version 6.2) and works before the product will be marketed and as long as the marketed product will be used."</seg>
<seg id="2715">"the holders of the approval for the institute are obligated to perform detailed studies and additional pharmaovigilance plan as described in the version 1 of the Risk Management Plan (RMP), as well as all additional actualizations of the RMP, which are agreed with CHMP."</seg>
<seg id="2716">"as in the CHMP" "guideline on Risk Management Systems for Medicinal products for human use, is intended to be submitted with the next Periodic Safety Update Report."</seg>
<seg id="2717">"irritation or other signs and symptoms on the treatment place, you should end the use of Altargo and speak to your doctor."</seg>
<seg id="2718">"do not address other salben, creams or lotions on the area that will be treated with Altargo if it was not expressly arranged from your doctor."</seg>
<seg id="2719">"it must not be applied in the eyes, on the mouth or on lips, in the nose or in the female genital area."</seg>
<seg id="2720">"if the saline is seen from Versee on one of these surfaces, wash the place with water and ask your doctor to consult any complaints."</seg>
<seg id="2721">"after getting the Salbe, you can cover the affected area with a sterilen association or a Gazeverband, unless your doctor has not recommended you to cover the area."</seg>
<seg id="2722">"it is offered in a aluminum tube with a plastic clasp, the 5, 10 or 15 grams of Salbe, or in a aluminum bag, the 0,5 g salbe."</seg>
<seg id="2723">Ambirix is used to protect hepatitis A and hepatitis B (diseases which affect the liver) in children aged between one and 15 years that are not immun against these two diseases.</seg>
<seg id="2724">Ambirix is used as part of one of two doses existing vaccination with protection against hepatitis B possibly only after appointments the second dose is achieved.</seg>
<seg id="2725">"for this reason ambirix not only be used, if immunisation exists a little risk of hepatitis B infection, and is ensured that from two doses can be guided to the end of two dosing."</seg>
<seg id="2726">If a refresher dose against hepatitis A or B is desired, Ambirix or another hepatitis C or -B vaccine will be given. "</seg>
<seg id="2727">Vaccines take effect by raising the immune system (the natural defect of the body). "</seg>
<seg id="2728">"after a child has received the vaccine, recognises the immune system the virus and surface of anti-surface as a" foreign "and generates antibody against it."</seg>
<seg id="2729">Ambirix contains the same components as that since 1996 brought a Twin80 adults and since 1997 approved vaccine Twinars children.</seg>
<seg id="2730">"the three vaccines will be applied to the protection against the same diseases, however Twin80 adults and Twinrix children under one of three cans of existing vaccines will be applied."</seg>
<seg id="2731">"because Ambirix and Twinrix Adult identical ingredients, some of the data that supports the use of Twinrix adult, also used as cover for the use of Ambirix."</seg>
<seg id="2732">The main indicator for the effectiveness was the proportion of the spiritually children who had developed a month after the last injection.</seg>
<seg id="2733">"in an additional study with 208 children, the effectiveness of the vaccine was compared to an sixty-month and a 12-month distance between the two injections."</seg>
<seg id="2734">Ambirix led at between 98 and 100% of the spiritually children a month after the last injection for the development of protective antibodies against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection from Ambirix in a six-month and at a 12-month distance between injections was similar.</seg>
<seg id="2736">"the common side-side effects of ambirix (observed if more than 1 of 10 vaccine) are headache, appetite, appetite, pain on the injecting, redness, sailness (tiredness) as well as availability."</seg>
<seg id="2737">Ambirix is allowed to react in patients that may possibly be hypersensitive (allergic) to the agents, one of the other components or neomycin (an antibiotic). "</seg>
<seg id="2738">August 2002 the European Commission commissioned the company GlaxoSmithKline Biologicals s.a. a permit for the launch of Ambirix in the whole</seg>
<seg id="2739">The standardized plan for the Grundimmunisation with ambirix consists of two vaccinations and the first dose at the date of choice and the second dose between six and twelve months after the first dose is given.</seg>
<seg id="2740">"if a refreshing is required for hepatitis A as well as for hepatitis B, it can be covered with the corresponding monovalous vaccines or with a Combinational vaccination."</seg>
<seg id="2741">The anti-hepatitis with the Combination of anti-hepatitis C (anti-HBsAg) - and anti-hepatitis C-virus (anti-HAV) -antibodies are in the same size as after vaccination with the respective monoval vaccines.</seg>
<seg id="2742">"it is not yet fully backed whether immunomnified individuals who have addressed to a hepatitis A- vaccine as protection, as it may also be protected with no longer immeasurable antibodies possibly by the immunological memory."</seg>
<seg id="2743">3 As with all injuries should be available for the rare case of an anaphylaktic reaction after the gift of the vaccine appropriate possibilities of medical treatment and monitoring always immediately available.</seg>
<seg id="2744">"if a quick protection against hepatitis B is required, the standardized basis is recommended, the 360 ELISA units form formalinactivated hepatitis C-virus and 10 µg recombinant hepatitis B-surface."</seg>
<seg id="2745">"with Hematical patients and persons with disorders of the immune system, according to the Grundimerization under circumstances will not be achieved in the anti-HAV- and anti-hecular antibodies, so in these cases the gift of other vaccines can be required."</seg>
<seg id="2746">"as a intradermal injection or intra-muscular appointments in the gesture must lead to an subtle impferment, these injections should be avoided."</seg>
<seg id="2747">"at Thrombocytopenie or blood circulation, Ambirix cannot be injected, since it can occur in these cases to intra-muscular gift."</seg>
<seg id="2748">If Ambirix had passed in the second life of a separate injection at the same time with a combined diphtherie- and haemophilus, acellulhilus tae type b-vaccine (DTPa-IPV / hib) or with a combined mask, Mumps-Röteln-vaccine was enough, was the immune response to all antigens sufficient (see section 5.1). "</seg>
<seg id="2749">Patients on immunosuppressive therapy or in patients with immune defective must be gone out that may not be adequate immune response.</seg>
<seg id="2750">"in a clinical trial, which was conducted with 3 vaccines of this formulation in adults, the incidence of pain, redness, swelling, maternity, gastroenteritis, headaches and fever comparable to the frequency, which was observed in the former Thiomersal and preservative vaccination."</seg>
<seg id="2751">Clinical trials were founded by 2029 vaccine Ambirix on a total of 1027 vaccines at the age of 1 to including 15 years.</seg>
<seg id="2752">In a study with 300 participants in the age of 12 to including 15 years the compatibility of Ambirix had compared with the 3 doses Combinary elements.</seg>
<seg id="2753">"only exceptions were the higher frequency of pain and strength at a calculation basis for a vaccine basis for a vaccine basis, but not on a calculation basis for each person."</seg>
<seg id="2754">"pain was observed after the Gabe of Ambirix at 50.7% of the Probanden, compared to 39,1% in the probanden following the gift of a dose of 3 doses Combinations."</seg>
<seg id="2755">"after the complete vaccine-cycle 66,4% of the Probanden, the Ambirix failed to get over pain, compared to 63.8% in the Probanden, which were shrink with the 3-dos- Combination."</seg>
<seg id="2756">"the frequency of Matity was comparable (d. h. over the entire vaccine cycle at 39,6% of the Probanden, the Ambirix had compared to 36,2% at the Probanden, which received the 3-doses Combinations."</seg>
<seg id="2757">The prevalence pain and skill was small and comparable to that which was observed by appointment of the Combinary vaccination with the 3 doses vaccines.</seg>
<seg id="2758">"in a comparative study at 1- until 11-year vaccine, the occurrence of local reaction and general respondents in the Ambirixgroup was comparable to that with the 3-doses combined with 360 ELISA units and the 10 µg recombinant hepatitis C-surface."</seg>
<seg id="2759">"however, at the 6- until 11- Jew, however, after vaccination with Ambirix was a most common appearance of pain (at injections) per dose, not per proband."</seg>
<seg id="2760">The proportion of vaccines that have heavy side effects during the 2-cans vaccines with Ambirix or during the 3-cans vaccines with 360 ELISA- units formalinactive hepatitis C-virus and 10 µg recombinable hepatitis C-surface-surface was statistically not different.</seg>
<seg id="2761">"in clinical trials that were carried out at vaccines at the age of 1 to including 15 years, the Seroconversionates for anti-HAV 99.1% a month after the first dose and 100% a month after the second, for month 6 administered dosage (d. h. in month 7)."</seg>
<seg id="2762">The Seroconversionary for anti-hbs were 74.3% a month after the first dose and 100% a month after the second to month 6 administered dosage (d. h. in month 7).</seg>
<seg id="2763">"7 In a comparative study, which was carried out at 12- until including 15-year-old, 142 two cans of Ambirix and 147 the standard combined combination with three doses."</seg>
<seg id="2764">"with the 289 persons whose immunity was worthwhile, the Seroprotection rates (SP in the table below) against Hepatitis B in the month 2 and 6 to Gabe of the 3 dosages, significantly higher than with Ambirix."</seg>
<seg id="2765">"the immune answers that have been achieved in a clinical comparison study at 1- to 11-year-, one month after completion of the full vaccine series (i.e. in month 7), are listed in the following table."</seg>
<seg id="2766">In both studies the vaccines got either a 2-cans-vaccines with ambirix or one 3-cans-vaccines with a Combine blades with 360 ELISA units and 10µg recombinant hepatitis C-surface.</seg>
<seg id="2767">"in people who were at the time of Grundimmunonization between 12 and 15 years old, the persistence of anti-HAV- and anti-hbs had been proven about at least 24 months after the immunisation of Ambirix in the 0-6-month vaccine."</seg>
<seg id="2768">"the immune response against both antigens was comparable with that, which corresponds to vaccination of 3 cans with a combined heat pump, consisting of 360 ELISA units. formalinactive hepatitis B-surface in a dosisvolume of 0,5 ml."</seg>
<seg id="2769">In a clinical study at 12- until including 15-year-old could be shown that the persistence of anti-HAV- and anti-hbs-antibodies can be compared to immunisation in the 0-6- months vaccine.</seg>
<seg id="2770">If the first dose ambirix in the second life is at the same time with the refreshing poistherie- and 8 Haemophilus and 8 Haemophilus and 8 Haemophilus (DTPa-IPV / hib) or with the first dose of a combined mascot-cops vaccine was sufficient for all antigens.</seg>
<seg id="2771">A clinical trial which was conducted with 3 cans of the current formulation in adults showed for the current formulation similar servo rotection and seroconversionary as for earlier formulation.</seg>
<seg id="2772">The vaccine is both before and after the restrays per testimony of the external particles and / or physical visible changes.</seg>
<seg id="2773">"according to Article 114 of the Directive 2001 / 83 / EC amended version, the state-release of a state laboratory or one for this purpose authorized laboratory."</seg>
<seg id="2774">14 Data AUF THE OFFSPRITZE OHNE needle 1 FERTIGSPRITZEN OHNE Nadeln 10 FERTIGSPRITZEN OHNE Nadeln</seg>
<seg id="2775">Suspension for injection 1 ready-sprayer with needle 10 ready-sprayer with needle 10 ready-spraying without needles 50 ready-spraying without needles 1 dosage (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 Completed without needle EU / 1 / 02 / 224 / 003 10 Completed without needles EU / 1 / 02 / 224 / 005 50 ready-spraying without needles</seg>
<seg id="2777">"hepatitis C-virus is usually transmitted by virushales foods and beverages, but can also be transmitted by other ways such as swimming in through waste water purified waters."</seg>
<seg id="2778">"you can feel very tired, have a dark Urine, a blue face, yellow skin and / or eyes (yellowing) and other symptoms that may make a stationary treatment necessary."</seg>
<seg id="2779">"as with all vaccines Ambirix cannot protect completely before an infection with hepatitis C or hepatitis B virus, even if the complete vaccine has been completed with 2 doses."</seg>
<seg id="2780">If you are already infected with hepatitis A- or hepatitis B-virus (although you / your child can not feel unlikely or sick / feel) a vaccination could not prevent any disorder.</seg>
<seg id="2781">"a protection against other infections that cause the liver compensate or symptoms that are similar to those after a hepatitis C or hepatitis C infection, cannot be conveyed."</seg>
<seg id="2782">• If you have already been an allergic reaction to ambirix or any component of this vaccine including Neomycin (an antibiotic).</seg>
<seg id="2783">An allergic reaction can be caused by jucking rashes or obstruction of the face or the tongue. • if you have occurred an allergic reaction to an earlier vaccination against hepatitis A or hepatitis B. • If you have a severe infection with fever before you / your child.</seg>
<seg id="2784">"• If you wish to have a protection against hepatitis B (i.e. within 6 months, and prior to the tender of the second vaccine)."</seg>
<seg id="2785">With a possible risk of infection with hepatitis B between the first and second impaires the doctor will advise you / your child from a vaccine with ambirix.</seg>
<seg id="2786">"instead, he will recommend you / your child 3 injections of a combined Hepatitis B and hepatitis B vaccine (360 ELISA units of an formal hepatitis C-virus and 10 micrograms of a recombinant hepatitis C-surface-surface)."</seg>
<seg id="2787">The second vaccination of this vaccine with reduced loss of effective components is usually given a month after the first dose and should give you a vaccine before end the vaccine.</seg>
<seg id="2788">"sometimes Ambirix is suffering from persons who suffer from heavy blood circulation, under the skin and not in the muscle tissue. • If you are captivating your child because of a disease or treatment in your own physical waste."</seg>
<seg id="2789">Ambirix can be given in these cases but the immune response to these people can not be sufficiently needed so that a blood test can be necessary to see how strong the reaction to vaccination is.</seg>
<seg id="2790">21 Save you to your doctor if you have received your child further medicines (including those who have received without casing) or if you have recently received it or Immunglobulins (antibodies) or has planned or this is planned in the near future.</seg>
<seg id="2791">But it can be that in this case the immune response to the vaccine is not sufficient and the person is therefore not protected against one or both hepatitis A and B viruses.</seg>
<seg id="2792">"if another vaccine should be given simultaneously with ambirix, should be covered in separate places and as possible as possible different limbs."</seg>
<seg id="2793">"if Ambirix should be administered at the same time or shortly before or after an injection of immunoglobulins, it is likely that the reaction to the vaccine is still sufficiently sufficient."</seg>
<seg id="2794">"usually, ambiance is not administered or nursing women, except there is urgent need to be covered both against hepatitis A as well as hepatitis B."</seg>
<seg id="2795">Important information about certain other components of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (Antibiotic).</seg>
<seg id="2796">"if you miss the agreed appointment for the second vaccine, talk to your doctor and arrange a new date as soon as possible."</seg>
<seg id="2797">♦ very frequent (more than 1 case per 10 verimpfans doses): • pain or discomfort at the single site or redness • Mature • Disability • Headache • Apply • Apceration</seg>
<seg id="2798">♦ frequently (up to 1 case per 10 verimpfans doses): • swelling on the injections • fever (over 38 ° C) • Benefness • gastric intestinal complaints</seg>
<seg id="2799">"other side effects, the days or weeks after vaccination with comparative Combine and hepatitis B very rare (less than 1 case per 10,000 verimprinted doses) have been reported:"</seg>
<seg id="2800">"these include only limited or extended outlet, the itching can be or blown-shaped, swelling of the eypartitions and of the face, scores breath or swallowing, sudden blood pressure and consciousness."</seg>
<seg id="2801">"flu-similar complaints, including Schüttelfrost, muscle - and joints, crindules, missilings such as tingling, loss of sensation or movement ability, counter parts, strong headache and stiffness of Nude, interruption of normal brain functions"</seg>
<seg id="2802">Ohnness disguises blood vessels, impairness or disease-esteem, disinflessness, diarrlessness, diarrlessness, diarrflness and blood-pain changed the inclination to bleeding or to Blutergens (blue spots), caused by waste of blood circulation. "</seg>
<seg id="2803">"23 Informing your doctor or pharmacist, if any of the listed unwanted side effects you have considerably impaired or you have side effects that are not specified in this package."</seg>
<seg id="2804">Ambirix is available in packs to 1 and 10 with or without needles and in packs to 50 without needles.</seg>
<seg id="2805">"on the basis of the data, which has become known for issuing the first approval for the author, represented by CHMP the view that the benefit-risk-relationship for ambirix remains positively."</seg>
<seg id="2806">"however, Ambirix had only been placed in one member state (in the Netherlands since May 2003), the available security data for this medicine is limited to the small patient position."</seg>
<seg id="2807">Ammonium can also be used in patients at the age of more than a month with incomplete Enzymdefect or with hyperammonium encephalopathy (brain compensation) in the history of history.</seg>
<seg id="2808">Ammonite is divided into meals - divided into several retailers among meals - swallowed under the food mixed or through a neurologists (thanks to the abdominiquests in the stomach of the stomach) or a Nasensonde (by the nose in the stomach's leading hose).</seg>
<seg id="2809">It was not a comparative study since failing could not be compared with another treatment or with placebo (a rumediation medication that could be compared without agents).</seg>
<seg id="2810">"ammonium can also lead to appetite, a abnorful imrails in the blood, depression, bulbs, mansion, lifession, liferation, ramperation, ramperation, rash, unpleasing body weight or weight gain."</seg>
<seg id="2811">The Committee for Humanarzysts (CHMP) succeeded at the conclusion that fosaps in patients with disorders of the urinary cycle to high ammonium health precaution prevents effectively.</seg>
<seg id="2812">"ammonite was approved under" exceptional circumstances, as due to the rarity of the disease at the time of admission only limited information on this medicine. "</seg>
<seg id="2813">"the use is manifested in all patients, with which a complete endowl is already manifested in the newborn age (within the first 28 life age)."</seg>
<seg id="2814">"in patients with late manipulated form (incomplete Enzymdefect, which is manifested after the first life-month, then there is an indication for use when in anamnese is a hypertension enceptional encephalopathy."</seg>
<seg id="2815">"for infants, for children who are not able to swallow tablets or for patients with canyons, AMMONAPS is also available in granulatform."</seg>
<seg id="2816">The daily dose is calculated individually taking into account the protest tolerance and the development of the daily protections of the patient.</seg>
<seg id="2817">"after the previous clinical experience is the normal daily dose of sodium glycolic at: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day in children with a body weight above 20 kg as well as with herent and adults."</seg>
<seg id="2818">"in patients, who suffer from an early fixed lack of carbamylphosphate synthetase or Ornithintranscarbamylase, is the substitution of Citrullin or arginine in a dosage of 0,17 g / kg / day or 3,8 g / m ² / day required."</seg>
<seg id="2819">Patients with an argininosuccinatare lack of arginine in a dosage of 0.3 - 0.7 g / kg / day or 8.4 - 15.4 g / m ² / day.</seg>
<seg id="2820">"AMMONAPS tablets may not be administrated patients with canyons, as a risk for the creation of Ösophagusulzera, when the tablets reach no immediately into the stomach."</seg>
<seg id="2821">"each tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, according to 2.5 g (108 mmol) sodium per 20 g of sodium-butyrat, which corresponds to the maximum daily dose."</seg>
<seg id="2822">AMMONAPS therefore should therefore be used in patients with more scended herziness or serious kidney-efficiency as well as with sodium-and-minded clinical states only with caution.</seg>
<seg id="2823">Da metabolic and excretion of sodium-ferbutyrat about the liver and kidneys is carried by AMMONAPS in patients with liver or kidney-infertility only with extreme caution.</seg>
<seg id="2824">The significance of these results in terms of pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contradicated (see 4.3).</seg>
<seg id="2825">At subcutaneous gifts of phenylacetate at young cattle (190 - 474 mg / kg) it came to a slowing of neuronal multiplication and an increased loss of neurons.</seg>
<seg id="2826">There also found a delayed maturation of ceremonial synapsen and a decreased number of functional thrillers in the brain and thus a disability of degrowth.</seg>
<seg id="2827">"it could not be observed if phenylacetate at the people into the mother's milk, and for this reason the use of AMMONAPS during the breastfeeding period is contaminated (see 4.3)."</seg>
<seg id="2828">"in clinical trials, AMMONAPS entered at 56% of the patients at least an unwanted event (AE) and at 78% of these unwanted events, that they were not associated with AMMONAPS."</seg>
<seg id="2829">"frequency is defined as follows: very frequent (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported from a 18 year old anorectic patient, which developed a metabolic encephalopathy in conjunction with Laktataziquia, Panzytopenie, peripheral Neuropathie and Pankreatitis."</seg>
<seg id="2831">A case of overdose occurred at a 5 month old miniddler with a accidental loss of 10 g (1370 mg / kg).</seg>
<seg id="2832">These symptoms go with the accumulation of phenylacetate that showed up to 400 mg / kg / day a dosisular neurotoxicity.</seg>
<seg id="2833">Phenylacetate is a metabolized active connection that caused by Acetyulation with glutamine to phenylacetylglutamine that will be signposted via the kidneys.</seg>
<seg id="2834">Stöchiometrical saw Phenylacetylutamine with urea comparable (both connections contain 2 nitrogen-glutamine); Phenylacetylamine is therefore suitable as alternative carriers for the secretion of surplus nitrogen.</seg>
<seg id="2835">"5 patients with disturbances of the urinary cycle may be assumed that for each gram is recorded between 0,12 and 0,15 g Phenylacetylglutamine-nitrogen."</seg>
<seg id="2836">"it is of significance that the diagnosis is early, and the treatment started immediately to improve the survival chances and the clinical result."</seg>
<seg id="2837">The prognosis of the early manipulated form of the disease with the appearance of the first symptoms in the newborn age was almost always infant and the disease led even in treating obitoneal dialysis and essential amino acids from the first life of life to death.</seg>
<seg id="2838">"by Hemmodialysis, the utilization of alternative pathways of nitrogen-cleaners, sodium-ferrous and possibly substitution of essential amino acids, it was possible to increase the survival rate newborn on postpartal (but within the first life-month) diagnostic diseases on 80%."</seg>
<seg id="2839">"in patients whose disease was diagnosed in the course of pregnancy, and have been treated before the first appearance of hypertension encepencephalopathy, was the survival rate 100%, but even in these patients it came with time with many for mental disabilities or other neurological deficits."</seg>
<seg id="2840">"in patients with late manipulated form of the disease (including feminine patients with heterobic enranscarbolylase-Mangels), which were treated by a hypertension envisbutyrat and then permanently with sodium sheetbutyrat and a protectreduced diet, was the survival rate 98%."</seg>
<seg id="2841">Existing neurological deficits are also little reversible and in some patients may occur another deterioration of neurological jurisdiction.</seg>
<seg id="2842">"it is known that phenylbutyrat to phenylacetate oxidized, which is construed in liver and kidney enzymatic with glutamine, with Phenylacetylglutamine."</seg>
<seg id="2843">The concentrations of phenylbutyrat and his metabolic osis in plasma and urine were obtained after Gaban of a single dose of 5 g sodium-feryl butyrat for single use as well as repetitive Gaben of ormal doses of up to 20 g / day (non-controlled studies).</seg>
<seg id="2844">The behaviour of phenylbutyrat and his metabolic were also investigated with cancer types of sodium-ferbutyrat (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">After a oral single dose of 5 g sodium-butyrat in tobacco form 15 minutes after taking measurable plasmaconconcentrations of phenylbutyrat.</seg>
<seg id="2846">In the majority of patients with urinary circations or hemmoglobinopathies (300-650 mg / kg / day up to 20 g / day) the next morning after-up fires no phenylates in the plasma.</seg>
<seg id="2847">"with three of six patients with liver cirrhosis, which were repeated with sodium-kranylbutyrat (20 g / day oral in three single parts), the middle of phenylocateculations on the third day five times higher than after the first gifts."</seg>
<seg id="2848">Secretion The medication is made within 24 hours to approximately 80 - 100% in the form of the jugular product Phenylacetylutamine over the kidneys signposted.</seg>
<seg id="2849">According to the results of the Micronucleus tests had copper-sodium-butyrat with toxic and not toxic doses covered rats (investigation 24 and 48 h after orous administration of 878 to 2800 mg / kg).</seg>
<seg id="2850">"AMMONAPS Granulat is taken either oral (infants and children, who are not able to swallow tablets) or on a neurologium or a Nasensonde."</seg>
<seg id="2851">"after the previous clinical experience is the normal daily dose of sodium glycolic at: • 450 - 600 mg / kg / day at newborn, infants and children with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day in children with a body weight above 20 kg as well as with herent and adults."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (especially branded amino acids), Carnitin and Serum protein in Plasma should be held within the Normalens."</seg>
<seg id="2853">"in patients, who suffer from an early fixed lack of carbamylphosphate synthetase or Ornithintranscarbamylase, is the substitution of Citrullin or arginine in a dosage of 0,17 g / kg / day or 3,8 g / m ² / day required."</seg>
<seg id="2854">"AMMONAPS Granulat contains 124 mg (5.4 mmol) sodium per gram sodium glycrate, according to 2.5 g (108 mmol) sodium, which is equivalent to the maximum daily dose."</seg>
<seg id="2855">"if Rattenfutes had been suspended in front of the birth of phenylacetate (active metabolit by phenylbutyrat), it came to lesions in the pyramids of the brain."</seg>
<seg id="2856">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported from a 18 year old anorectic patient, which developed a metabolic encephalopathy in conjunction with Laktataziquia, Panzytopenie, peripheral Neuropathie and Pankreatitis."</seg>
<seg id="2857">Stöchiometrical saw Phenylacetylutamine with urea comparable (both connections contain 2 nitrogen-glutamine); Phenylacetylamine is therefore suitable as alternative carriers for the retion of surplus-edge</seg>
<seg id="2858">"based on investigations on the excretion of Phenylacetylglutamine in patients with disorders of the urinary cycle can be adopted, that for each gram can be produced between 0.12 and 0.15 g Phenylacetylglutamine."</seg>
<seg id="2859">"already existing neurological deficits are also little reversible, and in some patients may occur another deterioration of neurological jurisdiction."</seg>
<seg id="2860">According to a oral individual dose of 5 g sodium-butyrat in Granulatform have been found 15 minutes after taking measurable plasmaconconcentrations of phenylbutyrat.</seg>
<seg id="2861">"during the duration of durability, the patient can store the finished product for a period of 3 months at a temperature of not over 25 ° C."</seg>
<seg id="2862">"with this procedure, the small exhibition spoon contains 0.95 g, the average measuring spoon 2,9 g, and the large measuring spoon 8,6 g sodium."</seg>
<seg id="2863">"if a patient has to get the medication over a probe, AMMONAPS can also be dissolved in water (the solvent of sodium-ferbutyrat is up to 5 g in 10 ml water)."</seg>
<seg id="2864">"in patients with these rare diseases, certain Leberenzymme, so that they accumulate the stuffy waste products that could collect from proteins in the body, not to fail."</seg>
<seg id="2865">"if you are employed at you laboratories, you must notify the doctor that you may have AMMONAPS, since sodium-apples the results of certain laboratory charges may affect."</seg>
<seg id="2866">"at intake of AMMONAPS with other drugs, please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="2867">"during the breastfeeding time you may not take AMMONAPS, since the medicine could go into the mother's milk and could harm your baby."</seg>
<seg id="2868">"in rare cases have also been plyness, headache, flavours, post-disorders that observing the desertness, memory disruptions and a deterioration of existing neurological states."</seg>
<seg id="2869">"if you notice any of these symptoms, please feel free to contact your doctor or with the notion of your health insurance for a corresponding treatment."</seg>
<seg id="2870">If you have forgotten the intake of AMMONAPS Take the appropriate dose as soon as possible with the next meal.</seg>
<seg id="2871">"blood circulation (red blood cells, white blood cells, Thrombozyten), verminderivory, depression, Ohnness, liaches, dropness, nausea, fobceration, unobstructuring, rust-proof, scaffection, necklash, kidnelling and anomal laboratory."</seg>
<seg id="2872">Please inform your doctor or pharmacist if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="2873">"you may not use AMMONAPS according to the on the Umcarton and the container after" "expiry date". ""</seg>
<seg id="2874">"as AMMONAPS, and contents of the pack AMMONAPS tablets are of white color and oval shape, and they are provided with the" "UCY 500" ""</seg>
<seg id="2875">"30 If you are employed at you laboratories, you must notify the doctor that you can influence AMMONAPS, since sodium-apples the results of certain laboratories."</seg>
<seg id="2876">"at intake of AMMONAPS with other drugs, please inform your doctor or pharmacist if you have taken other medicines or recently taken, even if it is not prescription-prescription medicine."</seg>
<seg id="2877">"you should take AMMONAPS distributed on the same retailer, or via a Magenfistel (tube, which runs through the abdominal wall directly into the stomach) or a Nasensonde (tube, which is led by the nose in the stomach)."</seg>
<seg id="2878">"31 • can be seen from the crucible measuring spoon granules, e.g. a knife push over the upper edge of the messengers, in order to remove overlap granules. • The recommended number of measuring spoon granules from the container."</seg>
<seg id="2879">"Angiox will be used to treat adult patients with" "loons coroneness" (ACS, decreased blood flow towards the heart), for example, in instabiler Angina (a form of pain in the chest) or Myokardinfarkt (heart attack) without "ST- Hebung" (an anomal measuring value at electrocardiologram or ECG). "</seg>
<seg id="2880">Will Angiox to prevent blood cages in patients applied to a PCI will take a higher dose and infusion can continue up to four hours after the procedure.</seg>
<seg id="2881">This can contribute to patients with anxiety or heart fall to the maintenance of blood flow to the heart and increase the effectiveness of a PCI.</seg>
<seg id="2882">"nearly 14 000 patients participated in the capitals of the treatment of ACS at all the treatment of angiox, with the effect of angirotan-IIb / IIIa-Inhibitor (GPI, another medicine to prevent blood pressure) and a GPI was compared to a glycoagulan) and a GPI."</seg>
<seg id="2883">"during the PCI the patient was often a Stent (a short tube, which began to prevent a clasp) and they were additionally given other medicines to prevent blood cages, such as Abciximab and aspirin."</seg>
<seg id="2884">"when the treatment of ACS was Angiox - with or without gifts of GPI - in preventing new events (deaths, heart incidents, or turascularization) after 30 days or a year are as effective as conventional treatment."</seg>
<seg id="2885">"in patients who subjected to a PCI it was anox in terms of all indicators just as effective as Heparin, except heavy blood vessels when it was significantly more effective than Heparin."</seg>
<seg id="2886">Angiox must not be used in patients who may possibly be hypersensitive (allergic) against bivalirudin, other hirudine or one of the other components. "</seg>
<seg id="2887">"it may not be applied in patients that recently had a blood-blood, as well as with people with rigid hypertension or serious kidney problems or a heart infection."</seg>
<seg id="2888">The Committee for Humanarzneix (CHMP) wrote to the conclusion that Angiox in the treatment of ACS and during an PCI is a convenience replacement for heparin.</seg>
<seg id="2889">September 2004 the European Commission commissioned the Company The Medicines Company UK Ltd.</seg>
<seg id="2890">For the treatment of adult patients with akutes coronartismen (instabile Angina / non-slist attack. (IA / NSTEMI)) at a emergency access or when an early intervention is planned.</seg>
<seg id="2891">The recommended Initiatives osis of Angiox in patients with ACS is a intravenous bolt from 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if the patient is carried out a PCI card, an additional bolt from 0,5 mg / kg and the infusion for the duration of the intervention on 1,75 mg / kg / h increases."</seg>
<seg id="2893">After the PCI can reproduce the reduced Infusionsdosis from 0.25 mg / kg / h for 4 to 12 hours.</seg>
<seg id="2894">"immediately before the procedure is to be administered a bolusement of 0,5 mg / kg, followed by an infusion of 1,75 mg / kg / h for the duration of the Rhinoplasty."</seg>
<seg id="2895">"the recommended dosage of angiox in patients with an PCI consists of a initials from 0,75 mg / kg body weight and an inaccurate infusion with a dose of 1,75 mg / kg body weight / h at least for the duration of the surgery."</seg>
<seg id="2896">The security and effectiveness of a sole bolt forcrie of Angiox was not investigated and is not recommended even if a short PCI procedure is planned.</seg>
<seg id="2897">"this value (ACT after 5 minutes) can be shortened under 225 seconds, should be a second boltion of 0,3 mg / kg / body weight."</seg>
<seg id="2898">"in order to reduce the appearance lower ACT values, the constitutive and diluted medicines before the application carefully mixed and the Bolusdosis can be administered rapidly."</seg>
<seg id="2899">"once the ACT Value is more than 225 seconds, another surveillance is no longer required, which is 1,75 mg / kg Infusionsdosis will be correct."</seg>
<seg id="2900">"in patients with a medium-heavy kidney function (GFR 30-59 ml / min), treated with Bivalirudin against ACS or not), should be a lower infusion rate of 1,4 mg / kg / h."</seg>
<seg id="2901">"lies the ACT value below 225 seconds, a second bolt dose of 0,3 mg / kg to administer and the ACT 5 minutes after the second Bolusdosis again."</seg>
<seg id="2902">"in patients with a medium-heavy nose, which resulted in the phase III I- PCI-study (replace-2) that was the ACT value 5 minutes to Gabe des Bivalirudin-Bolus without dosage adjustment on average 366 ± 89 seconds."</seg>
<seg id="2903">3 For patients with severe kidney treatment (GFR &lt; 30 ml / min) and also in dialysecular patients is angiox contaminated (see under Section 4.3).</seg>
<seg id="2904">The treatment with angiox can be initiated 30 minutes after termination of the intravenous Gabions or 8 hours after the end of the subcutaneous fors of the subcutaneous Heparin.</seg>
<seg id="2905">• Unknown hypersensitivity against the active ingredients or against Hirudine • active bleeding or increased blood circulation system due to a disturbance of the hermostacy system and / or irreversible inhibital bleeding. • severe unlocking dusation (GFR &lt; 30 ml / min) and for dialysis patients</seg>
<seg id="2906">Patients have been carefully supervisaged during treatment with regards to symptoms and signs of a blood flow especially if bivalirudin can be administrated in combination with another antiocagulan (see Section 4.5).</seg>
<seg id="2907">"even if with PCI-patients under Bivalirudine most bleeding points can occur in patients, which occur in a perkutaneous coronary intervention (PCI) during treatment in principle."</seg>
<seg id="2908">"in patients, the Warmarin take part and treated with Bivalirudin, should make a surveillance of INR-Werts (International normative-ratio Ratio), to ensure that the value is achieved before the treatment with bivalirudin back before the treatment existing level."</seg>
<seg id="2909">"proceeding from the knowledge of the working mechanism of antioagulanzien (Heparin, Warmarin, Thrombolytika or Thrombozytenderhmer) can be taken out of it that these agents will increase the blood circulation."</seg>
<seg id="2910">With the combination of bivalirudin with Thrombozytensional numbers or antioagulanzien are the clinical and biological hermostacy parameters in any case regularly.</seg>
<seg id="2911">"the animal experimental examinations are in relation to the pregnancy, the embryonic development, the childbirth or postnatal development insufficient (see below 5.3)."</seg>
<seg id="2912">"4612 were randomized to Bivalirudin alone, 4604 were randomized to Bivalirudin plus GPIIb / IIIa Inhibitor and 4603 were randomised to either imfractional Heparin or Enoxaparin plus GPIIb / IIIa Inhibitor."</seg>
<seg id="2913">"both in the bevalirudin group as well as in the with hepatitis, it joined women as well as patients over 65 years more frequently to adverse events than with male or younger patients."</seg>
<seg id="2914">Heavy bleeding have been defined according to the Acuity and TIMI sizes for heavy blood vessels as in the form of table 2.</seg>
<seg id="2915">Both light and heavy blood vessels performed less frequently than in the groups with heparin plus GPIIb / IIIa-Inhibitor and Bivaliprints plus GPIIb / IIIa- Inhibitor (see chart 2).</seg>
<seg id="2916">"an Acuity heavy blood flow was defined as one of the following events: inextraction, retrospitoneal, intraocular blood flow of ≥ 3 g / dl without apparent blood flow, redemining of hemoglobal blood flow, reoperation due to a blood flow, application of blood products to transfusion."</seg>
<seg id="2917">"further, less frequently observed blood localizations that occurred in over 0.1% (occasionally) were" other "score, retroperitoneal, Gastrointestinal, Ohr, nose or neck."</seg>
<seg id="2918">The following information about side effects are based on the data of a clinical study with bivalirudin at 6000 patients who undergoes to one PCI.</seg>
<seg id="2919">"both in the bevalirudin group as well as in the hepatarin manufacturing groups, it joined women as well as patients over 65 years more frequently to adverse events than with male or younger patients."</seg>
<seg id="2920">Both light and heavy blood vessels performed less frequently than in the comparative group under Heparin plus GPIIb / IIIa-Inhibitor.</seg>
<seg id="2921">"the following side effects, which are not listed above, were reported after comprehensive application in practice, and are arranged according to system design classes in chart 6."</seg>
<seg id="2922">"in case of overdose, the treatment with Bivalirudin is immediately dismissed and supervise the patient with regard to signs of a bleeding."</seg>
<seg id="2923">"Angiox includes Bivalirudin, a direct and specific Thrombinous inhibitor, which is located both at the catalytic center as well as at the Aniol bindingregion of Thrombin binds, regardless of whether Thrombin is bound in the liquid phase or at Gerinnsel."</seg>
<seg id="2924">"the bond of Bivalirudin at Thrombin, and thus its effect, is reversible, because Thrombin turn out the bond of Bivalirudin-Arg3-Pro4 slowly, making the function of the active center of Thrombin regenerated."</seg>
<seg id="2925">"in addition, through Bivalirudin with serum of patients, in which it has come in the past to heparinininduced Thrombozytopenie / heparinininducted Thrombosis syndrome (HIT / HITTS) was induced not thrombozyes reaction."</seg>
<seg id="2926">"in healthy Probanden and patients shows Bivalirudin a dosis- and concentralised antikoagulatory effect, which is occupied by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if you have performed a PCI for the patient in the following, an additional bolt of 0,5mg / kg Bivalirudin was given and infusion for the duration of the intervention on 1,75mg / kg / h."</seg>
<seg id="2928">In the arm A of the Acuity study was infractional Heparin or Enoxaparin accordance with the relevant guidelines for the treatment of akutem Koronaredelm (ACS) in patients with instabilistic Angina / non-ST slist attack.</seg>
<seg id="2929">Patients in arm A and B were also randomised to receive a GPIIb / IIIa Inhibitor at the beginning of the Angiography (at the time of Randomisation) or with PCI.</seg>
<seg id="2930">"in the Acuity study, the characteristics of high risks were distributed within 72 hours of required, equivalent to the 3 treatment of treatment."</seg>
<seg id="2931">"approximately 77% of the patients had recurrent Ischia, 70% had dynamic EKG- changes or increased cardiovascular biomarker, 28% had diabetes and about 99% of all patients undertaking care within 72 hours of angiography."</seg>
<seg id="2932">"primary analysis and results from the Acuity study for the 30-tage- and the 1- annual item for the overall population (ITT) and for patients, aspirin and Clopidogrel loud protocol (prior to angiography or prior to PCI), are presented in tables 7 and 8."</seg>
<seg id="2933">Acuity study; 30-days and 1-year risk difference for the combined repository and its components for patients who received aspirin and Clopidogrel loud protocol *</seg>
<seg id="2934">Patients, aspirin and Clopidogrel loud protocol got arm A Arm B Arm C UFH / Enox Bival + GPIIb / IIIa + GPIIb / IIIa risk Diff. "</seg>
<seg id="2935">"the frequency of blood cells both in ACUITY- as well as in the TIMI scale up to day 30 for the overall population (ITT) and for patients, aspirin and Clopidogrel loud protocol, is represented in table 9."</seg>
<seg id="2936">Patients who received aspirin and Clopidogrel Total population (ITT) according to protocol UFH / Enox Bival Bival + + alone + + GPIIb Inhibitor Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor% Inhibitor (N = 2842)</seg>
<seg id="2937">* Clopidogrel before Angiography or before PCI 1 A Acuity - Neale, intraocular blood cells of ≥ 3 g / dl without apparent blood flow, redemining of the hemian gloomy reversal of ≥ 3 g / dl with known blood flow, reoperation due to a blood circulation, application of blood products to transfusion. "</seg>
<seg id="2938">"the 30-day results, based on four-rolls and triple-end points of a randomised double blind study with over 6,000 patients who undergoes to a PCI (replace-2), are shown in table 10."</seg>
<seg id="2939">Clinical studies with a small number of patients supplied limited information on the application of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">Pharmacoinetic properties of Bivalirudin were evaluated in patients with patients treated as a perkutaneous coronary intervention (PCI) as well as in patients with ACS.</seg>
<seg id="2941">It is expected that bivalirudin as Peptid a cataboism in its amino acids in its amino acids with subsequent playback of amino acids in the body-pool.</seg>
<seg id="2942">The primary metaboose that resulting from the division of the Arg3-Pro4 bond of the N-terminal sequence by Thrombin is not effective due to the loss of its affinity to the Catalan centre of Thrombin.</seg>
<seg id="2943">The elimination is done by patients with normal kidney function after a process first order with a terminal semiconductor of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on safety, toxicity, toxicity in repetitive Gabe, genotoxicity or reproductions, the preclinical data can be seen no particular hazards for men."</seg>
<seg id="2945">The toxicity in animals with repetitive or continuous exposure (1 day to 4 weeks in a exposure to 10-fold of clinical steady-state-Plasmaconconcentration) is limited to overflowing pharmacological effects.</seg>
<seg id="2946">"side-effects as a result of a long-term physiological strain as response to a non-homeostatics Koagulation were comparable to those in clinical use, even at very much higher dosage, even at very much higher dosage, not observed."</seg>
<seg id="2947">"if the production of the used-made solution 17 does not occur under controlled and validated aseptic conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox is a gefrightened powder in single dose of type-1-glass to 10 ml, closed with a butyl rubber-blade and sealed a cap from squared aluminium sealed. "</seg>
<seg id="2949">"5 ml of Chile water for injecting Angiox will be given and easily switched up to everything completely dissolved, and the solution is clear."</seg>
<seg id="2950">5 ml are taken from the throughput and refuted with 5% iger glucoselsolution for injecting or with 9 mg / ml (0.9%) sodium finishes for injecting in a total volume of 50 ml to receive a final concentration of 5mg / ml bivalirudin.</seg>
<seg id="2951">"the holders of authorisation is agreeing to carry out the studies and pharmaovigbalance sheet, as well as in version 4 of the risk management plan (RMP), as well as any subsequent changes in the author, which was agreed from CHMP."</seg>
<seg id="2952">"according to CHMP guideline at risk management systems for human resources, the previously worked with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast pain due to a heart disease (akute coronator - ACS) • patients that are operational for the treatment of closures in blood vessels (Angioplasty and / or or perkutane Koronarangioplasty - PCI).</seg>
<seg id="2954">"• You are pregnant or suppose that you might be pregnant • You intend to get pregnant, you are currently breastfeeding."</seg>
<seg id="2955">"there were no investigations of effects on the transport system and the ability to use machinery, but you know that the effects of this drug are only available at short notice."</seg>
<seg id="2956">"should an blood occur, the treatment with angiox will be broken. • At the beginning of the injection or infusion you will inform your doctor about the possible signs of an allergic reaction."</seg>
<seg id="2957">Such reactions are rare (they appear at less than 1 of 1000 patients treated patients). • A particularly careful control is performed when you provide a radiotherapy (this treatment is referred to as a bed or Gamma-Brachytherapy). • The dosage you will receive from your body weight and from the type of therapy you will receive.</seg>
<seg id="2958">• 0.1 mg / kg body weight than injecting followed by an infusion (trophy) with 0.25 mg / kg body weight means a tenth of a millimeters body weight; 0.25 mg / kg body weight per hour means a quarter of a millimeters of medicinal per hour).</seg>
<seg id="2959">Probable if angiox can be administrated in combination with other gerinnacle or anti-thrombosis drugs (see section 2 "At the use of angiox with other medicinal products).</seg>
<seg id="2960">These are occasional side effects (with less than 1 of 100 patients treated patients). • Thrombosis (blood-minded) that could lead to serious complications like a heart attack.</seg>
<seg id="2961">This is a occasional secondary effect (with less than 1 of 100 patients treated patients). • Pain, bleeding and Bluterguss at the standpoint (after a PCI treatment). "</seg>
<seg id="2962">Please inform your doctor if any of the listed side effects you have considerably impaired or do not notice any side effects that are not specified in this usage information.</seg>
<seg id="2963">Angiox may not be applied after the label on the label and on the expiry date of the expiry date.</seg>
<seg id="2964">Polska The Medicines Company UK Ltd Tel.: + 800 843 633 26 LUB + 41 61 564 1320 Supersonable: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"Apidra is used to treat adults, young people and children from six years with diabetes who need a treatment with insulin."</seg>
<seg id="2966">Apidra is subcutaneous (under the skin) into the abdominal wall, the thigh or the upper arm injected or as a continuous infusion with an insulphum pump. "</seg>
<seg id="2967">Diabetes is an ailment in which the body is not enough intimacy to control the glucoespiegels (sugar) in the blood or the Insulin is not effective.</seg>
<seg id="2968">"Insulinglulisin is very slightly different from human insulin, and the change means that it works faster and has a shorter efficiency cycle than a short-effective human insulin."</seg>
<seg id="2969">"apidra was developed in combination with a slow insulin in patients with type 1 diabetes, where the body can not produce any insulin in two studies with a total of 1 549 adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">"in type 2-diabetes, where the body can not be effected in ineffective, apidra was investigated in a study with 878 adults."</seg>
<seg id="2971">The main indexator for the effectiveness was the change of concentration of the substance of the substance of the glycosity (HbA1c) in the blood that shows how well the blood sugar is adjusted.</seg>
<seg id="2972">"in the first study with adults with type 1-diabetes, after six months a lowering of 0,14% (from 7,60% to 7,46%) compared to a reduction of 0,14% at Insulinlisper."</seg>
<seg id="2973">In adults with type 2 diabetes the lowering of the HbA1c concentration 0.46% after six months with apidra compared to 0.30% for humanitarian Normalinsulin.</seg>
<seg id="2974">"Apidra must not be used in patients that may possibly be hypersensitive (allergic) against Insulinglulisin or any of the other components, or in patients who already suffer from a hypoglycaemic."</seg>
<seg id="2975">The doses of Apidra may have to be adjusted when it is administered along with a number of other medicines that can affect blood-glucoasts.</seg>
<seg id="2976">September 2004 the European Commission commissioned the company Sanofi-Avorio Germany GmbH is a permit for the establishment of Apidra in the entire European Union.</seg>
<seg id="2977">Apidra is known as subcutaneous injtion either in the area of the abdominiums of the thighs or of the Deltamuskels or subcording by continuous infusion in the area of the abdominal cord.</seg>
<seg id="2978">"due to the decreased glucoogenesis capacity and the diminated insulin can be envisaged in patients with a restriction of the liver function."</seg>
<seg id="2979">"any change of the efficiency, the brand (her-), the Insulphyps (normal, nph, drips, etc.), the type of insulin (animal insulin) and / or the manufacturer method can draw a change in the insulin demand."</seg>
<seg id="2980">"3 An insufficient dosage or breakthrough treatment, especially in patients with a insulin chargeable diabetes, can lead to a hyperglycemic and a diabetic Ketoazicer."</seg>
<seg id="2981">"the changeover of a patient at another Insulintype or an insulin another manufacturer should be carried out under strict physician supervision, and can make a change of dosage."</seg>
<seg id="2982">The time of awakening of a hypoglycemic depends on the working profile of the used Insuline and can therefore change in the conversion of the treatment schemas.</seg>
<seg id="2983">"among the substances that can increase the blood decreases, anale antidiabetic, anopyramid, Fibrate, Fluoxettin, Monoamin-oxididase (Mao) -Hemmer, Fluoxfyllin, Propoxyphs, Salizylyphs, Salizylyphs and Sulfonamid-antibiotics."</seg>
<seg id="2984">"in addition, under the effect of sympatholytika such as Betablockers, Clonidine, Guanethidine and reserves the symptoms of adrenwater counterregulation will be or lacking."</seg>
<seg id="2985">Animal experimental studies show no differences between Insu- linglulisin and Humaninsulin regarding pregnancy, the embryonic development, the birth or the postnatal development (see Section 5.3). "</seg>
<seg id="2986">"it is not known as Insulinglulisin into the human mother's milk, but generally occurs Insulin neither into the mother's milk, nor is it resorated after orous application."</seg>
<seg id="2987">"below are the clinical trials published by clinical trials published unwanted pharmaceuticals and sorted according to decreasing frequency of their appearance (very often: ≥ 1 / 100, &lt; 1 / $; rare: ≥ 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000); not known (frequency based on availability of availability)."</seg>
<seg id="2988">"kalt- welded, cool and blass skin, fatigue, nervousness or weakness, confusion, concentralism, excess dog, lifestivity, naughtness, nausea, nausea and corps."</seg>
<seg id="2989">Lipodystrophy fails to switch injecting the injecting within the injector range, can occur in the episode a lipodystrophy in the injection. "</seg>
<seg id="2990">Heavy hypoglycals with awareness can be given by an intra-muscular or subcutaneous injection of glucoagon (0.5 to 1 mg) which is given by a doctor or by intravenous gift of glucose by a doctor.</seg>
<seg id="2991">"after a glucoagonary project, the patient should be monitored in a hospital in order to identify the Ur- and severe hypoglycaemia and avoid similar episodes."</seg>
<seg id="2992">Insulin senkt the blood sugar levels through the stimulation of the peripheral glucoup (especially through scelettmusculature and fat) as well as by the inhibition of glucoproduction in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes showed that at subcutaner Ga- be carried out by Insulinglulisin the ingredient faster than at hu- manem Normalinsulin.</seg>
<seg id="2994">"in a study with 18 male people aged 21 to 50 years with type 1-diabetes melli- Tuon showed Insulinglulisin in therapeutic dosing range of 0,075 to 0,15 E / kg a disproportionate increase in glucodisproportionate effect, just as human insulin."</seg>
<seg id="2995">Insulinglulisin has a twice as fast active efficiency than normal human insulin and achieves complete glucoefficient effect about 2 hours earlier than human insulin.</seg>
<seg id="2996">"from the data was clear that at an application of Insulinglulisin 2 minutes before the meal is reached a comparative postprandious glycemic control, which is given 30 minutes before the meal."</seg>
<seg id="2997">"was cancelled Insulinglulisin 2 minutes before the meal, a better postprandious control was given than with humanly Normalinsulin, which was given 2 minutes before the meal."</seg>
<seg id="2998">"will Insulinglulisin 15 minutes after the beginning of the meal, there will be a comparative glycaemic control such as for humanly Normalinsulin, which is given 2 Mi- Nuts before the meal (see picture 1)."</seg>
<seg id="2999">"Insulinglulisin at Gabe 2 minutes (GLULISIN - before the beginning of the meal in comparison to humanitarian Normalinsulin, which was given 30 minutes (NORMAL - 30 min.) before the beginning of the meal (picture 1A), which was given 2 minutes (NORMAL - previously) before a meal (picture 1B)."</seg>
<seg id="3000">"Insulinglulisin at Gabe 15 minutes (GLULISIN - after the beginning of the meal compared to humanitarian Nor- malinsulin, which was 2 minutes (NORMAL - previously) before the meal (picture 1C)."</seg>
</doc>
</tstset>
